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Abstract
Genetic studies have revealed over 100 mutations in the gene encoding superoxide 
dismutase type-1 (SOD1) that cause Familial Amyotrophic Lateral Sclerosis (FALS). For 
the purpose of this thesis an in vitro model has been developed by stably over-expressing 
wild type (wt), G93A or G93R mutant SOD1 in neuronally derived ND7 cell line. It was 
found that wt-SODl could provide protection against a range of cell stresses including 
serum removal (plus retinoic acid); IFN-y, staurosporine; camptothecin; 
ischemia/reoxygenation; glutamate; and hydrogen peroxide (H2O2). In contrast, both mutant 
forms of SOD1 enhanced cell death with the G93R mutation being the more severe of the 
two mutations tested. Hence, the disease-associated mutations convert wt-SODl from a 
protective anti-apoptotic protein to a pro-apoptotic form. Most of the above stresses are 
FALS relevant stresses, which primarily induce apoptotic cell death in ND7 cells, implicated 
in FALS pathology.
The neuroprotective effect of various heat shock proteins (Hsps) in the above system 
was studied, utilising a Herpes Simplex Virus (HSV) - based gene delivery system. For the 
first time, it was demonstrated that in an in vitro model of mutant-SOD 1 -induced toxicity, 
the exogenous expression of Hsp27 and/or Hsp70 protects both G93A and G93R-SOD1- 
mutant expressing cells, under all the stresses tested, and the dual expression of Hsp27 and 
Hsp70 is more effective in protecting against mutant-SOD 1 cytotoxicity than either Hsp 
individually; as assessed by trypan blue and TUNEL analysis. In addition, G93A and G93R- 
SOD1 mutant expressing cells were markedly protected by caspase-8 and caspase-9 
inhibition. However no additive protective effect of Hsp and caspase inhibitor was observed.
To further investigate the protective effect of wt-SODl and damaging effect of the 
mutant, an HSV-based gene delivery system was utilised. Primary cultures of dorsal root 
ganglia (DRGs) from postnatal rats, wild-type mice, transgenic Hsp27 and transgenic Hsp70 
mice were infected with SOD1 viruses for wt-SODl and G93R-mutant SOD1 and subjected 
to stresses of NGF withdrawal, IFN-y and staurosporine treatment. Finally, the DRG 
experiments were repeated with additional delivery of Hsps via HSV vectors to further
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investigate the protective effect of the Hsps. These experiments provided further evidence 
on the protective role of Hsp27 and/or Hsp70 against mutant-SOD 1 induced toxicity.
*
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C h a p t e r  1 
I n t r o d u c t i o n
1. Introduction
The work described in this thesis attempted to investigate the potentially toxic effects 
of Familial Amyotrophic Lateral Sclerosis (FALS) associated SOD1 mutants G93A and 
G93R and the protective effects of its wild-type form, in an in vitro cellular model. As a 
result of substantial experimental evidence on the protective effects of heat shock proteins 
(Hsps) it was decided to investigate and test their neuroprotection in this system and further 
investigate the incorporated mechanisms. For this purpose, Herpes Simplex Virus type 1 
(HSV-1) based vectors, originally developed for gene therapy studies in the central nervous 
system, were utilised in order to efficiently over-express Hsps in mammalian neuronal cells.
Therefore the Introduction of this thesis focuses on the following aspects, which are directly 
relevant to the work presented here:
a. ALS disease genetics with reference to the SOD1 gene in hereditary ALS; the SOD 
multigene family; a detailed review on SOD1 gene in ALS and the experimental models of 
ALS along with other candidate genes that have been investigated; proposed toxic function 
of mutant SOD1.
b. The role of programmed cell death in FALS, an overview of apoptotic cell death.
c. Heat shock protein biology, their roles in the cell and in the context of neurodegeneration, 
as well as the role of Hsps as therapeutic targets in FALS and other neurodegenerative 
disorders. A brief account is also given of the viral vectors used in this study and their 
potential use in the development of gene therapeutic strategies for ALS and other diseases.
1.1 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an adult-onset, rapidly progressive and
ultimately fatal neurodegenerative disorder. The disease, also referred to as motor neuron
disease or Lou Gehrig’s disease, is caused by a progressive loss of motor neurons in the
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cortex, brainstem, and spinal cord (de Belleroche et al., 1995). On average the disease pro­
gresses for 3-5 years, leading to paralysis and premature death as a result of respiratory 
paralysis.
Approximately 10% of ALS cases are familial (FALS) (Camu et al., 1999), with the 
majority of cases considered to be sporadic (SALS) in the absence of any positive family 
history. The majority of FALS and SALS cases are clinically indistinguishable however 
there are some familial cases with clearly distinct features. Massive accumulation of 
neurofilaments is observed in motor neurons in both familial and sporadic ALS cases. 
Studies on animals have shown that motor neuron dysfunction precedes the onset of 
symptoms and that compensatory mechanisms are successful in maintaining motor functions 
until loss of motor units exceeds 50%, at which stage symptoms appear and rapid motor 
decline in the number of motor units occurs (Cote et al., 1993; Kennel et al., 1996). The 
progressive increase of the aged in the population is likely to be associated with a 
proportional increase of age-related disorders such as ALS (Riggs et al., 1992; Neilson et al., 
1994; Lilienfeld et al., 1993; Durrleman et al., 1989).
ALS may present in three main ways, either as a predominantly lower motor neuron 
(LMN) form designated progressive muscular atrophy (PMA) or as a predominantly upper 
motor neuron (UMN) form called primary lateral sclerosis (PLS), but what is more 
commonly seen is a mixture of both UMN and LMN deficits. ALS usually begins focally 
and then spreads and involves both corticospinal (upper) and spinal (lower) motor neurons. 
Lower motor neuron involvement results in muscle denervation of the affected muscles, loss 
of tendon reflexes and fasciculation, and subsequently muscle atrophy. The degeneration of 
corticospinal motor neurons results in additional focal spasticity. Before the disease spreads, 
clinical experience suggests that it starts with fatigue, cramp, muscle weakness and wasting 
of one or more limbs or fasciculation of the tongue (bulbar onset). Loss of reflexes is not as 
common as pathologically increased reflexes (Swash, 1999). In addition, ALS may 
primarily involve the bulbar muscles where it is known as progressive bulbar palsy (PBP) or 
the limbs where it is called spinal ALS.
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By reason of the progressive nature of the disease, the clinical picture may be 
incomplete at the onset of symptoms. The recently revised El Escorial system (Brooks,
1994) provides an outline for the criteria required for the diagnosis of suspected, possible, 
probable, and definite ALS based on clinical, electrophysiological, and neuropathological 
examination. The diagnosis of ALS requires the presence of both upper and lower motor 
neuron features with disease progression with the exclusion of any other disease that may 
account for these signs. A recent review reported that dementia is found in approximately 3- 
5% of ALS patients (Al Chalabi et al., 2000), however an earlier study had stated the figure 
as being as high as 15% (Hudson, 1981).
Even though the majority of sporadic and familial ALS cases are clinically identical, 
there are some minor features that distinguish the types, such as the average age of symptom 
onset; in SALS it is 56 years, whereas in FALS it is 46 years (Camu et al., 1999). There is 
no observed genetic anticipation. Overall, a male preponderance of 1.5:1 is reported 
worldwide, however this is not as pronounced in the >70 years age-group. The male 
preponderance only occurs in sporadic ALS and still remains unexplained (Haverkamp et 
al., 1995; Cashman et al., 1999). The duration of FALS is bimodal in that a small percentage 
of patients have a very poor prognosis, with an average survival of <2 years, while the 
remainder have a better prognosis than is observed in sporadic cases, with survival usually 
>5 years (Camu et al., 1999). Site of onset is variable, but bulbar onset is considered rare. 
Survival of individuals is not affected by age or gender, but instead by the site of symptom 
onset with longer survival being seen when the arms are affected first, compared to onset in 
the legs or oropharyngeal muscles (Mulder et al., 1986).
Despite more than a century of research, there is currently no cure for ALS. The drug 
riluzole is the primary form of treatment and acts by blocking glutamate release (Miller et 
al., 1996), although it has been demonstrated in rats that treatment with this drug may 
increase motor neuron survival by stimulating trophic activity in astrocytes (Peluffo et al.,
1997).
The underlying cause of ALS still remains unknown. Although the familial form of 
ALS comprises only 10% of all cases, it is frequently used as the basis of study because of
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the implicit genetic factors, with the aim of mapping and identifying gene(s) that trigger or 
predispose an individual to ALS. It is thought that identification of FALS genes may lead to 
a greater understanding of the mechanisms of cell death involved in all forms of ALS, which 
in turn, may lead to development of more effective treatments and therapies.
1.1.1 Epidemiology
The crude prevalence of ALS is estimated at being between 4-6/100,000 population 
and increases with age, peaking in the 60-75 years age-group at about 33/100,000 population 
and 14/100,000 population, for men and women respectively (Annegers et al., 1991; 
Traynor et al., 1999; Bobowick et al., 1973). The incidence rate of ALS is estimated at being 
between 1-3/100,000 person years and increases with age (Annegers et al., 1991; Traynor et 
al., 1999; McGuire et al., 1996) with a peak incidence rate being observed in the 55-75 years 
age-group of 10.5/100,000 for men and 7.4/100,000 for women, respectively. Ethnicity data 
from the United States (US) show lower rates of mortality from ALS among non-whites 
compared to whites, with a ratio of 1: 1.6, but exhibit age and gender differences similar to 
whites (Elian et al., 1993).
A latitude-related increase in ALS has been demonstrated, with geographic age- 
adjusted incidence rates ranging from 2.0 in Israel (32° latitude) to 8.0 in the northern 
Scandinavian countries (>60° latitude) (Kahana et al., 1984; Jokelainen, 1977; Tysnes et al., 
1991; Gunnarsson et al., 1996). Geographical differences of ALS worldwide may probably 
be due to regional differences in disease diagnosis, regional differences in genetic 
susceptibility and/or exposure to environmental factors. Four geographic areas with a high 
prevalence of ALS (clusters) are known and have been well-studied. In the western Pacific 
islands of Guam and Rota, the Chamorro population commonly suffer from two neurologic 
conditions; one is ALS, locally known as 'lytico'; and the other parkinsonism-dementia 
complex (PDC) of Guam, locally known as 'bodig'. Lytico and bodig can occur together in 
patients and families (Kurland, 1954), although the strong notion of an identical etiology has 
as yet not been proven (Oyanagi et al., 1999). The crude prevalence of ALS on Guam has 
fallen in the 1950s from 100/100,000 population, to 50/100,000 for men and 25/100,000 
population for women, in the 1990s (McGeer et al., 1997; Wiederholt et al., 1999; Zhang et
al., 1996). A similarly high prevalence of ALS is shown in two areas of the Japanese Kii 
peninsula (Yase et al., 1968; Handa et al., 1963), and also by a population of the western 
coast of former West Papua New Guinea, now Irian Jaya (Indonesia) (Gajdusek et al., 
1982). A fourth high-incidence area is found at the same pacific latitude, in the Gulf of 
Carpentaria (North Australia), in an isolated tribe at Anguru on Groote Eylandt (Kiloh et al., 
1980). In these South Pacific cluster areas, ALS is said to account for about one in 10 
deaths. In addition, an unusually high frequency of atypical Parkinsonism occurs in Guadel­
oupe (in the French West Indies), which is occasionally accompanied by ALS, reminiscent 
of that described in Guam (Chen et al., 1996). The potential reasons for these clusters are 
discussed below.
Smaller clusters of ALS, which are linked by professional or residential proximity, 
have been reported, for instance, from the same apartment building (n = 3) (Mekned et al., 
1982), a school (n = 3) (Hyser et al., 1987), a group of farm-rangers in South-Dakota (n = 4) 
(Hochberg et al., 1974; Kilness et al., 1977; Dal Canto et al., 1994.), as well as among mail 
carriers (n = 3) in a small town (Sanders et al., 1980), and also a small community (six cases 
of ALS between 1975 and 1983) near lake Michigan, Wisconsin, USA (Sienko et al., 1990; 
Taylor et al., 1989). In addition to being reported in Guam (Reed et al., 1975), conjugal ALS 
has also been reported in four couples outside the Western Pacific (Comblath et al., 1993; 
Maloo et al., 1987; Chad et al., 1982; Paolino et al., 1983). These ALS clusters may be the 
result of a common exposure or transmission of a causal agent, or alternatively they may be 
purely coincidental. The analysis of small clusters is usually complicated due to the lack of 
data on the total population of origin.
1.1.2 Environmental risk factors
Until recently, the environmental risk factors involved in neurodegeneration in ALS 
were largely unknown. In addition, genetic factors could not fully explain the endemic 
occurrence of ALS in the high-risk areas, such as in the Pacific (Bailey-Wilson et al., 1993; 
Ahlskog et al., 1995), and as a result evoked an animated discussion on gene-environment 
interactions. Cycad nuts, along with mineral content of the drinking water and also soil 
content were all suspected to be long-term environmental neurotoxic risks. Above all, atten-
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tion focused especially on the fruits of the locally growing cycad palms (Kisby et al., 1992; 
Spencer et al., 1991; Duncan, 1992), because of the fact that geographic incidence rates for 
ALS are strongly correlated with concentrations of cycasin in traditional food made from the 
toxic seed of the cycad plants (Zhang et al., 1996; Kisby et al., 1992). The pathogenic effect 
of cycasin appears to be a decrease of neuronal DNA repair, along with persistent up- 
regulation of Tau mRNA expression and also enhancement of excitatory neurotoxicity 
(Esclaire et al., 1999).
Other alleged environmental risk factors for ALS include a history of trauma to the 
brain and spinal cord, exposure to radiation, electrical shocks, strenuous physical activity, 
welding or soldering materials, as well as employment in petroleum, paint or dairy 
industries. However, there have not been any consistent reports of the exogenous risk factors 
for ALS. Although, in a population study, malignancies were reported in 10% of patients 
with motor neuron disease (Gubbay et al., 1985) but this association still remains 
unexplained. Another potential etiology of ALS is thought to be long-latency viral infection 
(Giraud et al., 2000; Karpati et al., 2000). A French study using reverse transcription- 
polymerase chain reaction (RT-PCR), found enterovirus nucleic acids in 15/ 17 spinal cords 
of sporadic ALS patients (Berger et al., 2000; Woodall et al., 1994; Muir et al., 1996; 
Swanson et al., 1995; Walker et al., 2001), but in no more than 20 spinal cords examined in 
other studies (Berger et al., 2000; Woodall et al., 1994; Muir et al., 1996; Swanson et al., 
1995; Walker et al., 2001).
In conclusion, there is inconsistency in exogenous risk factors reported in ALS, 
which might imply that these risk factors do not, as such, cause the pathology. Alternatively, 
it might reflect a complex interaction between a number of environmental factors and 
specific genetic susceptibilities.
1.1.3 Genetic Risk Factors
Extensive research has been carried out into the genetic risk factors associated with 
ALS. Familial ALS (FALS) is clinically and genetically heterogeneous and has multiple 
autosomal-dominant and recessive forms. Genetic analysis of FALS has implicated the
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involvement of several genes in ALS (Table 1.1; references are not included in the table but 
are cited in the text when the gene is mentioned). For the purposes of this thesis, these genes 
will be crudely divided into two groups “major genes” and “susceptibility genes”. The genes 
referred to as “major genes” cause ALS with a clearly monogenic inheritance pattern. They 
may either predominantly lead to ALS (ALS1-ALS6) or result in multisystem 
neurodegeneration (tauopathies and ALS with dementia and Parkinsonism) with ALS 
occurring as an occasional symptom.
Those referred to as “susceptibility genes” are the genes, which may trigger the 
cascade of neurodegeneration or alternatively act as susceptibility factors for 
neurodegeneration in concurrence with environmental risk factors or other (genetic) risk 
factors.
Table 1.1 Genetics of amyotrophic lateral sclerosis (ALS)
Classification Gene Localization Inheritance
M ajor genes
ALS1 SOD1 21q22 AD/AR
ALS2 ALSin 2q33-34 AR
ALS3 Unknown AD
ALS4 9q34 AD
ALS5 15q 12-21 AR
ALS6 18q21 AD
FTDP Tau 17q AD
FTD 9q21-22 AD
Susceptibility genes
Neurofilament heavy chain NF-H 22ql2.2
Neurofilament light chain NF-L 8p21
Peripherin PRPH 12q12-13
Glutamate transporter EAAT2 11 p 13-12
Glutamate receptor AMPA 5p33
Apolipoprotein E ApoE 19q 13.2
Ciliary neurotrophic factor CNTF 11 q 12.2
Debrisoquine hydroxylase CYP2D 22q 13.1
Apurinic apyrimidinic APEX 14q11-12
Mitochondrial DNA 
Manganese superoxide dismutase
COX
SOD2 6q25
P2 blood group P2 22ql 1
Abbreviations: AD, autosomal dominant; AR, autosomal recessive
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1.1.4 Major genes
I will first discuss the monogenic forms of ALS, which show clear Mendelian 
inheritance. Seven different gene loci have been reported for FALS, and three major genes 
(SOD1, ALSin and Tau) have been identified (Table 1.1).
The difficulty of clinically distinguishing ALS from other forms of motor neuron 
disorders, particularly in patients who do not exhibit the classical signs of each disease, is 
highlighted by the occasional finding of a deletion in one of the genes for spinal muscular 
atrophy, the survival motor neuron gene SMN1 (Corcia et al., 2002), centromeric SMN2 
(Veldink et al., 2001) and the neuronal apoptosis inhibitory protein gene, NAIP, in patients 
diagnosed with sporadic and familial ALS (Parboosingh et al., 1997; Orrell et al., 1997; 
Moulard et al., 1998; Jackson et al., 1996). Additionally, =2% of male patients diagnosed 
with ALS, in fact have Kennedy disease (SBMA, X-linked spinobulbar muscular atrophy) 
brought about by a trinucleotide expansion in the androgen receptor (Garofalo et al., 1993; 
Parboosingh et al., 1997).
Autosomal-dominant inheritance of FALS transpires in approximately 5-10% of 
patients suffering from ALS and is clinically and neuropathologically indistinguishable from 
sporadic ALS (Cudkowicz et al., 1997). Dominant FALS is characterized by large intra- and 
interfamilial variability of both age of onset and disease progression. In some pedigrees, 
incomplete penetrance has been observed (de Belleroche et al., 1995; Chio et al., 1987; 
Husquinet et al., 1980; Suthers et al., 1994) and confirmed by mutation analysis (Cudkowicz 
et al., 1998).
Autosomal-dominant FALS is genetically heterogeneous and currently two genes, 
one on chromosome 21 (SOD1) and the other on chromosome 17 (TAU) as well as three 
additional loci (one on chromosome 18 and two on chromosome 9), are known (Table 1.1).
Before linkage analysis and molecular diagnosis of ALS became available through 
molecular analysis, autosomal-recessive FALS was deemed very rare. Nevertheless, three 
forms of recessive ALS have already been recognized, and the genes for two of those, SOD1
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(ALS1) and ALSin (ALS2) have now been identified. Although in the majority of cases, 
SOD1 occurs as a dominant mutation, there are a small number of SOD1 mutations, which 
are recessive as discussed later in this chapter. In total these established forms of FALS 
probably account for approximately 20-30% of all FALS cases.
1.1.4.1 ALS1 (SOD1)
In 1991 the first ALS gene (ALS1), for an autosomal-dominant form of FALS, was 
mapped to chromosome 21 q (Siddique et al., 1991) and subsequently shown to be the 
cytosolic copper-zinc superoxide dismutase (SOD1) gene two years later (Rosen et al.,
1993). Therefore, SOD1 is a major gene and an important locus for autosomal dominant 
FALS and is the focus of this thesis; it will be discussed in greater detail later, after a brief 
overview of all the other major loci.
1.1.4.2 ALS2 (ALSIN)
Autosomal-recessive FALS was initially described in a large inbred family of several 
consanguineous matings in Tunisia showing linkage to the chromosomal region 2q33-34. 
Symptoms occur in the first or second decade of life and consist of progressive spasticity of 
the limbs as well as the facial and pharyngeal muscles with individuals displaying a rela­
tively long survival of approximately 15 to 20 years (Hentati et al., 1994).
The gene for ALS2 was recently identified in Tunisian and Kuwaiti families and 
named alsin or als2 (Hadano et al., 2001; Yang et al., 2001). Alternative splicing of this gene 
generates two transcripts one short and one long. Deletions affecting both transcripts give 
rise to the ALS2 phenotype, while homozygous deletions in exon 9 and affecting only the 
short form of the protein, cause a form known as juvenile primary lateral sclerosis (JPLS). 
JPLS is even rarer than ALS2 and its phenotypic presentation involves slowly progressive 
spastic paraparesis and muscle weakness of the oro-facial and ocular muscles.
Expression of the mouse ortholog of alsin was detected in neuronal cells throughout 
the brain and spinal cord. Alsin has protein domains with similarities to both pleckstrin and
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guanine-nucleotide exchange factors (GEFs) known to activate GTPases and therefore may 
act as a regulator/activator of GTPases, and modulate microtubule assembly, membrane or­
ganization and trafficking in neurons (Majoor-Krakauer et al., 2003).
1.1.4.3 ALS3
The majority of dominant FALS has not yet been assigned to any given locus and as 
a result is given the designation of ALS3 (Siddique et al., 1991).
1.1.4.4 ALS4
A second form of autosomal-dominant FALS (ALS4) has been localized to a locus 
on chromosome 9q34 in an extended family with juvenile onset. The mean age of onset is 
17 years and the disease has slow progression without any bulbar involvement. As yet the 
ALS4 gene has not been identified. At the outset, patients show difficulty in walking, with 
subsequent weakness and wasting of muscles of the hand and distal lower extremities; 
significant proximal weakness takes place in the fourth or fifth decade of life and loss of 
useful hand function by the sixth decade. Neuropathological examination revealed degenera­
tion extending to the dorsal roots, dentate nucleus, nucleus gracilis, and inferior olivary 
nucleus (Rabin et al., 1999).
1.1.4.5 ALS5
This form of autosomal-recessive FALS possesses clinical similarities to ALS2 
(Hentati et al., 1997). ALS5 is thought to be the most prevalent form of recessive ALS, and 
was identified in several ethnic groups such as North African, South Asian, and European. 
The ALS5 gene was mapped to chromosome 15q, but as yet remains to be identified (Cox et 
al., 2000).
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1.1.4.6 ALS6
Recently, a third locus for autosomal-dominant FALS was mapped to chromosome 
18q21 in a large European family exhibiting classic adult-onset ALS (Hand et al., 2001).
1.1.4.7 Tauopathies
ALS1, ALS4 and ALS6 all represent pure forms of autosomal-dominant FALS. 
However, ALS can additionally be part of a multisystem neurodegeneration comprising the 
Tauopathies and the combination of ALS with dementia and Parkinsonism. Mutations in the 
tau gene are associated with a clinical phenotype that incorporates frontotemporal dementia, 
Pick's disease, corticobasal degeneration, and familial progressive supranuclear palsy. This 
phenotype exhibits variability both within and between different families (Wilhelmsen et al., 
1994; Stanford et al., 2000; Bird et al., 1999; Spillantini et al., 2000; Bugiani et al., 1999; 
Pastor et al., 2001). The variability of clinical symptoms implies that tau pathology may play 
a part in a large number of neurodegenerative diseases, including ALS, where 
neurofilamentous deposits consisting principally of hyperphosphorylated Tau protein 
transpire. Tau mutations were first recognized in a syndrome known as frontotemporal de­
mentia and Parkinsonism complex (FTDP) (Wilhelmsen et al., 1994; Hutton et al., 1998), 
characterized by autosomal-dominant inheritance of behavioural disturbances, reduced 
speech and memory impairment; with the possibility of Parkinsonism and amyotrophy 
occurring later during the course of the disease. The prevalence of FTDP in the 60-70years 
age-group is estimated to be about 2.8 per 100,000 population (Stevens et al., 1998). The 
proportion of families with FTDP also possessing a mutation in the tau gene varies from 
approximately 13% to 40% (Houlden et al., 1999; Rizzu et al., 1999; Poorkaj et al., 2001).
In FTDP, mutations of the tau gene have an effect on the alternative splicing of exon 
10 and as a result lead to an excess of four-repeat Tau isoforms. The four-repeat protein Tau 
isoforms may lead to neurodegeneration through reduced binding of Tau to microtubules in 
axons. This might explain the accumulation of Tau protein as hyper-phosphorylated 
neurofilaments in the cytoplasm, which results in central and peripheral axonopathy and
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triggers amyotrophy and neuronal death (Heutink, 2000; Ishihara et al., 1999; Probst et al., 
2000; Goedert et al., 1998).
Guadeloupean Parkinsonism associated with frontolimbic dementia and ALS, is also 
regarded as a tauopathy as the result of the accumulation of Tau proteins, predominantly in 
the midbrain. While no mutations in the tau gene were observed in this group of patients, all 
cases were homozygous for the HI tau haplotype (Caparros-Lefebvre et al., 2002). The Tau 
polymorphism CA3663 is associated with the ALS, dementia-parkinsonism complex of 
Guam, which indicates that Tau is not the cause of the disease but possibly acts as a 
susceptibility gene (Schmidt et al., 2001; Poorkaj et al., 2001).
1.1.4.8 ALS with dementia and Parkinsonism
The clinical phenotype of FALS can be comprised of pure ALS, multisystem 
degeneration in the tauopathies, and ALS in association with dementia and Parkinsonism. 
Some mutations in SOD1 may trigger ALS associated with dementia, as observed in a family 
with the A76T mutation (Andersen et al., 1997). Parkinsonism is observed less frequently, 
suggesting reduced toxicity of SOD1 mutations to nigrostriatal dopaminergic neurons 
(Przedborski et al., 1996). The type of ALS, which occurs in Guam, is characterized by the 
familial co-occurrence of dementia, Parkinsonism and motor neuron signs. Analysis of the 
SOD1 gene in this disease uncovered an 111 3T mutation in (two of 23 unrelated) ALS 
patients from the Kii Peninsula of Japan (Kikugawa et al., 1997; Figlewicz et al., 1994).
Other genes predisposing to age-related multisystem neurodegeneration also 
symbolize a genetic contribution to ALS. Mutations in the tau gene result in varying 
symptomatology, as recently demonstrated in the FTDP (Wilhelmsen et al., 1994; Bird et 
al., 1999; Hutton et al., 1998; Clark et al., 1998; Dumanchin et al., 1998) and in familial 
atypical progressive supranuclear palsy (Stanford et al., 2000), while the ALS- 
frontotemporal dementia complex (FTD) is linked to chromosome 9q (Table 1) (Hosier et 
al., 2000). Nevertheless, these genes do not account for all of the familial aggregation of 
ALS, dementia and Parkinsonism (Ludolph et al., 1992; Rossor et al., 2000).
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Epidemiologic studies have revealed familial aggregation of classic ALS, dementia 
and Parkinsonism, suggesting that all three disorders may have common genetic factors. A 
significant increase in the risk for dementia and also for Parkinsonism, in first- and second- 
degree relatives of ALS patients has been observed in a number of case-control studies 
(Haverkamp et al., 1995; Majoor-Krakauer et al., 1994; Deapen et al., 1986; Gunnarsson et 
al., 1992). The cumulative incidence of dementia to 90years of age was significantly higher, 
approximately 15%, in relatives of ALS patients than in relatives of controls. In addition, the 
lifetime risk for contraction of Parkinsonism is 7% for relatives of ALS patients, a two-fold 
increase compared to relatives of controls (Majoor-Krakauer et al., 1994). Epidemiologic 
data also revealed an excess of familial co-occurrence of dementia and Parkinsonism in 
families of patients suffering from ALS; with patients with sporadic ALS almost 12 times 
more likely to have relatives with Parkinsonism, if a family member had dementia than if 
there was no family history of dementia (Majoor-Krakauer et al., 2003). This excess of co­
occurrence probably indicates a genetic susceptibility to widespread neurodegeneration.
Aside from the four loci described above, there are many more genes involved in 
syndromes with ALS, dementia and/or Parkinsonism. Machado-Joseph disease exhibits 
signs of familial amyotrophy associated with Parkinsonism and spinocerebellar symptoms, 
and is brought about by expansion of trinucleotide repeats in the SCA3 gene on 
chromosome 14. Other examples of genetic disorders presenting with both pyramidal and 
extra-pyramidal symptoms are familial aggregation of motor neuron disease, tic disorder and 
parkinsonism triggered by neuroacanthosis (Vance et al., 1987; Spitz et al., 1985; Rubio et 
al., 1997), and the autosomal-dominant inherited combination of parkinsonism and 
amyotrophy (Ziegler et al., 1972; Brait et al., 1973; Alter et al., 1976; Tranchant et al.,
1992). A familial ALS-dementia complex of autosomal-recessive inheritance was reported 
in some families, including inbred Old Amish sib-ships. The latter type of ALS, is a juvenile 
form of ALS with an exceptionally long survival ranging from 9 to 27 years, and is variably 
accompanied by dementia (Staal et al., 1968; Otero Siliceo et al., 1998). Another familial 
ALS-dementia complex exhibits an autosomal-dominant pattern of inheritance (Dazzi et al., 
1969; Finlayson et al., 1973; Pinsky et al., 1975; Gunnarsson et al., 1991). The familial 
occurrence of ALS with symptoms of dementia, Parkinsonism, or other central nervous 
system (CNS) symptoms is also observed in an increasing number of different genetic
multisystem neurodegenerative disorders, such as Huntington's disease, or neuroaxonal 
dystrophy (Rosenberg, 1982; Bots et al., 1973). Hence, family histories of patients with ALS 
should be investigated in detail, not only for ALS, but also for the other often-related 
disorders of dementia and Parkinsonism.
1.2 Structure, Evolution and Expression of Superoxide Dismutase CuZn- 
SOD (SOD1)
The evolution of aerobic organisms that can survive in oxygen-rich environments 
necessitates an effective defence system against reactive oxygen species (ROS), which are 
generated following single electron reductions of molecular oxygen. While physiological 
concentrations of ROS in aerobic organisms are advantageous and involved in cell 
signalling pathways and survival from invading pathogens, an unbalanced, elevated 
concentration of ROS may play a role in the development of various diseases, such as 
atherosclerosis, cancer, diabetes, hypertension, inflammation, and premature aging.
The superoxide dismutases (SODs) are the principal and most significant line of
antioxidant enzyme defence systems against ROS and particularly the superoxide anion
radicals. Three distinct isoforms of SOD have been observed in mammals, and their
genomic structure, cDNA, and proteins have been described. Two of the isoforms of SOD
have Cu2+ and Zn2+ in their catalytic centre and are localized to either intracellular
cytoplasmic compartment (CuZn-SOD or SOD1) or to the extracellular environment (EC-
SOD or SOD3). SOD1 has a molecular mass of approximately 32,000 Da and is present in
the cytoplasm, nuclear compartments, and lysosomes of mammalian cells (Chang et al.,
1988; Keller et al., 1991; Crapo et al., 1992; Liou et al., 1993). SOD3 is the most recently
discovered and least characterized member of the SOD family and exists as a homotetramer
of molecular weight 135,000 Da with high affinity for heparin (Marklund et al., 1982).
SOD3 was initially detected in human plasma, lymph, ascites, and cerebrospinal fluids
(Marklund et al., 1982 & 1986). The pattern of expression of SOD3 is highly restricted to
these specific cell type and tissues where its activity can surpass that of SOD1 and SOD2.
The last isoform of SOD has manganese (Mn) as a cofactor and is localized to mitochondria
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of aerobic cells (Mn-SOD or SOD2) (Weisiger et al., 1973) where it exists as a 
homotetramer with an individual subunit molecular weight of about 23,000 Da (Barra et al., 
1984). SOD2 has been shown to play a role in promoting cellular differentiation and 
tumorgenesis (St. Clair et al., 1994) and in shielding against hyperoxia-induced pulmonary 
toxicity (Wispe et al., 1992).
1.2.1 Evolution of SOD
The appearance of SOD enzymes was sparked by the proliferation of photosynthetic 
organisms that started to produce oxygen about 2 billion years ago. A range of antioxidant 
enzymes evolved to offset the toxic effects of by-products of oxygen metabolism. At this 
time two major types of superoxide dismutase appeared in prokaryotes as a result, 
copper/zinc-containing SODs and iron/manganese-containing SODs. Although both types 
of enzymes perform the same function, a strong argument against a common ancestor comes 
from their completely different crystal structures, use of different metal cofactors, and 
distinctive catalytic mechanism. The evolutionary tree for CuZn containing SOD, based on 
multiple sequence alignments with structural superimpositions of crystal structures, shows 
that at early stages of evolution, before the differentiation of fungi, plants, and metazoa, 
extracellular SOD diverged from the cytosolic form (Bordo et al., 1994). The SOD1 
structural core exists as a Greek key p-barrel motif, consisting of eight p-barrels (Getzoff et 
al., 1989). Amino acid substitutions, insertions and deletions, predominantly occur outside 
of this structural motif. The theory that CuZn-SOD evolution involved gene duplication and 
fusion followed by addition of exons I and III is supported by these data. The evolutionary 
rates of CuZn- and Mn-SOD during the last billion years have differed considerably. Mn- 
SOD proteins have evolved at a relatively constant rate compared to CuZn-SODs, which 
initially evolved unusually slowly and then extremely erratically in the past 100 million 
years (Smith et al., 1992; Rodriguez-Trelles et al., 2001). Why such a peculiar evolutionary 
rate occurred still remains unclear; one possible explanation put forward suggests that 
CuZn-SOD was trapped in a "folding-block" with most changes in amino acid composition 
being deleterious (Smith et al., 1992). The accumulation of silent mutations ultimately led 
to an escape from this "evolutionary hibernation" and a return to the faster evolutionary rate. 
While the plausibility of this theory remains dubious, the existence of aerobic life on Earth
provides evidence that SOD successfully evolved as a potent protective enzyme against 
oxygen toxicity.
1.2.2 SOD1 Gene Structure
The genomic sequence for SOD1 has been identified in the mouse (Benedetto et al., 
1991), rat (Kim et al., 1993; Hsu et al., 1992) and also human (Levanon et al., 1985). The 
SOD1 gene possesses five exons and four introns and exhibits striking similarity among 
species (Figure 1.1). The TATA and CCAAT boxes, along with several highly conserved 
GC-rich regions, have been localized in all three species with a similar pattern in the 
proximal promoter region. This high level of homology in the 5-flanking sequence implies 
that evolutionary factors have preserved key regulatory regions for this gene. The 3' end of 
SOD1 gene contains several poly(A) signal sequences that result in termination and hence 
generation of mRNA species with differing lengths. The consensus sequences GTGTT and 
a G/T cluster necessary for efficient formation of 3-termini have also been located in the rat 
SOD1 gene, downstream from the polyadenylation signal. In addition, several putative 
binding sites for NF1, Spl, API, AP2, GRE, HSF, and NF-kB transcription factors have 
been found from studies of the promoter region of the human SOD1 gene (Kim et al., 1994). 
The role of the transcription factors Spl and Egr-1 has been confirmed respectively in basal 
and inducible expression of human SOD1 (Mine et al., 1999).
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Figure 1.1. The genomic organization of the three members of the human SOD gene family. SOD3 
is placed in the middle in order to demonstrate areas of amino acid sequence homology between 
SOD1 and SOD3. No significant amino acid sequence homology exists between SOD2 and either 
SOD1 or SOD3. The size of each exon and intron is shown in base pairs, in association with the 
respective fragment. The figure was adapted from Zelko et al., (2002).
1.2.3 SOD1 Chromosomal Localization and Polymorphisms
The SOD1 gene has been localized in humans to chromosome 21 (region 21q22.1)
(Levanon et al., 1985), in bovine species to chromosome 1 (lq  12-14) (Schmutz et al., 1996),
and in the mouse to chromosome 16 (region 16B4-ter) (Francke et al., 1979). Human
chromosome 21 has been intensively investigated due to the association between Down’s
syndrome and trisomy 21. Although patients with Down’s syndrome exhibit an
approximately 50% increase in SOD1 activity as a result of higher levels of SOD1 protein,
the role of the enzyme in pathology associated with the disease remains uncertain. The
increased dosage of SOD1 gene correlates with some symptoms of Down's syndrome, such
as the pathological abnormalities of tongue neuromuscular junctions (Avraham et al., 1988;
Groner et al., 1994) but cannot totally account for the development of the major symptoms
(De La Torre et al., 1996). In contrast, more than 90 different mutations in the SOD1 gene
have been linked to ALS. Although only a small proportion of patients, 2% with ALS and
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10-15% with familial ALS, have mutations in the SOD1 gene, the discovery of these 
mutations in 1993 by Rosen et al., provided the first molecular insight into the pathogenesis 
of this debilitating disorder (Rosen et al., 1993). Since this discovery, several theories have 
been put forward to explain the mechanism of motor neuron damage brought about by 
mutations in SOD1. These theories will be discussed later.
1.2.4 SOD1 Transcriptional Regulation
The transcriptional regulation of all three isoforms of superoxide dismutase is highly 
controlled and dependent on extracellular and intracellular environments.
SOD1 has a widespread distribution in a variety of cells (Crapo et al., 1992). 
Cytoplasmic SOD1 expression is stable and its activity is frequently considered as an 
internal control for SOD1 gene expression.
1.2.5 Stimuli upregulating SOD1 expression
Although SOD1 is considered to be constitutively expressed, various physiological 
conditions can dramatically regulate its mRNA levels. A wide array of mechanical, 
chemical, and biological messengers such as heat shock (Hass et al., 1988; Yoo et al., 1999), 
shear stress (Inoue et al., 1996; Dimmeler et al., 1999), UVB- and X-irradiation (Isoherranen 
et al., 1997; Leecia et al., 2001; Yamaoka et al., 1994), heavy metals (Yoo et al., 1999), 
hydrogen peroxide (Yoo et al., 1999), ozone (Rahman et al., 1991), nitric oxide (Frank et al., 
2000), arachidonic acid (Yoo et al., 1999), and xenochemicals such as (3-naphthoflavone, t- 
butyl-hydroquinone, iodoacetamide (Yoo et al., 1999), 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(Cho et al., 2001), and phenobarbital (Ueda et al., 2002) result in elevation of SOD1 mRNA 
levels. Proximal promoter region analysis reveals Spl/Egr-l/WT-1 binding sites that are 
involved in basal and TPA inducible expression of SOD 1 (Mine et al., 1999) in addition to 
C/EBP cis-acting elements (Seo et al., 1996 & 1997), which are important for high-level 
expression in rat liver cells (Kim et al., 1997). SOD1 expression can also be prompted by 
ginseng saponins through activation of the transcription factor AP2 (Kim et al., 1996). 
Inside cells, metal ions are a potent source for the large-scale catalysis and generation of
ROS. In order to neutralize their harmful effects, the synthesis of SOD1 in the cell is 
increased through the metal responsive element located in the 5'-flanking region (Yoo et al., 
1999).
1.2.6 Stimuli down regulating SOD1 expression
SOD1 downregulation has been shown in alveolar type II epithelial cells and lung 
fibroblasts following exposure to hypoxia (Jackson et al., 1996). Mitomycin C, an anticancer 
drug, also suppresses the transcription of SOD 1 gene in human hepatoma HepG2 cells (Cho 
et al., 1997).
1.2.7 SOD1 Structure and Activities
Genetic analysis of Familial ALS has yielded seven loci and one disease gene SOD1 
as mentioned previously. Initially a role for free radicals was suggested in the disease 
process, although the mechanism by which the mutant brings about toxicity remains 
uncertain. Oxygen free radicals such as the superoxide anion (O2 ), the hydroxyl radical 
( OH), and other reactive oxygen species such as hydrogen peroxide (H2O2) and nitric oxide 
(NO), are generated in the cell by a number of metabolic reactions (Fullerton et al., 1998). 
The most important defence against the production of excessive free radicals is the 
collective action of three enzymes: superoxide dismutase (SOD), glutathione peroxidase, 
and catalase. SOD catalyses the conversion of superoxide to H2O2 and glutathione 
peroxidase and catalase then convert H2O2 to water (Brown, 1997). However, in the 
presence of NO, superoxide can form peroxynitrite (ONOO ), which can subsequently react 
to produce hydroxyl radicals. Superoxide is produced as a result of normal cellular 
metabolism and is extremely toxic, disrupting cellular activity by attacking membrane lipids, 
proteins, and DNA (Fullerton et al., 1998).
Prior to its association with FALS, SOD1 had been intensively investigated due to its 
biological importance as an antioxidant. SOD1 is an abundant protein comprising 
approximately 1% of total cytosolic protein (Bredesen et al., 1996) and is constitutively 
expressed in all cells in eukaryotes and highly conserved through evolution (Brown, 1997).
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The gene for human SOD1 is located on chromosome 21q22.1, spanning approximately 11 
kb of DNA (Andersen, 1997). It has five exons and yields a 153-amino-acid, 16-kDa protein 
that functions as a homodimer.
• j i  *7+
Each subunit holds one atom of both Cu and Zn within what is described as a 
cave-like active site (Siddique et al., 1996). The polypeptide chain is folded into a flattened 
cylinder of eight strands of anti-parallel [3-structure, which are arranged in two interlocking 
Greek key motifs forming the p-barrel. Two large non-helical loops extend from both the 
top and bottom of the p-barrel, with one containing most of the residues necessary for
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electrostatic guidance of O *, and other contributing to the dimer interface. The active site is 
located at one end of the P-barrel, with an opening facing out and away from the p-barrel 
and away from the other subunit, so the active sites are positioned in such a way that they 
are at opposite sides of the enzyme. The SOD1 dimer is extremely stable as a result of 
strong hydrophobic interactions and in addition the dimerization doubles the dismutase 
activity. Superoxide is steered toward the active site containing the Cu2+ atom through a
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positively charged channel (Siddique et al., 1996). The Zn is involved in maintaining pH 
stability of the dismutation reaction and also in the speedy dissociation of the H2O2 
generated, which can slowly inactivate SOD1 (Andersen, 1997). Access to the active site is 
limited by size and charge of the molecules, favouring 0 2‘ and excluding other larger 
molecules (Siddique et al., 1996). In addition to dismutase activity, SOD1 has a peroxidase 
function, catalysing oxidative reactions of substrates by hydrogen peroxide.
1.3 ALS Mutations of SOD1
An initial study of 13 autosomal dominant ALS families, carried out to establish a
causal link between the SOD1 gene and FALS, identified a total of 11 missense mutations in
two exons (Rosen et al., 1993). This discovery resulted in an explosion of SOD1 gene
screening in ALS pedigrees. At present, more than 90 different mutations occurring in all
five exons of this gene have been identified (Cudkowicz et al., 1997). There is a database
that lists all the SOD1 ALS mutations described (www.alsod.org). All of these mutations in
S0D1 are associated with the autosomal-dominant form of FALS, with the exception of two
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- D90A and D96N - which can cause both dominant and recessive ALS depending on the 
ancestry of the individual concerned; those individuals of Scandinavian ancestry with D90A 
and D96N SOD1 mutations generally display the recessive form of the disease whereas 
others display the dominant form (Andersen et al., 1995; Robberecht et al., 1996; Orrell, 
2000; Hand et al., 2001).
SOD1 mutations have been detected in 195/916 families exhibiting the autosomal- 
dominant form of ALS, suggesting that SOD1 is implicated in ± 21% (range 13-84%) of 
dominant FALS cases (Cudkowicz et al., 1997; Rosen et al., 1993; Jones et al., 1995; 
Pramatarova et al., 1994; Andersen et al., 1997; Juneja et al., 1997; Orrell et al., 1997 & 
1999; Aguirre et al., 1999). Additionally, 112 of 946 patients (or about 12%, range 2.5-23%) 
with apparently sporadic ALS were heterozygous for a SOD1 mutation (n=l 12) (Andersen et 
al., 1996; Cudkowicz et al., 1997; Jackson et al., 1997; Orrell et al., 1997). The mutation 
pattern in sporadic ALS cases is similar to that observed in FALS cases (Radunovic et al., 
1996; Hayward et al., 1996). Sporadic ALS, which results as a consequence of a SOD1 
mutation, may represent a new dominant mutation, or incomplete penetrance of a dominant 
mutation in the parents. A number of the SOD1 mutations occur as recurrent mutations or as 
founder mutations, occasionally having a worldwide distribution.
One confirmed autosomal recessive mutation, which has been documented, is the 
D90A mutation in exon 4. This missense mutation, involving an A to C transversion, results 
in the substitution of aspartic acid for alanine at codon 90, and can cause ALS, both in the 
homozygous state or in the compound heterozygous state with the D96N mutation (Hand et 
al., 2001; Mezei et al., 1999). The recessive inheritance of the D90A mutation has been 
documented largely in Scandinavian families (Andersen et al., 1995, 1996 & 1997). In other 
parts of the world, the D90A mutation is not a common cause of recessive FALS and in the 
heterozygous state typically results in the dominant form of ALS (Robberecht et al., 1996; 
Aguirre et al., 1999; Jackson et al., 1997; Radunovic et al., 1996; Khoris et al., 2000; Morita 
et al., 1996). Homozygotes for this mutation, in the Northern Scandinavian population, 
exhibit a uniform disease phenotype with insidious onset, mean age of onset of 44 years, 
ranging from 20-94. The slowly ascending paresis commences distally in the lower 
extremities and has relatively slow progression with a mean survival of about 14 years)
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(Aguirre et al., 1999; Andersen et al., 1996). In the population of northern Sweden and 
Finland, this type of ALS1 accounts for 9.6% (44/451) of ALS cases (Andersen et al., 1997; 
Sjalander et al., 1995), in addition a 10-fold increase in the allele frequency of the D90A 
mutation was found (1-2%) in this population (Andersen et al., 1996; Harris et al., 1974). A 
study of 28 recessive D90A pedigrees demonstrated that 20 families shared the same 
founder haplotype (Al-Chalabi et al., 1998), while a number of founders were detected in 
eight families with the dominant D90A mutation. Hence, it was proposed that there may be a 
protective factor that is tightly linked to the mutation in SOD1 in the genetically, rather 
homogenous, northern Scandinavian population which reduces susceptibility to ALS; this 
would also explain the very long disease duration in the Scandinavian patients.
Hand et al., (2001) also reported an ALS family in which affected individuals carried 
both a single copy of the SOD1 D90A recessive mutation and also a copy of a novel 
mutation D96N; this is the first description of compound heterozygosity in ALS and SOD1. 
The D96N mutation has been proposed to be another recessive mutation (Hand et al., 2001). 
An affected individual homozygous for the L84F mutation has been described, however, as 
yet, no further evidence exists that indicates this is a recessive mutation (Boukaftane et al.,
1998).
So far, of the alterations identified in the SOD1 gene, the majority are base 
substitutions resulting in missense mutations. Three exonic insertions (Andersen et al., 
1997; Jackson et al., 1997; Kato et al., 1996) and one exonic deletion (Pramatarova et al.,
1994), which result in premature termination of the protein, have been described. 
Structurally, the earliest of these alterations takes place at the last codon of exon 4 (Jackson 
et al., 1997), with others lying within exon 5, so even though the protein is truncated only 
the last exon is lost. Importantly, exon 3, which encodes the active site, remains unaffected. 
Besides the ALS associated mutations, a number of variants and polymorphisms have been 
identified (Orrell, 2000). Initially, it was speculated as a result of the failure to detect 
mutations in exon 3, that as it encoded the active site, it was privileged from mutations and, 
so far, only three have been reported (Andersen et al., 1997; Boukaftane et al., 1998; Orrell 
et al., 1997). Only approximately 10-20% of ALS families carry SOD1 mutations (Camu et 
al., 1999), which reflects existence of families that do not link to chromosome 21 or ALS3
locus. Mutations have also been detected in sporadic ALS cases; however it is not clear as 
to whether all of these are truly sporadic. No mutations have been detected in individuals 
with the form of ALS seen in the Chamorro people of Guam (Figlewicz et al., 1994).
Recent investigations have focused on the question of which is the common 
denominator, the toxic function common to so many different mutant proteins - if indeed 
such a common denominator actually exists. Theoretical analysis based exclusively on 
molecular models predicts that biochemical properties of the mutant enzymes would be 
either affected dramatically or only secondarily depending on the single mutation 
investigated. Although so far, only a very limited subset of FALS-SODls has been 
investigated (Hayward et al., 2002; Rodriguez et al., 2002; Tiwari et al., 2003), experimental 
data acquired with recombinant proteins or in vivo implies that a certain degree of 
heterogeneity exists among mutations. Consequently, the mechanisms through which 
expression of the mutant SOD1 enzymes result in motoneuron injury and death remain con­
troversial. It is believed, on the whole, that the gain of a novel toxic function by the SOD1 
enzyme is responsible for the acquisition of the pathological phenotype. As to whether this 
function resides (1) in the tendency of mutant enzymes (as a consequence of either alteration 
of the p-barrel structure or disruption of the dimer interface) to form insoluble aggregates 
thereby obstructing intracellular functions, or (2) in a novel enzyme activity (as a 
consequence of alteration of the metal-binding active site), or (3) in disruption of metal 
homeostasis is presently debated.
As mentioned previously, SOD1 is an abundant component of many cell types, and 
accounts for up to 1% of total cytoplasmic proteins in some areas of the CNS (Pardo et al., 
1995). It has been proposed that formation of insoluble aggregates of misfolded mutant 
SOD1 may play a part in FALS associated cell death, in a fashion similar to that which 
occurs in other neurodegenerative "conformational" diseases. As to whether SOD1 
aggregates symbolize a cause, a correlate or a consequence of processes leading to cell death 
is still debated (Brown, 1998). Neurons and astrocytes of SALS patients are known to 
contain cytoplasmic aggregates that exhibit immunoreactivity for SOD1 and ubiquitin 
similar to inclusion bodies observed in SOD 1-linked FALS patients (Bruijn et al., 1998). 
SOD 1-associated FALS mutants have altered solubility and enhanced stability as a result of
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inhibition of the degradation activity of proteasomes (Shinder et al., 2001). Recently, the 
relevance of SOD1 aggregates in FALS pathology has been questioned, with for instance, 
reports that the formation of SOD1 aggregates is independent of induction of cell death (Lee 
et al., 2002; Takeuchi et al., 2002).
The toxicity of SOD 1 aggregates may arise either through the sequestration of other 
proteins required for neuronal function or through impairment of transport of other 
substrates vital for neuronal viability (Julien, 2001). In addition, SOD1 aggregates may 
reduce proteasome activity required for normal protein turnover (Urushitani et al., 2002). 
This may be critical, given that the proteasome not only plays a part in the degradation of 
misfolded proteins, but also in the regulation of transcription factors.
1.3.1 Clinical Differences of Different Mutations.
The most common FALS mutation, an alanine to valine shift at codon 4 (A4V), is 
coincidently the first within the SOD1 gene and accounts for 50% of all reported mutations 
in North America (Rowland, 1998). This mutation results in the most aggressive form of 
FALS, and exhibits an unusually short survival of only 1.5 years compared to the histidine 
to arginine shift at position 46 (H46R) which has an average life expectancy of 18 years 
following disease onset (Ratovitski et al., 1999).
A study carried out by Cudkowicz et al. (1997) of FALS-associated-SODl mutations 
established a number of findings. Firstly it was established that SOD1 mutations are 
specific to FALS. On the whole, FALS with or without SOD1 mutations are clinically 
similar but the age of onset in FALS with a SOD1 mutation is slightly earlier, with a mean 
age of 46.9 years compared to non-SODl patients where the mean age is 50.5 years 
(Cudkowicz et al., 1997). However, some clinical characteristics of SOD1 FALS cases 
depend on the specific mutation, for example, upper motor neuron signs are always absent in 
SOD1 A4V cases (Cudkowicz et al., 1998). Mutations are found in approximately 23% of 
families, highlighting the possible existence of at least one more disease gene.
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There is a sizeable variation in disease severity as measured by age at symptom onset 
and disease duration. Of all the clinical variables tested, bulbar onset and two specific 
mutations were demonstrated to modulate age of onset or survival. Generally bulbar-onset 
patients are older when their illness begins whereas individuals with the G37R and L38V 
mutations display an earlier age of onset. In terms of survival, the A4V mutation is 
associated with shorter survival, compared to mutations G37R, G41D, and G93A, which 
predict longer disease duration. It is important to note that mutations that predict earlier 
disease onset such as G37R and L38V are not the same as those that are associated with 
shorter duration of disease, such as A4V, suggesting that the factors that modulate timing of 
disease differ from those implicated in rate of progression of the disease (Cudkowicz et al., 
1997).
Age of onset varies with mutations, for instance the mutation LI06V is associated 
with the earliest onset and has a mean age of 35.5 years and II13T has the latest onset with a 
mean age of 58.9 years (Cudkowicz et al., 1997). The fact that II13T was found to have the 
latest age of onset may in some way account for the finding of this mutation in many 
apparently sporadic ALS cases (Deng et al., 1995; Jones et al., 1993 & 1994). It is possible 
that relatives of these apparently sporadic cases died before reaching this late age of onset, 
as a result eliminating any family history. Nevertheless, other SOD1 mutations have also 
been identified in SALS (Orrell, 2000).
The first study of the structural location of FALS mutations within SOD1 revealed 
from the 12 mutations investigated that the mutations altered conserved interactions crucial 
to structural folding and dimer contact, rather than catalysis (Deng et al., 1993). Thus far, 
the majority of mutations have been found to affect the backbone of the protein or regions 
involved in dimerization of the two subunits. The position and type of amino acid 
modification may determine the potential effect on the protein and its function. The H46R 
and H48Q mutations are two interesting mutations that have been detected in highly 
conserved residues within the copper-binding domain. The H46R mutation has been 
described in Japanese ALS families and is associated with a slowly progressive phenotype 
and a relatively long survival of approximately 17.3 years (Aoki et al., 1993). In 
comparison, in a British ALS family the nearby residue 48 is mutated; this H48Q shift is
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associated with a severe phenotype with rapid progression and a very short survival, of only 
8 months (Enayat et al., 1995; Shaw et al., 1997). The markedly different effect of these two 
mutations accentuates the point that SOD1 mutations have quite varied effects on phenotype 
and prognosis (Enayat et al., 1995; Orrell et al., 1999).
1.3.2 Effect of SOD1 Mutations
The discovery of the association between SOD1 mutations and ALS led to a lot of 
speculation as to the mechanism by which the mutant SOD1 could trigger ALS. Initially, 
given the crucial role of SOD1 in detoxifying free radicals, it was attractive to propose that 
mutations in the enzyme resulted in reduced activity, thus permitting the cellular 
accumulation of harmful superoxide (Rosen et al., 1993). There have been reports of 
reduced SOD1 activity in the cerebrospinal fluid (CSF) of ALS patients (Bracco et al., 1991) 
and free radicals have been implicated in neuronal injury in several neurological disorders 
(Rosen et al., 1993). Alternatively, it was thought that overactive mutant SOD might 
produce excessive amounts of hydrogen peroxide, which may be rapidly converted, in the 
presence of ferrous ions, to the more toxic hydroxyl radical (Fullerton et al., 1998; Imlay et 
al., 1988). A dominant negative effect would mean that not only would the mutant be 
dysfunctional, but also additionally it could impair the activity of the normal enzyme, 
resulting in a reduction in activity of more than 50% (Deng et al., 1993). On the other hand, 
a mutation could cause the enzyme to gain a function. However, none of these hypotheses 
addressed how a ubiquitously expressed gene could result in such selective motor neuron 
death.
An initial approach undertaken to answer these questions was to determine the 
activity of the mutant SOD1. Analysis of red blood cell enzyme activity of six individuals 
with different SOD1 mutations, established average mutant activity to be less than half 
(41%) that of controls, providing support for the dominant negative theory (Deng et al.,
1993). A study by Rosen et al. (1994) on the A4V SOD1 mutation, which results in a 
clinically severe FALS phenotype, found that in lymphoblastoid cell lines the SOD1 enzyme 
activity was 50% that of normal; protein levels were reduced compared to normals, but not
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to 50%. In sporadic ALS cases and FALS cases without SOD1 mutations activities were 
normal (Garofalo et al., 1995).
Not all FALS mutations bring about a decrease in SOD 1 activity, as demonstrated by 
the study of the G37R mutation, which retains full specific activity, but displays a two-fold 
reduction in polypeptide stability, resulting in an overall reduction to 40-60% of normal 
enzyme activity. The G85R SOD1 mutation, on the other hand, results in the production of 
an inactive protein. In order to assess the influence of the mutant on the stability or activity 
of the normal enzyme, SOD1 mutants with reduced half-life and reduced free radical 
scavenging abilities were expressed with normal SOD1. Normal subunits were found to be 
unaffected in activity or half-life (Borchelt et al., 1995). In general, enzymes are present in 
excess amounts. Therefore one cannot help but wonder how, especially in the case of SOD 
where three isoforms of the enzyme are found to be present, such a slight reduction is 
sufficient to produce disease. Loss of function mutations commonly produce autosomal 
recessive phenotypes, and even in heterozygous carriers of recessive mutation where 50% 
reduction of enzyme is found, individuals are clinically unaffected. As a result of the 
difficulty in reproducing erythrocyte and CSF enzyme activity results (Rowland, 1995), 
transgenic mice expressing wild type and mutant forms of human SOD1 have been 
developed as models for ALS.
Mice expressing mutant G93A-SOD1 developed motor neuron disease that was not 
observed in mice expressing wild-type SOD1 at similar levels (Gurney et al., 1994). In mice, 
expression of G86R-SOD1 mutation, which corresponds to human G85R, resulted in motor 
neuron degeneration, even though there was no reduction in activity of SOD (Ripps et al.,
1995). It was shown by Wong and colleagues (Wong et al., 1995) that although transgenic 
mice expressing human G37R-SOD1 develop severe motor neuron disease, mice expressing 
the wild-type human SOD1 gene at similar and higher levels do not exhibit the disease state. 
In addition, another important study created mice completely deficient for the SOD1 enzyme 
by deletion of the entire coding sequence of mouse SOD1 gene (Reaume et al., 1996). These 
animals develop normally and exhibit no signs of motor neuron disease; however they 
exhibit increased vulnerability to motor neuron loss following axonal injury, suggesting that 
SOD1 may play a larger role in situations of injury as opposed to development and function 
(Siddique et al., 1996). This suggests that motor neuron death comes about as a result of
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mutant-mediated toxicity as shown by the development of disease in transgenic mice with 
mutant SOD1 in the absence or elevation of wild-type SOD1 (Bruijn et al., 1998). Yeast 
mutants null for SOD1 enzyme were rescued just as efficiently by FALS-associated SOD1 
mutants as by wild type, substantiating the activity of the mutant enzyme (Rabizadeh et al.,
1995).
In neuronal cells, over-expression of wild-type SOD1 inhibits apoptosis whereas 
over-expression of FALS-associated SOD 1-mutants promotes apoptosis, supporting a gain- 
of-function effect (Rabizadeh et al., 1995). Additionally, it was observed that no SOD1 null 
mutations had been found in FALS patients as would be the case if loss of activity had been 
the cause of the disease (Brown, 1995). All this observed and experimental evidence gave 
support to the concept that FALS is caused not as a result of loss or reduction in SOD1 
activity, but rather by the acquisition of a harmful toxic property by the mutant enzyme.
1.3.3 Proposed Toxicity of Mutant SOD1
Three of the properties of mutant SOD1 that have been investigated include altered 
substrate reactivity, metal toxicity, and abnormal interactions with proteins. Altered 
reactivity for certain substrates has been observed for mutant SOD1 enzyme. Dismutase 
activity of FALS-associated SOD1 mutants is normal but peroxidase activity is enhanced 
(Wiedau-Pazos et al., 1996; Yim et al., 1996). The peroxidase reaction is copper-dependent 
as the mutant reaction is more sensitive to inhibition by copper chelators than the wild-type 
enzymes. X-ray crystallographic studies have revealed the active channel of FALS mutants 
to be slightly larger than the wild type, providing support to the theory that H2O2 now has 
access to the mutant enzyme (Yim et al., 1996). The subsequently generated hydroxyl 
radical has a number of possible fates, either it may react with a histidine residue within the 
active site, thus inactivating the enzyme or it could react with molecules within the active 
site, or simply exit the active site and react with other molecules (Bredesen et al., 1996).
Following the discovery of FALS mutations in the SOD1 gene, it was thought that as 
a dominant disorder, mutations would bring about at most a 50% reduction in SOD1 
activity, thus doubling the steady-state concentration of superoxide within the cell.
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Superoxide reacts with nitric oxide in a reaction that is three times faster than that with wild- 
type SOD1 resulting in the formation of peroxynitrite, which in turn can then form 
nitronium-like intermediates capable of nitrating tyrosine residues (Beckman et al., 1993). 
Increased nitrotyrosine levels have been reported in sporadic and familial ALS cases as well 
as in animals (Abe et al., 1995; Beal et al., 1997; Ferrante et al., 1997).
It has been shown that mutant SOD1 has reduced stability (Alexianu et al., 1998) 
which could mean that there may be reduced buffering of copper and zinc, both of which 
can be neurotoxic (Brown, 1995). The H46R and H48Q SOD1 mutations directly affect 
copper-binding ligands and consequently these mutants cannot bind any copper (Casareno et 
al., 1998; Siddique et al., 1996). The zinc-binding site of the enzyme can be dramatically 
altered by FALS mutants, consequently enabling the mutant to influence the redox 
behaviour of the enzyme (Lyons et al., 1996). Interestingly, it is thought that mutations 
throughout the entire protein may have this same effect on the zinc-binding site thereby 
accounting for the fact that so many different mutations can yield a common toxic property. 
The affinity for zinc in the mutant enzyme is thought to be reduced by up to 30-fold in 
comparison to wild-type (Crow et al., 1997). Nevertheless, measurements of concentrations 
of total copper and zinc in both sporadic and familial ALS cases with a range of controls did 
not uncover any relationship between free Cu and Zn with disease, severity, age of disease 
onset, or SOD1 activity (Cha et al., 2000).
The instability of the mutated protein may be sufficient for the mutant protein to 
precipitate and form toxic aggregates (Brown, 1995). This is important considering that 
SOD1 represents approximately 1% of cytosolic protein therefore changes in folding, 
solubility, or degradation of such an abundant protein may potentially result in aggregates. 
This is consistent with the detection of SOD1 immunoreactive inclusion bodies in motor 
neurons expressing mutant SOD1 but not with wild-type SOD1 (Bredesen et al., 1996; 
Bruijn et al., 1998; Durham et al., 1997). A recent study in a mutant SOD1 mouse model of 
ALS has shown aggregation and formation of inclusion bodies, to be distinct processes 
(Bracco et al., 1991). In addition, aggregation is seen as an early event in disease 
pathogenesis and may be used as a biochemical marker, whereas inclusion-body formation
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takes place later via microtubule retrograde transport and is detectable only after 
manifestation of the disease.
Mutant SOD1 displays at least two novel protein interactions, which can be detected 
by a yeast interaction trap system (Kunst et al., 1997). One is with Lysyl-tRNA synthase 
(KARS), which is involved in protein synthesis and the other with translocon-associated 
protein delta (TRAP-5), which is involved in transport of newly synthesized proteins into 
the endoplasmic reticulum. It is believed that interaction between mutant SOD1 and either 
of these proteins could result in abnormal localization or function and as a result prevent the 
transfer of important proteins essential to cell survival or even lead to formation of 
aggregates; this may divert the actions of chaperones from other important processes and 
lead to dire consequences.
1.4 Mechanisms of motor neuron degeneration in ALS
Several mechanisms for the degeneration of motor neurons in ALS have been put 
forward. In this section I will discuss the mechanisms most relevant to familial ALS, which 
are oxidative stress, copper toxicity, neurofilaments, glutamate excitotoxicity, apoptosis, and 
the basis of selectivity of cell death.
1.4.1 Oxidative Stress
Oxidative stress is the condition which arises as a result of an imbalance between the
physiological production of potentially toxic reactive oxygen species (ROS) such as
superoxide, hydrogen peroxide and hydroxyl radical which are products of normal
metabolism of molecular oxygen (Coyle et al., 1993) and the physiological scavenging
activities. These include enzymatic activities (superoxide dismutase, catalase, peroxidase
and peroxiredoxin), low molecular weight antioxidant species (Vitamin E, ascorbate,
glutathione), in addition to more complex forms of protection such as systems for transport
and buffering of metals and induction of transcription factors. Intracellular antioxidant
defence can be thought of as acting at three levels: prevention of damage, i.e. prevention of
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electron leakage which results in generation of ROS; interception of potentially dangerous 
ROS, i.e. scavenging by antioxidant molecules; and repair of damage, i.e. removal of 
molecules which have been damaged by ROS (Aimer et al., 2001 & 2002). In this process, 
the proper handling of transition metal ions such as copper and iron is essential, as these 
metals are able to undergo redox cycling and as a result generate toxic ROS.
Different tissues differ in their susceptibility to oxidative stress. The central nervous 
system (CNS) is particularly sensitive to this type of damage for several reasons such as low 
levels of a number of antioxidant enzymes (catalase and GSH-peroxidase); a high content of 
easily oxidised substrates (e.g. membrane polyunsaturated lipids); and an inherently high 
flux of ROS generated through neurochemical reactions such as dopamine oxidation 
(Halliwell, 1992). Oxidative stress in nervous tissue can be detrimental as a result of several 
interacting mechanisms, including direct damage to vital molecular species, increase in free 
intracellular Ca and release of excitatory amino acids.
A role for ROS-mediated oxidative stress in ALS, was put forward by a number of 
investigators who reported elevation of typical oxidation products such as malondialdehyde, 
hydroxynonenal, oxidised proteins, DNA and membrane phospholipids in both sporadic and 
familial ALS patients, as well as in several model systems (Andrus et al., 1998; Beal et al., 
1997; Bogdanov et al., 2000; Bogdanov et al., 1998; Ferrante et al., 1997; Fitzmaurice et al., 
1996; Gurney et al., 1994; Hall et al., 1998; Liu et al., 1998; Liu et al., 1999; Rizzardini et 
al., 2003; Shaw et al., 1995; Shibata et al., 2001).
Damage brought about by free radicals may become prominent in mitochondria, 
where the majority of the cellular production of ROS occurs and whose harmful effects are 
directed toward mitochondrial proteins, lipids, as well as mitochondrial DNA. Almost all of 
the energy of the brain is derived from oxidative metabolism of the mitochondrial 
respiratory chain. Brain mitochondria are particularly vulnerable to oxidative damage as a 
result of the extensive generation of cellular oxidants by this organ. There exists a 
considerable amount of evidence of mitochondria damage in both SALS and FALS patients 
(Beal, 2000; Borthwick et al., 1999; Brown, 1998; Curti et al., 1996; Dhaliwal et al., 2000; 
Fujita et al., 1996; Nakano et al., 1987; Swerdlow et al., 1998) that can be ascribed to
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intracellular oxidative stress. Such damage may lead to the triggering of apoptotic cell death 
of motor neurones, thought to take place in ALS (Guegan et al., 2001; Martin, 1999). ROS 
are extremely well known inducers of cell death and are known to regulate both early and 
late stages of apoptosis; protection against apoptosis can be achieved through inhibition of 
ROS production (Fleury et al., 2002).
Reactive oxygen species (ROS) have also been implicated in aging and 
overexpression of SOD1, and SOD/catalase mimetics have been found to dramatically 
extend lifespan in both Drosophila (Parkes et al., 1998) and C. elegans (Melov et al., 2000). 
Evidence suggests an age-related accumulation in oxidative damage to DNA, and in 
particular mitochondrial DNA, in the brain (Mecocci et al., 1993). The oxidative stress 
theory provides an attractive explanation for ALS, because it accounts for cumulative 
damage in a late-onset, progressive disease as well as places the major target for damage as 
the central nervous system. The argument for oxidative stress as a mechanism of disease is 
strengthened by the finding of mutations in the Cu, Zn superoxide dismutase (SOD1) gene 
in a number of FALS cases (Deng et al., 1993; Rosen et al., 1993). A reduction in SOD1 
activity does not cause ALS, some SOD1 FALS mutants have reduced free radical 
scavenging ability (Borchelt et al., 1995), and chronic inhibition of SOD1 activity leads to 
motor neuron degeneration, reversed by treatment with antioxidants (Rothstein et al., 1994).
The spontaneous reaction of superoxide with nitric oxide leads to the formation of 
peroxynitrite and the subsequent formation of highly reactive nitronium intermediates 
capable of nitrating tyrosine groups of proteins and forming the stable 3-nitrotyrosine 
compound (Beckman et al., 1993; Cha et al., 2000). It is thought that nitric oxide is not 
present in motor neurons, but NOS is induced following injury (Bruijn et al., 1997). 
Increased levels of nitrotyrosine have been reported in sporadic and familial ALS cases as 
well as in animals (Abe et al., 1995; Beal et al., 1997; Ferrante et al., 1997; Tohgi et al.,
1999). In vivo evidence of increased tyrosine nitration, which is coincident with the earliest 
pathological abnormalities, comes from studies of 3-nitrotyrosine levels in SOD1 G37R 
mouse. Nonetheless, no increase in protein-bound nitrotyrosine was detected at any stage 
(Bruijn et al., 1997).
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There is other evidence of oxidative pathology in the disease besides elevated levels 
of nitrosylated proteins such as an increase in damage to protein (Shaw et al., 1995), DNA, 
and phospholipids (Bogdanov et al., 2000; Ferrante et al., 1997; Smith et al., 1998). 
Furthermore, there is an increase in metallothionein immunoreactivity in ALS (Sillevis 
Smitt et al., 1992). Metallothionein functions in metal homeostasis (in particular Zn2+) and 
detoxification, as well as in free radical scavenging. The increases in ALS are believed to 
be local, possibly as a result of slower breakdown (Blaauwgeers et al., 1996; Radunovic et 
al., 1997).
On the other hand, the ability of SOD1 mutants to utilise H2O2 as a substrate,
9 4 -probably as a result of increased availability of the Cu site, may result in generation of 
hydroxyl radicals and cellular damage. The most reactive species, which is the hydroxyl 
radical, is not generated directly by any known enzymatic reaction, but H2O2 slowly 
decomposes to OH, a reaction that is accelerated in the presence of Fe2+ (Coyle et al., 1993). 
A number of SOD1 mutations have exhibited enhanced copper-dependent peroxidase 
activity (Bogdanov et al., 1998; Liu et al., 1998; Wiedau-Pazos et al., 1996; Yim et al.,
1996), although this finding has been disputed by some reports (Singh et al., 1998). 
Alterations in the structure of SOD1 mutants suggest that H2O2 has access to the mutant 
enzyme (Yim et al., 1996). ALS associated mutant SOD1 has reduced zinc affinity 
compared to NF subunits which possess a high affinity that is sufficient enough to remove 
zinc from SOD. This may as a result lead to a reduction in superoxide scavenging and 
increased catalysis of tyrosine nitration by peroxynitrite (Crow et al., 1997).
Other lines of evidence suggest that novel properties of the FALS-associated SOD1 
mutant enzyme involve imbalance of ROS. It remains unclear as to how mutant SOD1 
causes oxidative stress, and which molecules represent direct targets/propagators of damage, 
however evidence is accumulating in relation to the role of SOD 1-bound copper ions in 
mediating oxidative damage toward other proteins, for instance those involved in 
mechanisms of intracellular signal transduction (Casciati et al., 2002; Ferri et al., 2001; 
Volkel et al., 2001).
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FALS-associated SOD1 mutants may elicit an imbalance of ROS metabolism as a 
result of their imperfect folding, possibly leading to a loosening of protein structure; this 
would in turn result in the modification of the active site and alteration in the substrate 
specificity of the enzyme. For instance, as suggested by studies in vitro (Wiedau-Pazos et 
al., 1996) and in vivo in yeast (Roe et al., 2002), modification of copper geometry at the 
active site could exacerbate the reported peroxidative activity of SOD1.
It is not clear as to whether elevated oxidative stress and protein aggregation are 
causally connected. In addition, it is not known whether FALS-associated mutant SOD1 
proteins found in aggregates are modified (cleaved, oxidised, de-metallated or otherwise 
covalently modified) (Valentine, 2002). It is possible that aggregation of protein is caused 
by the increased oxidative reactivity of misfolded mutant SOD1 or that the aggregates 
themselves are the mediators of the oxidative reactions. AGE-modified FALS-associated 
SOD1 has been detected both in neuronal Lewy body-like hyaline inclusions as well as 
astrocytic hyaline inclusions of FALS patients and transgenic mice (Valentine, 2002). 
Additionally, it has been suggested that mutant SOD1 that is aggregated, but still active, 
may mediate the formation of ROS. It has also been proposed that misfolded SOD1 may 
contribute to generation of intracellular ROS by loss of the ability to buffer copper.
There are several defence mechanisms committed to reducing the levels of oxidants 
such as SOD, catalase, ascorbic acid (vitamin C), and a-tocopherol (vitamin E). An 
imbalance between oxidant and antioxidant mechanisms may result in neuronal damage, as 
observed in vitamin E deficiency, which may lead to neurological symptoms (Coyle et al.,
1993). In ALS, the benefit of antioxidants was demonstrated by vitamin E treatment of 
transgenic SOD1 mutant mice (Gumey et al., 1996) as well as in cell cultures (Troy et al.,
1994). Clinical trials of antioxidants however, have been rare and not as successful as 
expected. No increased survival was observed in ALS patients on treatment with a selection 
of free radical scavenging antioxidants (Louwerse et al., 1995; Vyth et al., 1996). Given the 
evidence of oxidative damage, these conflicting data could be the result of incorrect dosing, 
inappropriate patient selection, or choice of antioxidant for the particular disease under 
consideration (Delanty et al., 2000). Furthermore, it is very likely that the complex 
biochemistry of free radicals may not lend itself to such treatments.
1.4.2 Copper Toxicity
Redox-active transition metals are useful but dangerous trace elements. Copper is 
essential to the life of cells and acts as a cofactor for many enzymes, however, if copper ions 
are not properly transported, stored or utilised, redox reactivity results in risk of damage to 
cells and tissues.
Under normal conditions, intracellular "free" copper ions are virtually non existent 
(Rae et al., 1999) as a complex mechanism of copper buffering has evolved to prevent 
metal-mediated oxidative stress. Copper buffering is achieved through the simultaneous 
action of a number of proteins in a process than can be thought of as a chain of consequent 
events regulating extracellular transport, uptake, intracellular delivery from chaperones (e.g. 
copper chaperone for SOD1 (CCS), COX 17 and Atxl) to specific targets (such as SOD1 and 
cytochrome c oxidase) and/or storage in copper scavenging systems (such as GSH and 
metallothioneins) (Puig et al., 2002).
If intracellular uptake is impaired, inactivation of copper-dependent proteins takes 
place with loss of their function. This is not the case in SOD 1-associated FALS, in which no 
change is observed in total copper content, not even in experimental conditions in which 
CCS is missing (Subramaniam et al., 2002).
Once copper ions are inside the cell they must be dealt with appropriately, by 
chaperoning them to substrates, either enzymes or thioneines. When these substrates are 
unavailable, absent, or unable to effectively bind the copper, the cell is presented with an 
unfavourable situation in which there is an excess amount of toxic, radical-generating metal 
ions. This may be taking place in SOD 1-associated FALS, as it is known that several SOD1 
mutants no longer possess the ability to bind metals properly in vitro and possibly in vivo 
(Hayward et al., 2002). Although differences among different SOD1 mutants in their ability 
to bind copper (and zinc) have been reported (Hayward et al., 2002), this appears to be to a 
general characteristic of FALS-associated SOD1, supporting the previously suggested 
hypothesis that SOD1 plays a key role in the buffering of copper. This hypothesis is based 
on the observation, of the existence of a pool of inactive copper-free enzyme, in human cell
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models; this inactive enzyme is re-activated in response to copper overload and may 
symbolize a secondary defence to metal-induced oxidative stress (Petrovic et al., 1996; 
Steinkuhler et al., 1991 & 1994).
In man, SOD1 is present in a single copy per haploid genome and FALS is a 
dominantly inherited disease which has a penetrance close to 1, with patients being in 
general heterozygous for mutant SOD1. Therefore, alteration of half of SOD1 molecules in 
patients may lead to an imbalance of either copper buffering or copper chemistry, when 
bearing in mind that SOD1 is a very abundant protein, representing up to 1% of total 
proteins in several cell types. The notion of "aberrant copper chemistry" of FALS-associated 
SOD1 was initially suggested in pioneering studies on altered geometry of the active site 
(Carri et al., 1994) and reactivity of mutant proteins in vitro (Wiedau-Pazos et al., 1996; 
Yim et al., 1996). Subsequent studies in cells expressing FALS-associated mutant SOD1, 
supported a role for alteration of copper as a reason for increased oxidative stress (Corson et 
al., 1998; Gabbianelli et al., 1999).
In the SOD1 dimer, each subunit contains one atom of both Cu2+ and Zn2+ (Siddique 
et al., 1996). Since copper may be neurotoxic, one possible path of investigation was the 
affinity with which the mutant SOD1 molecules might bind the copper atom. 
Conformational alterations in the molecule such as relaxed folding may lead to exposure of 
the copper atom or permit it to interact with other molecules. The observation that copper 
chelators prevent the abnormal effect of FALS-associated-SODl-mutants provides support 
to the importance of copper (Azzouz et al., 2000; Gabbianelli et al., 1999; Ghadge et al., 
1997; Wiedau-Pazos et al., 1996). Investigation of the D90A SOD1 mutation revealed 
normal binding of copper (Marklund et al., 1997). An investigation of a number of SOD1 
mutants identified a common property, the ability to bind copper, which is accomplished by 
means of the copper chaperone for SOD (CCS). This proposed a mechanism for SOD1 
mutant-mediated disease as being through aberrant copper chemistry as well as a possible 
therapeutic approach through the use of CCS inhibitors (Corson et al., 1998).
Copper is specifically delivered to SOD1 by CCS, and yeast cells with a null 
mutation in the yeast equivalent (LYS7) have normal levels of SOD1 however they fail to
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incorporate copper and as a result have no superoxide scavenging activity (Culotta et al.,
1997). There is strong homology between CCS and SOD1 molecules with conservation of 
the amino acids essential for mediating SOD1 homodimerization and it is through this 
region that the interaction between CCS both with wild-type SOD1 and FALS-SOD1- 
mutants takes place (Casareno et al., 1998). More importantly, this region of homology also 
contains most of the copper and zinc ligands, in addition to most of the amino acids mutated 
in FALS (Casareno et al., 1998). The H46R and H48Q SOD1 mutations contain no copper 
because of the absence of an essential ligand, however both interact with CCS. It was 
proposed that the chaperone interacts with these mutants and attempts to deliver copper, 
even if the enzyme is not able to accept it, resulting in the release of copper into the cell and 
subsequent toxicity (Casareno et al., 1998).
This model is consistent with the absence of an ALS phenotype in SOD1 null mice, 
as without an interaction between SOD1 and CCS, transfer of copper cannot take place. 
This theory is supported by mice with targeted disruption of the CCS gene, which display a 
similar phenotype to SOD1 null mice (Wong et al., 2000). Although these mice are viable 
and express normal levels of SOD1 protein, they have reduced SOD1 activity. This 
decrease in activity is the result of a defect in the incorporation of copper into SOD1, and 
other copper manipulations for instance uptake, distribution, or incorporation into other 
enzymes remain unchanged (Wong et al., 2000). The free intracellular copper concentration 
is very low, which implies that the copper chelating activity of the cell is high and that the 
CCS is required to deliver copper to SOD1 (Rae et al., 1999). In yeast the absence of CCS 
does not change the number of SOD1 molecules, however it does reduce the ratio of active, 
copper-containing enzymes to inactive, copper-less molecules (apo form). Further support 
for a role of CCS in the disease mechanism in ALS comes from the co-localization of CCS 
and SOD1 within degenerating cells (Casareno et al., 1998; Rothstein et al., 1999). Potential 
therapeutic approaches may comprise CCS inhibition (Corson et al., 1998) or disruption of 
the interaction of CCS-SOD1 to prevent copper-mediated toxicity (Casareno et al., 1998). 
The only reported study in two ALS pedigrees of the CCS gene on chromosome 11 was 
unsuccessful in detecting linkage (Orlacchio et al., 2000).
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Further support to the notion of altered metal homeostasis in ALS comes from the 
observation of increased levels of expression of metallothioneins (MT), in the spinal cords 
of patients (Sillevis-Smitt et al., 1992) and FALS transgenic mice (Gong et al., 2000), where 
changes in MT expression take place prior to the onset of motor deficits or significant motor 
neuron pathology. In addition, FALS mice arrive at the onset of clinical signs and death 
considerably earlier in response to the reduction of MT expression (Nagano et al., 2001; 
Puttaparthi et al., 2002). These findings are consistent with the hypothesis that the metal- 
mediated free radical production brought about by either mutant SOD1 or mishandled metal 
ions might be associated with the degeneration of motor neurons in FALS.
Lastly, a possible relationship between ALS and metal homeostasis is represented by 
modulation of proteasome functionality. It has been suggested that overexpression of some 
FALS-SOD1-mutants such as A4V, G85A or G93A, may result in neuronal death through 
inhibition of proteasome activity, as a result of accumulation of mutated/misfolded protein 
with time (Urushitani et al., 2002). One may speculate that, upon moderate oxidative stress, 
cell proteolytic activity is increased as a "scavenging" response with the intention of 
removal of oxidised products; this initial step may or may not be accompanied by formation 
of small aggregates, depending on the cell type or on the extent of production of ROS. When 
the damage from the oxidative stress exceeds a critical threshold, the activity of the 
proteasome is impaired as a result of it being over loaded. Reduction of proteasome activity 
required for normal turnover of protein would result in malfunctioning of overall cell 
metabolism.
1.5 Susceptibility Genes
Taking into consideration that mutations in ALS genes occur in patients with familial 
as well as sporadic ALS, it is likely that more than 10% of ALS can be explained by the 
multiple autosomal-dominant and -recessive forms. Since at present, there is no evidence 
for any specific environmental cause for sporadic or familial ALS, most remaining cases of 
the disease are thought to be triggered by the interaction of several genes and environmental 
factors.
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I will now describe here some of the genes potentially contributing to the 
development of ALS. For the context of this thesis, these genes are referred to as 
“susceptibility genes”, as mutations in these genes may only lead to ALS in the presence of 
other genetic or environmental risk factors.
1.5.1 Neurofilaments
One of the most commonly reported pathological findings in ALS is the aberrant 
accumulation of neurofilaments in perikarya and proximal axons of motor neurons, however 
it remains unclear as to whether this has a central role in the disease process or is merely a 
harmless by-product (Cleveland et al., 1996). The neurofilaments are a major component of 
the axonal cytoskeleton and since motor neurons possess very large NF-rich axons, this 
structural attribute is one of the strongest clues to the selective vulnerability of motor 
neurons in ALS. A role of neurofilaments is to maintain axon structure and calibre (Julien et 
al., 1999). In ALS, axonal loss is size-dependent, with principal loss being of large fibers 
(Sobue et al., 1987).
The first experimental evidence for the involvement of neurofilaments in the 
pathogenesis of ALS came from the generation of mouse models expressing high levels 
(three to four time’s normal) of wild-type mouse NF-L (Xu et al., 1993) and wild-type 
human NF-H (Cote et al., 1993). In these animals, NF accumulation was associated with 
axonal degeneration, proximal swelling, and severe skeletal muscle atrophy, suggesting that 
neurodegeneration can be triggered by the accumulation of NF in motor neurons. There was 
however, no significant loss of motor neurons and in addition the extent of overexpression 
caused some trepidation about the specificity of the toxic effect as well as the rate of protein 
degradation. Consequently, a mouse model was created which expressed only a modest 
level of mutant NF-L, and this gave rise to selective degeneration of motor neurons 
accompanied by NF accumulation (Lee et al., 1994). Further support for the role of NF in 
the disease came from the description of severe neurofilamentous pathology in association 
with an SOD1 mutation in an ALS individual (Rouleau et al., 1996).
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Although NFs are obligate heteropolymers, each of the three NF subunits can form 
heterodimers with peripherin which is another neuronal intermediate filament (IF) protein 
and is also a component of the IF inclusion bodies seen in ALS. The expression of 
peripherin with NF-H and NF-M, in the absence of NF-L, prevents IF formation in cells 
(Beaulieu et al., 1999). Further studies investigating the role of peripherin in ALS show that 
sustained overexpression of wild-type peripherin in mice triggers massive and selective 
degeneration of motor axons during ageing. Onset of peripherin-mediated disease was 
brought about by a deficiency of NF-L protein (Beaulieu et al., 1999). In mice, the 
overexpression of NF-L can rescue the NF-H phenotype (Meier et al., 1999). However, in 
mice null for NF-L and overexpressing NF-H, protein aggregates occur in the absence of 
motor neuron death, whereas animals with overexpression of peripherin have toxic 
inclusions, which result in death (Beaulieu et al., 2000). These findings suggest that the type 
and location of the IF aggregates may play a part in its toxicity.
Mice carrying the G85R SOD1 mutation and a deleted NF-L gene display a slower 
disease onset and reduced disease progression (Williamson et al., 1998); indicating neuronal 
vulnerability to SOD1 mutant toxicity is reduced in the presence of lower levels of NF. 
However, overexpression of human NF-H in G37R-SOD1 mutant mice results in a 65% 
increase in lifespan of the G37R animals (Couillard-Despres et al., 1998). Confirmation of 
these findings comes from a study in which both NF-L and NF-H were overexpressed with 
another SOD1 mutant (Kong et al., 2000). In mice, the overexpression of human NF-L with 
G37R-mutant-SODl, leads to excess NF in motor axons but does not accelerate the disease 
process mediated by the mutant SOD1 enzyme, suggesting that the increase of NF may 
protect motor neurons from SOD1 mediated toxicity (Couillard-Despres et al., 2000). One 
mechanism that can explain this finding is that extra NF proteins may act as a sink for toxic 
oxygen radicals, however no differences in pattern or amount of nitrotyrosine or carbonyl 
modifications have been observed, suggesting that nitration occurs normally within neurons 
(Strong, 1999). In sporadic ALS cases selective suppression of NF-L mRNA has been 
observed without any alteration to mRNA levels of other NF subunits or neuronal nitric 
oxide synthase (NOS); since NF-L is thought to function as a sink for free reactive nitrating 
species this suggests that the motor neurons are unable to effectively buffer reactive nitrating 
species (Strong, 1999).
An alternative hypothesis for the way in which neurofilaments play a part in the 
mechanism and selectivity of motor neuron disease comes from the neurofilament- 
dependent slowing of axonal transport as neurofilamentous accumulation occurs 
(Williamson et al., 1999). The first evidence that mutations in SOD1 modified the NF 
network came from an SOD1 G93A mouse model in which axonal transport was impaired 
(Zhang et al., 1997). Proteins synthesized in the neuron cell body are delivered by means of 
axonal transport to the axon, which has both fast and slow components. The slow transport 
component may be subdivided again, in accordance with the speed of the movement, into 
slow component a (SCa -0.5 mm day1) which transports NF proteins, tubulin, actin, and 
slow component b (SCb -1-2 mm day'1), which also carries tubulin and actin along with 
other proteins (Williamson et al., 1999). In transgenic mice expressing human SOD1 -G37R 
or -G85R, examination of rate and composition of slow axonal transport revealed that 
reduced slow transport was evident months ahead of clinical features of disease (Williamson 
et al., 1999). In the G37R mice, there was a marked reduction in the transport of all three 
subunits of NF, by a factor of two, whereas fast transport remains unaffected.
In addition, it was found that by limiting the expression of NF within cells and by 
preventing the localization of NF in the axon, SOD1 mutant-mediated diseases in mice with 
or without axonal neurofilaments were impossible to differentiate; suggesting that axonal 
NF is not a prerequisite for disease pathology (Eyer et al., 1998). This indicates that the 
disruptions of NF observed in ALS are secondary. In a recent study NF content was reduced 
by disruption of each of the three NF genes and the ensuing effect was studied in the context 
of a SOD1 FALS mutation. The large decrease in NF caused a significant reduction in 
axonal calibre but did not prevent loss of motor neurons (Nguyen et al., 2000). The 
conclusions drawn from the study were that neither high NF burden nor large calibre axons 
could provide an explanation for the selective degeneration of motor neurons in ALS.
In summary, even though the accumulation of neurofilaments is a common 
pathological characteristic of ALS, the content of NF does not appear to be responsible for 
the selective death of motor neurons. The creation of several animal models with NF 
transgenes has provided insight into the role played by these elements in ALS. Recent 
evidence has highlighted both the interactions of various filament proteins and the
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expression levels of each type of protein as having a strong influence on the course of the 
disease. In addition, it is becoming clear that the cellular location of NF accumulation, i.e. 
perikaryal versus axonal, may be crucial to the disruption of cellular function, in particular 
the axonal transport system. In sporadic ALS cases, mutations in the heavy NF subunit may 
be a risk factor, however they are not common.
1.5.2 Excitotoxicity Genes
The term excitotoxicity denotes a phenomenon in which the excessive or prolonged 
activation of excitatory amino acid receptors leads to damage and eventually death of the 
neurons involved. The activation of these receptors is normally transitory and results in 
depolarization and neuronal excitation. In the brain, glutamate is the principal excitatory
*ym1
neurotransmitter. It is released by a Ca -dependent mechanism from vesicles in the 
presynaptic terminals and subsequently diffuses across the synaptic cleft where it activates 
specific receptors.
There are two types of glutamate receptors ionotropic and metabotropic. There are 
three families of ionotropic receptors: kainic acid (KA), N-methyl-D-aspartate (NMDA), 
and a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA). There are also three 
groups of metabotropic glutamate receptors (mGluRs) of which a total of eight (1-8) 
subunits have been identified (Meldrum, 2000). Since elevated levels of glutamate may be 
neurotoxic, it is essential that there is rapid clearance of the glutamate from the synaptic and 
extracellular environment; this is the role of specific glutamate transporters in the 
surrounding astrocytes and neurons. A cascade of intracellular events such as calcium and 
sodium influx is triggered by the stimulation of the glutamate receptors and results in 
activation of oxidant generating pathways. It is thought that elevated activity may be 
responsible for neurotoxic effects (Rothstein, 1996). Activation of the ion-gated receptors 
leads to an influx of Ca2+ into the cell, which exerts many changes, including cell swelling 
(Leigh et al., 1996) and results in the activation of a number of enzymes such as NOS which 
may lead to the formation of NO. In the presence of superoxide, the generated NO can react 
to produce harmful peroxynitrite, which results in nitrosylation and inactivation of several 
proteins.
Reduced levels of glutamate and aspartate in brain and spinal cord of patients 
provided the first sign of a possible role for glutamate excitotoxicity in ALS (Plaitakis et al., 
1988). A dramatic increase in glutamate and aspartate levels in ALS were identified by CSF 
studies (Rothstein et al., 1990) however not all studies stand in agreement (Perry et al., 
1990). Abnormal transport or metabolism was suggested as the underlying problem, as a 
result of the findings of ratios of the amino acids and products of metabolism (Rothstein et 
al., 1990). Additionally, as the same protein regulates the clearance of extracellular 
glutamate and aspartate in ALS and levels of both amino acids are altered, this would imply 
a defective or inefficient transport mechanism (Rothstein, 1996). In ALS patients, a defect in 
high-affmity glutamate transport with disease, region, and chemical specificity has been 
identified (Rothstein et al., 1992). Chronic inhibition of glutamate transport gives rise to 
slow neurotoxicity in spinal cord cultures, providing further support for defective glutamate 
transport in ALS (Rothstein et al., 1993). Neuronal cell death, which arises as a result of 
chronic inhibition of SOD1, is enhanced by blockage of glutamate transport and prevented 
by treatment with a glutamate receptor antagonist (Rothstein et al., 1994).
The identification of three glutamate transporters -  EAAC1 (excitatory amino acid 
carrier-1), GLT-1 (rat glial glutamate transporter), and GLAST (rat glial glutamate and 
aspartate transporter) has enabled the specificity and localization of these transport proteins 
as well as the role of each subtype in ALS to be studied. EAAC1 is specific to neurons, 
while GLT-1 and GLAST are specific to astrocytes (Rothstein et al., 1995). Through use of 
anti-oligopeptide antibodies, it was established that GLT-1 is significantly reduced in ALS, 
whereas EAAC1 is modestly decreased and levels of GLAST remain unchanged (Rothstein 
et al., 1995). Importantly, the reduction in GLT-1 was found in some, but not all, ALS 
specimens, which may account for the lack of alterations in concentrations of amino acids in 
some samples (Perry et al., 1990). The levels of mRNA for each of these transporters were 
found to be unchanged which suggests the reduction in GLT-1 protein might be the result of 
a translational or posttranslational alteration (Bristol et al., 1996). Inhibition of synthesis of 
GLT-1 or GLAST, through use of antisense oligonucleotides, resulted in increased 
extracellular glutamate, excitatory neurodegeneration, and paralysis. Loss of neuronal 
EAAC1 did not result in a reduction in extracellular glutamate but produced mild toxicity
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(Rothstein et al., 1996). This highlights glial transporters as the principal glutamate 
transporters and as being essential in preventing neurotoxicity.
Abnormal GLT-1 (also known as EAAT2, excitatory amino acid transporter 2) 
mRNA was identified in non-SODl familial as well as sporadic ALS cases (Lin et al., 
1996), providing a possible explanation for the reduction in functional protein. About 60- 
70% of sporadic ALS patients exhibit a 30-95% loss of the EAAT2 protein in motor cortex 
and spinal cord (Lin et al., 1998). In ALS patients, several abnormal EAAT2 mRNAs have 
been identified in abundance in affected areas but not in other areas of the brain. These 
aberrant mRNAs are found to be present in approximately 65% of sporadic cases. Initial 
investigations suggest the proteins synthesized from these abnormal mRNAs are prone to 
rapid degradation and exert a dominant negative effect on the normal EAAT2 protein, 
leading to a loss of activity (Lin et al., 1998). Alternative splice forms of EAAT2 mRNA, 
which are non-pathogenic, have also been identified (Nagai et al., 1998).
There are several possible causes, which could account for the generation of this 
abnormal mRNA. The identification of multiple aberrant mRNAs suggests a defect in 
mRNA processing or alternatively, there may be mutations in the EAAT2 gene (Bai et al., 
1998; Lin et al., 1998). To elucidate this both linkage and mutation analysis was used to 
study the EAAT2 gene on chromosome 1 lp. No linkage was detected in 16 ALS pedigrees 
however mutation screening identified one novel mutation in a SALS patient and two novel 
mutations in two siblings affected with FALS (Aoki et al., 1998). The SALS mutation may 
be functionally significant, but those that are present in the FALS cases do not modify the 
amino acid. It has been concluded that mutations in the gene for EAAT2 are rare and do not 
account for the frequent detection of abnormal mRNA. A subsequent study identified three 
novel EAAT2 transcripts, none of which were found to be disease-specific; indicating that 
abnormally spliced RNA is unlikely play a major role in the pathogenesis of ALS (Meyer et 
al., 1999). Recently, EAAT2 splice variants were detected not only in ALS patients but also 
in controls and among individuals with Alzheimer's disease, which suggests that 
qualitatively the presence of the variants may not explain ALS pathology, but that there may 
be some quantitative modifications that affect motor neuron degeneration (Flonig et al.,
2000).
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Currently, riluzole is the only effective approved treatment for ALS, which has a 
neuroprotective role, which may be due to its ability to inhibit presynaptic glutamate release 
(Doble, 1996). Treatment with riluzole has been shown to prolong survival in both ALS 
patients and in animal models (Gumey et al., 1996; Lacomblez et al., 1996). Extended 
survival has been reported by studies among treated patients (Bensimon et al., 1994; 
Lacomblez et al., 1996; Riviere et al., 1998). Another alternative potential treatment is 
provided in the form of carboxyfullerenes, which are antioxidants, and operate by blocking 
glutamate receptor-mediated excitotoxicity (Dugan et al., 1997).
A glutamate analog, p-N-oxalyl-L-a, p-diaminopropionate (p-ODAP or BOAA), 
which is found in chickpeas, is believed to be responsible for upper motor neuron 
degeneration in lathyrism (Rothstein et al., 1992). A related toxin which is found in the 
cycad fruit, P-methylamino-L-alanine (BMAA), has been implicated in the ALS syndrome 
of Guam, although this theory has recently been brought into question because of the low 
level of consumption and long latent period (Meldrum, 2000). All these data provide support 
to the glutamate toxicity model.
Even though there is strong evidence for a link between glutamate excitotoxicity and 
ALS it is difficult to comprehend how the fast action of the glutamate receptors and 
transporters corresponds to very slow and progressive nature of damage to motor neurons 
brought about by the disease. A process may exist which chronically triggers glutamate 
release (Smith et al., 1995). Alternatively, the astrocytes expressing EAAT2 may play a role 
in mediating this damage. Early indicators of disease in ALS are astrocytic inclusions that 
stain with SOD1 and ubiquitin antibodies and which increase with the decrease of EAAT2 
(Bruijn et al., 1997). In transgenic mouse models, damage to astrocytes is mediated by 
SOD1 mutants, which may lead to a reduction of EAAT2 levels and account for motor 
neuron degeneration (Bruijn et al., 1997). Additional support for this comes from astrocytes, 
which have been shown to interact directly with degenerating motor neurons via a process, 
which occurs during the early stage of disease involving mitochondrial vacuolation of motor 
neurons (Levine et al., 1999). Recently a study investigated further into the active 
participation of astrocytes in ALS by selectively expressing mutant SOD1 in astrocytes in a
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mouse model of disease. This restriction of mutant SOD1 was enough to bring about 
astrocytosis but not degeneration of motor neurons (Gong et al., 2000).
1.5.3 Apolipoprotein E
The association of apolipoprotein E (APOE) alleles with Alzheimer's disease 
initiated the investigation of these alleles in ALS. The frequencies of apolipoprotein E 
(ApoE) e2, s3 and s4 genotypes in familial and sporadic ALS do not vary from those in the 
general population (Mui et al., 1995), thereby excluding ApoE mutations as a major cause of 
ALS. However in some studies, the ApoE genotype has been reported to have an effect on 
the age of onset and clinical presentation of sporadic ALS. The e 3/s 3 genotype may extend 
survival in patients suffering from ALS, whereas the s4 allele may predict an earlier age at 
onset (Al-Chalabi et al., 1996). In comparison, a significantly higher proportion of ALS 
patients with the e3/s4 genotype had bulbar symptoms, while the patients with e2/e3 
genotype appeared to be predisposed to limb onset. Therefore, as in Alzheimer's disease, it 
has been suggested s2 and s3 alleles are protective in ALS, while the e4 allele may play a 
deleterious role (Warwick Daw et al., 2000; Drory et al., 2001; Strittmatter et al., 1993).
The exact mechanism of the deleterious effect of the s4 allele remains unknown, but 
it may be the result of the absence of the protective allele’s s2 and e3. The gene products of 
APOE e2 and s3 genes have cysteine residues, essential for detoxification of lipid 
peroxidation product 4-hydroxy-nonenal (HNE), which triggers apoptosis and is increased in 
the spinal cord of patients suffering from ALS. The e4 gene product has no cysteine resi­
dues, and as a result lacks the ability to protect against HNE-mediated apoptosis. This may 
be a possible explanation for the correlation between these APOE genotypes and 
susceptibility to neurodegeneration (Pedersen et al., 2000). However, other studies of ApoE 
in ALS have not confirmed the association of the s4 allele with early-onset, shortened 
survival or the presence of bulbar symptoms at onset (Mui et al., 1995; Bachus et al., 1997; 
Smith et al., 1996). In addition, studies in Guam of patients with the ALS-Parkinsonism- 
dementia-complex (ALS-PDC) found no association with any of the ApoE alleles (Chen et 
al., 1996; Waring et al., 1994).
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1.5.4 Ciliary neurotrophic factor (CNTF)
A reduction in the levels of ciliary neurotrophic factor (CNTF), a survival factor in 
spinal motor neurons, may play a role in the development of ALS. This conclusion is based 
on several lines of evidence. First, a decrease in the levels of CNTF was found in the 
corticospinal tract neurons of patients with ALS (Ono et al., 1999). Second, abolition of 
CNTF gene expression in knockout mice results in progressive motor neuron degeneration 
(Masu et al., 1993). Third, the frequency of the homozygous state for a mutation in the 
CNTF gene, resulting in absence of CNTF, is slightly increased in patients with sporadic 
ALS (Orrell et al., 1995). Since there is no increase in heterozygosity for CNTF mutations in 
ALS patients, the role of CNTF in ALS seems modest (Orrell et al., 1995; Takahashi et al.,
1994).
1.5.5 Cytochrome P450 debrisoquine hydroxylase (CYP2D6)
Protein polymorphisms in the gene encoding cytochrome P450 debrisoquine 
hydroxylase (CYP2D6) are responsible for the reduced metabolism of exogenous toxins, 
thereby forming one of the risk factors associated with Parkinson’s disease (Smith et al., 
1992). Three studies have been carried out to investigate the potential role of the 
CYP2D6(b) allele as a risk factor for ALS. One study of 57 ALS patients and controls, 
found no association between this allele and ALS (James et al., 1994). The second study 
reported a considerable increase in the frequency of the CYP2D6(b) allele in 50 ALS 
patients (Siddons et al., 1996). The frequency of this mutant allele is higher in the Chamorro 
people than in Caucasians, although no differences have been found between healthy 
Chamorro people and patients with Guamanian ALS-PDC (Chen et al., 1996).
1.5.6 Apurinic apyrimidinic endonuclease (APEX)
The apurinic/apurimidinic exonuclease (APEX nuclease) gene encodes a 
multifunctional DNA repair enzyme, thought to be a risk factor for ALS, with reduced levels 
of APEX nuclease found in the frontal cortex of patients with ALS (Kisby et al., 1997). 
There are two reports of APEX gene mutations which lead to a decrease in the level and
activity of the enzyme in ALS: mutations were found in four of 117 patients with sporadic 
ALS and in four of nine twins with ALS, but not in controls (Olkowski et al., 1998; 
Hayward et al., 1999; Tomkins et al., 2000). APEX nuclease may also play a part in the 
Guamanian ALS-PDC, as a metabolite of cycasin, methylazoxy-methanol (MAM), a 
potential environmental genotoxin in Guamanian ALS found to cause a considerable 
reduction in neuronal APEX levels and activity (Esclaire et al., 1999). Though APEX 
mutations do not account for a significant proportion of ALS, the role of DNA damage in 
etiology of ALS may be importance.
1.5.7 Mitochondrial metabolism
There is accumulating evidence that inherited or acquired mitochondrial dysfunction 
contributes to the pathogenesis of ALS (Beal et al., 2000). Evidence of mitochondrial 
dysfunction has been found in muscle biopsies of patients with sporadic ALS (Wiedemann 
et al., 1998), and increased oxidative damage has been found in the central nervous system 
tissue from autopsied sporadic and familial ALS patients (Pedersen et al., 1998; Shaw et al., 
1995; Bowling et al., 1993).
One of the earliest pathological findings in SOD 1-mutant transgenic mice is mito­
chondrial vacuolization, suggesting that the leakage or translocation of mutant SOD1 in 
mitochondria may be the initial event sparking further degeneration (Dal Canto et al., 1994; 
Jaarsma et al., 2001; Kong et al., 1998; Wong et al., 1995). Mutations in mitochondrial 
(mt)DNA, such as depletion of mtDNA or multiple deletions of mtDNA (Vielhaber et al., 
2000), as well as a mutation of the mtDNA-encoded subunit 1 of cytochrome c oxidase, 
have been described in ALS (Comi et al., 1998). Mitochondrial dysfunction in ALS may 
additionally result from decreased levels of mitochondrial manganese superoxide dismutase 
(SOD2); encoded by a nuclear gene on chromosome 6. An Ala9Val mutation in SOD2 has 
been detected in some patients with sporadic ALS (Van Landeghem et al., 1999), while 
SOD2 knockout mice have been found to exhibit degeneration of neurons in basal ganglia 
and brainstem, and progressive motor disturbances with paresis (Melov et al., 1998; 
Lebowitz et al., 1996). Furthermore, cultured murine cortical neurons with reduced levels of 
SOD2 show greater sensitive to glutamate neurotoxicity compared to neurons with intact
S0D2 activity (Li et al., 1998). In S0D1 transgenic mice, dysfunction of SOD2 exacerbates 
disease expression (Andreassen et al., 2000).
1.5.8 Selectivity of Cell Death in ALS
One of the unanswered questions with the regards to the study of ALS concerns the 
highly selective cell death of motor neurons. Figure 1.2 provides an overview of the 
motomeurone degeneration process in amyotrophic lateral sclerosis. Investigations have 
shown that with extended patient care degeneration of the cortex may take place (Takahashi 
et al., 1997), in addition a number of ALS cases have displayed (Bruijn et al., 1997) 
astrocytic damage, suggesting a more broad-ranging degeneration than previously thought. 
However, the majority of research has focused on those characteristics of motor neurons, 
which increase their vulnerability to damage.
As mentioned previously, SOD1 is a ubiquitously expressed protein and no alteration 
is observed in its abundance in motor neurons. However, a reduction in the activity of 
molecular chaperones is observed in mutant SOD1 cells and is thought to result in the 
accumulation and inefficient removal of mutant SOD1 (Bruening et al., 1999). Induction of 
stress-inducible heatshock proteins prevents the formation of mutant SOD1 aggregates 
suggesting reduced levels of available chaperones leaves mutant expressing SOD1 cells 
vulnerable to both physiological and environmental stress (Bruening et al., 1999). 
Alternatively, the high level of mitochondrial activity required by motor neurons and high 
neurofilament content, as a result of their large size and the ratio of cell body to axonal 
length, may render motor neurons selectively vulnerable. In sporadic ALS cases and 
controls, analysis of a number of physiochemical properties of NF failed to find distinctions 
in the purified protein (Strong, 1999). Abnormalities of collagen have been described in the 
spinal cord of ALS patients and implicated in selective vulnerability (Ono et al., 1998).
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Figure 1.2 A schematic representation of the biochemical systems potentially involved in the 
process of motoneurone degeneration, a-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptors, N-methyl-D-aspartate (NMDA) receptors and metabotropic receptors (metabo) 
are the three main subtypes of excitatory amino acid receptor. The three glutamic acid transporters 
are EAAT-1, EAAT-2 and EAAT-3. Abbreviations: IP3, inositol (1,4,5) trisphosphate; SOD, 
superoxide dismutase; trk, tyrosine receptor kinase; VSCC, voltage-dependent Ca2+ channels: VSSC, 
voltage-dependent Na+ channels. Diagram adapted from Louvel et al., (1997).
There is support for an increase in calcium levels, mitochondrial volume, as well as 
numbers of synaptic vesicles within the motor nerve terminal of ALS patients (Siklos et al., 
1996). A deficiency in calcium-binding proteins such as calbindin D28k and parvalbumin, 
specific to cells damaged early in ALS, has been put forward as the reason for their 
particular vulnerability (Alexianu et al., 1994). The toxicity of SOD1 mutants is calcium- 
dependent and the selective death of motor neurons has been proposed to be the result of a 
combination of both calcium entry during the course of neurotransmission and the 
deficiency of Ca-binding proteins (Roy et al., 1998). Increased expression of calbindin D28k 
in motor neuron cells through viral infection (Ghadge et al., 1997; Ho et al., 1996) or
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treatment with vitamin D3 (Alexianu et al., 1998) increases resistance to cell death, as a 
consequence of several mechanisms, for instance, mutant SOD1, antibody-induced calcium 
influx, as well as oxidative injury. This implies that correction of calcium-buffering 
properties of motor neurons may provide an effective therapy for ALS.
Neurofilaments possess multiple calcium-binding sites and may play a part in 
calcium homeostasis (Julien et al., 1999). The increase in the levels of free Ca2+ within a cell 
results in the activation of Ca-dependent enzymes including xanthine oxidase and 
phospholipase A2, which may lead to an increase in the levels of superoxide anion, as well 
as NOS, with the latter leading to formation of NO, (Coyle et al., 1993). In addition, 
elevation in intracellular Ca2+ induces expression of the par-4 gene and the prostate 
apoptosis response-4 protein, which promotes apoptosis (Pedersen et al., 2000).
The subunit GluR2 of AMPA glutamate receptor confers calcium impermeability to 
the receptor. Investigations have revealed human spinal motor neurons lack detectable 
levels of GluR2 mRNA, suggesting on these particular cells the AMPA receptors are 
calcium-permeable (Williams et al., 1997). However, reports have determined that rather 
than complete lack of GluR2, a subset of AMPA receptors has intermediate calcium 
permeability levels (Greig et al., 2000). Therefore there is no overall change in the relative 
levels of GluR2 or Ca permeability of AMPA receptors between motor neurons and those 
neuronal cells not affected by ALS (Vandenberghe et al., 2000). Furthermore, in vitro 
studies in motor neurons and other cells also expressing AMPA/KA Ca2+ channels, 
comparing the effects of short-term exposure to AMPA and kainite, demonstrate the 
specificity of the stimulant and the reaction of the cell is distinct in motor neurons (Carriedo 
et al., 2000). The variation in desensitization of AMPA receptor in motor neuron cannot 
explain the selective vulnerability to injury. Instead, the susceptibility of motor neurons 
appears to be a result of higher density of functional AMPA receptors, which when 
pharmacologically reduced to levels observed in other cell types, eradicates the selective 
vulnerability to AMPA receptor agonists (Vandenberghe et al., 2000).
The mitochondria are the principal target of this calcium-mediated cellular damage. 
A large proportion of the cell's free radicals are generated by this organelle and it is
75
estimated, in the course of electron transfer to molecular oxygen, approximately 1-5% of 
electrons are lost and go on to form superoxide anions (Green et al., 1998). A critical role is 
played by mitochondria in the regulation of apoptosis and a correlation exists between 
increases in mitochondrial calcium and increases in free radicals associated with cell death 
(Beal, 2000; Stout et al., 1998).
A decrease in the activity of mitochondrial DNA (mtDNA)-encoded cytochrome c 
oxidase (cox) has been described in sporadic ALS cases. The same observation has been 
made in muscle biopsies from individuals with defects in mtDNA, suggesting that 
mitochondrial-encoded genes may play a role in the disease. The reduction in the activity of 
cox may play a part in neuronal death and come about as a result of oxidative damage to 
mtDNA (Borthwick et al., 1999). Alterations in mtDNA which arise as a result of decreased 
levels of membrane-associated mitochondrial SOD has been shown to account for the 
reduction in cox activity, suggesting defects in mtDNA are significant in sporadic ALS 
cases (Dhaliwal et al., 2000; Vielhaber et al., 2000). Chronic inhibition of mitochondria 
through complex II and IV blockers leads to selective motor neuron death. Prevention of 
cell death in this in vitro model is through treatment with free radical scavengers, 
AMPA/kainate receptor blockers, riluzole, and caspase inhibitors (Kaal et al., 2000). Even 
though the basal levels of oxidative metabolism are unchanged in ALS patients, once 
challenged with a stressful condition, the ability to compensate is reduced (Curti et al.,
2~b1996). In the course of neurotransmission, there is also a release of Zn at the presynaptic 
terminal. The AMPA receptors are Zn2+-permeable, thereby enabling its entry into the cell 
where it can result in generation of ROS (Sensi et al., 1999). Mitochondrial metabolism is 
sensitive to levels of Zn2+ and it is thought it may have a more potent effect than calcium 
(Weiss et al., 2000).
Mitochondrial DNA is a lot more sensitive than nuclear DNA to oxidative damage 
because of the lack of protective histones and efficient repair mechanisms. Neurons are 
more vulnerable to mtDNA damage because of their very high-energy requirements and the 
accumulation of damage to mtDNA may to some extent explain the progressive nature of 
the disease. The apoptotic cascade may be triggered by a reduction in the integrity of the 
mitochondria thereby resulting in cell death.
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In a recent review of the advances in ALS research, the possibility of a pathway 
combining several of the proposed mechanisms in motor neuron death was proposed. 
Briefly, glutamate transport can be affected in a number of ways, for instance, by oxidative 
stress, alterations in EAAT2, or antibodies to voltage-gated calcium channels. Once
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activated, receptors bring about an influx in Ca , which is aggravated as a result of the lack 
of calcium-binding proteins, and which results in disturbances in mitochondrial metabolism 
as well as the activation of a number of enzymes such as NOS. Nitric oxide spontaneously 
reacts with superoxide anion to generate peroxynitrite, which nitrosylates and consequently 
damages proteins (Al Chalabi et al., 2000). An excess of NO may also lead to an increase in 
production of O ’ by inhibition of mitochondrial electron flow, thereby resulting in further 
generation of ONOO' (Torreilles et al., 1999).
The nitrosylation reaction is copper-dependent with the likely source of free copper 
being mutant SOD1, even in the presence of CCS. The target proteins for nitrosylation 
include the neurofilament subunits, which may lead to abnormal accumulation of NF and the 
subsequent disruption of the neurofilament network and axonal transport. In the presence of 
increased peripherin and decreased NF-L this reaction is enhanced (Al Chalabi et al., 2000). 
Mutant SOD1 has increased copper-dependent peroxidase activity, which results in the 
formation of hydroxyl radical that can also act on the NF network. It is logical to assume 
that disturbances of any of the molecules at any point in this complicated and at present 
incomplete pathway might lead to the cell death seen in ALS.
1.6 Cell Death and Apoptosis in Amyotrophic Lateral Sclerosis
The work described in this thesis utilises a model neuronal cellular system where 
apoptosis is a key feature and both Hsp27 and Hsp70 have a protective anti-apoptotic effect. 
As apoptosis is inhibited by Hsps, it is therefore necessary that this section provide a brief 
overview of the molecular pathways of programmed cell death (intrinsic and extrinsic 
pathways), before mentioning Hsps. In addition the mechanism by which this physiological 
process, which acts in all multicellular organisms, contributes to neurodegeneration and the 
role of this process in ALS will be discussed. It should be noted that the term- programmed
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cell death (PCD) is a physiological process in which molecular programs that are intrinsic to 
the cell are activated to trigger its destruction; the term is frequently used interchangeably 
with ‘apoptosis’ which is only one morphological form of PCD (Clarke, 1990) characterized 
by membrane blebbing, cell shrinkage, nuclear condensation and DNA fragmentation. The 
following sections, briefly discuss the molecular composition of the PCD machinery, 
followed by PCD in ALS and how targeting of PCD has led to the disclosure of molecular 
targets for the development of drugs for prevention and treatment of neurodegenerative 
diseases and ALS in particular.
1.6.1 Molecular pathways of Programmed Cell Death (PCD)
The principal mediators of programmed cell death are the proteolytic enzymes 
known as ‘caspases’, which cleave their substrates after specific aspartic acid residues. 
Caspases exist in nearly every animal cell as zymogens known as ‘procaspases’, and become 
activated in response to intracellular signalling pathways initiated by various cellular 
signals, such as DNA damage and withdrawal of trophic support. In total, the family of 
mammalian caspases comprises 15 members, which can be divided into initiators 
(procaspases 2, 8, 9 and 10) and effectors (procaspases 3, 6 and 7) of PCD pathway. The 
first caspases to become activated in the PCD cascade are the initiator caspases. The initiator 
caspases possess long amino-terminal prodomains that contain specific protein-protein 
interaction motifs. It is through these domains, that initiator caspases 8 and 9 are activated 
after being aggregated by the adaptor molecules FADD (Fas-associating protein with death 
domain); (Muzio et al., 1998) and Apafl (apoptotic protease-activating factor 1); (Li et al.,
1997), respectively. The activated initiator caspases subsequently cleave effector 
procaspases into their active forms, which are responsible for events such as mitochondrial 
damage, nuclear membrane breakdown, DNA fragmentation, chromatin condensation and, 
eventually, cell death.
The Bcl2 family of proteins, which are implicated in the regulation of PCD, contain 
members that have either anti-PCD (for instance Bcl2 and Bcl-xL) or pro-PCD (for instance 
Bax and Bak) acting (Gross et al., 1999). The members all share some degree of structural 
similarity and can have up to four Bcl2-homology domains (BH1-BH4). In addition to the
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many Bcl2 members that contain BH domains, such as Bcl2 per se and Bax, there exist 
molecules that share sequence homology only with the BH3 domain, such as Bid or Bim. 
These BH3 only proteins function as intracellular death ligands, proximal to multidomain 
Bcl2 members, and additionally can connect with proximal signal transduction pathways 
(Letai et al., 2002). Multidomain Bcl2 members can regulate the release o f mitochondrial 
apoptogenic factors such as cytochrome c, Smac/Diablo, or apoptosis-inducing factor (AIF) 
and as a result can preserve or disrupt mitochondrial integrity. In addition, Bcl2 can also 
inhibit initiator caspases by means of mitochondrial independent mechanism (Marsden et al., 
2002).
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Figure 1.3 The molecular pathways involved in the process of Programmed Cell Death (PCD). 
Three different PCD molecular pathways have been recognized: the mitochondrial pathway (also 
called intrinsic), the death receptor pathway (also called extrinsic), and the ER pathway. Diagram 
adapted from Guegan et al., (2003).
1.6.1.1 The death receptor/Extrinsic PCD pathway
The extrinsic PCD pathway (figure 1.3) is triggered on activation of cell surface 
death receptors such as Fas/CD95 and the tumour necrosis factor receptor 1 (TNFR1).
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Activation of death-receptor is produced by specific ligands known as death activators, for 
instance, the Fas ligand binds to Fas, and TNFa binds to TNFR1. On binding, the 
intracellular ‘death domains’ on these receptors associate with the ‘death effector domains’ 
on an adaptor protein, for instance, Fas associates with FADD, and TNFR1 associates with 
FADD and TRADD (TNFR-associated protein with death domain). Adaptor proteins then 
recruit pro-caspase 8, and result in its activation. Activated caspase 8 triggers the activation 
other caspases, either directly or indirectly, through cleavage of Bid (fig. 1.3). The extrinsic 
PCD pathway is particularly instrumental in pathological conditions in which inflammation 
is a prominent characteristic. In addition to being activated by the extrinsic pathway, it 
appears that procaspase 8 is also cleaved by a mechanism that depends on the intrinsic 
pathway (Slee et al., 1999).
1.6.1.2 The mitochondrial/intrinsic PCD pathway
In the intrinsic PCD pathway, death receptor independent stimuli can instigate PCD 
by bringing about translocation of pro-PCD molecules (such as Bax) to the mitochondria, 
resulting in subsequent release of mitochondrial apoptogenic factors (such as cytochrome c) 
to the cytosol (fig. 1.3). Cytochrome c released from the mitochondria interacts with two 
other cytosolic factors (Li et al., 1997), Apafl and procaspase 9, resulting in the subsequent 
activation of caspase 3. The formation of this Apafl-cytochrome c multimeric complex may 
function to increase the local concentration of procaspases for intermolecular cleavage, and 
to set a relatively high threshold of caspase activation in order to ensure an occasional 
leakage of cytochrome c does not trigger PCD (Budihardjo et al., 1999).
Another mitochondrial inter-membrane protein that is released into the cytosol on 
induction of PCD is Smac/Diablo (Du et al., 2000; Verhagen et al., 2000). Once in the 
cytosol, Smac/Diablo interacts with several inhibitors of apoptosis (IAPs), thereby reducing 
the inhibitory effect of IAPs on initiator (such as caspase 9) and effector caspases (such as 
caspase 3) (Chai et al., 2000; Srinivasula et al., 2000). In contrast to cytochrome c and 
Smac/Diablo, the release of AIF and endonuclease G from the mitochondrial intermembrane 
space does not result in caspase activation (Susin et al., 1999; Li et al., 2001). Under certain 
death-inducing stimuli, AIF translocates from the mitochondria to the nucleus where it
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triggers large-scale DNA fragmentation through caspase-independent mechanisms (Susin et 
al., 1999). In the same way, endonuclease G, which is normally involved in the replication 
of mitochondrial DNA, can translocate to the nucleus on induction of PCD, and as a result 
bring about fragmentation of nuclear DNA (Li et al., 2001). The AIF homologue wah-1, in 
Caenorhabditis elegans has been described to associate and cooperate with endonuclease G 
to promote DNA degradation and apoptosis (Wang et al., 2002).
Stress in the endoplasmic reticulum (ER), such as disturbance of calcium 
homeostasis and accumulation of unfolded proteins, can also result in PCD (Nakagawa et 
al., 2000) through activation of caspase 12; which in turn can cleave caspase 9 (Morishima 
et al., 2002). Pro-PCD members of the Bcl2 family -  for instance Bax and Bak - function at 
the ER to preserve calcium homeostasis as well as regulate ER-dependent PCD (Scorrano et 
al., 2003).
1.6.2 Programmed Cell Death in Amyotrophic Lateral Sclerosis
Early on in the effort to ascertain the nature of mutant SODl’s gained toxic function, 
it was discovered that transfected neuronal cells expressing mutant SOD1 cDNA were dying 
by apoptosis (Rabizadeh et al., 1995). Subsequently similar observations were made in 
transfected PC-12 cells (Ghadge et al., 1997) and in primary neurons obtained from 
transgenic mice expressing mutant SOD1 (Mena et al., 1997). All these in vitro data have 
led many investigators to believe that mutant SOD1 may kill motor neurons by activating 
PCD; a term used for cell death mediated by specific signalling pathways. Ever since the 
identification of neuronal apoptosis inhibitory protein (NAIP) as a candidate gene for an 
inherited ALS-related disorder known as spinal muscular atrophy, the possible implication 
of PCD in ALS has been rather appealing to the field of motor neuron diseases (Roy et al., 
1995).
1.6.3 Morphology of dying motor neurons
In light of the acknowledged proapoptotic properties of mutant SOD1 observed in 
vitro, it may be wondered whether, dying spinal cord motor neurons of transgenic mutant
S0D1 mice, also present features of apoptosis, whose morphological hallmarks include 
cytoplasmic and nuclear condensation, compaction of nuclear chromatin into sharply 
circumscribed masses along the inside of the nuclear membrane, and preservation of struc­
ture of organelles (at least up until the cell is broken into membrane-bound fragments called 
apoptotic bodies that are phagocytosed). This question has been investigated in several 
morphological studies carried out in transgenic mutant SOD1 mice (Dal Canto et al., 1995; 
Migheli et al., 1999; Pasinelli et al., 2000; Vukosavic et al., 2000). Most of the ailing 
neurons are atrophic, in these animals, and their cytoplasm is dominated with vacuoles 
corresponding to dilated rough ER, Golgi apparatus, and mitochondria (Dal Canto et al., 
1995). Ultrastructural studies in these mice (Guegan et al., 2003) indicate that the ailing 
neurons have diffusely condensed cytoplasm and nuclei, along with irregular shapes. At 
present, the actual type of cell death remains to be determined.
Clarke (1999) reported the dying neurons display non-apoptotic morphology. 
However Guegan et al. (2003) were able to detect apoptotic cells in the spinal cord of 
transgenic mutant SOD1 mice and estimated that in end-stage transgenic S0D1G93A mice, 
which have lost about 50% of their anterior-horn motor neurons, about two apoptotic cells 
will be seen per 40jim-thick section of the lumbar spinal cord. It has been observed that the 
vast majority of these apoptotic cells no longer display definite morphological 
characteristics or express phenotypic markers that enable their identification as neurons or 
glia (Guegan et al., 2003). However, less than 15% of the spinal cord apoptotic cells are still 
immunoreactive for specific proteins such as neurofilament or glial fibrillary acid protein 
(Pasinelli et al., 2000), which suggests that in the mutant SOD1 model, both neuronal and 
glial cells are dying by apoptosis (Vukosavic et al., 2000). The rareness in this mouse model 
of ALS, of apoptotic motor neurons, reflects the difficulty in detecting these cells by 
morphological means due to the supposed low daily rate of motor neuron loss (Chiu et al.,
1995) and the extremely rapid clearance of apoptotic bodies. Forms of PCD exist which 
possess morphological features distinct from apoptosis (Clarke, 1999; Yaginuma et al., 
1996; Sperandio et al., 2000), making it difficult to rule out the possibility that a non- 
apoptotic form of PCD triggers mutant SOD 1-related cellular degeneration.
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Using morphological criteria such as size, shape and aggregates of Nissl substance, 
in human ALS cases, Martin (Martin, 1999) has arranged residual spinal cord motor neurons 
in ALS post-mortem samples in three categories that he considers reflect various stages of 
degeneration. In the chromatolysis stage, motor neurons still look like their normal 
counterparts apart from the fact that the cell body appears swollen and round, the Nissl 
substance dispersed, and the nucleus unconventionally placed. Prominent cytoplasmic 
hyaline body inclusions can be seen in some chromatolytic neurons. In the attritional stage, 
the cytoplasm and the nucleus both appear homogenous and condensed, whereas the cell 
body which has a hazy multipolar shape appears shrunken. In the so-called apoptotic stage, 
the affected motor neuron is approximately one-fifth of its typical diameter, with the 
cytoplasm and nucleus both extremely condensed, and the cell body has a fusiform or round 
shape devoid of any process. In particular, in none of these three stages do residual motor 
neurons exhibit a significant number of cytoplasmic vacuoles or nuclear condensation 
accompanied by round chromatin clumps. Collectively, these findings propose that, while 
degenerating neurons in both human ALS and its experimental models do display some 
characteristics reminiscent of apoptosis, the vast majority of dying cells cannot be labelled 
confidently as typically apoptotic.
1.6.4 Expression of apoptotic markers
In addition to exhibiting singular morphological features, apoptotic cells may also 
display a variety of cellular alterations. Detection of intemucleosomal DNA cleavage by 
means of either gel electrophoresis or in situ methods has emerged as a popular means of 
providing evidence for the occurrence of apoptosis in all kinds of pathological situations, 
including ALS. However, like many of these apoptotic markers, DNA fragmentation 
detected by in situ methods, such as terminal deoxynucleotidyl transferase-mediated nick 
end labelling, is now well recognized as also taking place in nonapoptotic cell death, 
including necrosis (Clarke, 1999). Therefore the value of DNA cleavage as a specific marker 
of apoptosis, evidenced by in situ techniques, may be limited. In addition to this limitation, 
conflicting results have been obtained from the search for DNA fragmentation in ALS post­
mortem samples.
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In one autopsy study, an in situ method was used to detect DNA fragmentation in 
spinal cord motor neurons, which gave positive results in ALS and negative in control 
specimens (Yoshiyama et al., 1994). In two other similar studies, fragmentation of DNA was 
not only detected in the motor cortex and spinal cord of ALS specimens, but also, though to 
a lesser extent, in control specimens (Ekegren et al., 1999; Migheli et al., 1994.). A 
subsequent study, detected intemucleosomal fragmentation of DNA in affected (e.g., motor 
cortex and spinal cord) but not in spared brain regions (e.g., somatosensory cortex) of ALS 
cases (Martin, 1999), as well as in diseased motor neurons, only at the somatodendritic 
attrition and apoptotic stages but not at the chromatolytic stage (Martin, 1999). The author 
of that study has also documented DNA fragmentation, by gel electrophoresis, in anterior- 
horn gray matter of the spinal cord and motor cortex of ALS cases (Martin, 1999), a 
technique not commonly used to identify apoptosis in the nervous system simply because in 
many neurological situations, it is difficult to obtain samples with a sufficiently high 
proportion of dying cells. In contrast to all these positive findings, other groups, utilising 
similar techniques and tissue samples, have been unsuccessful in providing any evidence of 
intemucleosomal DNA cleavage in post-mortem tissue from human ALS cases or from 
animal models of the disease (Migheli et al., 1994 & 1999; He et al., 2000). Though the 
actual reason for these conflicting results is unclear, the reliability and even the specificity of 
such findings are brought into question.
Two other apoptotic markers also studied in ALS, include the LeY antigen (Hiraishi 
et al., 1993) and fractin (capase-cleaved actin) (Suurmeijer et al., 1999), which make the pic­
ture less ambiguous. Hiraishi et al. (1993) demonstrated that the expression of the 
carbohydrate LeY antigen, which results from the co-operative action of the 
fucosyltransferases al(r)2  and al(r)3, showed good correlation with the presence of 
apoptosis in both normal and tumour tissue. However, not all Le -positive cells showed 
signs of apoptosis and necrosis not associated with Le antigen expression. Neither of these 
markers was detected in spinal cords of controls but both were highly expressed in spinal 
cords of ALS cases (Yoshiyama et al., 1994) and transgenic SODlG93A mice (Vukosavic et 
al., 2000). Similarly, increased levels of the apoptosis-related protein prostate apoptosis 
response-4 (Rangnekar, 1998) were detected in spinal cord samples from both ALS patients 
and transgenic mutant SOD1 mice compared to their respective controls (Pedersen et al.,
2000). Together with the morphological data summarized above, these findings provide 
support to the idea that apoptosis occurs in ALS. However, all of these studies fail to 
provide definite mechanistic insights into the significance of these alterations in the 
pathogenesis of ALS.
1.6.5 Activation of apoptotic molecular pathways
As the results of morphological studies remain unclear, it appears that a more 
realistic approach to assessing the role of apoptosis in ALS may be to ascertain whether the 
neurodegenerative process in transgenic mutant SOD1 mice, irrespective of the morphology 
of the dying cells, involves known molecular mediators of PCD, and whether targeting such 
crucial and key factors can affect the course of the disease.
PCD is a multistep mechanism that involves a complex interaction between survival 
pathways which are activated by trophic factors and death pathways, activated by various 
stresses. Thus far, two pathways have been most implicated in neuronal survival. One is the 
PI3K pathway, which activates Akt (also known as protein kinase B) to suppress the 
activation of proapoptotic proteins, and the other the extracellular signal-regulated 
kinase/MAPK (ERK/MAPK) pathway, which activates antiapoptotic proteins (Harper et al.,
2001).
Fas appears to contribute to the death of embryonic motor neurons in primary 
cultures (Raoul et al., 2002), but whether it contributes to the death of mature motor neurons 
and to the process of neurodegeneration in transgenic mice expressing mutant SOD1 
remains to be shown. Other important molecules in PCD signalling include ceramide, 
MAPKs (JNK and p38), and the transcription factors activator protein-1 and NF-kB (Harper 
et al., 2001; Gupta, 2001).
In light of the supposed proapoptotic properties of mutant SOD1 (Rabizadeh et al.,
1995), it is attractive to suggest that the mutant protein may be a death-signalling molecule 
in itself, either by directly interacting and setting in motion the PCD cascade, or by 
indirectly interacting with a variety of intracellular targets such as trophic factors, Bcl-2
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family members, or even mitochondria. Particularly appealing targets are the mitochondria, 
not only because they contain mutant SOD1 (SOD1) but because they are structurally and 
functionally altered in transgenic mutant SOD1 mice (Kong et al., 1998; Browne et al.,
1998), and because they play a critical role in PCD (Kroemer et al. 2000). Of additional 
relevance to the issue of death and survival signals, in the mutant SOD1 model, are the 
Western blot and immunohistochemical demonstrations of the weakening of the surviving 
signal mediated by PI3K/Akt in spinal cords of transgenic mutant SOD1 mice, prior to the 
development of overt neuropathological features (Warita et al., 2001). Several secondary 
alterations arise in spinal cords of transgenic mutant SOD1 mice, on initiation of the mutant 
SODl-mediated neurodegenerative process, such as microglial cell activation (Aimer et al.,
1999) and T cell infiltration (Alexianu et al., 2001), both of which may release a surplus of 
cytokines and other pro-PCD mediators. Thus, while the nature of the initial death signal in 
transgenic mutant SOD1 mice remains indefinable, in a more advanced stage of the disease 
the increased expression of a number of extracellular inflammation-related factors such as 
IL-lp, IL-6, and TNF-a (Nguyen et al., 2001) may result in the amplification of death 
signals that are already reaching motor neurons in this mouse model of ALS, by activating 
death receptors such as Fas (Raoul et al., 2002). Elevation in levels of IL-ip also occurs in 
human ALS spinal cords (Li et al., 2000).
1.6.6 The role of the Bcl-2 family in motor-neuronal cell death in ALS
The Bcl-2 family, implicated in the regulation of PCD, is composed of both 
suppressors of cell-death for instance Bcl-2 and Bcl-xL and promoters such as Bax, Bad, 
Bak, and Bcl-xS (Chao et al., 1998). Within the nervous system several of these molecules 
are present and active and appear to be powerful modulators of neuronal death. Levels of 
Bcl-2 mRNA appear significantly decreased and Bax mRNA levels significantly increased 
in the lumbar cord compared with those of controls, in both human ALS cases and affected 
transgenic SOD1G93A mice (Mu et al., 1996; Vukosavic et al., 1999). This is consistent 
with the finding in both human ALS cases and symptomatic transgenic S0D1G93A mice, that 
the expression levels in the spinal cord of the antiapoptotic proteins Bcl-2 and Bcl-xL are 
either unchanged (Ekegren et al., 1999; Troost et al., 1995) or decreased (Martin, 1999; 
Vukosavic et al., 1999), compared to expression levels of the proapoptotic proteins Bax and
Bad which increase (Martin, 1999; Ekegren et al., 1999; Vukosavic et al., 1999). More 
importantly, it should be noted that a very similar pattern of changes in expression of 
selected pro- and anti-cell death Bcl-2 family members was found in spinal cords of affected 
transgenic SODlG86R mice compared with their wild-type counterparts (Gonzalez de Aguilar 
et al., 2000). However, none of these changes are observed in young asymptomatic 
transgenic S0D1G93A mice, but they clearly become more prominent as the 
neurodegenerative disease process progresses (Vukosavic et al., 1999). Regarding function, 
Bax is not only upregulated but is also expressed primarily in its active homodimeric confor­
mation, in the spinal cords of both ALS patients and affected transgenic mice expressing 
mutant SOD1 (Martin, 1999; Vukosavic et al., 1999). Bax is markedly relocated from the 
cytosol to the mitochondria (Martin, 1999; Guegan et al., 2001; Przedborski et al., 2003); 
this relocation is, under many cellular conditions, a prerequisite to the employment of the 
mitochondria-dependent apoptosis pathway.
During the neurodegenerative process in ALS, it appears as though the fine-tuned 
balance between cell-death antagonist and agonist of the Bcl-2 family is upset in favour of 
pro-cell death forces. This view is supported by the finding that overexpression of Bcl-2, 
probably by buffering some of the pro-cell death force (Vukosavic et al., 1999), alleviates 
neurodegeneration and hence prolongs survival in transgenic SODlG93Amice (Kostic et al., 
1997); in addition to this a similar beneficial effect of Bcl-2 was reported in mutant SOD1- 
transfected PC-12 cells (Ghadge et al., 1997).
Two other important members of the Bcl-2 family, which appear to play a role in 
ALS, are Bid and Harakiri. These two potent pro-PCD peptides participate in the cell death 
process, either directly or indirectly, by modulating the effect of Bax. Bid appears to be 
highly expressed in the spinal cord of transgenic SOD1G93a mice and attains its most active 
form following cleavage, during the progression of the disease (Guegan et al., 2002). 
Harakiri's expression has been detected specifically in spared motor neurons of ALS spinal 
cord specimens but not of control, some of which exhibited an abnormal morphology 
reminiscent of that labelled by Troost et al. (Troost et al., 1995) as apoptotic (Shinoe et al.,
2001).
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As in other pathological circumstances, it is doubtful that mutant SOD1 directly 
produces the observed changes in Bax. It is more likely that mutant SOD1 triggers 
intracellular signalling pathways, which consequently bring about Bax upregulation and 
translocation. This scenario would be consistent with what is currently known about the 
regulation of Bax and its activation is in PCD. The tumour suppressor protein p53 is one of 
the rare molecules known to regulate Bax expression (Miyashita et al., 1994). Under normal 
conditions, basal levels of p53 in the cell are very low, but once activated, as seen in 
pathological situations, there is a rapid increase in p53 mRNA and protein levels, as well as 
posttranslational modifications that stabilize the protein (Appella et al., 2001).
Evidence supporting activation of the p53 pathway in ALS comes from increased 
levels of p53 in the nuclear fraction of affected brain regions in ALS patients (Martin, 2000), 
along with increased levels of p53 immunostaining in neuron nuclei of transgenic S0D1G86R 
mice (Gonzalez de Aguilar et al., 2000). In spite of this compelling evidence that p53 is 
activated in ALS, two independent studies investigating the cross of G93A mice with p53- 
knockout mice, have been unsuccessful in providing any supportive data for an actual role 
for this transcription factor in mutant SODl-mediated neurodegeneration (Prudlo et al., 
2000; Kuntz et al., 2000).
1.6.7 Caspases in the ALS neurodegenerative process
An instrumental role for caspases in ALS neurodegeneration is supported by the fact 
that benzyloxycarbonyl-Val-Ala-Asp(0-methyl)-fluoromethylketone, an irreversible broad- 
caspase inhibitor, attenuates mutant SODl-mediated cell death in transfected PC-12 cells 
(Ghadge et al., 1997) as well as in transgenic S0D1G93A mice (Li et al., 2000).
All of the identified caspases are placed in groups based on their function. One 
group, which is now thought to play a key role in cytokine maturation, includes caspases -1, 
-4, -5, -11, -12, and -14. Among this group the most attention, in ALS, has been given to 
caspase-1, which is the key enzyme responsible for the activation of IL-1. Procaspase-1 is 
expressed at high levels in spinal cord motor neurons, and its activation coincides with the 
development of the glial response and with the initial stage of motor neuron loss in the
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spinal cord of transgenic mutant SOD1 mice (Pasinelli et al., 1998 & 2000; Vukosavic et al., 
2000; Li et al., 2000; Guegan et al., 2001). In spite of the possible indirect role of caspase-1 
in PCD, chronic inhibition of caspase-1 by means of a dominant negative mutant of the 
enzyme has been demonstrated to be effective in prolonging the life of transgenic S0D1G93A 
mice (Friedlander et al., 1997).
At present, the status of the other members of the caspase-1 subfamily is unknown in 
ALS. Some preliminary studies have shown that caspase-12, known to be activated 
following ER stress (Nakagawa et al., 2000), is expressed in motor neurons of nontransgenic 
mice, and to a greater extent in those of symptomatic transgenic S0D1G93A mice (Guegan et 
al., 2003). In symptomatic transgenic S0D1G93A mice, the majority of the motor neurons 
that stain immunopositive for caspase-12 appear condensed, shrunken, and vacuolized 
(Guegan et al., 2003) Although further work on caspase-12 remains to be carried out in this 
model of ALS, preliminary data suggests that sick cells represent the site of an ER stress 
whose occurrence may well play a role in the overall cascade of deleterious events that 
ultimately underlies the demise of spinal cord motor neurons in the mutant SOD1 model 
(Guegan et al., 2003). By contrast, caspases -2, -3, -6, -7, -8, -9, and -10 have been 
implicated in apoptosis; however their roles can be further sub-divided into "initiator" and 
"effector."
Interestingly, although significant glial response and IL-lp production takes place 
early in transgenic mutant SOD1 mice, activation of procaspase-8, just like the induction of 
TNF-a (Nguyen et al., 2001), is only detected near the end stage in the spinal cords (Guegan 
et al., 2002). This implies that, in this ALS model, TNF/caspase-8 may be a relatively late 
contributor to the process of degeneration. Another initiator of PCD is caspase-2, whose 
activation occurs in the spinal cord of affected transgenic mutant SOD1 mice (Guegan et al.,
2003). However, caspase-2 ablation in transgenic SODl09^  mice has been reported to make 
no impact to the expression of the disease (Bergeron et al., 1998), suggesting that whatever 
the role is of caspase-2 in ALS, it is not essential. Caspase-9 is a third caspase initiator, 
whose role is crucial in the so-called mitochondria-dependent PCD pathway (Kroemer et al.,
2000). Evidence of a prominent role of this mitochondrial pathway has been documented in 
specimens of spinal cord of both ALS patients and transgenic SOD1G93a mice (Guegan et
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al., 2001). The study showed that while cytochrome c is confined to the mitochondria in 
cells in the control samples, it is diffusely distributed in the cytosol in many of the spared 
cells, especially neurons in the pathological samples.
It has also been shown in transgenic mutant S0D1G93A mice that the mitochondrial 
cytochrome c translocation to the cytosol coincides with the translocation of cytosolic Bax 
to the mitochondria and activation of procaspase-9, prior to activation of downstream 
executioner caspases such as procaspase-3 and procaspase-7. As caspase-9 is believed to be 
so crucial under many cell-death situations, it is possible that the translocation of 
cytochrome c and activation of procaspase-9 observed in ALS may represent significant 
pathological events. The finding that prevention of mitochondrial cytochrome c release 
lengthens the lifespan of transgenic S0D1G93A mice is consistent with this view (Zhu et al.,
2002).
Procaspases -3, -6, and -7 make up the effector caspases, all of which have short 
prodomains and lack intrinsic enzymatic activity. However, once effector caspases are 
cleaved, for example by initiator caspases, they acquire the capacity to cleave a large 
number of intracellular substrates, which probably eventually results in the demise of the 
cell. Consistent with this, it has been reported that key effector caspases such as caspase-3 
and caspase-7 are indeed activated in spinal cords of transgenic mutant SOD1 mice in a 
manner that appears to be time-dependent and which parallels the time course of the 
neurodegenerative process (Pasinelli et al., 2000; Vukosavic et al., 2000); in addition, 
activation of procaspase-3 has also been observed in spinal cord samples from ALS patients 
(Martin, 1999). However, current data on the sequence of events in the PCD cascade suggest 
that, once effector caspases have been activated, the cell death process has reached a point of 
no return, at least under certain pathological situations. This suggests that, in these specific 
conditions, the death commitment point is situated upstream of these caspases, and as a 
result, interventions aimed at inhibiting these downstream caspases may be unsuccessful in 
providing any real neuroprotective benefit (Zheng et al., 2000). It remains to be determined 
whether this applies to the demise of motor neurons in ALS.
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1.7 Towards the Development of ALS Therapies
ALS is among the many neurodegenerative diseases for which there is currently no 
cure. The following sections provide a short overview of what is currently available to 
patients suffering from ALS, what is being developed and the targets for the development of 
these new and hopefully more effective treatments. The use of viral vectors in the context of 
gene therapy is also discussed, followed by a description of the HSV-1 based vectors which 
were originally developed for in vivo gene delivery' in the central nervous system and which 
were subsequently utilised in the work presented in this thesis.
1.7.1 Current treatment and potential therapies for ALS
To date, multiple clinical trials have been completed using individual agents 
including recombinant human ciliary neurotrophic factor (rHCNTF), riluzole, insulin-like 
growth factor-1 (IGF-1), topiramate, alpha-tocopherol (vitamin E), creatine, selegine, 
nimodipine, verapamil, and gabapentin (Bensimon et al., 1994; Borasio et al., 1998; 
Desnuelle et al., 2001; Jackson et al., 2001; Kwiecinski et al., 2001; Miller et al., 1996 & 
2001; Cudkowicz et al., 2003; Groeneveld et al., 2003). Regrettably however, none of these 
single agents has produced significant benefit. Currently, as mentioned previously Riluzole 
is the only FDA-approved drug for ALS patients, and has a modest effect on survival, 
respiratory capacity and rate of declining strength, but not on total strength, quality of life, 
or functional capacity (Lacomblez et al., 1996). From data obtained from animal models, it 
is known that anti-glutamate agents are thought to affect the initiation but not the propaga­
tion of motor neuron degeneration; the converse being true for antioxidant agents (Gurney et 
al., 1996; Torreilles et al., 1999; Ochs et al., 2000; Simpson et al., 2003).
A combinational drug treatment that addresses different pathophysiologic 
mechanisms makes sense and is necessary to achieve the most significant benefit (Eisen et 
al., 1999; Mitsumoto et al., 2001; Carter et al., 2003). Several reports, utilising different 
laboratory models of motor neuron degeneration, support the benefit of combination drug 
therapy (Bilak et al., 2001; Iwasaki et al., 1999; Kriz et al., 2003; Mohammadi et al., 2001; 
Nagano et al., 1999 & 2003; Zhang et al., 2003). Some success has been obtained from
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limited combination drug trials, suggesting synergistic effects between different drugs 
(Stevie et al., 1998; Cudkowicz et al., 2003). Recently rasagiline in combination with 
riluzole was found to be a promising clinical combination with survival being extended by 
approximately 20% in ALS mouse model (Waibel et al., 2004). In addition the combination 
of minocycline with riluzole was also shown to provide a greater neuroprotective effect than 
riluzole alone and currently phase III trial in ALS is currently underway (Gordon et al.,
2004).
Extracellular deatfi signals
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Figure 1.4 Diagram shows how programmed cell death may be targeted in amyotrophic lateral 
sclerosis. In a transgenic mouse model of amyotrophic lateral sclerosis (ALS), initiator caspases 
activate downstream effector caspases primarily through the recruitment of the mitochondrial 
programmed cell death pathway. Interfering with different molecular elements of this cascade (red 
boxes), and particularly with caspase activation, has been shown to significantly delay disease onset 
and mortality in this experimental model of ALS. Abbreviations: Cyt., cytochrome; DN, dominant 
negative; FasL, Fas ligand; IETD Ile-Glu-Thr-Asp-fluoromethylketane; tBid, truncated Bid; Tg, 
transgenic; zVAD-fmk, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. Diagram adapted 
from Vila et al., (2003).
Inhibition of PCD, through use of pan-caspase inhibitor zVAD-fmk (Li et al., 2000) 
and through over-expression of Bcl-2 (Kostic et al., 1997), in transgenic mice that express 
mutant SOD1, delays but does not permanently prevent neurodegeneration, suggesting that
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PCD may be triggered as a result of a direct effect, but from an indirect effect of the mutant 
protein on the PCD machinery (Guegan et al., 2003). In keeping with this view, mutant 
SOD1 has the susceptibility to form intracellular aggregates, the presence of which in the 
cytosol of motor neurons might impair microtubule dependent axonal transport (Cleveland 
et al., 2001) and tie-up important molecular chaperones (Bruening et al., 1999). It might 
therefore be possible that mutant SOD1, promotes protein aggregation, which then brings 
about important motor neuron disturbances that consequently trigger PCD. Interfering with 
PCD can delay neuronal death and prolong survival in experimental models of ALS. 
However, eventually these mice die despite the different interventions indicating that 
targeting the PCD cascade can slow the death process but cannot stop it. Figure 1.4 shows 
how interference with different molecular elements of the PCD cascade may significantly 
delay disease onset in ALS.
1.7.2 Viral gene delivery for ALS?
In addition to trials and intensive research towards the development of effective ALS 
treatments, described earlier on, gene therapy, utilising viral vectors or other means, has also 
been developed in the recent years. There were two types of gene therapy; the first involves 
the delivery of a functional gene to an individual who has a defective copy gene concerned 
and the second involves the delivery of genes, the protein products of which provide 
beneficial effect in treatment of symptoms of the disease concerned. In ALS the second 
approach has shown a certain degree of promise.
The strategy for the development of gene therapy procedures for ALS aims to deliver 
factors protective for the motor neuron or factors with neurorestorative properties in a safe 
and standardised manner. For example, delivery of genes encoding neurotrophic factors such 
as either IGF-1 (insulin-like growth factor 1) or GDNF (glial-derived neurotrophic factor), 
via engineered adeno-associated virus (AAV), to promote the survival of neurons (Kaspar et 
al., 2003).
Naturally occurring trophic factors that promote the survival and growth of motor 
neurons (Elliot et al., 1996; Oppenheim, 1996) have been attractive candidates for such a
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therapy; however they have had a disappointing history in ALS. Driven mostly by hope and 
little more than suggestive pre-clinical evidence, trials carried out with ciliary neurotrophic 
factor and brain-derived trophic factor have been unsuccessful. Although IGF-1 brought 
about a mild slowing of disease in ALS patients in a North American trial (Lai et al., 1997) 
results of a European trial were negative (Borasio et al., 1998). The multiple failures have 
triggered a growing pessimism for the overall trophic strategy, although they could reflect 
the use of wrong neurotrophins or, even simply, failure to deliver the neurotrophin 
effectively to the target cells of the spinal cord.
HSV-1 has a number of properties which make it a good candidate for the 
development of vectors for the delivery of genes to the nervous system and hence 
development of ALS therapies: (a) natural tropism for neurons, (b) large -150 kb viral 
genome allowing the insertion of multiple therapeutic genes <20 kb (c) ability to establish 
asymptomatic life-long latent infections. However, disadvantages include vector toxicity and 
an inability to maintain long-term transgene expression, as a result of latency-associated 
problems; studies to overcome these problems are ongoing.
Although many studies were reported to have delivered various genes to muscle and 
motor neurons of different animal ALS models and through utilising different viral vectors, 
at present the optimal vector remains uncertain. Examples of successful trials utilising viral 
gene delivery include the study conducted by Azzouz et al. (2000) in transgenic ALS mice 
demonstrating increased motoneuron survival and improved neuromuscular function 
following intraspinal injection of an AAV encoding Bcl-2. Kaspar et al. (2003) extended the 
lifespan of SOD1-G93A transgenic mice by approximately 5 weeks through viral deliver of 
IGF-1 via AAV, however similar delivery of GDNF was much less effective. Azzouz et al. 
(2004) showed that delivery of VEGF (vascular endothelial growth factor) via lentiviral 
vector prolonged survival in an ALS mouse model. However the last two studies only 
increased survival of the SOD1G93A transgenic mice by approximately 30%.
More recently, Raoul et al. (2005) showed that intraspinal injection of a lentiviral 
vector producing RNAi-mediated silencing of SOD1 substantially reduced both onset and 
progression of the disease in SOD1G93A transgenic mice. In addition, Ralph et al. (2005)
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similarly demonstrated, through RNAi and lentiviral vectors, a delay in onset of ALS 
symptoms in SOD1G93A transgenic mice by more than 100% and an extension in survival 
by nearly 80% of their normal life span. The improved survival observed in these latter 
studies is probably due to the direct approach of targeting the genetic factor underlying the 
disease.
1.7.3 HSV-based Viral Vectors and Gene Therapy
This section will only briefly refer to herpes simplex virus type 1 (HSV-1) -based 
viral vectors for gene delivery in the central nervous system and highlight its potential as a 
means of efficient gene delivery to the CNS for the therapy of ALS and other 
neurodegenerative diseases. HSV-based vectors were used in this study (Chapters 4 and 5) 
as a highly efficient in vitro mechanism of gene delivery to cells, originally being developed 
for purposes of gene therapy. Information on the vectors utilised here will be provided (see 
also Introduction of Chapter 4) following an overview of HSV-1 and gene therapy.
1.7.3.1 Basic HSV-1 biology and the rationale behind the development of HSV-1 
vectors
The optimum HSV viral vector should not only deliver the gene of interest 
efficiently but also drive its long term expression and have no cytopathic effects; it should 
also be incapable of replication and unable to illicit an immune response and should not 
interfere with host cell’s normal cellular functions. Herpes simplex virus-1 (HSV-1) based 
vectors are attractive for use in gene delivery as HSV-1 can infect a wide-range of dividing 
or non-dividing cells (i.e. virtually any human cell). In neurons the virus enters a lifelong 
latent state where it remains latent and episomal. The virus has evolved the ability of 
retrograde transport and can spread from the site of original infection to the site of latency in 
the spinal ganglia (Cook and Stevens, 1973). In addition, during latency, RNA species called 
the latency-associated transcripts (LATs) are generated by transcription of the long repeat 
region of the viral genome.
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As reviewed by Latchman and Coffin (2001), HSV-1 infection of permissive cells 
results in the expression of more than 80 viral genes in a well coordinated manner of 
immediate early (IE), early (E), and late (L) gene products (Lokensgard et al., 1994) with 
subsequent cell lysis and release of progeny virions. Activation of IE genes occurs through 
the interaction of the tegument protein, vmw65 (also called virion protein 16, VP 16 or a- 
transinducing factor, a-TIF) with cellular factors which then transactivate the promoters of 
the immediate early (IE) genes and as a result initiate an efficient lytic infection (Batterson 
et al. 1983). The initial expression of IE genes is enhanced by the tegument protein, vmw65 
which enters the nucleus with the viral genome and works in cohort with the cellular factor 
octamer binding protein-1 (Oct-1) to bind to a consensus sequence in the IE gene promoter 
enhancers. Vmw65 cannot bind DNA directly and relies on the cellular POU domain protein 
Oct-1 and one other cellular factor known as host cell factor (HCF) in order to form a 
multicomponent complex on the TAATGARAT (where R is a purine) motifs which are 
present in all the IE gene promoters (Gaffney et al., 1985). Five virally encoded IE genes 
exist, they are: ICPO, ICP4, ICP22, ICP27, and ICP47.
In the course of a productive infection in cultured cells, HSV-1 gene expression 
takes place in a tightly regulated cascade which allows for the controlled expression of three 
classes of genes: the immediate early (IE) or “a ” genes, the early (E) or “P” genes and the 
late (L) genes or “y” genes (Honess and Roizman 1974). The “a ” gene products, infected 
cell polypeptides (ICP) ICPO, ICP4, ICP22 and ICP27 all have regulatory functions, and 
they act together to regulate the expression of all classes of viral genes (Roizman and Sears,
1996). The “f3” genes which are expressed next encode many of the proteins involved in the 
synthesis of viral DNA (Honess and Roizman 1974) and the late (L) genes or “y” genes 
mainly encode the virion components (Batterson and Roizman 1983). With the exception of 
ICP47 (which is also an “a ” gene product), the IE proteins have regulatory effects on E and 
L gene expression and are therefore responsible for co-ordinating a well-ordered temporal 
cascade of viral gene expression and viral replication.
Although it does not bind to DNA, ICPO is an activator of E and L genes and
therefore of viral replication. It is not essential for infection but its deletion significantly
impairs viral replication. ICP4 encodes a nuclear phosphoprotein that is not only essential
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for viral growth but also controls the expression of E and L genes through both 
transcriptional and posttranscriptional mechanisms (DeLuca and Schaffer 1985). In addition, 
ICP4 also negatively regulates IE gene expression and is therefore an essential regulatory IE 
gene and is the major transcriptional regulator of HSV-1 (DeLuca et al. 1985). ICP27 is 
required for the prevention of apoptosis in infected human cells. ICP27 also contributes to 
the shutoff of host protein synthesis observed during lytic infection, by means of impairment 
of host cell pre-mRNA splicing (Hardy and Sandri-Goldin 1994). ICP22 is not essential for 
viral growth but has been shown to promote efficient late gene expression in a cell type 
dependent manner (Sears et al. 1985). ICP47 is not essential for viral replication and does 
not play a part in IE gene expression. However, it has been shown that ICP47, which is a 
cytosolic protein, binds to the transporter associated with antigen processing (TAP) and as a 
result retains MHC class I molecules in the endoplasmic reticulum, and blocks peptide 
translocation. This consequently inhibits antigen presentation via the MHC class I pathway 
and is thought to be a mechanism through which the virus escapes host immunity (Hill et al. 
1995).
Following IE gene expression, the next genes to be transcribed are the E genes. The 
E gene products include enzymes, which are essential for viral DNA replication. Synthesis 
of viral DNA takes place via a rolling circle mechanism that produces head-to-tail 
concatemers of the HSV-1 genome (Jacob et al. 1979). L gene expression is triggered by 
ICP4 and ICP27 and only takes place after viral DNA synthesis. L gene products include 
structural proteins of the capsid, tegument and envelope, which allow assembly of the virus. 
The viral DNA concatemers are cleaved into genome length units and packaged into the 
capsids within six hours of infection. The newly formed capsids covered with tegument 
proteins bud out of the nucleus, thereby acquiring the glycoprotein envelope and are 
transported to the cell surface via the endoplasmic reticulum. The lytic life cycle is rapid and 
results in cell death within ten hours of infection (Fink et al 1996).
Deletion of the major viral transactivator protein ICP4 dramatically reduces the 
expression of the ~80 HSV-1 genes. However, even though the majority of the virus genome 
is not transcribed, mutants incorporating the ICP4 deletion are still cytotoxic (Marshall et 
al., 2000). The majority of this toxicity is due to the products of the other regulatory IE
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genes, ICPO, ICP22, and ICP27 (Marshall et al., 2000; McFarlane et al., 1992; Palella et al., 
1988) and is further reduced when these other regulatory IE genes are inactivated together 
with ICP4. Thus, an optimal HSV vector should not express significant amounts of any of 
the regulatory IE genes.
1.7.3.2 Viral vectors used in this study
The viruses utilised in this study were made by Dr. Marcus Wagstaff and Dr Rob 
Coffin. The Hsp and HSF-1 viruses created by Dr Marcus Wagstaff have proved to be very 
useful in efficiently over-expressing Hsps or HSF-1 in neuronal (Wagstaff et al., 1999; 
Wagstaff et al., 1998; Zourlidou et al; 2004) and non-neuronal cells (Brar et al., 1999; 
Jamshidi et al., 2004). The SOD1 viruses created by Dr Rob Coffin have been used in this 
study to deliver wt-SODl and G93R-SOD1 mutant to neuronal cells (Patel et al., 2005). The 
recombinant vectors 17+pR19 and 17+pR20.5 were designed so that they can express high 
levels of the transgene (Hsps or reporter genes) during latency (see also Introductions of 
Chapter 4 & Chapter 5).
The Hsp and HSF-1 transgenes were driven by the human cytomegalovirus 
immediate-early (CMV-IE) promoter that was inserted immediately downstream of the 
latency associated transcript promoter 2 (LAT P2); (figure 1.5a). This expression construct 
was introduced into the non-essential LAT region of the IE2 deleted mutant HSV-1 DNA. 
The CMV-IE promoter drives the transcription of the transgene as well as the bovine growth 
hormone polyadenylation sequence. The use of the LAT PI and LAT P2 promoters with the 
CMV-IE promoter is thought to facilitate expression throughout viral latency in neurons.
For the SOD viruses the vector also contained green fluorescent protein (GFP) 
reporter gene whose expression was driven by CMV promoter with the SOD1 gene 
expression driven by the RSV promoter, with the latent associated transcript LAT P2 region 
(from HSV-1) between the two promoters to gain long-term expression of both transgenes 
(figure 1.5b). This virus lacks the ICP27 gene, is deleted for the endogenous LAT P2 
regions thereby preventing recombination with the inserted LAT P2-containing expression 
cassette pR20.5 outside the LAT region. The pR20.5 cassette consists of a central LAT P2
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element flanked by two heterologous promoters (CMV-IE and RSV) arranged in a back-to- 
back orientation, allowing simultaneous expression of either wt-SODl or G93R-SOD1 
mutant (under the Rous Sarcoma Virus - RSV- promoter) and GFP (under CMV-IE 
promoter) and enabling long term expression of both transgenes. This cassette was inserted 
into a plasmid to enable insertional inactivation of the gene encoding virion host shut off 
protein (vhs), which has been shown to play a role in pathogenesis and latency (Strelow and 
Leib, 1995) and further disabled the HSV virus.
(a)
LAT PI LAT P2
HSV-1 Flanking HSV-1 Flanking
< ■ Sequence CM V -IE G F P  o r  H SP Sequence
f 1
pA BGH polyA
(b)
LATP2
HSV-1 Flanking W t-or RSV CMV-IE G F P HSV-1 FlankingSequence Mut SOD1 Sequence
Figure 1.5 (a) The pR19 cassette utilising the 17+ virus construct (b) The pR20.5 cassette utilising 
the 17+ virus constructs.
Figure 1.5 shows the expression cassettes, which were inserted into the non-essential 
2 kb LAT region of the HSV-1 genome of an EE2-deleted mutant HSV-1 strain (IE2 is the 
essential gene that encodes ICP27; HSV-1 strain 17+; GenBank™ accession number
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HE ICG) (Wagstaff et al., 1999). The IE genes ICP4 and ICP27 are essential for viral 
replication. Therefore ICP27 was deleted in these virus types. These viruses were designed 
to produce a less cytopathic, latent, non-replicating viral mutant, which was tested and found 
to be suitable for gene delivery (Wagstaff et al., 1999; Kalwy et al., 2003). These viruses 
were grown on B 130/2 cells which complement for the deleted ICP27 (Howard et al., 1998).
1.8 Heat Shock Proteins
1.8.1 Overview
The idea that heat shock proteins (Hsps) are therapeutic targets for 
neurodegenerative diseases is supported by a significant amount of experimental evidence, 
which will be described in later sections. Before reviewing the links of Hsps to 
neurodegenerative disease and specifically to ALS, it is essential to provide an overview of 
the Hsp families and their roles in the cell.
Stress or heat shock proteins (Hsps) were first discovered in 1962 (Ritossa, 1962) as 
a set of highly conserved proteins whose expression was induced by a heat shock. Subse­
quently it was shown that many other stresses could induce expression of these proteins 
(Jacobson et al., 1997). Mammalian Hsps have been organized in two groups according to 
their size: high molecular weight Hsps and small Hsps. The high molecular weight group 
includes three major families: Hsp90, Hsp70, and Hsp60. Some of them are expressed 
constitutively while the expression of others is stimulated by stressful conditions. In 
addition, these proteins can undergo relocation to different sub-cellular compartments. High 
molecular weight Hsps, such as Hsp70, are ATP-dependent chaperones and need co­
chaperones to modulate their conformation and ATP binding. In contrast, small Hsps, for 
instance Hsp27, are ATP-independent chaperones (Jacobson et al., 1997). The term 
molecular chaperone is given to a functionally related set of proteins divided into several 
classes or families according to their molecular weight. A cell may express multiple 
members of the same chaperone family; for example, the yeast S. cerevisiae produces 14 
different versions of the chaperone Hsp70 (Craig et al., 1999). Proteins from the same class
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of molecular chaperones frequently exhibit significant amounts of sequence homology and 
are structurally and functionally related, while there are hardly any homology exists between 
chaperones from different families. However, in spite of this diversity, most molecular 
chaperones share common functional features.
Hsps have a cytoprotective function through which they can enable cells to adapt to 
gradual changes in their environment and to survive in otherwise lethal conditions. The 
different pathways through which Hsps modulate cell death are only now beginning to be 
understood.
1.8.2 Heat shock proteins function as chaperones
The Hsp70 family of stress proteins represents the most conserved and best studied 
class of Hsps. Human cells possess several Hsp70 family members including stress 
inducible Hsp70, constitutively expressed Hsc70, mitochondrial Hsp75, and Grp78, 
localized in the endoplasmic reticulum (Jaatela et al., 1999). Under normal conditions, 
Hsp70 proteins act as ATP-dependent molecular chaperones by assisting in the folding of 
newly synthesized polypeptides as well as the assembly of multiprotein complexes, in 
addition to the transport of proteins across cellular membranes (Murakami et al., 1988; 
Beckmann et al., 1990; Shi et al., 1992). Under conditions of stress, the synthesis of 
inducible Hsp70 boosts the ability of cells to deal with increased concentrations of unfolded 
or denatured proteins (Nollen et al., 1999).
Principal members of the Hsp90 family comprise the ATP-dependent chaperones 
Hsp90a, Hsp90p, and Grp94 (Csermely et al., 1998). The two Hsp90 isoforms are 
constitutively expressed in eukaryotic cells and are essential for their viability. These 
proteins constitute 1-2% of cytosolic proteins and can accumulate further in response to 
stress. Hsp90 proteins have been shown to associate with several signalling proteins, 
including ligand-dependent transcription factors such as steroid receptor (Nathan et al., 
1995), ligand-independent transcription factors such as MyoD (Shaknovich et al., 1992), 
tyrosine kinases such as v-Src (Hartson et al., 1994), and serine/threonine kinases such as
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Raf-1 (Wartmann et al., 1994); the main chaperone role of these proteins is the promotion of 
the conformational maturation of these transcription factors and signal transducing kinases.
Mammalian Hsp60, also known as chaperonin, is a constitutive protein found mainly 
within the mitochondrial matrix, although 15-20% of the protein is located in the cytosol. 
Hsp60 plays a part in the folding of mitochondrial proteins and assists in the proteolytic 
degradation of misfolded or denatured proteins in an ATP-dependent manner. The 
chaperone function of Hsp60 is regulated by its co-factor Hsp 10, which binds to Hsp60 and 
regulates substrate binding and ATPase activity. In the presence of ADP, two molecules of 
Hsp 10 bind to one Hsp60 molecule. Hsp60 and Hsp 10 do not always operate as a single 
functional unit, as only newly imported proteins are severely affected by inactivation of 
Hsp 10 (Bukau et al., 1998).
Proteins of the small Hsp family, that include Hsp27 and the a-crystallins, range in 
size from 15 to 50kDa and share sequence homologies as well as biochemical properties 
such as phosphorylation and oligomerization. For instance, Hsp27, a protein abundantly 
expressed in several cell types and tissues at specific stages of differentiation and 
development, can form oligomers up to lOOOkDa in size. These powerful ATP-independent 
chaperones defend the cell against protein aggregation (Ehmsperger et al., 1997). The 
affinity of small Hsps for the proteins to be chaperoned is most probably modulated through 
their phosphorylation and oligomerization status. The dimer of Hsp27 appears to be the 
building block for the multimeric complexes. Hsp27 oligomerization is a dynamic process, 
which is dependent on the phosphorylation status of the protein and exposure to stress 
(Garrido et al., 2002). Hsp27 can be phosphorylated at three serine residues with 
oligomerization being enhanced through its dephosphorylation. This phosphorylation is a 
reversible process catalyzed by the MAPKAP kinases 2 and 3 in response to a range of 
stresses, including differentiating agents, mitogens, inflammatory cytokines such as TNFa 
and IL-1{3, hydrogen peroxide, and other oxidants.
Most Hsps are involved in the proper folding and/or elimination of misfolded
proteins, thereby contributing to cell survival. Some of the important house-keeping
functions ascribed to the molecular chaperones include: (1) the import of proteins into
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cellular compartments; (2) the folding of proteins in the cytosol, endoplasmic reticulum, and 
mitochondria; (3) the degradation of unstable proteins; (4) dissolution of protein complexes; 
(5) prevention of protein aggregation; (6) the control of regulatory proteins; as well as (7) 
the refolding of misfolded proteins (Bukau et al., 1998). The accumulation of abnormally 
folded proteins in the nucleus or the cytosol that comes about as a consequence of stress, 
such as increased temperatures, free oxygen radicals, heavy metals, and even antibiotics 
(Sherman et al., 2001), results in the formation of aggregates that disturb normal cellular 
function and as a result trigger cell death (Sherman et al., 2001). Such a mechanism appears 
to be involved in the pathogenesis of lesions that are characteristic of many 
neurodegenerative disorders.
The factors that define the specificity of the chaperone activity are the structure of 
the chaperone as well as the size and localization of the protein to be chaperoned (Table 
1.2). Recently, it has been recognized that Hsps also regulate apoptosis with Hsp27 and 
Hsp70 possessing antiapoptotic properties, while Hsp60 and Hsp 10 are thought to possess 
both proapoptotic or anti-apoptotic properties depending on sub-cellular localisation - 
mitochondrial (Samali et al., 1999; Xanthoudakis et al., 1999) or cytoplasmic (Lin et al., 
2001; Kirchhoff et al., 2002) respectively. Hsps are thought to function at multiple points in 
the apoptotic signalling pathway (Fig. 1.6).
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Figure 1.6 Diagram illustrating the regulation of mitochondrial cell death pathways by Hsps. Hsp27 
binds to cytochrome c (Bruey et al., 2000); Hsp70 and Hsp90 bind to Apaf-1 (Beere et al., 2000; 
Pandey et al., 2000; Saleh et al., 2000) in all cases leading to inhibition of caspase activation. 
Additional negative effect of Hsp27 and Hsp70 on events both further upstream and downstream 
have been described (Jaattela et al., 1998; Paul et al., 2002; Pandey et al., 2000). Hsp60 and HsplO 
possess the ability to directly promote the proteolytic maturation of caspase-3 (Samali et al., 1999; 
Xanthoudakis et al., 1999). Hsp90 interacts with RIP-1 kinase and Akt and thereby promotes NF-kB- 
mediated inhibition of apoptosis (Lewis et al., 2000; Sato et al., 2000). Induction of caspase 
activation triggers proteasome activation (Dallaporta et al., 2000). Hsps facilitate the degradation of 
proteins via the ubiquitin/proteasome system (Mathew et al., 2001). Figure adapted from Parcellier et 
al., (2003).
Hsps are grouped into families according to their molecular weight however there is 
some confusion that exists about their nomenclature. Table 1.2 provides a list of the major 
Hsp families; references are not included in the table but are cited in the text when an Hsp is 
mentioned.
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Table 1.2 Heat shock protein families and the functions o f some of their members
Heat Shock 
Protein Family
Main Members Examples of Function
Hsp90
Hsp90a, Hsp90(3 
Grp94
Major role in signal transduction; 
maintains inactive form of steroid 
receptor; it has >100 known “clients”
Hsp70
Hsp70(Hsp72),
Hsc70(Hsp73),
Grp78 (BiP), 
Grp75(mitochondria), 
Hsx70
(primates only)
Molecular chaperone; translocation 
and assembly of multiprotein 
complexes; provides protection 
against many stresses; anti-apoptotic 
actions; degradation of substrates via 
the proteasome
Hsp60
Hsp60
(mitochondria), 
GroEL (prokaryotic)
Folds “molten globule” proteins or 
domains; mitochondrial protein 
folding
Hsp56 Hsp56 (FKBP56)
Protein folding; maintains inactive 
form of steroid receptor; a co-factor of 
Hsp90
Hsp40
Hdjl (Hsp40), 
Hdj2(Hsdjl), Hsc40, 
Csp, Tpr2, auxilin, 
etc
Protein folding; stimulates Hsp70 
ATPase activity in PD and 
polyglutamine disease inclusions
Hsp32 Hsp32 (HOI) Antioxidant
Hsp27
Hsp27, Hsp25, 
Hsp22,Hsp26, 
aA-crystallin, aB- 
crystallin
Actin binding; protein folding; anti- 
apoptotic functions; degradation of 
certain substrates via the proteasome; 
provides protection against stresses
Others
Ubiquitin 
Hsp 10
UPS-Protein degradation (ubiquitin) 
A regulator and co-factor of Hsp60
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1.8.3 Hsps as anti-apoptotic molecules
For some time now it has been known that cells induced to accumulate Hsps 
subsequently become more tolerant to cytotoxic insults, a phenomenon termed 
"thermotolerance" (Parsell et al., 1993; Li et al., 1980; Li et al., 1982). This increased 
cellular survival is linked to the expression of Hsps and their ability to prevent cell death.
The recent discovery of relationship between Hsp expression and increased cell 
survival, has pointed to Hsps as playing a crucial role in the regulation of the apoptotic cell 
machinery. Investigations have confirmed that Hsp27 and Hsp72 increase cell survival in 
response to apoptotic stimuli (Mehlen et al., 1996; Mosser et al., 1992; Samali et al., 1996). 
Therefore it is apparent that the protective effect of Hsps during thermotolerance is due, to 
some extent, to the ability of these proteins to inhibit apoptosis (Mosser et al., 1992). A large 
amount of attention has focused on elucidation of the molecular mechanism by which Hsps 
mediate their anti-apoptotic abilities, due to their potential role as key death determinants 
within cells. Hsp72 has been reported to inhibit apoptosis via a direct interaction with Apaf- 
1, thus preventing the docking and subsequent activation of pro-caspase-9 (Beere et al., 
2000; Saleh et al., 2000). Furthermore, Hsp90 negatively regulates caspase activity by 
inhibiting the cytochrome c-mediated Apaf-1 oligomerization (Pandey et al., 2000). In 
accordance with these observations interactions between Hsp27 and key components 
necessary for the activation of caspases have also been observed.
The following sections discuss Hsp70 and Hsp27 which are the major Hsps used in 
this study and their roles in stress, in cell death pathways, in proteolytic degradation by the 
proteasome and finally in neurodegeneration and ALS in particular.
1.8.4 The Hsp70 System
The Hsp70 proteins make up the central part of a ubiquitous chaperone system that is 
present in most compartments of eukaryotic cells, in eubacteria, as well as in many archaea. 
The most extensively studied representative of this chaperone group is the DnaK protein, 
from the bacterium E. coli; DnaK is the Hsp70 of E. coli. The Hsp70 proteins are involved
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in a wide variety of cellular processes, such as protein folding as well as in the degradation 
of unstable proteins. In these processes, the common function of Hsp70 appears to be that of 
binding short hydrophobic segments in partially folded polypeptides, thus preventing 
aggregation and arresting the folding process (Craig et al., 1999; Flynn et al., 1991).
In vivo, DnaK and many other Hsp70 chaperones interact with two classes of partner 
proteins, the Hsp40 and the GrpE proteins, which regulate critical steps of its functional 
cycle. Moreover, in the past years, additional partner proteins have been identified, 
particularly in eukaryotic cells, and a number of them link Hsp70 to other chaperone 
systems.
1.8.4.1 Structural and Functional Properties of Hsp70
Hsp70 is made up of two functional domains, one is an N-terminal ATPase domain, 
and the second a smaller C-terminal peptide-binding domain. Both the crystal structures of 
the ATPase domain and the peptide-binding domain of DnaK have been determined 
(Flaherty et al., 1990; Harrison et al., 1997; Zhu et al., 1996). The Hsp70 ATPase domain 
consists of two subdomains separated by a cleft containing the nucleotide-binding site 
(Flaherty et al., 1991). The peptide-binding properties of the C-terminal domain are 
determined by the nature of the bound nucleotide. In the ATP state, although with low 
affinity, there is a rapid binding and dissociation of the peptide substrates (Schmid et al., 
1994). However, the rates of peptide binding and dissociation decrease by more than two 
orders of magnitude when there is no nucleotide or ADP bound to the N-terminal domain, 
whereas the affinity increases significantly. Therefore, ATP hydrolysis acts as a molecular 
switch for Hsp70 between the two states, which are characterized by high dynamics/ low 
affinity or low dynamics/high affinity. As yet, the full-length structure of Hsp70 has not 
been determined, hence, we have no direct information on how communication between 
nucleotide binding and peptide binding takes place at a molecular level. However, insight 
into how this communication might occur may be provided by the X-ray crystal structure of 
the peptide-binding domain of DnaK co-crystallized with a heptapeptide bound to its active 
site (Zhu et al., 1996).
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1.8.4.2 Hsp70: A Potent Anti-apoptotic Protein
Hsp70 has been shown to inhibit apoptosis and as a result increase the survival of 
cells exposed to a wide range of lethal stimuli (Jaattela et al., 1992; Mosser et al., 1997). 
Hsp70 overexpression protects cells from stress-induced apoptosis, both upstream and 
downstream of the caspase cascade activation (Fig. 1.6). In addition, some preliminary data 
suggests that Hsp70 could protect the cells from energy deprivation and/or ATP depletion 
associated with cell death (Wong et al., 1998).
Elevated levels of Hsp70, achieved through either transient or stable transfections, 
not only reduce or block caspase activation but also suppress mitochondrial damage and 
nuclear fragmentation (Buzzard et al., 1998). Further support of these findings were 
provided by Li et al. (Li et al., 2000) who found Hsp70 inhibited apoptosis downstream of 
cytochrome c release and upstream of caspase-3 activation. This antiapoptotic effect is 
exerted through the Hsp70-mediated modulation of the apoptosome. Hsp70 has been 
demonstrated to directly bind APAF-1, and as a result prevent the recruitment of 
procaspase-9 to the apoptosome (Saleh et al., 2000; Beere et al., 2000). The ATPase domain 
of Hsp70 is thought to be essential for this interaction (Saleh et al., 2000; Mosser et al.,
2000).
Interestingly, Hsp70 may prevent cell death in conditions during which caspase acti­
vation does not take place either as a result of addition of exogenous caspase inhibitors 
(Creagh et al., 2000) or after inactivation of the apaf-1 gene (Ravagnan et al., 2001). In 
addition, it has been shown that cells deleted of apafl are protected from apoptosis induced 
by serum withdrawal by over-expression of Hsp70 (Ravagnan et al., 2001); indicating that 
Apaf-l is not the sole target of the antiapoptotic action of Hsp70. Hsp70 appears to directly 
bind AIF (apoptosis inducing factor) and prevent AIF-induced chromatin condensation. 
Hsp70 has been found to neutralize the apoptogenic effects of AIF not only in-vitro, but also 
in cells microinjected with recombinant Hsp70 and/or AIF protein, in addition to cells 
transiently transfected with AIF cDNA. Hsp70 has been shown to inhibit apoptosis induced 
by overexpression of full-length AIF, which has to transit mitochondria to become 
apoptogenic (Susin et al., 1999; Loeffler et al., 2001), as well as AIF deficient for the
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mitochondrial localization sequence (AIFA1-100). It appears endogenous levels of Hsp70 
are sufficiently high enough to control AIF-mediated apoptosis as down-regulation of Hsp70 
through use of antisense construct, sensitizes the cells to serum withdrawal and AIF 
(Ravagnan et al., 2001).
In addition, Hsp70 has also been shown to rescue cells from a later stage of apoptosis 
than any known survival-enhancing drug or protein. In TNF-induced apoptosis, Hsp70 did 
not prevent the activation of caspase-3 but exerted effects further downstream preventing 
morphological changes characteristic of dying cells (Jaattela et al., 1998). Hsp70 is also 
thought to act at earlier stages of the apoptotic pathway, for instance by preventing JNK 
activation (Meriin et al., 1999). Park et al. (2001) have recently shown that Hsp70 binds to 
and acts as a natural inhibitory protein of c-Jun N-terminal Kinase (JNK1) and that the 
binding is independent of the ATPase domain of Hsp70 (Mosser et al., 2000). However, 
JNK inhibition accomplished through this binding is not sufficient to prevent apoptosis 
(Mosser et al., 2000), putting a question mark over the role of JNK itself in apoptosis. In 
addition, Hsp70 has also been shown to associate with the pro-apoptotic proteins p53 and c- 
myc (Jolly et al., 2000). However, the functional impact of these interactions in the “Hsp70 
survival effects” remains unknown (Jolly et al., 2000). Another apoptosis regulatory protein, 
which interacts with Hsp70, is Bag-1, reported to function as a co-chaperone of Hsp70, and 
simultaneously regulating the activities of proteins such as Bcl-2 and Raf-1. Hsp70/Bag-1 
has been shown to regulate Raf-l/ERK kinase and cell growth in response to stress (Song et 
al., 2001).
The data discussed above shows that Hsp70 inhibits apoptosis and these properties 
may be attributed to the neutralizing interactions of Hsp70 with several proapoptotic effec­
tors including Apaf-1, AIF and possibly signalling molecules such as JNK-1, p53, or c-myc. 
Presently, it is not clear whether these neutralizing interactions synergize in some way to 
determine the broad cytoprotective effect of Hsp70.
In addition to the roles of Hsp70 described so far, there is also strong evidence for a 
cytoprotective role for Hsp70 under different stresses (mainly heat and hypoxia and 
ischemia/reperfusion), as demonstrated by various in vitro and in vivo studies (Kiang and
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Tsokos, 1998). The present study deals with the inducible Hsp70, the over-expression of 
which is known to protect several systems under conditions of stress.
1.8.4.3 Protective properties of Hsp70 in neuronal systems in vitro
The following studies provide some examples of in vitro protection achieved through 
over-expression of Hsps in a variety of different cell types. Kabakov et al. (2003) reported 
protection from delayed apoptosis following over-expression of Hsp70 in human endothelial 
cells during post hypoxic reoxygenation. Brar et al. (1999) demonstrated in primary 
cardiomyocytes, that over-expression of Hsp70 via HSV-based vector protects against 
apoptosis-inducing stimuli as well as against thermal and hypoxic stress. In addition, studies 
on cardiomyocyte-derived cell lines or primary cells either transiently or stably over­
expressing Hsp70 also indicated a strong protective effect of Hsp70 under both thermal and 
ischemic stresses (reviewed by Latchman, 2001). In cell culture models over-expression of 
inducible Hsp70 protects from ischemia (Papadopoulos et al., 1996; Xu and Giffard, 1997; 
Kiang and Tsokos, 1998). In addition, Hsp70 over-expression through HSV-based viral 
vectors protects dorsal root ganglion neurons from thermal and ischemic stresses but was 
found to have no protective effect against apoptosis (Wagstaff et al., 1999).
1.8.4.4 Protective properties of Hsp70 in neuronal systems in vivo
The following studies provide some examples of in vivo protection achieved in 
different cell types through over-expression of Hsp70. Transgenic mice over-expressing 
Hsp70 demonstrated less infarction than the wt-littermates, following transient focal 
ischemia, transient global ischemia, or kainic acid-induced seizures; in addition Hsp70 over­
expression reduced the number of apoptotic cells (Tsuchiya et al., 2003). Over-expression of 
inducible Hsp70 by either viral or transgenic expression has been shown to provide 
protection against cerebral ischemia in animal models of stroke (Plumier et al., 1997; Rajdev 
et al., 2000; Yenari et al., 1998 & 1999), but as yet the mechanisms of this neuroprotection 
are not fully understood. Interestingly, Hsp70 was recently shown to reduce protein 
aggregation in a model of global ischemia and its induction with geldanamycin blocked 
apoptotic astrocyte death induced by glucose deprivation (Giffard et al., 2004).
110
Overall, it is clear Hsp70 and members of the Hsp70 family have many important 
and diverse roles. However, the principal function of these proteins is to prevent the 
misfolding of denatured proteins. Under conditions of stress, increasing the levels of Hsp70 
may prevent aggregation and misfolding of denatured proteins and assist in either their 
correct folding or their degradation by the proteasome. The potential role of the proteasome 
in neurodegeneration is discussed later in a separate section. Additional studies on Hsp70 
are needed due to its clinical importance and its potential as a therapeutic agent.
1.8.4.5 Hsp70 and co-factor roles on protein degradation by the proteasome
The ability to facilitate the degradation of intracellular proteins by the 
ubiquitin/proteasome system is another protective function recently proposed for Hsps. The 
ubiquitinylation system marks proteins for degradation by the 26S proteasome, a 
multicatalytic protease consisting of a catalytic 20S and a regulatory 19S subunit. One of the 
key signals that allow protein recognition is misfolding. A cooperation has been reported 
between the ATP-dependent molecular chaperones Hsp90 and Hsp70 and the 
ubiquitinylation machinery, for instance, it is thought the proteins could encourage the 
degradation of proteins such as the endoplasmic reticulum-associated apoprotein B by the 
ubiquitin-proteasome (Gusarova et al., 2001), but as yet, the molecular mechanisms 
involved remain largely unknown.
The co-chaperone CHIP (C-terminus of Hsc70-interacting protein) is an ubiquitin 
ligase, which on interaction with Hsp70, efficiently ubiquitinylates captured unfolded 
proteins, and subsequently associates with the 19S subunit of the proteasome (Council et al., 
2001; Murata et al., 2001; Meacham et al., 2001). The ubiquitin-like domain containing 
protein BAG-1, which is another co-chaperone for Hsp70 and Hsc70, also binds to the 
proteolytic machinery in an ATP-dependent manner, supplying an additional link between 
the Hsc70/ Hsp70 chaperone system and the 26S proteasome (Luders et al., 2000). BAG-1 
and CHIP cooperate to shift the activity of the chaperone systems from one of protein 
folding to that of protein degradation (Demand et al., 2001).
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The role of Hsps in the proteosomal degradation of unfolded substrates demonstrates 
a degree of specificity, in that Hsc70 for instance, is necessary for the degradation of actin, 
a-crystallin, glyceraldehyde-3-phosphate dehydrogenase, (3-lactalbumin, and histone H2A, 
but is not required for the degradation of bovine serum albumin, lysozyme, and oxidized 
RNase A (Bercovich et al., 1997). In the same way by interacting with CHIP, Hsp70, and 
Hsp90 specifically favour the degradation of the Parkin protein, CFTR (cystic fibrosis 
transmembrane-conductance regulator) and the glucocorticoid receptor (Meacham et al.,
2001).
1.8.5 The Small Heat Shock Protein Family
1.8.5.1 Overview of Hsp27 and the small Hsp family
Hsp27 is a member of the small heat shock proteins (sHsps), a family of abundant 
and ubiquitous stress proteins, which are detectable in virtually all organisms from 
prokaryotes to mammals (Arrigo et al., 1994). To date, nine different members of the family 
of sHsps have been identified, varying in size from 15 to 30 kDa: Hsp27, p20, HspB3, 
MKBP/HspB2, HspB8, HspB9, cvHsp, a-A crystallin and a-B crystallin (Arrigo et al., 
1987; Boelens et al., 1998; Ingolia et al., 1982; Iwaki et al., 1997; Kappe et al., 2001; Kato 
et al., 1994; Klemenz et al., 1991; Krief et al., 1999). Although low amino acid homology is 
shared between members of this family, they are grouped together because of their similar 
structural and functional properties, with all sHsps containing a conserved core region that 
was identified first within the crystallin proteins of the vertebrate eye (De Jong et al., 1993). 
Termed the crystallin box, this domain consists of 80-100 amino acids in the C-terminus of 
the protein and has an IgG-like fold, which is proceeded by a short more freely flexing C- 
terminal extension. In contrast, the N-terminus of sHsps is a lot more variable in both 
sequence and length (De Jong et al., 1998) and contains the WDPF motif, involved in 
oligomerization of the protein (Bova et al., 2000).
Hsp27 levels are generally low within unstressed cells and it exists predominantly as
a large oligomeric unit of up to 800 kDa, frequently comprised of six tetrameric complexes
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of the protein. The size of the oligomeric unit depends on several physical and chemical 
parameters, which include temperature, pH, ionic strength and the degree of phosphorylation 
of the individual monomers. An increase in the level of expression of Hsp27 during the 
stress response is preceded by a phosphorylation-induced reorganization of the multimeric 
status of the protein. Phosphorylation takes place on three different serine residues, Ser-15, 
Ser-78 and Ser-82 and results in the redistribution of the large oligomer into smaller 
tetrameric units (Rouse et al., 1994; Lavoie et al., 1995; Zantema et al., 1992). 
Phosphorylation of Hsp27 is catalysed by MAPKAP kinases 2 and 3 (Landry et al., 1992; 
Ludwig et al., 1996; Stokoe et al., 1992), which in turn are activated by the phosphorylation 
of p38 MAP kinase (Freshney et al., 1994). Recent evidence suggests that the delta isoform 
of protein kinase C may also phosphorylate Hsp27, however, this only seems to occur in a 
stimulus-dependent manner (Kato et al., 2001), such as with treatment with phorbol esters. 
Increased phosphorylation of Hsp27 is detectable, after exposure to stress, within several 
minutes with a subsequent increase in the expression levels of the protein occurring within 
several hours (Landry et al., 1991). The induction of Hsp27 is generally transient and the 
protein returns to basal levels following removal of the stress. Interestingly, at specific 
stages during development and cell differentiation, increased expression of Hsp27 is 
transiently induced and occurs alongside the differentiation-mediated decrease of cellular 
proliferation (Pauli et al., 1989). Experiments in mouse embryonic stem cells suggest that 
aberration of this accumulation is enough to abort the differentiation process resulting in the 
death of the cells (Mehlen et al., 1997).
The complexes formed by the sHsps with non-native proteins in vitro are extremely 
stable (Lee et al., 1997; Ehmsperger et al., 1997 & 1998; Haslbeck et al., 1999). Even 
though the non-native protein is not spontaneously released, these complexes are not dead­
end traps for the unfolded protein. It has been demonstrated, as proof of principle, that a 
bound enzyme can be shifted back to its native state by addition of a specific ligand that 
stabilizes the functional conformation of the protein (Ehmsperger et al., 1997). However, up 
to now and in contrast to other chaperones, no active-release mechanism has been detected. 
Interestingly, in a number of organisms the expression of a sHsp and an Hsp70 chaperone is 
genetically linked (Michelini et al., 1999). This along with the finding that the in vivo 
overexpression of Hsp70 has a beneficial effect on the clearance of aggregates suggests that
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sHsps may operate together with other ATP-dependent members of the chaperone family 
(Kampinga et al., 1994). In vitro experiments, in which Hsp70 was added to preformed 
sHsp/substrate complexes has provided biochemical proof for this co-operation. Hsp70 was 
able to promote folding of the protein to its native state in the presence of ATP (Ehmsperger 
et al., 1997). Independently, experiments which screened cell lysates for factors that 
promote the refolding of sHsp-bound proteins (Lee et al., 1997 & 2000) also identified 
Hsp70 as the significant player in the reactivation of proteins rescued from aggregation by 
sHsps.
It appears sHsps function by binding non-native proteins once large quantities of 
unfolded proteins are formed, as can happen as a result of stress conditions or 
overexpression of proteins. This binding prevents the formation of large aggregates and 
subsequently makes it easier for Hsp70 or other potential ATP-dependent chaperone systems 
to refold the protein. This cooperation of different components of the cellular chaperone 
machinery therefore enables the separation in both space and time of two key properties of 
molecular chaperones, binding and folding.
1.8.5.2 Hsp27 and its mechanism of cytoprotection
A range of different roles for Hsp27 during cellular stress have been put forward to 
account for the cytoprotective effects observed with increased expression of this protein 
such as its role as a molecular chaperone, direct interference with the mechanisms of caspase 
activation, modulation of oxidative stress and regulation of the cytoskeleton.
1.8.5.3 Hsp27 as a molecular chaperone
Like other members of the Hsp family, Hsp27 functions as a molecular chaperone 
helping to refold non-native proteins. By forming complexes with such proteins, it prevents 
their non-specific aggregation thereby allowing them to be subsequently restored to their 
native structure in co-operation with ATP-dependent chaperones such as Hsp70 (Beissinger 
et al., 1998; Ehmsperger et al., 1997). Unlike most other Hsps, the chaperone function of 
sHsps occurs in an ATP-independent manner (Jakob et al., 1993) with the C-terminal
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responsible for the molecular chaperone function (Muchowski et al., 1997). The intracellular 
accumulation of misfolded proteins can elicit a stress response resulting in increased Hsp 
expression (Ananthan et al., 1986). Excessive amounts of damaged proteins can form large 
aggregates, which act as a signal for the induction of apoptosis (Soldatenkov et al., 1997).
The increased expression of Hsp27, in stressed cells containing high levels of 
damaged proteins, assists in the repair or destruction of these proteins thereby promoting 
recovery of the cell. This ability of Hsp27 to assist the recovery of stress-induced protein 
denaturation may increase the cell survival rate by limiting the amounts of misfolded 
proteins that may potentially be responsible for triggering of apoptosis. For example, 
overexpression of Hsp27 enhances the rate of recovery from aggregation of nuclear protein 
(Kampinga et al., 1994). During the temperature-induced stress response, increased 
expression of Hsps is accompanied by a shut-off of general protein and mRNA synthesis 
(DiDomenico et al., 1982). Cuesta and co-workers (2000) have shown that Hsp27 can itself 
operate as an inhibitor of cellular protein synthesis. They showed that Hsp27 interacted in 
vitro with eIF4G, a cap-binding initiation factor necessary for translation of most cellular 
mRNAs. The eIF4G factor was prevented from initiating the start of translation as a result of 
this interaction (Cuesta et al., 2000). Since under stress conditions, protein synthesis could 
potentially result in their incorrect folding and accumulation of protein aggregates, this inter­
action could be a protective mechanism to further restrict stress related accumulation of 
misfolded proteins. Interestingly, Hsp27 expression has also been reported to promote 
recovery of RNA and protein synthesis following heat shock (Carper et al., 1997), which 
may provide the cell with a survival advantage.
Furthermore, the molecular chaperone function of Hsp27 is responsible for the 
regulation of apoptosis by means of its interaction with protein kinase B (Akt). Akt 
activation has been shown to inhibit apoptosis in a number of systems (Ahmed et al., 1997; 
Kaufmann-Zeh et al., 1997; Kennedy et al., 1997; Khwaja et al., 1997; Kulik et al., 1997). 
Akt is activated through an association with HSP27, during both heat and hydrogen 
peroxide-induced cell stress (Konishi et al., 1997). This Hsp27-mediated activation of Akt is 
likely to play a part in the increased resistance to apoptosis seen in cells expressing high 
levels of Hsp27 (Kaufmann-Zeh et al., 1997).
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1.8.5.4 Inhibition of caspase activation and activity
Over recent years, evidence showing that Hsp27 can inhibit apoptosis by means of a 
direct inhibition of caspase activation has accumulated (Garrido et al., 1999; Samali et al.,
2001). It is not implausible, that as a molecular chaperone Hsp27 could regulate the acti­
vation of caspases by way of an ability to interact with one or more components of the 
apoptosome complex/caspase-9 activation complex; the apoptosome is formed by 
interaction of cytochrome-c with Apaf-1, triggering the ATP-dependent oligomerization of 
Apaf-1 and it’s binding to procaspase-9. So far, a number of different studies have provided 
evidence of interactions of Hsp27 with critical components of the apoptosome. Hsp27 
negatively regulates the activation of pro-caspase-9 through an ability to interact with 
cytochrome c, which consequently prevents the correct formation/function of the 
apoptosome complex (Bruey et al., 2000; Concannon et al., 2001). In addition, it has also 
been shown that by interacting with the pro-caspase-3 molecule, Hsp27 can inhibit caspase- 
3 activity (Concannon et al., 2001; Pandey et al., 2000). Interestingly, even though Pandey 
et al. (Pandey et al., 2000) were unable to show a direct interaction between Hsp27 and 
cytochrome c they conclude that Hsp27 may play a role both upstream and downstream of 
cytochrome c release in a stimulus-dependent manner.
Recent evidence has demonstrated that the mitochondrial fraction of thermotolerant 
Jurkat cells contains a significant pool of Hsp27 (Samali et al., 2001). This is reminiscent of 
another endogenous anti-apoptotic protein Bcl-2, which functions to inhibit apoptosis by 
preventing cytochrome c release from the intermembrane space of mitochondria (Kluck et 
al., 1997; Yang et al., 1997). Therefore it is interesting to speculate that Hsp27 may operate 
in a fashion similar to Bcl-2. It has been observed that Hsp27 may protect against apoptotic 
stimuli by blocking cytochrome c release (Samali et al., 2001).
Exposure of cells rendered thermotolerant to an apoptotic stimulus did not result in 
loss of mitochondrial membrane potential (Aij/m) and subsequent release of cytochrome c 
associated with non-thermotolerant cells (Samali et al., 2001). When a similar experiment 
was performed using cells transfected with antisense Hsp27, the loss of Av|/m and release of 
cytochrome c were not inhibited (Samali et al., 2001), therefore suggesting that in
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thermotolerant cells Hsp27 is responsible for inhibition of these factors. On the other hand, 
Bruey et al. (Bruey et al., 2000) did not see an effect by Hsp27 on release of cytochrome c. 
One possible explanation for these conflicting observations may be the different model 
systems used in these experiments. Usually, when Hsp27 is transfected into cells its 
expression is under control of foreign viral gene promoters and not as is the case during heat 
shock, the transcription factor, HSF-1. Under conditions of stress, HSF-1 not only mediates 
the induction of Hsp27 but also a variety of other proteins. Therefore, the conflicting 
evidence seen in these two reports may be due to the fact that Hsp27 localises to 
mitochondria during heat shock, a translocation that may be dependent on the synthesis of 
other proteins induced by activation of HSF-1.
Recently however, Paul et al. (Paul et al., 2002) have reported that while Hsp27 
localises to the mitochondrion, this localisation of Hsp27 alone is not sufficient to prevent 
cytochrome c release and that Hsp27-mediated prevention of cytochrome c release was due 
to the ability of Hsp27 to maintain integrity of the actin network and prevent the 
translocation of pro-apoptotic factors from the actin cytoskeleton to the mitochondrion 
where they can trigger the release of cytochrome c (Paul et al., 2002).
A thorough investigation of the significance of the mitochondrial pool of Hsp27 
remains to be carried out. The idea that the protective roles of Hsps are exerted at the level 
of the mitochondrion is not an entirely new concept. It was previously suggested by Polla 
and co-workers that on exposure to oxidative stress, mitochondria are the targets of the 
protective effects of Hsps (Polla et al., 1996). In addition, it has also been shown in PC 12 
cells, that a novel set of sHsps are localised to the mitochondria where their role is to protect 
cells against thermal and oxidative stresses (Downs et al., 1999). These findings add further 
support to the suggestion that the mitochondrion may be the primary site for the protective 
effects of Hsp27. As the mitochondrion plays such a key role in the execution of apoptosis it 
would seem a suitable location for Hsp27 and other Hsps to elicit their anti-apoptotic 
characteristics.
In addition, Hsp27 has also been shown to interact with another component of the 
apoptotic cell death machinery, pro-caspase-3 (Concannon et al., 2001; Pandey et al., 2000).
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This interaction would appear to be with the inactive form of the molecule and therefore it is 
highly plausible to suppose that the binding of Hsp27 to pro-caspase-3 prevents its 
activation, possibly by preventing initiator caspases, such as caspase-9, from acquiring 
access to the necessary residues whose cleavage results in activity of the enzyme. The 
elucidation of critical residues, on both of these molecules, which are responsible for their 
interaction should aid in further characterizing the role this interaction may play, if any at 
all, in regulation of apoptosis. Interestingly, an interaction with pro-caspase-3 has also been 
shown to occur for a-B crystallin, another of the sHsps (Kamradt et al., 2001).
It appears as though Hsp27 is adapted to inhibit apoptosis induced by a variety of 
different mechanisms as Hsp27 expression is also associated with inhibition of apoptosis 
initiated by the binding of death ligands to cell surface receptors such as Fas (Mehlen et al., 
1996). The activation of Fas signalling is not predominantly associated with cytochrome c 
release and apoptosome formation. In this case receptor binding leads to the direct activation 
of pro-casapse-8 with the subsequent downstream activation of pro-caspase-3. As it has been 
shown that Hsp27 interacts with pro-caspase-3 it may be that the function of this interaction 
is principally to inhibit apoptosis associated with the activation of death receptors. It has 
been shown, however, that Hsp27 can interact with Daxx (Charette et al., 2000), a protein 
implicated as being mediator of Fas-induced apoptosis (Yang et al., 1997). Apoptosis 
mediated by Daxx is caspase-independent and involves the recruitment of the apoptosis 
signal regulating kinase (Askl), which is a MAP kinase kinase that activates JNK. 
Interaction of Daxx with both Fas receptor and Askl is blocked by interaction with Hsp27 
(Charette et al., 2000). On the other hand, in some cell systems the activation of death 
receptors is additionally associated with amplification of the caspase cascade by way of 
caspase-8-mediated release of cytochrome c from the mitochondria. It could be argued that 
inhibition of Fas activated caspases by Hsp27 is a consequence of its ability to prevent the 
cytochrome c -mediated amplification of the caspase cascade. However, it seems a lot more 
plausible that this is mediated through a synergistic effect of interacting both with 
cytochrome c as well as pro-caspase-3.
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1.8.5.5 Chaperone activity of Hsp27 and its anti-apoptotic function
For Hsp27, it appears that the chaperone activity can be dissociated from its 
antiapoptotic function. Hsp27 is an ATP-independent chaperone that prohibits the 
aggregation and promotes the refolding of denatured proteins in vitro as mentioned 
previously. In vitro studies have shown that the 33 amino acids of N-terminal region 
adjacent to the highly conserved a-crystallin domain of the protein are not necessary for its 
chaperone activity (Gio et al., 2000). However, it has been shown that this region is essential 
for cytochrome c binding and for the antiapoptotic properties of the protein (Bruey et al., 
2000). Therefore, Hsps may exert the apoptosis-regulatory function, at least to some extent, 
through protein-protein interactions not directly related to their chaperone function. Future 
studies will unravel the fine mechanisms of such interactions and will provide invaluable 
information on the potential therapeutic role of Hsps, particularly in the context of 
neurodegeneration.
1.8.5.6 The role of Hsp27 in prevention of stress-induced disruption of the cytoskeleton
Hsp27 has been accepted as being a potent regulator of cytoskeletal dynamics 
particularly actin microfilaments. Within cells, the principal function of the cytoskeleton is 
to maintain the shape of the cell and this function is modulated both by the spatial 
arrangement in addition to the polymerisation dynamics of its different elements (Liang et 
al., 1997).
A number of studies have shown that overexpression of Hsp27 increases the stability 
of F-actin microfilaments on exposure to stresses such as hypothermia (Lavoie et al., 1993), 
oxidants (Huot et al., 1995) and cytochalasin D (Guay et al., 1997). During the course of 
stress, the integrity of filamentous actin structures is disturbed by the disorderly severing 
and aggregation of the filaments, resulting in a situation that is potentially damaging for cell 
morphology. During the course of heat stress, it is suggested that the association of Hsp27 
with F-actin may function as an adaptive response to changes within the cellular 
environment, to stabilise the structure of the cytoskeleton as well as prevent its 
disaggregation. The exact mechanism by which F-actin is stabilised by Hsp27 is not well
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understood. Turkey and murine Hsp25, which are homologues of human Hsp27, have been 
shown to inhibit actin polymerisation (Benndorf et al., 1994; Miron et al., 1991; Wieske et 
al., 2001), an activity dependent on the degree of phosphorylation of Hsp25 and on its 
structural organization. Non-phosphorylated monomers of Hsp25 and Hsp27 are active in 
inhibiting actin polymerization compared to phosphorylated monomers and non- 
phosphorylated oligomeric forms which are inactive (Lavoie et al., 1993; Benndorf et al., 
1994). In contrast, Preville et al. (1998) have found that phosphorylation of Hsp25 is not 
required for protection of cells against disruption of the actin cytoskeleton and that the 
protection of the actin network is probably as a result of the redox change mediated by 
Hsp25 as opposed to a direct effect on actin by this protein. Irrespective of the mechanism 
by which Hsp27 inhibits actin polymerisation it would appear that the loss of Hsp27's actin- 
capping ability allows actin polymerisation, and as a result potentially stabilises and 
remodels the actin cytoskeleton in the course of stress.
Other components of the cytoskeleton, in addition to actin microfilaments, have been 
reported to interact with Hsp27. An interaction of Hsp27 and a-B crystallin, another 
member of the sHsp family, with various intermediate filaments has been reported (Pemg et 
al., 1999). It is suggested that these interactions may manage the connections in cellular 
networks between filaments, an event that may be important for cell survival. There is also 
evidence suggesting that Hsp27 co-localizes with tubulin/microtubules, however, the signif­
icance of this interaction is not fully understood (Hino et al., 2000). It is questionable 
whether the association of Hsp27 with elements of the cytoskeleton promotes increased 
cellular survival by insulating this dynamic network and preventing its destruction, which 
could ultimately lead to cell death.
1.8.5.7 Modulation of intracellular redox potential by Hsp27
A major role in cell death is played by the generation of high levels of intracellular 
reactive oxygen species (ROS), which are induced by a variety of different stimuli. 
Electrons escaping from the electron transport chain and reacting with oxygen molecules 
normally occurs within cells resulting in low levels of ROS. However, on exposure of cells 
to certain toxic stimuli, such as TNF-a or hydrogen peroxide, there is a rapid increase in the
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levels of intracellular ROS due to mitochondrial dysfunction. The ROS generated can lead 
to oxidative damage to the cell, potentially resulting in demise of the cell either by apoptosis 
or necrosis depending on the levels of ROS generated. A number of studies have 
demonstrated the protective effects of sHsps, such as Hsp27 and a-B-crystallin, against ROS 
generated through TNF-a stimulation as well as oxidative stress induced by hydrogen 
peroxide and menadione (Mehlen et al., 1995). These findings resulted in the theory that 
sHsps could function as inhibitors of ROS action, by modulating and preserving the 
intracellular redox potential. While Hsp27 lacks any endogenous ROS detoxifying activity, 
it has the ability to increase intracellular levels of glutathione (Mehlen et al., 1996), which is 
a tripeptide with numerous intracellular functions, including ROS detoxification and 
regulation of cell death. Interestingly, cells treated with agents that lower levels of 
glutathione, exhibit an enhancement in the induction of stress proteins including Hsp27 (Ito 
et al., 1998), which suggests that the expression of sHsps functions as a buffering system to 
prevent the oxidation of proteins, which normally occurs when there is an intracellular 
increase in the levels of ROS. This ability of sHsps to increase and maintain glutathione in a 
reduced form correlates with an increase in the activity of an enzyme involved in the ROS- 
glutathione pathway, known as glucose-6-phosphate dehydrogenase (Preville et al., 1999).
In summary, there is no doubt that at times of stress, the expression of Hsp27 serves 
as a protective mechanism to increase cellular survival. The precise mechanism of how this 
protection is mediated by Hsp27 is highly complex, as can be seen from the variety of 
different roles proposed for the protein. It is clear from these observations that the function 
of Hsp27 is a highly adapted and dynamic one, in which post-translational modifications 
play a key role. In response to a stress event, the expression of Hsp27 is only transiently 
induced, following which levels of expression fall drastically, thereby permitting 
overexpression only when its cytoprotective properties are required. Based on the evidence 
from a number of studies, two distinct roles have been suggested for Hsp27 during stress: 
(1) to sustain the normal function of cells through interaction with and stabilization of the 
cytoskeleton as well as by facilitating the repair or removal of damaged proteins and 
(Concannon et al., 2003) (2) to prevent apoptosis by obstructing caspase activation by way 
of an ability to sequester cytochrome c and pro-caspase-3 in addition to acting as a redox 
modulator (Concannon et al., 2003).
No doubt, full elucidation of the role of Hsp27 will have several potential uses as 
therapies for a number of various ailments. The therapeutic benefit of using exogenous 
Hsp27 has already been proven by a number of gene therapy experiments. Previously, 
Wagstaff and co-workers (1999) demonstrated that the delivery of exogenous Hsp27 to 
cultured neuronal cells by means of HSV-based vectors provides protection against 
apoptosis induced by a variety of stimuli. In addition, Kalwy et al. (2003) demonstrated the 
protective effects of overexpression of Hsp27, via a HSV vector, in an in vivo model of 
neuronal cell death. As a number of neurodegenerative diseases such as Parkinson’s disease, 
come about as a result of excessive death of neuronal cells, some of which is apoptotic in 
nature, the use of gene therapy to deliver exogenous Hsp27 may help in providing a better 
prognosis for these diseases (Zourlidou et al., 2004). Similar effects have been shown in 
cardiac cells exposed to hypoxia and thermal stress (Brar et al., 1999). In addition, a number 
of different approaches are being developed to upregulate the endogenous levels of Hsp27 
and other Hsps including the use of cytokines such as IL-2 and the use of pharmacological 
agents that could be administered to patients to induce enhanced Hsp expression in a non­
stressful manner (Latchman, 1998).
1.8.5.8 Protective properties of Hsp27 in neuronal systems in vitro
Wagstaff et al. (1999) demonstrated for the first time that in vitro over-expression of 
Hsp27 protects primary sensory neurons and neuronal cell lines against both thermal and 
ischemic stress and against apoptosis induced by nerve growth factor withdrawal or serum 
withdrawal plus retinoic acid treatment.
More recently, in vitro study conducted by Shimura et al. (2004) found that Hsp27 
rescued cells from pathological hyperphosphorylated tau-mediated cell death. Hsp27 
preferentially bound only the pathological hyperphosphorylated tau and facilitated its 
degradation without ubiquitination, which otherwise does not undergo efficient degradation 
by the proteasome.
Wyttenbach et al. (2002) described an additional novel property of Hsp27, reporting 
that Hsp27 in vitro can suppress polyQ-mediated cell death in a cellular model of
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Huntington’s disease (HD). Mutant huntingtin brought about increased levels of ROS in 
neuronal and non-neuronal cells, resulting in cell death. Hsp27 significantly reduced ROS 
content in these cells, thereby providing evidence that Hsp27 may protect cells against 
oxidative stress. This protection conferred by Hsp27 was regulated by its phosphorylation 
status and was found to be independent of its ability to bind to cytochrome c. In contrast to 
Hsp70, Hsp27 suppressed polyQ death but not polyQ aggregation.
1.8.5.9 Protective properties of Hsp27 in neuronal systems in vivo
Another example of the neuroprotective role of Hsp27 is reflected in the study
conducted in sensory neurons by Lewis et al. (1999), which showed that Hsp27 plays a role
in promoting neuronal survival after axotomy in vivo and following NGF withdrawal in 
vitro. Their findings suggest that Hsp27 contributes significantly to the survival of sensory 
neurons under these conditions and in addition is likely to be an important factor for survival 
of adult sensory neurons too. A subsequent study by Benn et al. (2002), extended the above 
findings, and showed in adult rats that both motor and sensory neurons up-regulate Hsp27 in 
its active phosphorylated form following injury to a peripheral nerve. However, in neonatal 
rats the expression of Hsp27 is much lower following such injury, and only a minority of 
cells expressing the protein survive.
Further roles of Hsp27 in in vivo neuronal systems, relevant to the present study are 
those described by Kalwy et al. (2003) and Akbar et al. (2003). Kalwy et al. (2003) 
exogenously expressed Hsp27 by means of HSV-based viral vectors in the rat hippocampus 
and demonstrated a significant increase in survival following kainic acid administration. 
This was the first report demonstrating protection through exogenous expression of Hsp27 
in an in vivo model of neuronal cell death. Subsequently, Akbar et al. (2003) developed 
transgenic mice expressing human Hsp27 at high levels in the brain, spinal cord and other 
tissues and tested whether Hsp27 conferred in vivo neuroprotection against kainite induced 
neuronal cell death; Hsp27 expression in the mouse brought about a reduction in kainate- 
induced toxicity and mortality by at least 50% and reduced neuronal cell death in the CA3 
region of hippocampus, in addition to attenuating caspase-3 induction.
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A recent in vivo study conducted by Efthymiou et al. (2004), on isolated perfused 
hearts from mice over-expressing Hsp27 found they were more resistant to 
ischemia/reperfusion injury (using infarct size as an end point) compared to hearts from non- 
transgenic littermates. This is the first study that demonstrates that over-expression of Hsp27 
provides protection against lethal ischemia/reperfusion injury in the intact heart.
Finally, Wang et al. (2004) more recently demonstrated a further important role of 
Hsp27 in vivo through generation of transgenic Drosophila lines using the upstream 
activating sequence/GAL4 system. Over-expression of either Hsp26 or Hsp27 extended the 
mean lifespan of the flies by 30% and was accompanied by increased stress resistance in 
these flies.
1.8.5.10 Novel role of Hsp27 in proteasome-mediated protein degradation
Recently, a novel important role has been discovered for Hsp27 in protein 
degradation of certain substrates via the proteasome. Like BAG-1, HSP27 possesses an 
ubiquitin-like domain, enhances the catalytic activity of the 26S proteasome machinery, as 
well as increases the degradation of ubiquitinylated proteins in response to stressful stimuli. 
In contrast to Hsp70 and Hsp90, Hsp27 has been found to directly interact with ubiquitin 
(Parcellier et al., 2003). This ability of Hsp27 to directly interact with ubiquitin could 
explain the recently described co-localization of Hsp27 with ubiquitinylated proteins and the 
20S proteasome in cytoplasmic inclusions that characterize a variety of degenerative 
diseases (Zatloukal et al., 2002).
The ubiquitin/proteasome system itself plays a part in the modulation of apoptosis. 
Regulatory molecules implicated in apoptosis, such as caspases through interaction with 
some IAPs, have been identified as substrates of the proteasome. Hsps could indirectly 
influence apoptosis by assisting the degradation of death regulatory proteins. NF-kB is one 
of these regulatory proteins whose several steps of activation involve the 
ubiquitin/proteasome system including maturation of the transcription factor subunits, 
activation of Ik K s ( I - k B  kinases), as well as degradation of I - k B . The kinase RIP (receptor-
interacting protein), which connects TNF-R1 engagement by TNFa to activation of NF-kB,
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is associated with Hsp90 and geldanamycin-induced disruption of Hsp90 facilitates the 
proteasome-mediated degradation of RIP, thereby inhibiting NF-kB activation.
Consequently, a picture emerges in which Hsps and the ubiquitin/proteasome system 
work together to modulate death pathways. This cooperation may involve co-chaperones, for 
instance CHIP or BAG-1, whose expression may be altered in human diseases. It is expected 
that an improved understanding of the "protein triage" machinery will offer new avenues in 
the therapeutic manipulation of death pathways such as those regulated by NF-kB or IAPs.
In conclusion, recent evidence suggests a number of connections between Hsps and 
the apoptotic machinery. These connections involve the chaperone functions of these 
proteins, their ability to interact with death regulatory proteins as well as perhaps their 
ability to connect the protein folding machinery to the protein degradation pathway by 
means of interactions with co-chaperones such as those described above, CHIP and BAG-1. 
Further studies will reveal whether these proteins are useful targets for potential therapeutic 
manipulation of the apoptotic pathways.
1.8.6 Chaperones in neurodegenerative diseases
The accumulation of misfolded proteins in aged organisms is particularly 
pronounced in post-mitotic cells, such as neurons. The threat of damaged proteins increases 
even further, if the protein is protease-resistant The difficulties of protein degradation 
together with an impaired protease activity and chaperone action in aging neurons, results in 
a massive accumulation of these proteins and triggers neurodegeneration (Macario and 
Conway de Macario, 2001).
Oxidative damage and inflammatory processes are more prevalent during aging, and
not only accompany but aggravate neurodegeneration (Gibson et al., 2000; Goodman and
Mattson, 1994; Hemmer et al., 2001). A number of molecular chaperones are involved in the
maintenance of cellular redox status (Arrigo, 1998) and work to protect neurones against
oxidative stress (Lee et al., 1999; Yu et al., 1999). The involvement of Hsps in the process
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of neurodegeneration and their therapeutic importance have only recently become evident. 
This section provides a brief account on the aspects of heat shock protein roles in a range of 
neurodegenerative disorders, as shown in many studies utilising cellular in vitro models or 
in vivo models of the diseases and human post mortem material.
1.8.6.1 Polyglutamine diseases
Polyglutamine repeats generate proteins, which are more susceptible to aggregation. 
Huntington's disease (HD) like Parkinson's disease is usually a late-onset, progressive 
neurodegenerative disease associated with selective neuronal loss as well as abnormal 
protein accumulations. HD belongs to the group of polyglutamine (polyQ) repeat diseases 
which also includes dentatorubropallidoluysian atrophy (DRPLA), spinal and bulbar 
muscular atrophy (SBMA) and spinocerebellar ataxias type 1, 2, 3 (also known as 
Machado-Joseph disease, MJD), 6, 7, and 17. PolyQ diseases are characterized by the 
expansion of glutamine within the ORF of the relevant protein. The expanded polyQ domain 
is toxic and consequently leads to neuronal dysfunction and degeneration.
Abnormal protein accumulation such as nuclear inclusions incorporating the disease 
protein and other components, have led to multiple in vitro and in vivo studies investigating 
the protective potential of molecular chaperones against abnormal aggregate formation and 
toxicity, as discussed below. Chaperones co-localize with the aggregates of these 
polyglutamine-containing proteins and increased levels of chaperones such as that of Hsp40, 
Hsp60, Hsp70, Hsc70, HsplOO work toward inhibiting polyglutamine-containing protein 
aggregation and to slow disease progression (Carmichael et al., 2000; Cummings et al., 
1998; Hughes and Olson, 2001; Krobitsch and Lindquist, 2000).
Several reports have demonstrated that increased expression of the Hsp70/Hsp40 
chaperone system can suppress polyQ-induced neurotoxicity in fly models (Kazemi- 
Esfarjani and Benzer, 2000; Warrick et al., 1999; Chan et al., 2000; Femandez-Funez et al., 
2000) and also in a mouse model of polyQ disease (Cummings et al., 2001).
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1.8.6.1.1 Huntington’s disease
Huntington’s disease (HD) is an autosomal dominantly inherited progressive 
neurodegenerative disease. The mutant gene has been localised to chromosome 4pl6.3 with 
the gene product huntingtin found to be widely distributed in both neurones and 
extraneuronal tissues. Huntington’s disease comes about as a result of a mutation resulting 
in the expansion of a trinucleotide (CAG) repeat encoding glutamine. As yet the etiology of 
Huntington’s disease remains unknown but increasing evidence suggests important role of 
altered gene transcription, mitochondrial dysfunction and excitotoxicity. The expanded 
polyglutamine stretch results in a conformational change and abnormal protein-protein 
interactions. Mutant huntingtin can bind to transcription factors, resulting in reduced levels 
of acetylated histones. One of the consequences of this appears to be a decreased expression 
of genes, which may play critical roles in neuronal survival.
In vitro experiments carried out in yeast by Muchowski et al. (2000) demonstrated 
that Hsp70 and Hsp40 can interact with mutant huntingtin and inhibit the formation of 
detergent insoluble fibrillar aggregates. Sittler et al. (2001) first demonstrated with 
geldanamycin that huntingtin protein aggregation in cells can be suppressed by chemical 
compounds activating a specific heat shock response. Geldanamycin is a benzoquinone 
ansamycin that binds and inhibits heat shock protein Hsp90 and triggers a heat shock 
response in mammalian cells; at nanomolar concentrations geldanamycin induces the 
expression of Hsp40, Hsp70 and Hsp90 and inhibits HD exon 1 protein aggregation in a 
dose-dependent manner in mammalian cells.
Some other examples include the study by Dedeoglu et al. (2002) where striatal 
lesion sizes were evaluated in homozygous and heterozygous Hsp70 over-expressing mice 
and wt controls receiving 3-nitropropionic acid or malonate. Mice over-expressing Hsp70 
exhibited increased resistance to malonate and 3-nitropropionic acid. Malonate and 3- 
nitropropionic acid are well-characterized inducers of animal models of HD, which inhibit 
succinate dehydrogenase, leading to mitochondrial dysfunction and triggering the generation 
of superoxide radicals, secondary excitotoxicity and apoptosis.
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However, studies conducted by Hansson et al. (2003) in a mouse model of HD, 
found that Hsp70 has only modest effects on disease progression. Hansson et al. (2003) 
crossed R6/2 mice, expressing exon 1 of the HD gene with an expanded CAG repeat, with 
mice over-expressing Hsp70. The resulting R6/2-Hsp70 transgenic exhibited a 5- to 15-fold 
increase in Hsp70 expression in neocortical, hippocampal and basal ganglia regions; this 
correlated with a delayed loss of body weight compared to R6/2 mice. However, 
overexpression of Hsp70 did not affect the number or size of nuclear inclusions, the loss of 
brain weight, reduction of striatal volume, reduction in size of striatal projection neurons, 
development of paw clasping phenotype or early death of the mice. In addition it was noted 
that in older R6/2-hsp70 mice a large proportion of the Hsp70 protein was accumulated in 
nuclear inclusions.
Recently, Hay et al. (2004) reported a progressive decrease in Hdjl, Hdj2, Hsp70, 
alphaSGT and betaSGT brain levels in the R6/2 mouse model of HD. All these proteins 
were found to co-localise with nuclear but not with extranuclear aggregates. The mRNA 
level of Hdj 1 and alphaSGT do not change, therefore it is possible that the decrease in 
protein levels is a result of their sequestration into aggregates, or possibly due to an increase 
in protein turnover, as a result of their relocation to the nucleus. It was found that Hsp70 
over-expression in the R6/2-Hsp70 transgenic delayed aggregate formation by one week but 
had no effect on the detergent-solubility of aggregates and did not alter the course of the 
neurological phenotype. However it was shown through organotypic slice cultures from 
transgenic HD mouse that pharmacological agents, radicicol and geldanamycin, both 
induced and maintained various Hsps for at least three weeks, and altered the detergent 
soluble properties of polyQ protein aggregates (Hay et al., 2004).
Finally, in vitro experiments conducted by Wyttenbach et al. (2002) reported that 
Hsp27 suppressed polyQ-induced ROS formation in cells caused by huntingtin and 
conferred protection to neuronal and non-neuronal cells against poly-Q-mediated toxicity 
without reducing polyQ-protein aggregation. These findings demonstrate that oxidative 
stress brought about by polyQ expansion contributes to cell death and suggests an important 
new role for Hsp27 in preventing toxicity associated with polyQ expansions.
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1.8.6.1.2 Hsps and other polyQ diseases
As mentioned above, other polyQ diseases include dentatorubropallidoluysian 
atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA) and Machado-Joseph 
disease (MJD). Adachi et al. (2003) cross-bred spinal and bulbar muscular atrophy (SBMA) 
transgenic mice with mice over-expressing human Hsp70 and demonstrated amelioration of 
the disease phenotype and found that the nuclear localisation of the mutant androgen 
receptor (AR) as well as of monomeric mutant AR was reduced, suggesting a possible 
Hsp70-mediated AR degradation. In a previous study, in an in vitro cellular system, it had 
been shown that overexpression of Hsp70 and Hsp40 resulted in an enhanced mutant AR 
solubility and proteosomal degradation as well as a decrease in the mutant AR half-life 
(Bailey et al., 2002).
In spinocerebellar ataxia type 1 (SCA1), which is characterized by loss of motor 
coordination as a result of degeneration of cerebella Purkinje cells and brain stem neurons, 
the expanded protein aggregates into nuclear inclusions containing chaperones, ubiquitin, 
and proteosomal subunits (components of the protein refolding and degradation machinery). 
Cummings et al. (2001) crossbred SCA1 mice with inducible Hsp70 over-expressing mice to 
determine whether enhancing chaperone activity may alleviate the phenotype in a mouse 
model by reducing protein aggregation. Although the amount of nuclear inclusions in 
Purkinje cells remained unchanged, further analysis revealed that high levels of Hsp70 
protect against neurodegeneration and preserved dendritic arborisation in the cerebellum.
Interestingly, it has been found that Hspl04 and its bacterial homolog, ClpB, can 
solubilise small protein aggregates in collaboration with Hsp70/Hsp40modulators of polyQ 
aggregation. Direct interaction of the prokaryotic ClpB (Hspl04) and DnaK (Hsp70) in the 
ATP-dependent resolubilization of aggregated proteins has been reported with the chaperone 
complex described thought to facilitate the transfer of intermediates between ClpB and 
DnaK during refolding of substrates from aggregates (Schlee et al., 2004).
129
1.8.6.2 Chaperones and Alzheimer's disease
Alzheimer’s disease is the best-known example of folding-related neurodegenerative 
disease. Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by the 
relentless decline of cognitive function, alterations in judgement, perception and personality, 
and ultimately the loss of essential qualities that define a human existence. The many signs 
and symptoms of AD are the sign of the dysfunction of diverse brain regions. The 
histopathological hallmarks of AD are numerous senile plaques and neurofibrillary tangles 
in specific regions of the brain. Senile plaques comprise an extracellular core of aggregated, 
fibrillar [3-amyloid peptide (A|3), which is accompanied to varying degrees by microglial 
cells, astrocytes, and dystrophic neuronal processes (Hauw et al., 2001; Cummings et al., 
2004). A(3 is cleaved from the p-amyloid precursor protein (PAPP) by enzymes generically 
named P-secretase (or p-amyloid cleaving enzyme, BACE) and y-secretase (Cummings et 
al., 2004; Hardy et al., 2002). Neurofibrillary tangles (NFT) consist of intracellular fibrils, 
which are composed of aberrantly polymerised, hyperphosphorylated tau, a protein that 
normally participates as a monomer in the assembly and stabilisation of microtubules (Lee et 
al., 2001). In addition to plaques and tangles, an elaborate and inconsistent mixture of other 
lesions are found in the AD brain, such as cerebral p-amyloid angiopathy, granulovacuolar 
degeneration, neuropil threads, Lewy bodies, and selective but widespread degeneration of 
neurons and their connections (Hauw et al., 2001; Cummings et al., 2004).
A number of studies demonstrated the induction of small heat-shock proteins 
(Hsp27, crystallin), Hsp70 and ubiquitin (a 6kDa heat-shock protein, which labels damaged 
proteins and directs them for proteolytic degradation) in neurons affected by Alzheimer's 
disease and in surrounding astrocytes. Neuronal chaperones have been found to be localized 
in neuritic plaques and neurofibrillary tangles (Cisse et al., 1993; Hamos et al., 1991; Perez 
et al., 1991; Renkawek et al., 1993; Shinohara et al., 1993).
In the affected neuron in Alzheimer's disease, the accumulated chaperones
participate in an attempt to sequester the p-amyloid and other damaged proteins (Hamos et
al., 1991; Kouchi et al., 1999). However, aB-crystallin the small heat-shock protein
enhanced the neurotoxicity of the amyloid-p 1-40 peptide probably by maintaining it in a
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nonfibrillar, highly toxic form (Stege et al., 1999). Cytoplasmic Hsp60, which is a specific 
chaperone for actin and tubulin, is found to be decreased in Alzheimer's disease-affected 
neurons resulting in both the deficiency and aggregation of cytoskeletal proteins (Schuller et 
al., 2001). Non-affected nerve cells of Alzheimer sufferers, such as olfactory neurons 
(Getchell et al., 1995) also exhibited a reduction in expression of Hsp70.
In Alzheimer’s disease (AD), which is a progressive amnesic dementia there is 
evidence of post-translational hyperphosphorylation, enzymatic cleavage, and 
conformational alterations of the microtubule-associated protein tau. A recent study by 
Petrucelli et al. (2004) showed that CHIP and Hsp70 regulate tau ubiquitination, degradation 
and aggregation. CHIP was found to interact directly with the microtubule-binding domain 
of tau, induce tau ubiquitination, increase the levels of insoluble aggregated tau and 
interestingly in addition, CHIP was found to be present in tau lesions in human post mortem 
brain tissue. The same study found that the levels of tau were reduced in mice over­
expressing Hsp70 and that Hsp70 induction through geldanamycin or HSF-1 led to a 
decrease in steady-state tau levels and in detergent insoluble and hyperphosphorylated tau. 
Previously, Shimura et al. (2004) reported tau binding to Hsc70, and also the requirement 
for phosphorylation prior to ubiquitination by CHIP. CHIP rescues phosphorylated tau- 
induced toxicity; however the study by Petrucelli et al. (2004) further explores the opposing 
action of Hsp70 and CHIP on tau ubiquitination and aggregation. CHIP, Hsp70, parkin, and 
Pael-R (see section 1.8.6.3 below on PD) have been shown to form a complex both in vitro 
and in vivo with the amount of CHIP in the complex increasing during ER stress (Imai et al.,
2002). CHIP was shown to promote the dissociation of Hsp70 from parkin and Pael-R, 
thereby facilitating parkin-mediated Pael-R ubiquitination. Finally, Dou et al. (2003) found 
that in transgenic mice and in AD brains tau aggregation is inversely related to levels of 
Hsp70 and Hsp90 and that these elevated levels are responsible for enhanced tau solubility 
and it’s binding to microtubules.
1.8.6.3 Chaperones and Parkinson's disease
Parkinson’s disease is an age-related disorder characterized by a progressive 
degeneration of dopaminergic neurons in the substantia nigra and demonstrating a
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corresponding motor deficit. An increasing amount of evidence shows that in addition to 
oxidative stress and mitochondrial dysfunction, defects in protein folding are also key 
elements of Parkinson’s disease etiology. Similar to Alzheimer’s disease, glial and astroglial 
cells of Parkinson’s disease sufferers exhibited the expression of aB-crystallin and as with 
the neurofibrillary tangles, aggregated proteins in Lewy bodies had a large content of 
various heat-shock proteins (Jellinger, 2000). Dietary restriction induced expression of 
Hsp70 and Grp78 and paralleled a protective effect in a Parkinson’s disease model (Duan 
and Mattson, 1999). Interestingly, the protein parkin, whose mutations trigger the autosomal 
recessive juvenile parkinsonism was identified as an ubiquitin-ligase playing an important 
role in the degradation of ER misfolded proteins, such as a G-protein coupled membrane 
receptor, called Pael and synphilin, an a-synuclein interacting protein (Chung et al., 2001; 
Imai et al., 2001).
As reviewed by Bonini (2002), molecular chaperones were the first modifiers 
described to hinder the progression of neurodegeneration in Drosophila. Hsp70 was 
identified as a potent suppressor of disease phenotype in both HD and PD in flies. 
Specifically, Hsp70 expression in Drosophila prevented dopaminergic neuronal loss 
associated with a-Syn. In addition, Auluck et al. (2002) demonstrated that interference with 
the endogenous chaperone activity in flies accelerated a-Syn toxicity. Interestingly, 
although increased expression of Hsp70 suppressed a-Syn toxicity, it did not alter the 
microscopic appearance of neuronal inclusions.
Auluck et al. (2002) also reported the presence of Hsp70 and Hsp40 in LBs and LNs 
of post mortem PD brain. LBs, which are the neuropathological hallmarks of the disease, 
were shown to contain many other Hsps such as Hsp27, aB-crystallin, torsinA, Hsp90, 
HspllO and ubiquitin. The presence of Hsps in LBs provides an additional link between 
Hsps and the disease, however as yet, their role in the process of neurodegeneration remains 
unclear.
Recently, Klucken et al. (2004) crossed a-Syn and Hsp70 transgenic mice and found 
that Hsp70 reduced high molecular weight and detergent insoluble a-Syn species but did not
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change the total amount of soluble monomeric a-Syn. This same study reported Hsp70 over­
expression provided protection against a-Syn toxicity in an in vitro cellular model of a-Syn 
aggregation (human H4 neuroglioma cells) in addition to a reduction of detergent insoluble 
a-Syn species. It was suggested by Auluck et al. (2002) that Hsp70 protection from a-Syn 
toxicity can be dissociated from prevention of a-Syn aggregation. It would therefore be 
interesting to investigate whether overexpression of Hsp70 in the double transgenic mouse, 
besides reducing aggregation, could in addition ameliorate dopaminergic cell death and 
improve the disease phenotype of the model described by Klucken et al. (2004).
1.8.6.4 Chaperones in Amyotrophic Lateral Sclerosis
In addition to the various previous reports on the role of Hsps in neurodegeneration 
there are a few important recent studies related to Hsps in various ALS models and in post 
mortem ALS brains. These studies have been described above in the previous sections of the 
Introduction of this thesis (Bruening et al., 1999; Vleminckx et al., 2002; Batulan et al., 
2003; Kieran et al., 2004). These studies highlight the potential of Hsps as therapeutic 
targets for this disease, but further work is necessary for a better understanding of the role of 
Hsps in ALS pathology. Evidence from the abovementioned ALS studies and other 
neurodegenerative disease models, suggests that pharmacological agents that induce the 
expression of molecular chaperones in neurons could be a fruitful strategy for the treatment 
of ALS.
In a transgenic mouse model of this disease, over-expressing human mutant SOD-1, 
arimoclomol drug treatment resulted in a reduction in the rate of disease progression, 
associated with Hsp induction (Kieran et al., 2004). Arimoclomol is a hydroxylamine 
derivative that acts as a co-inducer of Hsp expression and was found to successfully increase 
HSF-1 activation in the spinal cord of arimoclomol treated mice and resulted in a 
corresponding increase in the protein levels of Hsp70, Hsp90 and to a lesser extent, Hsp27. 
Importantly, arimoclomol treated mice exhibited significant improvement in motomeurone 
survival and hind limb muscle function and exhibited a 22% increase in lifespan.
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In other studies, in cultured neurons, mutant SOD-1 toxicity was delayed by gene 
transfer of Hsp70 (Bruening et al., 1999). Interestingly, aB-crystallin and Hsp27 were found 
to be upregulated in the spinal cord of mutant SOD-1 mice but not mice over-expressing wt 
SOD-1, while Hsp70 levels were normal (Vleminckx et al., 2002). Finally, Batulan et al. 
(2003) demonstrated the existence of a high threshold for induction of the stress response in 
motor neurons due to their reduced ability to activate HSF-1.
Neurodegenerative diseases such as ALS, PD, AD and the prion diseases all have the 
assembly of structurally unrelated proteins into intracellular or extracellular amyloid fibrils 
in common. Therefore, since all the intermediates that are formed early in these diseases can 
be highly cytotoxic for the neurons (Bucciantini et al., 2002; Walsh et al., 2002), it is 
possible that there might be common mechanisms in amyloid formation and toxicity, and 
hence common strategies for the development of neuroprotection.
These above studies highlight the therapeutic potential of Hsps and raise the 
possibility that Hsps may be used as therapeutic agents in neurodegenerative diseases. 
However further work is necessary to fully understand the role of Hsps in ALS pathology. 
Evidence from the above mentioned studies, in the context of neurodegenerative diseases 
and ALS, suggest that agents possessing the pharmacological ability to induce the 
expression of molecular chaperones in neurons could provide an effective strategy for the 
treatment of ALS and other neurodegenerative diseases.
In view of the multiple functions of Hsps, in addition to suppressing protein 
misfolding and aggregation, it is evident that manipulation of the Hsp expression in animal 
models is a potential starting point to develop neuroprotective strategies for ALS and other 
similar neurodegenerative diseases. In summary, ALS is characterised not only by 
aggregation of protein but also mitochondrial dysfunction, formation of reactive oxygen 
species, oxidative stress and cell death. Hsps have been implicated in all the above 
pathways, as mentioned earlier in the introduction of this thesis, as a consequence Hsps 
comprise eligible candidates for neuroprotection in ALS.
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Therefore it was decided to investigate the effects of Hsps against mutant SOD1 
associated toxicity. This work looks at the mechanism by which mutant SOD1 triggers cell 
death and the effects of Hsp27 and/or Hsp70, singly and in combination, against the 
damaging effects of mutant SOD1 in both a neuronally-derived ND7 cell line and primary 
cell culture systems.
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1.9 Aims and Objectives
The aims of the project, for which results are presented in this thesis, were as follows:
• To characterize and utilize an in vitro mutant-SODl toxicity cellular model system in 
order to test various hypotheses with regards to the effect of wt and FALS-associated- 
SOD1 mutants in neuronal cells.
• To test the protective role of Hsps, in particular Hsp27 and Hsp70, against mutant-SODl 
associated toxicity under various stresses paralleling conditions relevant to FALS in the 
above in vitro system.
• To subsequently investigate the underlying mechanisms of the protective effects of Hsps 
in this model.
The following three Chapters describe:
• The characterization of this model system and discuss its limitations and advantages in 
relation to the literature as well as suggest further experiments (Chapter 3).
• The utilization of this model system and HSV-based vectors to study the neuroprotective 
properties of Hsps (Chapter 4). Along with preliminary investigations into the mechanism 
of the protection provided by Hsp27 and/or Hsp70 and the effects of ApoE on this model 
system (Chapter 4)
• The creation of a primary cell culture (DRG) model system by means of HSV-based 
vectors incorporating wt-SODl and G93R-mutant-SODl to further study the 
neuroprotective properties of Hsps and investigate their mechanism of protection (Chapter
5).
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C h a p t e r  2 
M a t e r ia l s  a n d  M e t h o d s
2.1 Laboratory Reagents
2.1.1 General Suppliers
General analytical grade laboratory chemicals were purchased from the following 
companies: Sigma Chemical Company Ltd., Poole Dorset, UK; BDH Merck Ltd., 
Lutterworth, Leicestershire, UK; Boehringer Mannheim, Lewes, East Sussex, UK. 
Phosphate buffered saline (PBS) was made up from PBS tablets (1 tablet in 500ml ddH20) 
purchased from Invitrogen Ltd, Paisley, UK. All solutions were made up using MilliQ 
18MQ water (Millipore), which was autoclaved where necessary. General laboratory 
plasticware was purchased from BDH Merck Ltd. and Ependorff, Cambridge, UK.
2.1.2 Cells, Viruses and Transgenic mice
The SOD1 stable cell lines and SOD1 viruses were constructed in our laboratory by Dr 
Yolanda Collaco-Moraes. The Hsp viruses were constructed in our laboratory by Dr Marcus 
Wagstaff. The transgenic Hsp27 (Tg-Hsp27) mice were a gift from Professor J. de 
Belleroche, Imperial College, London, UK. The Hsp70 transgenic mice (Tg-Hsp70) were a 
gift from Dr. C.E. Angelidis, Dalhousie University, Canada. The Hsp27 transgenic mice 
incorporate a transgene containing human Hsp27 cDNA with a chicken - actin promoter and 
cytomegalovirus enhancer (pCAGGS) (see Akbar et al., 2003). The Hsp70 transgenic mice 
incorporate human inducible Hsp70 gene under the regulation of p-actin promoter (see 
Plumier et al., 1995). The ApoE protein isoforms were a gift from Dr B.S. Thilakawardhana, 
Royal Free Hospital, University College London.
2.1.3 Molecular Reagents and Plasmids
All the restriction endonucleases and DNA modifying enzymes and their respective buffers
were supplied by Promega Southampton, UK; except for the enzyme BamHl which was
purchased from New England Biolabs, UK. For PCR, nucleotides, buffers and Taq
Polymerase were obtained from Bioline, London, UK. The DNA lkb molecular weight
marker was purchased from Invitrogen Ltd, Paisley, UK. The altered site II in vitro
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mutagenesis system was purchased from Promega, Southampton, UK. DNA sequencing was 
performed by MWG-Biotech AG (Ebserberg, Germany). The plasmid vectors used were: 
pcDNA3neo from Invitrogen Ltd, UK, into which SOD1 cDNA was cloned. Human 
fibroblast SOD1 cDNA was obtained from ATCC (Accession no: #61646).
2.1.4 SDS-PAGE Reagents
Acrylamide/bisacrylamide (30% w/v) solution for polyacrylamide gels was purchased from
rT 'l /  T ‘1 M
Amresco Ltd., Ohio, USA. Protein molecular weight Rainbow marker, Hybond -C 
nitrocellulose membranes, Enhanced Chemiluminescence system (ECL) and Kodak X- 
OMAT imaging photographic film were all purchased from Amersham Pharmacia Biotech, 
Little Chalfont, Bucks., UK. The photographic chemicals for developing and fixing were 
purchased from X-OGRAPH Ltd., Tetbury, UK.
2.1.5 Antibodies
Hsp27 antibody, (goat polyclonal; product no: SC-1049; diluted 1:1000 in 4% milk/PBS) 
and p-actin antibodies (goat polyclonal; product no: SC-1616; diluted 1:1000) were 
purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Hsp70 antibody (mouse 
monoclonal; product no: SPA-810; diluted 1:1000 in 4% milk/PBS) and the SOD1 (rabbit 
polyclonal antibody; product no: SOD-100; 1:1000) was from Stressgen Ltd., UK. 
Secondary horseradish peroxidase-linked antibodies used for Western immunoblotting were 
all from DAKO Ltd., Glostrup, Denmark; anti-mouse IgG biotinylated (Cat no. BA-9200) 
and anti-rabbit IgG biotinylated (Cat no. BA-1000).
2.1.6 Tissue Culture Reagents
All tissue culture media and reagents were purchased from Invitrogen Ltd, Paisley, UK 
unless otherwise stated. All plasticware used was obtained from Nunc Ltd., Roskilde, 
Denmark unless otherwise stated. Sterile 0.2pM and 0.45pM disposable filters were 
obtained from Millipore, Watford, UK. All trans-Retinoic acid was purchased from Sigma 
was resuspended in dimethylsulfoxide (DMSO) and aliquoted into stocks of 3 mg/ml and
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kept in -80°C freezer until required, minimizing all exposure to light. Antibiotics Geneticin® 
(G418-sulphate) and Zeocin™ were purchased from Invitrogen Ltd, Paisley, UK. All 
caspase-inhibitors Z-VAD-FMK (inhibits caspase -1-like proteases), Z-IETD-FMK 
(irreversible caspase-8 inhibitor), Z-LEHD-FMK (irreversible caspase-9 inhibitor) were 
obtained from Calbiochem®; all were solubilised in DMSO as per supplier protocol and 
stock solutions of 50mM, lOmM and 20mM prepared, respectively; aliquots were kept at - 
20°C and used at a final concentration of lOpM. Hexamethylene bisacetamide (HMBA) was 
purchased from Sigma and solubilised in double distilled water, filtered sterilized and kept 
in -4°C until required. HMBA was used at a final concentration of 3 mM.
2.1.7 Cell Death Detection and Quantification
Trypan blue was purchased from Sigma Chemical Company Ltd, Poole, Dorset, UK. 
TUNEL (terminal dUTP nick end labelling) reagent was purchased from Roche Molecular 
Biochemicals, GmbH, Mannheim, Germany.
2.1.8 Equipment
The Trans-Blot™ cell transfer tanks and the Bio-Rad GS-800 densitometer were purchased 
from Bio-Rad Laboratories Ltd., Hertfordshire, UK.
The Zeiss microscope was purchased from Carl Zeiss Mico-Imaging Inc., New York, USA. 
Labsystems Multiskan RC plate reader, Finland.
The Beckman Centrifuge was purchased from Beckman Coulter Inc., California, USA.
All gas cylinders were supplied by the British Oxygen Company, BOC Ltd, Guildford, UK.
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2.2 Cell Culture
Media and reagents were all sterile on purchase or sterilised by either autoclaving or 
filtering through 0.2pm filters. All cell culture work was carried out under sterile conditions 
in a laminar flow cabinet. Cells were passaged 25 times after which they were discarded. All 
tissue culture preparations were carried out under sterile conditions in a Laminar flow safety 
cabinet. All viral preparations were carried out in line with Health and Safety Executive 
category 2 conditions.
2.2.1 Cell Biology
Cell lines were frozen down in 1ml aliquots and stored in liquid nitrogen until needed and 
were maintained at 37°C while in culture in either a 5% CO2 incubator in a humidified 
atmosphere or on a rotary roller apparatus (for roller bottles). All cell manipulations were 
carried out under sterile conditions by means of standard aseptic techniques.
2.2.2 Mammalian Cell Lines and Growth Media
ND7 Cells A hybrid cell line created by the fusion of immortalised HGPRT-mouse 
neuroblastoma cells (N18Tg2) with rat post-mitotic neonatal dorsal root ganglion neurons 
(Wood et al., 1990). ND7 cells were cultured in Liebovitz L I5 media containing 10% foetal 
calf serum (FCS), 100 units ml'1 penicillin and streptomycin, supplemented with 0.35% 
(w/v) D(+)-glucose, 2mM L-glutamine lOOx and 0.375% (w/v) sodium bicarbonate. Wild- 
type SOD1, G93A, G93R and empty vector control ND7 stable cell lines were created 
previously by Dr. Yolanda Collaco-Moraes. These stably transfected cell lines were cultured 
in the presence of 800pg ml'1 of Geneticin-G418 sulphate (Invitrogen) and SOD1 expression 
was monitored prior to experimentation by western blotting.
MAM49 Transformed baby hamster kidney cells (BHK) cell line, a fibroblast cell line 
grown in Dulbecco's modified Eagle's medium containing 10% FCS and 100 units ml'1 
penicillin and streptomycin and cultured in the presence of 800pg ml'1 of G418 and 175pg
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ml'1 zeocin selection to maintain two plasmids, one containing the viral gene ICP4 and the 
other containing viral gene ICP27.
2.2.3 Growth Conditions and Storage of Mammalian Cell Lines
Cells were grown in 80cm2, 175cm2 flasks, or 800cm2 roller bottles in the appropriate 
growth medium (see section 2.2.2). All cell lines were passaged when they were 80-90% 
confluent and not used for more than 25 passages. ND7 cells were passaged by pouring off 
the old media and replacing with 10ml of fresh media. Cells were dislodged and the 
resulting cell suspension was aliquoted into fresh culture flasks to a final dilution of 1:10 in 
fresh growth media.
BHK MAM49 cell line was passaged by washing in Hanks Balanced Salt Solution (HBSS) 
at room temperature, and incubating for 2-3minutes with 5ml per 175cm2 culture flask of 
10% (v/v) trypsin in versene at 37°C/5% CO2 . The effect of trypsin was neutralised by 
adding 5ml of growth media, the cells were vortexed to prevent clumping, and split 1:10 in 
fresh growth media.
For long-term storage, frozen stocks were made by pelleting the cell suspension from one 
175cm2 flask. The cell pellet was resuspended in a 1:1 mix of 1ml of 20% FCS in 
appropriate cell media and 1ml of 15% dimethylsulphoxide (DMSO; Merck Ltd, Poole, 
Dorset, U.K.) in appropriate media and transferred to 2x 1.5ml cryotubes. The vials were 
then transferred to -80°C freezer for 2 weeks, in an insulated box to ensure gentle freezing 
and subsequently to liquid nitrogen. For recovery, frozen cells from one vial were rapidly 
thawed at 37°C and transferred immediately to 15ml of growth media, and pelleted in a 
standard bench-top centrifuge at 20°C, l,000rpm for 5 minutes. The resulting pellet was 
resuspended in 10ml of appropriate fresh growth media and seeded into T25cm2 TC flasks 
with appropriate concentration of selection for respective cell line and passaged once 80% 
confluent.
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2.2.4 SOD1 and SODl-mutant stable cell lines
The SOD1 stable cell lines were created in our laboratory by Dr Yolanda Collaco-Moraes. 
Human wild type SOD1 or SOD1 mutant cDNA was inserted into pCDNA3neo mammalian 
expression vector under control of a CMV promoter and transfected into ND7 cells using the 
calcium phosphate procedure. Briefly, ND7 cells were grown in 6-well plates at a density of 
approximately 10,000 cells per well and 5pg per well of the expression vector incorporating 
wt-SODl, G93A or G93R-mutant-SODl as well as empty pCDNA3neo vector control were 
transfected using the calcium phosphate method (Stow and Wilkie, 1976; Gorman, 1986). 
G418-sulphate was added to the media 48h post transfection at final concentration of 
800pg/ml (Smith et al., 1997; Reeves et al., 1999). After 5-10 days approximately 80-100 
individual G418-resistant colonies per construct were isolated using a micropipette under the 
x40 objective of a light microscope under sterile conditions in a laminar flow cabinet. The 
media was replaced every 2-3 days with fresh G418-sulphate containing media. Stable cell 
lines were produced, with clones selected being neomycin resistant. Clones expressing either 
wt or mutant SOD1 were identified by means of Western blot.
2.3 Induction of Cell Stress
2.3.1 Serum withdrawal (plus lpM all-trans retinoic acid)
ND7 cells undergo apoptosis when subjected to serum-withdrawal and addition of all-trans 
retinoic acid (Howard et al, 1993).
Apoptosis Media: 50% DMEM
50% Ham's F- 12 medium 
5pg ml"1 human transferrin 
250ng ml'1 bovine insulin 
30nM sodium selenite
lOpM all-trans retinoic acid (stock dissolved in DMSO)
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The wt-SOD, ND7 empty vector control and G93A and G93R mutant stable cell lines were 
rinsed gently with 1ml well'1 of 1 x PBS. They were subsequently incubated in 1ml well'1 
apoptosis media for 24 and 48 hour time points at 37°C/5% CO2 . The cells were harvested 
at the appropriate time points and cell death assessed by Trypan blue exclusion (see Section 
2.6.1) and number of apoptotic cells determined by TUNEL analysis (see section 2.6.2).
For serum-withdrawal and all-trans retinoic acid addition experiment retinoic acid was 
added to final concentration of lpM per well with cell death being assessed by Trypan blue 
exclusion as before (section 2.6.1) and the number of apoptotic cells were determined by 
TUNEL analysis (section 2.6.2).
2.3.2 IFN-y treatment, Staurosporine and Camptothecin administration
Optimal concentrations of IFN-y, staurosporine, camptothecin, hydrogen peroxide and 
glutamate were determined by death curves; the concentration used of each substance is 
provided below under each separate insult.
Cells were plated out so as to attain 70% confluency the following day, in 6 well plates. The 
cells were rinsed gently with 1ml well’1 of 1 x PBS and 2ml of fresh ND7 growth media 
added per well. IFN-y was then added to each well to a final concentration of 50ng/ml. Cells 
were gently harvested, centrifuged and the pellet resuspended in lx PBS at 24h and 48h time 
points and cell death immediately assessed by trypan blue exclusion assay and by terminal 
dUTP nick end labelling (TUNEL) (see section 2.6).
For staurosporine experiments, 70% confluent ND7 cells were rinsed gently with 1ml well’1 
of 1 x PBS and 2ml of fresh ND7 growth media added per well. Staurosporine in DMSO 
(Sigma), was added to a final concentration of lpM per well. Cells were gently harvested, 
centrifuged and the pellet resuspended in lx PBS at 2h, 4h, and 6h and 8h time points and 
cell death immediately assessed by trypan blue exclusion assay and by terminal dUTP nick 
end labelling (TUNEL) (see section 2.6).
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For camptothecin experiments, 70% confluent ND7 cells were rinsed gently with 1ml well"1 
of 1 x PBS and 2ml of fresh ND7 growth media added per well. Camptothecin in DMSO 
(Sigma), was added to a final concentration of lpM per well. Cells were gently harvested, 
centrifuged and the pellet resuspended in lx PBS at 24h and 48h time points and cell death 
immediately assessed by trypan blue exclusion assay and by terminal dUTP nick end 
labelling (TUNEL) (see section 2.6).
2.3.3 Hydrogen Peroxide and Glutamate Treatment
Cells were plated out so as to attain 70% confluency the following day, in 6 well plates. The 
cells were rinsed gently with 1ml well"1 of 1 x PBS and 2ml of fresh ND7 growth media 
added per well. Hydrogen peroxide was then added to each well at a final concentration of 
lOpM. Cells were gently harvested, centrifuged and the pellet resuspended in lx PBS at 24h 
and 48h time points and cell death immediately assessed by trypan blue exclusion assay and 
by terminal dUTP nick end labelling (TUNEL) (see section 2.6).
For glutamate experiments, 70% confluent ND7 cells were rinsed gently with 1ml well"1 of 1 
x PBS and 2ml of fresh ND7 growth media added per well. Glutamate was added to a final 
concentration of 5pM per well. Cells were gently harvested, centrifuged and the pellet 
resuspended in lx PBS at 24h and 48h time points and cell death immediately assessed by 
trypan blue exclusion assay and by terminal dUTP nick end labelling (TUNEL) (see section 
2 .6).
2.3.4 Simulated Ischemia Followed by Re-oxygenation
Ischemia can be simulated in vitro by incubating the cells in a physiological buffer 
containing raised levels of lactic acid and potassium, and decreased pH along with inhibitors 
of electron transport and glycolysis. This method is based on one devised by Esumi et al., 
1991 for simulating ischemia upon cardiomyocytes and has been further adapted by Dr. Jing 
Zhao (The Rayne Institute for Cardiovascular Studies, United Medical and Dental Schools, 
London, UK) and used successfully in our laboratory on cells lines and Dorsal root ganglia 
(DRG) neurons by Dr Marcus Wagstaff.
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Control Buffer: 118mM NaCl
24mM NaHC03 
4mM KC1 
ImM NaH2P04 
2.5mM CaCl2 
1.2mM MgCl2 
0.5mM EDTA 
2mM sodium pyruvate 
lOmM D-glucose 
pH 7.4
Ischemic Buffer: Control Buffer containing:
20mM sodium lactate 
12mM KC1 
pH 6.2
Both mutants, wt-SOD and empty vector control ND7 stable cell lines were plated out in 6 
well plates so as the wells were 70% confluent the following day. Once 70% confluent the 
cells were rinsed gently with 1ml well'1 of 1 x PBS. 1ml of ischemic buffer was then added 
to each well and the plate placed in an ischemic chamber 37°C/5% C 02 for 4 hours. The 
cells were then taken out the chamber and the ischemic buffer was removed and 2ml of fresh 
appropriate growth media added to each well.
After 24 hours the cells were harvested and cell death assessed by Trypan blue exclusion 
and by terminal dUTP nick end labelling (TUNEL) (see Section 2.6).
2.3.5 Caspase inhibitors
All caspase-inhibitors, zVAD-fmk (inhibits caspase-1-like proteases), zIETD-fmk 
(irreversible caspase-8 inhibitor) and zLEHD-fmk (irreversible caspase-9 inhibitor) were 
purchased from Cabiochem and were dissolved in DMSO. The cells were incubated for lh 
with the inhibitors at a final concentration of lOpM, prior to experimentation. DMSO alone
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was used in the non-caspase inhibitor treated cells at all times; as the inhibitors were 
dissolved in DMSO. Following incubation the cells were subjected to a range of death 
insults described above. After 24 hours the cells were harvested and cell death assessed by 
Trypan blue exclusion and by terminal dUTP nick end labelling (TUNEL) (see Section 2.6).
2.4 HSV-based Viral Vectors
2.4.1 Production of high titre stock of recombinant virus
The viruses used in this study were constructed and characterised Dr Marcus Wagstaff. Hsp 
or green fluorescent protein (GFP) under the control of cytomegalovirus immediate early 
(CMV-IE) promoter were introduced into a disabled HSV vector (Wagstaff et al., 1999). 
The Hsp cDNAs incorporated into the disabled HSV vector were Chinese hamster Hsp27, 
rabbit Hsp56, and inducible human Hsp70. The viral vectors lack the gene encoding the 
essential HSV immediate early protein ICP27 and hence were grown on a complementing 
transformed Baby Hamster Kidney (BHKs) cell line that had been stably transfected to 
express ICP27 (Howard et al., 1998), thereby allowing lytic growth of the virus and enabling 
the preparation of high titre viral stocks.
A 175cm tissue culture flask containing the appropriate cell line grown at 37°C/5% CO2 
until 70-80% confluent was infected with lx l0 6 plaque forming units (pfu) of an initial 
stock of virus (from 2.2.8). Infection occurred in 10ml serum free DMEM Media for 1 hour 
after which viral replication was allowed by addition of 10ml growth media supplemented 
with 3mM HMBA. Cells were dislodged by vigorous shaking and harvested 3-5 days later 
and stored at -80°C as an intermediate viral stock.
For large-scale viral culture of wild type and partially disabled vectors, 10x175cm2 flasks of 
100% confluent cells were split into 10x850cm2 roller bottles (Coming Glass Works, 
Coming, New York, USA) and grown in 100ml of growth media without selection at 
37°C/5% CO2 . Once 80% confluent, the old media was poured off and cells were infected 
with Ixl05-lx l0 6 pfu of virus per RB (from the intermediate viral stock) and grown in 50ml
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of fresh growth media supplemented with 3mM hexamethylene bisacetamide (HMBA) 
without selection at 32°C/0.5rpm for 3-5 days until complete CPE was observed. HMBA 
was added in order to induce immediate early gene transcription in the absence of virion 
protein VP 16 (VMW65), a coat protein required for infection, for HSV mutant 1764 viral 
DNA (Ace et al., 1989). Cells were dislodged and harvested with supernatant by vigorous 
shaking of the roller bottle and immediately frozen at -80°C. After defrosting, the cellular 
debris was removed by centrifugation in a standard benchtop centrifuge at 3500rpm for 
45minutes at 4°C. The supernatant was then removed and filtered through a 0.45pm filter 
(necessary to minimise debris carry-over) and then spun at 12000 rpm for 2 hours at 4°C in a 
Beckman JA10 rotor in pre-autoclaved pots. The supernatant was poured off and the pots 
inverted in the tissue culture hood for approximately 3-5minutes. The subsequent viral pellet 
was gently resuspended in a minimum amount of serum-free DMEM (typically 100-150pl 
per 250ml pot). The resuspended pellet was then sonicated for 10 seconds in a water bath 
sonicator and chilled on ice between each sonication for a minute. This process of sonication 
was repeated 5 times until the solution was completely homogeneous, after which the virus 
was aliquoted into cryotubes in 20pl aliquots and stored at -80°C. All Virus stock was titred 
as in section (2.4.3) and over-expression of the appropriate gene to be delivered to the cells 
confirmed.
2.4.2 Viral Infection of Cells
Cells were infected with recombinant viruses for subsequent in vitro assays. Virus was 
added to 70% confluent cells in 0.5ml w ell1 (6-well plate) or 0.25ml well'1 (24-well plate) 
of serum free DMEM and plates were incubated at 37°C/5% CO2 for 1 hour. The viral 
media was taken off after the hour and replaced with 2ml well'1 (6-well plate) or 1ml well'1 
(24-well plate) of appropriate full growth media. Cells were incubated overnight at 
37°C/5% CO2 , prior to each assay. The virus efficiency was approximately 95-100%. The 
HSV viral vector used in the case of SOD1 viruses also expressed GFP enabling 
successfully infected cells to be monitored under UV light. All virus work was carried out in 
a categorised room in class 11 safety cabinets and all resulting waste such as pipette tips, 
media and plastic-ware was disinfected in 1% virkon for a minimum of 2 hours prior to 
autoclaving followed by incineration.
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Infection titre of virus on the stable cell lines was defined by multiplicity of infection (m.o.i. 
= number of pfu per cell; m.o.i. optimised by titration). ND7 cell lines were infected at an 
m.o.i. of 10 pfu cell'1.
2.4.3 Titration of Virus on Complementing Cells
MAM49 cells complementing HSV-1 ICP4 and ICP27 were seeded in a 24 well plate and 
grown at 37°C/5% CO2 to 80% confluency. A 1: 10 serial dilution was made of the virus 
from lxlO'2 - lxlO*10ml and added to the wells each containing 0.5ml of serum free DMEM. 
The plate was incubated for 1 hour at 37°C/5% CO2 . After lhour the media was taken off by 
pipette and replaced with 2ml 1:2 of 1.6% (w/v) carboxymethyl cellulose (CMC): growth 
media supplemented with 3mM HMBA. The cells were then returned to the incubator for a 
further 48 hours at 37°C/5% CO2 . The numbers of plaques in each well were counted under 
the microscope in order to determine virus titre in plaque forming units per ml (pfu/ml). Hsp 
expressing viruses had no reporter gene for visualisation of the virus so titration was 
performed as described for the other viruses containing reporter genes except that infected 
cells were observed under light microscopy and “white” plaques were counted in the cell 
monolayer on the culture dish. A viral plaque is as a patch of cells, which display a distinct 
morphology and can be easily distinguished; within a viral plaque the infected cells are 
rounded up and attached to the plate with most still alive. Viruses expressing green 
fluorescent protein (GFP) as a reporter gene were detected by simply viewing the infected 
cells under a microscope with UV light, with GFP positive cells fluorescing green.
2.4.4 Assessment of efficiency of gene delivery
Efficiency of gene delivery in cells infected with viruses expressing green fluorescent 
protein GFP reporter gene was calculated under an inverted fluorescent microscope by 
means of UV light at a wavelength of 520nm. The infected green cells expressing GFP were 
counted in relation to the total number of cells present in the well and the percentage 
efficiency of gene delivery was then calculated.
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2.4.5 Purification of Viral Recombinants by Plaque Selection
After UV light visualisation as in Section 2.4.4 green plaques were picked from the 
monolayer using a P20 Gilson micropipette set at 5pl underneath an inverted fluorescent 
microscope. The green fluorescent cells were isolated using a pipette tip and sucked up into 
the pipette and transferred to a freezing vial containing 100p.l of serum free DMEM. The 
resulting suspensions were then freeze-thawed three times. lOpl and 90pl of the mix were 
then added to separate 35mm-diameter wells of 80% confluent MAM49 cells each 
containing 0.5ml of serum free DMEM. The cells were incubated for 1 hour at 37°C/5% 
CO2 prior to addition of CMC/FGM and incubation for 48 hours as in Section 2.6.5. In order 
to purify the viruses by cloning this 2-day cycle of picking, infecting and visualising was 
carried out until all infected plaques appeared green under UV light. The whole well was 
harvested by scraping and after three cycles of freeze-thawing, a sample (1 OOjlxI) of the 
mixture was added to non-complementing BHKs as above and examined by microscopy for 
any viral plaques indicating replication. The 'master' stock with no detectable activity was 
then titrated and infected onto a 24-well plate as in Section 2.4.3 and plaques counted and 
the pfu (number of plaque forming units per ml of viral suspension) calculated.
2.4.6 Treatment of Cells after Viral Infection
Cells were infected with virus 24h prior to stress (for virus infection: see section 2.4.2; for 
induction of cell stress: see section 2.3). Efficiency of virus infection was assessed prior to 
stress (see section 2.4.4). Following subjection of cells to stress, cells were gently harvested, 
centrifuged and the pellet resuspended in lx PBS at 24h and 48h time points and cell death 
immediately assessed by trypan blue exclusion assay and by terminal dUTP nick end 
labelling (TUNEL) (see section 2.6).
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2.5 Analysis of Protein Levels
2.5.1 SDS-polyacrylamide gel electrophoresis and Immunoblotting
SDS-PAGE
12% acrylamide gels were used to resolve proteins of molecular weight less than 50 kDa.
The gel composition and buffers were adapted from Sambrook et al., (1989).
6 x SDS gel loading buffer: 300mM TrisHCl (pH6.8)
600mM DTT
10% SDS
30% glycerol
0.1% bromophenol blue
5 x Tris-glycine electrophoresis buffer: 25mM Tris.HCl
250mM Glycine 
0.1% SDS
Composition of 12% polyacrylamide resolving gels and stacking gel (in ml; total volume 10
ml):
Resolving 12% Stacking gel
H20  3.3 6.8
30% Acrylamide 4.0 1.7
1.5 M Tris.HCl (pH 8.8) 2.5
1.0 M Tris.HCl (pH 6.8) - 1.25
10% SDS 0.1 0.1
10% Ammonium persulfate 0.1 0.1
TEMED 0.004 0.01
For immunoblotting of cell lysates, between 20-50pg of total protein was loaded on the gels 
in a total loading volume of between 10-20pl. Equal loading of protein samples was
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confirmed by performing a Bicinchoninic (BCA) Protein Assay (see section 2.5.4). The 
appropriate volume of 6xSDS loading buffer was added to each sample and the total loading 
volume adjusted by addition of cell lysis buffer. The samples were denatured in a heating 
block by heating at 95°C for 5min prior to loading. The gel plates were cleaned with dh^O 
and 70% ethanol prior to use. The appropriate percentage acrylamide resolving gel was 
prepared and poured into the gel assembly and over-layered with water saturated 
isopropanol to create a level interface. After polymerisation of the resolving gel had taken 
place the isopropanol was poured off and the top of the gel rinsed a few times with dThO to 
remove the isopropanol. The stacking gel was then poured on top of the polymerised 
resolving gel. The protein samples along with high range molecular weight protein standards 
(Rainbow Markers, Amersham International Pic, Little Chalfont, Bucks, UK) were loaded 
on to the gel. The large polyacrylamide gels were electrophoresed in the appropriate gel 
electrophoresis apparatus with Tris-Glycine electrophoresis running buffer at 180Volts, 
40mA per gel, for 5-6 hours or until the dye front had reached the base of the gel.
2.5.2 Transfer of protein
Western transfer buffer (pH 8.3): 25 mM Tris.HCl
192 mM Glycine 
20% (v/v) Methanol
The protein samples, which had been run and separated on the gel, were then transferred to 
nitrocellulose filters. A nitrocellulose membrane and 6 pieces of 3MM (Whatman) paper 
were cut to the same size as the SDS-page gel. A stack was formed inside the minicell 
cassette consisting of three pieces of 3MM paper, the SDS-page gel, the nitrocellulose filter 
and the remaining three pieces of 3MM paper, all of which were presoaked in transfer 
buffer; the side containing the nitrocellulose membrane was placed nearer the anode. 
Transfer was carried out in a Bio-Rad Trans-blot™ Cell protein transfer apparatus at 200mA 
for 6h at room temperature or at 100mA overnight at 4°C.
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2.5.3 Immunodetection
Membranes were blocked in blocking buffer (lx  PBS, 4% (w/v) skimmed milk powder, 
0.1% polyoxyethylene sorbitan monolaurate - Tween 20) for 1 hour at room temperature by 
shaking gently on a shaker platform. The blocking buffer was removed and the membrane 
was then incubated with primary antibody diluted in 4% (w/v) skimmed milk powder in lx 
PBS for a period of 1 hour at room temperature on the shaker (see section 2.1.4 for details of 
primary antibodies used). The membrane was washed for 10 minutes in wash buffer (lx 
PBS, 0.1% Tween 20) by constant shaking on the shaker at room temperature and this was 
repeated three times to wash off any unbound antibody. The membrane was then incubated 
at room temperature on the shaker with the appropriate anti-IgG horseradish peroxidase 
(HRP) conjugated secondary antibody diluted to the required concentration in 4% block 
buffer (see section 2.1.4 for details of secondary antibodies used). Any unbound secondary 
antibody was removed by washing the membrane three times for 10 minutes in wash buffer 
at room temperature on a shaker. The bound horseradish peroxidase was then detected using 
enhanced chemiluminescence (ECL™, Amersham International Pic, Little Chalfont, Bucks, 
UK) according to the manufacturer’s protocol and the resulting light emissions were 
visualized by exposure to X-ray film for 5 seconds-1 hour, depending on the strength of the 
signal. Membranes were stripped by submerging the membrane in stripping buffer and 
incubating at 50°C for one hour with occasional agitation, prior to re-blocking and re­
probing.
Western blot antibody stripping buffer
lOOmM p-mercaptoethanol
2% SDS
62.5mM Tris.HCl (pH 6.7)
2.5.4 Protein Assay
The amount of protein in the samples was quantified by means of a Bicinchoninic (BCA) 
Protein Assay Reagent Kit, according to the manufacturer’s protocol. In brief, bovine serum 
albumin (BSA) standards were prepared and cell lysates diluted using lOpl lysate and 40pl
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loading buffer in the absence of bromophenol blue or DTT. 50pl standards and cell lysates 
were added to each well of a 96 well microplate along with 200pl of BCA working reagent 
and the plate incubated for lh at 37°C. The absorbance was measured at 560nm on a plate 
reader (Labsystems Multiskan RC plate reader) using Labsystems Genesis Communication 
software, and the protein concentration was calculated from the standard curve.
2.6 Cell Viability Assays
2.6.1 Trypan Blue Exclusion Assay
Cell survival was assessed by the trypan blue exclusion assay. Trypan blue assay relies on 
the ability of living cells to exclude the dye and hence remain opaque whereas non-viable 
cells are unable to exclude the dye and therefore stain blue. Each of the stable cell lines were 
harvested and spun at lOOOrpm for 5 mins. The remaining cell pellet was then resuspended 
in 200pl of 1 x PBS (phosphate-buffered saline). 20pl of each sample were mixed gently 
with the same volume of 0.04% (w/v) Trypan Blue (Sigma Chemical Company Ltd, Poole, 
Dorset, U.K.). The suspension was incubated at room temperature for about 2-3 minutes 
and lOpl of this mix were then loaded on a haemocytometer counting chamber (Weber 
Scientific International Ltd., U.K.) and the number of viable/non viable cells counted on a 
haemocytometer counting chamber at 40x magnification. Similar numbers of total cells 
(live/dead) were observed in each case. 200-300 cells were counted and classified as live or 
dead in each case.
2.6.2 TUNEL
Programmed cell death, or apoptosis, was detected using the fluorescent in situ cell death
detection kit, supplied by (Roche Molecular Biochemicals, GmbH, Mannheim Germany).
Labelling of 3’-hydroxyl ends of DNA fragments was carried out using terminal
deoxynucleotidyl transferase (TdT) and rhodamine-conjugated nucleotides (Roche
Molecular Biochemicals, GmbH, Mannheim Germany). The kit enables detection of DNA
fragmentation by labelling breaks in DNA strands using terminal deoxynucleotidyl
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transferase (TdT) to incorporate nucleotide polymers containing fluorescein-conjugated 
dUTP. This TdT-mediated dUTP nick end labelling (TUNEL) assay can therefore be used 
to allow detection of individual apoptotic cells in cultures of cells in chamber slides. The 
method used was modified slightly from that supplied with the kit.
ND7 stable cell lines and DRGs were fixed in 4% paraformaldehyde (dissolved in PBS by 
heating at 60°C and adjusting the pH to 7.4 by using 10M NaOH) for 10 minutes and 15 
minutes at room temperature. The cells were then washed carefully three times with PBS 
and then permeabilized with 0.1% Triton X-100 in PBS for 10 minutes at room temperature. 
The cells were then washed twice with PBS and lOOpl of TUNEL reaction mix was added 
(containing calf thymus TdT, reaction buffer and labelled nucleotide polymers in accordance 
with manufacturer’s protocol) to the ND7 stable cells and 50pl to the DRGs and the plates 
incubated in the dark at 37°C for 60 minutes and 90 minutes respectively. After 60 and 90 
minutes respectively the TUNEL reaction mix was removed and the reaction stopped by 
adding PBS with ImM EDTA, for 5min at room temperature. The ND7 stable cells were 
then washed twice with PBS and stored in PBS in the dark at 4°C until microscopy. The 
coverslips with DRGs were washed twice with PBS mounted onto slides and stored in the 
dark overnight at 4°C until microscopy.
Volumes for TUNEL labelling for one well of 24-well plate:
5x Reaction Buffer 20pl
25mM CoCl2 lOpl
25mM labelled dUTP lpl
20U/pl Td Transferase lp.1
Double distilled H2O 68pl
100pl
The samples were visualised at 40x magnification using fluorescein optics and the numbers 
of positive staining, apoptotic cells, in three confluent fields of view were counted for each 
sample. Triplicate wells/coverslips were counted per independent experiment. The number
155
of positive nuclei were counted and expressed as a percentage of the total cell number. 
Similar numbers of total cells (live/dead) were observed in each case. A minimum of 200- 
300 cells were counted and classified as live or dead in each case.
2.7 Primary Cell experiments
2.7.1 Genomic DNA extraction from mouse tails
All animal care and procedures were carried out in accordance with the UK Animals 
(Scientific Procedures) 1986 Act. Approximately 0.5cm of tail was removed from each 
animal and incubated in proteinase K buffer (lOOmM Tris, pH 8.5, 5mM EDTA, 200mM 
NaCl) including Proteinase K enzyme at a final concentration of 100 pg/ml. Tails were left 
to digest overnight, shaking at 55°C, after which half of the digest was subjected to 
phenol/chloroform extraction prior to ethanol precipitation. An equal volume of Tris- 
equilibrated phenol was added to the digest and mixed by inversion of the tube and then 
centrifuged at 13000 rpm in a bench top centrifuge for 10 mins at room temperature. The 
aqueous phase was then removed and re-extracted with an equal volume of phenol, mixed 
and re-centrifuged. The remaining aqueous phase was removed and subjected to chloroform 
extraction and re-centrifuged at 13000 rpm for 10 mins at room temperature. After this 
extraction the aqueous phase was added to 2 volumes of ethanol and left on ice for 30 mins 
and then centrifuged at 13000 rpm for 20 mins at 4°C. As much supernatant as possible was 
removed and the samples of DNA then allowed to air-dry overnight on the bench at room 
temperature. The samples were then resuspended in 40pl of sterile distilled H2O by gentle 
agitation for 2 hours at room temperature, so as to not shear the DNA.
2.7.2 Culture of primary neurons
DRG (dorsal root ganglia) sensory neuron cultures of the peripheral nervous system were 
prepared from newborn Harlan Sprague-Dawley rat pups at postnatal day and Hsp27 and 
Hsp70 transgenic mice (C57 black x ) 8-12 weeks old. The animals were sacrificed by 
cervical dislocation followed by decapitation.
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2.7.3 DRG Dissection
Postnatal rats and mice were sacrificed by cervical dislocation followed by decapitation, 
ensuring to remove the head above the base of the spine. Using fine scissors cuts were made 
through the base of the spine and from the start of the neck down on each side of the animal 
in order to isolate the spinal cord.
Excess tissue was trimmed away from the spine, with care being taken so as not to cut into 
the spine. The spine was then placed in a fresh dish with the dorsal side (back) facing 
upwards. The spine was cut along the length to remove the top half and reveal the DRG and 
spinal cord. The spinal cord was discarded and No.5 forceps used to pinch out the DRGs, 
which were collected into 900pl HBSS in 35mm Petri dish. Dorsal root ganglia have a 
sheath that needs to be removed as it hinders dissociation and also introduces excess non­
neuronal cells such as glia and fibroblasts into the culture. Dissociation of DRGs was as in 
section 2.7.5 below.
2.7.4 Dissecting Media
Hanks Balanced Salt Solution (HBSS), Ca/Mg free + lOOunits/ml penicillin and 
streptomycin.
2.7.5 Dissociation Protocol
The enzymes used for dissociating the ganglia are trypsin and collagenase (type 11), 
provided by Worthington (Lome Labs). Enzymes stocks were made as lOx solutions in 
calcium and magnesium free HBSS.
Trypsin stock was made up at 1% in HBSS, filter sterilised, and stored in lOOpl frozen 
aliquots.
Collagenase stock was made up at 3% in HBSS, filter sterilised, and stored in lOOpl frozen 
aliquots.
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The dorsal root ganglia (DRG) cultures of both mice and rats were dissociated in a IOOjj.1 
mix of 0.3% collegenase/0.1% trypsin for 25min. Following enzyme treatment 1ml of 
growth media was added to the dish to stop the enzyme reaction and the ganglia dissociated 
through either a silanised flame polished pipette or a Gilson blue tip, approximately 10 times 
with care being taken not to introduce air bubbles as this leads to shearing of the cells. The 
dissociated ganglia were then transferred to a 15ml centrifuge tube and spun at 900rpm for 
5min at room temperature.
Following centrifugation supernatant was removed and the pellet carefully resuspended in 
appropriate growth media, see section 2.7.7. The cells were plated in 50pl droplets on 
laminin-coated coverslips, see section 2.7.6. Neurons were left to attach overnight in the 
incubator at 37°C/5% CO2 and then flooded with appropriate growth media next day.
2.7.6 Preparing coated coverslips/dishes for culturing cells
Laminin (Sigma) is used for growth of all types of sensory, sympathetic and 
parasympathetic neurons. Prior to application of the laminin the coverslips were coated with 
Poly-D-Omithine (pORN) (Sigma) as laminin does not adhere to uncoated plastic or glass 
surfaces.
A working solution of pORN was made in 0.15M Boric acid (Sigma) and sterilised by 
filtration through a 0.22pM filter. The coverslips were placed in a Petri dish and covered 
with pORN solution ensuring all coverslips were covered and then left at room temperature 
overnight. The next day the coverslips were washed three times with sterilised distilled 
water and left to stand and air-dry, in a tissue culture hood. Batches of pORN coated 
coverslips were made and stored in the dark at room temperature until needed.
Laminin stocks were stored in aliquots at -20°C until required. When required the laminin 
was allowed to thaw at 4°C in the fridge and then diluted to a final working concentration of 
20pg/ml. Approximately 50pl of laminin was added to each coverslip and then left in the 
incubator at 37°C/5% CO2 overnight. Prior to plating the cells, the coverslips were washed
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twice with appropriate growth media with care being taken to prevent the laminin drying 
out.
2.7.7 Culture Media
The culture media used is a basic defined media supplemented with NFG (Nerve growth 
factor).
Powdered F14 (Imperial) lOx stock was made and stored at -20°C in 50ml aliquots.
Per 500ml culture media:
50ml F14 (lOx stock)
450ml distilled H20
Approx. 1ml '/io diluted conc. HC1 (to adjust pH to 7.0) 
lg sodium bicarbonate 
2mM glutamine
0.35% w/v Bovine Serum Albumin (BSA)
16pg/ml putrescine 
60ng/ml progesterone 
38ng/ml sodium selenite 
340ng/ml triiodothyronin (T3)
400ng/ml L-thyroxine
All the above constituents were obtained from Sigma apart from glutamine, which was 
purchased from Life Technologies.
Media was filter sterilised and aliquoted into 50ml aliquots and used for two weeks. The 
media was supplemented with lOng/ml of NGF (NGF was stored in aliquots at -20°C) and 
20pM cytosine (3-D-arabinofuranoside (Ara-C) (Sigma), an anti-mitotic agent.
159
2.7.8 Removal of excess non-neuronal cells from postnatal preparations
Non-neuronal cells become an increasing problem with developmental age. To reduce the 
number of non-neuronals, the cells were spun through a column of 6% metrizamide (Sigma 
M3383) in culture media following enzyme dissociation. This high-density solution removes 
the non-neuronals, which are too small to pass through the solution. The much larger 
neurons pass through the solution and collect in a pellet at the bottom of the tube. After 
centrifugation at 900rpm for 5 minutes, the metrizamide/non neuronal mixture was tipped 
off and discarded.
2.8 Statistical Analysis
The data generated from 3-5 replicate experiments were pooled and analyzed by one-way 
analysis of variance (ANOVA) test, to identify differences between treatments such as over­
expression of different Hsps. One-way ANOVA test is a parametric test and makes the 
following assumptions: the observations are independent, the sample data has a normal 
distribution and the scores in different groups have homogenous variances. One-way 
ANOVA was carried out first in order to identify any significant differences between 
groups. As t-tests are not recommended for multiple comparisons due to the increased risk 
of a type I error, as a result of more tests performed, multiple comparisons were performed 
with post hoc Bonferroni t-test using SPSS software. The significance level was set at 
p<0.05 unless stated otherwise. Bonferroni t-test is a modified t-test in which the P value is 
multiplied by the number of tests performed on the same data. This test makes the chance of 
obtaining significance less likely and as a result eliminates the chance of obtaining a false 
positive.
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Ch a pt e r  3
The Effects of Wild Type and FALS-associated Mutant SOD1 Over­
expression in the Neuronal ND7 Cell Line
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3.1 Introduction
The alteration in the expression of a protein is a mechanism by which one can gain a 
better understanding of its biological roles. Consequently, cell lines that stably overexpress 
particular genes of interest are widely used to study the role of proteins in a particular 
cellular context. This chapter describes the establishment of an in vitro cellular system that 
allowed the study of wt-SODl and the disease associated mutants, G93A and G93R, which 
were stably over-expressed in the neuronal ND7 cell line. The advantages of the system 
along with some of the limitations are also discussed.
The ND7 cell line was prepared by fusion of post-mitotic rat dorsal root ganglion 
neurons with the N18Tg2 mouse neuroblastoma cell line, with subsequent drug selection for 
the resistant ganglion cells (Wood et al., 1990). This cell line is very useful as a result of its 
ability to proliferate indefinitely in culture whilst also retaining many of the characteristics 
of the neuronal cells; it can also be differentiated under certain conditions, leading to arrest 
of growth and outgrowth of neuronal processes. Consequently it is therefore possible to 
establish stable neuronal cell lines that proliferate indefinitely, over-expressing the gene of 
interest and enabling one to conduct multiple and reproducible experiments in large cell 
populations. There are also well known stresses that induce ND7 cells to undergo both 
apoptotic and/or non-apoptotic cell death (both of which are found to occur in the brains of 
ALS patients) and for this reason these cells provide a suitable model for studies of both 
cellular toxicity and the assessment of neuroprotection.
As discussed in Chapter 1 (Introduction), there is considerable evidence that oxidative 
stress and free radical mediated reactions involving superoxide, hydroxyl and peroxynitrite 
anions participate in the mechanism of nerve cell death in Amyotrophic Lateral Sclerosis. 
Important enzymes involved in the detoxification of superoxide free radicals are the 
mitochondrial manganese-dependent and the cytosolic and extracellular copper/zinc-dependent 
forms of superoxide dismutases (SOD), which convert the superoxide anion into hydrogen 
peroxide, which is then further detoxified by enzymes such as catalase and glutathione 
peroxidase. The importance of SOD in handling free radicals throughout periods of 
oxidative stress is well established, for example in protection against reperfusion damage in
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ischemic brain (Fridovich, 1983; Imaizum et al., 1990; Liu et al., 1989; Yang et al., 1994). A 
role for reactive oxygen species (ROS) such as superoxide in neuronal apoptosis has also been 
implicated, as increased levels are detected early on following activation of apoptosis and 
injection of SOD1 has been shown to delay apoptosis (Estevez et al., 1998 & 2000). In 
addition, mutations in copper/zinc dependent SOD (SOD1) are associated with a subset of 
cases of familial motor neurone disease/amyotrophic lateral sclerosis (FALS) (Rosen et al., 
1993). Indeed, high levels of SOD1 are found in motor neurones and nigral neurones, which 
may reflect the specific demands of these cell populations (Bergeron et al., 1996).
Transgenic mice over-expressing FALS causing SOD1 mutations (G93A, G93R, G37R 
and G85R) develop progressive paralysis with motor neurone loss (Gurney et al., 1994), thereby 
providing a valuable mouse model of disease although the loss of upper motor neurones typical of 
the human form of the disease is never observed in these transgenic mice.
The development of disease in SOD1 mutant mice is attributed to a gain of function 
and not reduced enzyme activity as endogenous SOD 1 activity is evident and mice, which are 
null for SOD1, do not exhibit motor neurone degeneration (Reaume et al., 1996). Several 
lines of study have been developed to determine the property of the mutant SOD1 bringing 
about the toxic gain of function which include increased tyrosine nitration, peroxidation, 
excitotoxicity, aggregation of SOD1, copper toxicity and reduced Zn2+ affinity (see reviews by 
Cleveland and Rothstein (2001) and Beckman et al., (2001)). Mutant forms of SOD1 possess
94-differing degrees of dismutase activity but the reduced affinity for Zn affects their catalytic 
activity resulting in superoxide generation from oxygen (Crow et al., 1997). The zinc 
deficiency (Beckman et al., 2001) could also occur in sporadic ALS cases and thus underlie this 
aetiology of this form of the disease where a modest zinc deficiency has already been reported 
(de Belleroche et al., 1987).
Evidence of apoptosis is also observed in transgenic mice overexpressing FALS 
associated SOD1 mutations from the elevated levels of caspase-1 and caspase-3 (Li et al., 
2000; Pasinelli et al., 2000) and from the observation that neuroprotection can be achieved by 
crossing these SOD1 transgenics with mice overexpressing Bcl-2 (Kostic et al., 1997). Cell
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culture experiments further substantiate the pro-apoptotic properties of FALS associated SOD1 
mutations (Rabizadeh et al., 1995).
Therefore, from what was known about wt-SODl at the time of the establishment of 
the model system presented here, it was suggested that wt-SODl could reduce the cell death 
triggered by various stimuli whereas the mutants would enhance cell death under the same 
circumstances. The work described here adds to the literature and studies the effects of 
SOD1 and FALS associated SOD1 mutants in cell culture on a wide variety of death-inducing 
stimuli both apoptotic and nonapoptotic in order to characterise their mode of action. The two 
mutant forms of SOD1 chosen for this study were, G93A, which has been widely reported 
(Cudkowicz et al., 1997) and a second mutation, G93R, which has only been reported in a 
single family (Orrell et al., 1995 & 1997). These findings suggest that the disease-associated 
mutations appear to convert wt-SODl from an anti-apoptotic protein, which protects cells 
from cell death associated with different types of cell stress to forms, which have a 
universally damaging effect (Patel et al., 2002). This as well as the limitations of the system 
is discussed in this chapter.
3.2 Establishment of Cell Lines Stably Expressing SOD1 and FALS- 
associated SOD1 mutants
This section briefly describes the establishment and characterisation of the model 
system used in this study. The SOD1 stable cell lines were created in our laboratory by Dr 
Yolanda Collaco-Moraes. The human fibroblast SOD1 cDNA obtained from ATCC 
(Accession no: #61646) was cloned into the mammalian expression vector pcDNA3neo 
(Invitrogen Ltd, UK). This vector allowed high levels of protein expression in mammalian 
cells and permitted the simultaneous selection for cells with the inserted gene using G418- 
sulphate, as the vector also contains a neomycin resistance cassette.
Briefly, ND7 cells were grown in 6-well plates and the above mentioned expression 
vector incorporating wt-SODl, G93A or G93R-mutant-SOD 1 as well as empty 
pCDNA3neo vector control were transfected using the calcium phosphate method. G418- 
sulphate was added to the media 48h post transfection at final concentration of 800pg/ml
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and after 5-10 days approximately 80-100 individual G418-resistant colonies per construct 
were isolated.
3.3 Identification  and C haracterisation  o f  O ver-exp ressin g  C lones
3.3.1 Western Blotting
Following colony selection, the clones that were growing normally were screened for 
expression of SOD1 or mutant SOD1 by means of Western blotting as described in section 
2.5. Figure 3.1 shows the clear overexpression of the 16kDa SOD1 and mutant SOD1. The 
concentration of each of the protein samples was determined by performing a protein assay, 
which is described in section 2.5.4, and equal amounts of protein were loaded in each lane.
Wt-
SODl
Actin
SOD1
F ig u re  3.1, Level o f SOD1 expression in the wt-SODl (lane 2), G93A (lane 3) and 
G93R (lane 4) mutant SOD1 cells compared to the empty vector control (lane 1) cells.
3.4 R esponses o f C ell L ines to Several D eath-indu cin g Stim uli
The following sections describe the responses of control, wt-SODl and FALS- 
associated SOD1 mutants on exposure to various death inducing cellular stresses, such as 
serum withdrawal both in the presence and absence of lpM retinoic acid, IFN-y, 
staurosporine, simulated ischemia/reperfusion, glutamate, hydrogen peroxide and 
camptothecin (for conditions see section 2.3 of Chapter 2). Various studies have utilised 
stable cell lines expressing toxic or other genes of interest and through a variety of agents
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investigated their responses to a range of stresses brought about by these agents, which is 
discussed further in the Discussion. The relevance of the stresses used here to FALS is 
explained in each section prior to each of the respective results obtained. Cell death was 
quantified by the trypan blue exclusion assay and the number of apoptotic cells assessed by 
TUNEL analysis as described in section 2.6.1 and 2.6.2 respectively.
3.4.1 Serum Removal and Serum Removal plus lpM retinoic acid
Serum is an essential requirement for maintenance and growth of cell lines and its deletion 
from cell culture media is known to lead to cell death and/or differentiation (for example see 
Poser et al., 2003). In this present system, serum removal is used as a known apoptotic and 
differentiating stimulus for ND7 cells (Howard et al., 1993). It can be used to project and 
potentially compare the effect of deprivation of neurones from a wide range of survival 
signals in the brain, a situation which is linked to neurodegeneration. It is therefore used as a 
stress potentially relevant to the disease.
The effect of over-expressing SOD1 or FALS-associated SOD1 mutations on cell viability 
in stably transfected neuronal cells was investigated. Human wild type SOD1 or SOD1 
mutant cDNA was inserted into the mammalian expression vector pCDNA3neo under 
control of a CMV promoter and transfected into ND7 cells. Expression of SOD1 was 
detected by means of western blotting in ND7 cells. Cells were incubated for various 
lengths of time in the appropriate medium in the absence of foetal calf serum and in the 
presence or absence of lpM all-trans retinoic acid (RA) (as the retinoic acid was dissolved 
in DMSO it was used as a control in the absence of RA); serum withdrawal in the presence 
of all-trans retinoic acid induces high levels of apoptosis without significant differentiation. 
The response of the ND7 cell line to conditions of serum withdrawal has been well 
characterised in the past. ND7 cells either go through morphological differentiation into a 
mature neuronal phenotype with dendrite-like processes or undergo programmed cell death 
(Howard et al., 1993).
As seen in Figure 3.2a and 3.2b, total cell death and apoptotic cell death were measured in 
these cell lines following serum deprivation at 24h and 48h time points, in order to assess
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the extent of cell death in the cell lines from serum withdrawal, in five independent 
experiments.
Total cell death was determined using the trypan blue exclusion assay in ND7 cells 
expressing either the vector cassette (vector control) or expressing the wild-type SOD1 gene, 
G93A mutant or G93R mutant gene. Cell death was found to be significantly attenuated in 
stable cell lines over-expressing wild-type SOD1, being decreased by 12% (p<0.05) and by 
25% (p<0.0005) at 24h and 48h respectively, compared to the vector control (Figure 3.2a). 
On the other hand, cells expressing the G93R mutation exhibited a significantly enhanced 
cell death which was increased by 64% at 24h and 32% at 48h compared to a vector 
transfected control cell line (p<0.0005) and increased by 86% at 24h compared to the wild- 
type expressing cell line (p<0.0005). However, cells expressing the G93A mutation did not 
exhibit a large increase in death as seen with the G93R mutant, with levels of death being 
approximately 16% (p<0.005) and 8% (p<0.0005) at 24h and 48h respectively compared to 
the vector control cell line, but compared to the wild-type expressing cells at 24h and 48h, 
cell death was significantly increased by approximately 31% and 44% respectively 
(p<0.0005).
Apoptotic cell death following serum withdrawal was assessed using the TUNEL labelling 
method in ND7 cells expressing the vector cassette (vector control) or expressing the wild- 
type SOD1 gene, G93A mutant or G93R mutant gene (Figure 3.2b). Wild-type SOD over­
expressing cells showed a significantly reduced number of TUNEL positive cells at 24h, 
being decreased by 16% at 24h and 27% at 48h (p<0.0005) while the G93R mutation 
brought about a 82% increase in TUNEL positive cells at 24h and 37% at 48h compared to 
vector control (p<0.0005). At the 24h time point the G93R cell line exhibited a 118% 
increase in TUNEL positive cells and approximately 2 times the number of TUNEL positive 
cells compared to the wild-type SOD1 over-expressing cells. Although the G93A mutant 
did not exhibit a substantial increase in cell death, cell death was approximately 22% and 
8% higher at 24h and 48h respectively than vector control (p<0.005). Compared to wt-SODl 
cells the G93A mutant exhibited a 46% and 48% increase in cell death at 24h and 48h 
respectively (p<0.0005).
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Figure 3.2a
Control
Figure 3.2 Levels of cell death in untreated control, wild type or mutant SOD1 
expressing cells at 24h.
a. ND7 cell death following 24h of no treatment/no stress. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of no treatment/no stress of engineered 
ND7 cells expressing wt or mutant SOD1. Bars represent mean -^ S.D. calculated for 
triplicate counts per sample (n), n=5.
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Figure 3.2b
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Figure 3.2 Effect of serum withdrawal on cell death in control, wild type or mutant 
SOD1 expressing cells at different time points.
b. ND7 cell death following 24h and 48h serum removal. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h and 48h of serum deprivation of 
engineered ND7 cells expressing wt or mutant SOD1. Bars represent mean ^ .D . calculated 
for triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
control ND7 empty vector cell line.
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Figure 3.2c
Control Wt-SODl G93A G93R
Figure 3.2 Effect of serum withdrawal on cell death in control, wild type or mutant 
SOD1 expressing cells at different time points.
c. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of serum deprivation for 24h and 48h. Bars 
represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant 
differences were calculated as above with /?<0.0005. *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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On addition of lp,M retinoic acid and serum deprivation, wt-SODl cells exhibited a 22% 
and 24% reduction in death at 24h and 48h respectively compared to vector control 
(p<0.0005); (Figure 3.3a). The G93A mutant cells once again exhibited a smaller increase in 
cell death with death increasing by approximately 13% (p<0.0005) and 7% (p<0.01) at 24h 
and 48h respectively compared to vector control. The G93R mutant increased cell death by 
approximately 41% and 35% at 24h and 48h respectively compared to vector control 
(p<0.0005). Compared to wt-SODl cells the G93A cells exhibited a 44% and 42% increase 
in cell death at 24h and 48h respectively and the G93R cells exhibited an increase of 
approximately 80% and 78% at 24h and 48h respectively (p<0.0005).
TUNEL assessment of cell death brought about similar results. Wt-SODl cells exhibited a 
decrease of in the number of TUNEL positive cells by approximately 30% compared to 
vector control at both 24h and 48h time points (p<0.0005); (Figure 3.3b). G93A cells saw 
an increase in number of TUNEL positive cells by approximately 17% and 13% at 24h and 
48h respectively compared to vector control (p<0.0005). The G93R mutant cells exhibited 
an increase of approximately 56% and 50% at 24h and 48h respectively compared to vector 
control (p<0.0005). Compared to wt-SODl cells the G93A cells exhibited an increase of 
66% and 61% in the number of TUNEL positive cells and G93R cells an increase of 120% 
and 113% at 24h and 48h respectively (p<0.0005). These results from neuronal cell lines 
suggest that over-expressing wild type SOD1 inhibits or in some way delays apoptosis 
whereas the G93R mutation is proapoptotic.
In a smaller number of experiments the cell lines were incubated for the same time period in 
the presence of normal growth medium. A small but marked difference was observed 
between cell death in the various cell lines with wt-SODl providing a reduction in death 
compared to control and the mutants G93A and G93R exhibiting a slight increase in death 
compared to control with the G93R mutant exhibiting a slightly higher death than G93A. 
However, the effect of serum withdrawal on the mutants was greater even though the basal 
levels of death were higher.
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Figure 3.3 Levels of cell death in untreated control, wild type or mutant SOD1 
expressing cells at 24h.
a. ND7 cell death following 24h of no treatment/no stress. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of no treatment/no stress of engineered 
ND7 cells expressing wt or mutant SOD1. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5.
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Figure 3.3b
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Figure 3.3 Effect of serum withdrawal plus lpM retinoic acid on cell death in control, 
wild type or mutant SOD1 expressing cells at different time points.
b. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to conditions of serum deprivation for 24h or 48h in the presence of lpM 
retinoic acid. The proportion of cell death was assessed by trypan blue exclusion assay, after 
24h and 48h of serum deprivation plus lpM retinoic acid. Bars represent mean -^ S.D. 
calculated for triplicate counts per sample (n), n=5. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with the 
control ND7 empty vector cell line.
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Figure 3.3c
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Figure 3.3 Effect of serum withdrawal plus lpM retinoic acid on cell death in control, 
wild type or mutant SOD1 expressing cells at different time points.
c. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of serum deprivation plus lpM retinoic acid for 
24h and 48h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=3) 
and significant differences were calculated as above with p<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with the control ND7 
empty vector cell line.
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3.4.2 Staurosporine treatment
Having established that wild type SOD1 had a protective effect against serum deprivation 
and serum deprivation in the presence of lpM retinoic acid, whereas the mutants had a 
damaging effect, it was decided to further investigate the effect of the wild type SOD 1 and 
the mutants on the response to other death-inducing stimuli. Therefore, a time course 
experiment was carried out in order to analyse the response of the different cell lines to 
treatment with staurosporine, which has been shown to induce apoptotic death in a variety of 
different neuronal and non-neuronal cell types. Staurosporine is a bacterial alkaloid that 
inhibits a number of cellular kinases (Gill et al., 2003) and is frequently used as an inducer 
of the mitochondrial apoptotic pathway. Staurosporine has been shown to induce 
cytochrome c release (Krohn et al., 1998), caspase activation (Krohn et al., 1998 & 1999), 
intracellular ROS accumulation (Krohn et al., 1998; Kruman et al., 1998 Prehn et al., 1997), 
and an increase in [Ca ] (Kruman et al., 1998). Intracellular cascades activated by 
staurosporine depend on its concentration, with lOOnM concentration inducing cell death 
through an apoptotic mechanism characterised by release of cytochrome c and a lpM 
concentration of staurosporine inducing cell death through a mechanism, in which caspase 
activation is detected, but which shows several nonapoptotic features (Deshmukh et al., 
2000). Death curves were carried out and a lpM concentration of staurosporine was chosen 
to be the optimal concentration.
Total cell death was assessed by trypan blue exclusion, following lpM staurosporine
addition. Cells in 6-well plates at approximately 90% confluency were incubated in full
growth media containing 1 pM staurosporine for a period of 2h, 4h and 6h. In these
experiments (Figure 3.4a) it was shown that the G93R mutant clearly enhanced the degree of
cell death produced by staurosporine (2-6 hours) and a similar effect of the G93A mutant
was also observed, albeit less dramatic. However the wild type SOD1 showed a significant
protective effect both when compared to the effect of over-expressing the mutant and also
compared to the control cells containing only empty expression vector. Hence, as with the
effect of serum removal and serum removal plus retinoic acid, both the mutants enhanced
the damaging effects of staurosporine in comparison to the wild type protein, which
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produced a protective effect. At the 2hr time point wt-SODl provided a protective effect 
with death being reduced by approximately 17% compared to control vector (p<0.0005). 
Both the G93A and G93R mutants showed an increase in cell death, at 2hr, with death 
increasing by approximately 18% and 32% respectively compared to vector control 
(p<0.0005). At the 4hr and 6hr time points, wt-SODl provided a reduction in death by 
approximately 12% (p<0.005) and 20% (p<0.0005) respectively, compared to vector 
control. In comparison the G93A and G93R mutant both exhibited increases in cell death 
with death increasing by approximately 30% and 21% at 4hr and 6hr respectively for G93A 
and 46% and 30% at 4hr and 6hr respectively for G93R mutant, compared to vector control 
(p<0.0005).
TUNEL analysis revealed similar results with the number of TUNEL positive cells being 
reduced in the wt-SODl cells by approximately 21% at 2hr compared to vector control 
(p<0.05); ((Figure 3.4b). Both G93A and G93R saw an increase in TUNEL positive cells by 
approximately 17% (p<0.05) and 48% (p<0.0005) respectively, compared to vector control. 
At 4h and 6hr time points, wt-SODl cells saw a reduction in TUNEL positive cells by 
approximately 11% and 23% (p<0.0005) respectively, compared to vector control. The 
number of TUNEL positive cells in both mutants increased at 4hr and 6hr by approximately 
32% and 26% respectively for G93A and 48% and 37% respectively for G93R, compared to 
vector control (p<0.0005).
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Figure 3.4a(i) Staurosporine Kill Curve - Effect of different concentrations of 
staurosporine on cell death in control, wild type or mutant SOD1 expressing cells at 2h 
time point.
a(i). Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 
expressing cells exposed to 0.1 pM; 0.5pM; lpM; 2pM; 5pM staurosporine treatment for 
period of 2h. The proportion of cell death was assessed by trypan blue exclusion assay. Bars 
represent mean ±S.D. calculated for triplicate counts per sample (n), n=5. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (p<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with the control ND7 empty vector cell line.
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Figure 3.4a(ii) Staurosporine Kill Curve - Effect of different concentrations of 
staurosporine on cell death in control, wild type or mutant SOD1 expressing cells at 4h 
time point.
a(ii). Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 
expressing cells exposed to 0.1 pM; 0.5pM; lpM; 2pM; 5pM staurosporine treatment for 
period of 4h. The proportion of cell death was assessed by trypan blue exclusion assay. Bars 
represent mean -^ S.D. calculated for triplicate counts per sample (n), n=5. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (p<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with the control ND7 empty vector cell line.
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Figure 3.4 Levels of cell death in untreated control, wild type or mutant SOD1 
expressing cells at 24h.
b. ND7 cell death following 24h of no treatment/no stress. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of no treatment/no stress of engineered 
ND7 cells expressing wt or mutant SOD1. Bars represent mean ^ .D . calculated for 
triplicate counts per sample (n), n=5.
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Figure 3.4 Effect of staurosporine on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
c. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to staurosporine treatment for periods of 2h, 4h or 6h. The proportion of cell 
death was assessed by trypan blue exclusion assay. Bars represent mean -^ S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (/?<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
control ND7 empty vector cell line.
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Figure 3.4 Effect of staurosporine on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
d. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of staurosporine for periods of 2h, 4h or 6h. Bars 
represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant 
differences were calculated as above with /?<0.0005. *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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3.4.3 IFN-y administration
Subsequently, the cells were treated with IFN-y for 24h and 48h, which is known to induce 
cell death in a variety of neuronal and non-neuronal cell types (Figure 3.5a). IFN-y proteins 
are found to be significantly elevated by 1.5- to 2-fold in late-stage G93A-SOD1 mouse 
spinal cords (Hensley et al., 2003). Therefore it was decided to investigate the effects of 
IFN-y treatment further. As with serum deprivation and staurosporine, an enhanced cell 
death was observed in the cells over-expressing the G93R mutant and to a slightly lesser 
extent with the G93A mutant, whereas the cells over-expressing the wild type were 
significantly protected compared to the mutant cells (Figure 3.8). At the 24h and 48h time- 
point wt-SODl reduced death by approximately 23% (p<0.0005) and 19% (p<0.05) 
respectively compared to vector control. The G93A and G93R mutant exhibited an increase 
in cell death with death increasing by approximately 15% (p<0.0005) and 11% for G93A 
and 49% (p<0.0005) and 46% (p<0.0005) for G93R at 24h and 48h respectively compared 
to vector control.
TUNEL analysis showed a reduction in the number of TUNEL positive cells expressing wt- 
SODl with the number of TUNEL positive cells decreasing by approximately 33% and 18% 
at 24h and 48h respectively compared to vector control (p<0.0005) (Figure 3.5b). The G93A 
and G93R mutant expressing cells exhibited an increase in the number of TUNEL positive 
cells with the number of TUNEL positive cells increasing by approximately 13% at both 
24h (p<0.0005) and 48h (p<0.005) for G93A and 54% (p<0.0005) and 56% (p<0.0005) for 
G93R at 24h and 48h respectively, compared to vector control.
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Figure 3.5 Levels of cell death in untreated control, wild type or mutant SOD1 
expressing cells at 24h.
a. ND7 cell death following 24h of no treatment/no stress. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of no treatment/no stress of engineered 
ND7 cells expressing wt or mutant SOD1. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5.
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Figure 3.5 Effect of IFN-y on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
b. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to IFN-y treatment for 24h and 48h. The proportion of cell death was assessed 
by trypan blue exclusion assay. Bars represent mean ^ .D . calculated for triplicate counts 
per sample (n), n=5. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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Figure 3.5 Effect of IFN-y on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
c. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed IFN-y for 24h and 48h. Bars represent mean 1 S.D. calculated 
for triplicate counts per sample (n=3) and significant differences were calculated as above 
withp<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the control ND7 empty vector cell line.
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3.4.4 Hydrogen Peroxide (H2O2) treatment
Altered reactivity for certain substrates has been observed for mutant SOD1 enzyme. 
Dismutase activity of FALS-associated SOD1 mutations is normal but peroxidase activity 
appears to be enhanced (Wiedau-Pazos et al., 1996; Yim et al., 1996). X-ray 
crystallographic studies have revealed that the active channel of FALS mutant is slightly 
larger than that of the wild type, providing support to the theory that H2O2 has access to the 
mutant enzyme (Yim et al., 1996). Hydrogen peroxide (H2O2) is well known to inactivate 
Cu, Zn SOD through the oxidation of a histidine ligand for copper. The reaction is thought 
to be a two-step process, with the anion of hydrogen peroxide (HOO) first reducing Cu to 
Cu1+. The reduced copper is then thought to react with a second hydrogen peroxide to 
produce a strong oxidant with the reactivity of a hydroxyl radical that has a high probability 
of then attacking a nearby histidine ligand. Therefore it was decided to investigate the 
effects of H2O2 treatment further in the SOD1 expressing stable cells.
G93A and G93R mutant SOD1 over-expressing cells exhibited an increase in total cell death 
of approximately 10% (p<0.05) and 44% (p<0.0005) respectively at the 24h time point 
compared to control (Figure 3.6a). At the 48h time point the cell death increased to 
approximately 25% and 51% for G93A and G93R respectively compared to control 
(p<0.0005). Wt SOD1 cells were protected against the insult with cell death being reduced 
by approximately 16% and 26% at 24h and 48h respectively compared to control 
(p<0.0005).
TUNEL analysis further supported the cell death results with the number of TUNEL positive 
cells for the G93A and G93R mutant increasing by approximately 16% (p<0.05) and 52% 
(p<0.0005) respectively at 24h and 29% (p<0.0005) and 55% (p<0.0005) respectively at 48h 
compared to control (Figure 3.6b). Wt-SODl cells exhibited a reduction in the number of 
TUNEL positive cells with number of TUNEL positive cell decreasing by approximately 
16% and 28% (p<0.0005) at 24h and 48h respectively compared to control.
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Figure 3.6 Effect of lOpM H2O2 on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
a. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to H2O2 treatment for periods of 24h and 48h. The proportion of cell death was 
assessed by trypan blue exclusion assay. Bars represent mean ^ .D . calculated for triplicate 
counts per sample (n), n=5. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with the control ND7 
empty vector cell line.
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Figure 3.6 Effect of lOpM H2O2 on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of H2O2 for periods of 24h and 48h. Bars 
represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant 
differences were calculated as above with p<0.0005. *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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3.4.5 Glutamate administration
Besides oxidative stress, glutamate-mediated excitotoxicity is considered to be an important 
factor of motor neuron degeneration observed in ALS. In fact, glutamate accumulation into 
the synaptic cleft results in excessive post-synaptic receptor stimulation, calcium entry and 
cell death (Choi, 1988; Beal, 1992; Coyle and Puttfarcken, 1993). Consistently, in ALS, 
there is evidence that a defect in glutamate turnover leads to increased levels of extracellular 
glutamate with resulting deleterious consequences (Atlante et al., 2001; Leigh and Meldrum, 
1996; Doble 1999). Therefore it was decided to investigate the effects of glutamate 
administration in the SOD1 expressing stable cells.
Mutant SOD1 expressing cells exhibited an increase in total cell death with death increasing 
by approximately 6% and 46% (p<0.0005) for G93A and G93R respectively at 24h 
compared to control (Figure 3.7a). At the 48h time point the G93A and G93R mutant 
exhibited an approximately 21% (p<0.0005) and 63% (p<0.0005) increase in cell death 
respectively compared to control. Wt-SODl expressing cells provided a protective effect 
with cell death reduced by approximately 23% (p<0.0005) and 10% (p<0.05) at 24h and 48h 
respectively compared to control.
TUNEL analysis supported the total cell death results. At the 24h time point G93A and 
G93R expressing mutant cells exhibited an increase in the number of TUNEL positive cells 
with the number of TUNEL positive cells increasing by approximately 10% (p<0.05) and 
54% (p<0.0005) respectively compared to control (Figure 3.7b). At the 48h time point 
G93A and G93R mutant cells exhibited an approximately 21% (p<0.05) and 62% 
(p<0.0005) increase in the number of TUNEL positive cells respectively compared to 
control. Wt-SODl cells exhibited an approximately 27% (p<0.0005) and 17% (p<0.01) 
reduction in the number of TUNEL positive cells at 24h and 48h respectively compared to 
control.
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Figure 3.7 Effect of 5pM Glutamate on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
a. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to Glutamate treatment for periods of 24h and 48h. The proportion of cell 
death was assessed by trypan blue exclusion assay. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (/?<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
control ND7 empty vector cell line.
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Figure 3.7 Effect of 5pM Glutamate on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of Glutamate for periods of 24h and 48h. Bars 
represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant 
differences were calculated as above with /?<0.0005. *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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3.4.6 Camptothecin administration
Similar results were also observed when the cells were treated with camptothecin (Figure 
3.8a). Camptothecin works by targeting topoisomerase I, inducing single strand breaks, 
thereby affecting the cells capacity to replicate and eventually leading to apoptotic death 
mediated by caspase activation. Wt-SODl expressing cells exhibited a decrease in cell death 
with death decreasing by approximately 24% and 21% at 24h and 48h respectively, 
compared to vector control (p<0.0005). The mutants once again exhibited an increase in cell 
death with death increasing by approximately 25% and 27% for G93A at 24h and 48h 
respectively (p<0.0005). The G93R mutant showed a larger increase in death in line with 
previous results with death increasing by 43% at both 24h and 48h respectively compared to 
vector control (p<0.0005).
TUNEL analysis revealed a reduction in the number of TUNEL positive cells in the cells 
expressing wt-SODl with the number of TUNEL positive cells being reduced by 
approximately 30% and 31% at 24h and 48h respectively compared to vector control 
(p<0.0005) (Figure 3.8b). The mutants on the other hand exhibited an increase in the number 
of TUNEL positive cells with the number increasing by approximately 29% (p<0.0005) and 
7% (p<0.05) for G93A at 24h and 48h respectively, compared to vector control. The G93R 
mutant once again exhibited a much larger increase in TUNEL positive cells with number 
increasing by approximately 53% and 39% at 24h and 48h respectively compared to vector 
control (p<0.0005).
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Figure 3.8 Effect of Camptothecin on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
a. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to Camptothecin treatment for periods of 24h and 48h. The proportion of cell 
death was assessed by trypan blue exclusion assay. Bars represent mean ^ .D . calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
control ND7 empty vector cell line.
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Figure 3.8 Effect of Camptothecin on cell death in control, wild type or mutant SOD1 
expressing cells at different time points.
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of Camptothecin for periods of 24h and 48h. Bars 
represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant 
differences were calculated as above with p<0.0005. *, **, *** indicates statistically 
significant difference between means, when comparing with the control ND7 empty vector 
cell line.
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3.4.7 Cell - line responses to Simulated Ischemia/Reoxygenation.
In view of the role of SOD as an antioxidant and in dealing with free radicals formed in 
cells, it was of particular interest to investigate the response of these cells to a period of 
simulated ischemia followed by reoxygenation which has been used in the past to induce 
cell death in ND7 cells and also to demonstrate the neuroprotective role of Hsps (Wagstaff 
et al., 1999). Briefly, the cells were plated in 6-well plates and subjected to ischemia for a 
period of lh, 2h, 3h or 4h followed by 24h of reoxygenation. The control buffer (pH 7.4) 
was used at all times and the cell death observed was between 5-10% in the various cell 
lines (data not displayed). It is clear, however, that the cytotoxic effect observed of the 
ischemic buffer is because of its additional components and the reduced pH.
An increase in death was observed in all the cell lines on ischemia/reperfusion over ischemia
alone. The greater the period of ischemia the greater was the death observed and the greater
the corresponding death seen on reoxygenation. The deleterious effects of the mutants were
more clearly observed on reoxygenation. The results of this experiment (Figure 3.9)
paralleled those obtained for the other stimuli, indicating over-expression of both the
mutants significantly enhanced the degree of cell death observed, with the G93R mutation
having a stronger and more dramatic effect than the G93A mutation. However, cells
transfected with the wild type SOD1 showed significantly reduced cell death compared to
the cells expressing either of the two mutants corroborating that the mutants had a
particularly damaging effect in the response to simulated ischemia/reoxygenation as with the
other stimuli. G93A mutant cells exhibited an approximately 11%, 14% and 27%
(p<0.0005) increase in total cell death following lh, 2h and 3h of ischemia respectively
compared to ND7 empty vector control (Figure 3.9a). G93R mutant cells showed a larger
increase with death increasing by approximately 18%, 42% (p<0.0005) and 55% (p<0.0005)
following lh, 2h and 3h periods of ischemia respectively compared to ND7 empty vector
control (Figure 3.9a). Wt-SODl cells exhibited a protective effect with death being reduced
by approximately 29% (p<0.05), 26% (p<0.005) and 26% (p<0.0005) following lh, 2h and
3h periods of ischemia respectively compared to ND7 empty vector control (Figure 3.9a). A
larger increase in death was observed on reoxygenation. G93A cells exhibited an increase in
cell death by approximately 18% (p<0.005), 13% and 16% (p<0.005) at lh, 2h and 3h of
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ischemia followed by 24h of reoxygenation respectively compared to control (Figure 3.9a). 
G93R cells exhibited a more dramatic increase in cell death with death increasing by 
approximately 60%, 72% and 87% following lh, 2h and 3h of ischemia followed by 24h of 
reperfusion compared to control (p<0.0005) (Figure 3.9a). Wt-SODl cells exhibited a 
reduction in cell death with death being reduced by approximately 31%, 32% and 27% after 
lh, 2h and 3h of ischemia followed by 24h of reoxygenation compared to control 
(p<0.0005).
TUNEL analysis revealed similar results with the number of TUNEL positive cells of both 
mutants increasing following increasing periods of ischemia and increasing further on the 
corresponding reoxygenation compared to control (p<0.0005) (Figure 3.9b). Wt-SODl cells 
exhibited a protective effect with the number of TUNEL positive cells being reduced at each 
instance compared to ND7 empty vector control.
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Figure 3.9 Effect of simulated ischemia and ischemia followed by 24h of reoxygenation 
on cell death in control, wild type or mutant SOD1 expressing cells at different time 
points.
a. Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to lh, 2h or 3h of ischemia and lh, 2h or 3h of ischemia followed by 24h of 
reoxygenation. The proportion of cell death was assessed by trypan blue exclusion assay. 
Bars represent mean ±S.D. calculated for triplicate counts per sample (n), n=5. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (/?<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with the control ND7 empty vector cell line.
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Figure 3.9 Effect of simulated ischemia and ischemia followed by 24h of reoxygenation 
on cell death in control, wild type or mutant SOD1 expressing cells at different time 
points.
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of lh, 2h or 3h of ischemia lh, 2h or 3h of 
ischemia followed by 24h of reoxygenation. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=5) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the control ND7 empty vector cell line.
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3.4.8 4hr Ischemia plus 24h of Reoxygenation
Wt-SODl expressing cells exposed to 4hr ischemia+24h reoxygenation exhibited a 
reduction in death of approximately 19% compared to vector control (p<0.01); (Figure 
3.10a). The G93A and G93R mutant expressing cells exhibited an increase in death of 
approximately 13% and 86% respectively compared to vector control (p<0.0005) (Figure 
3.10a).
TUNEL analysis revealed a similar trend with the number of TUNEL positive cells for wt- 
SOD1 cell line being reduced by approximately 24% compared to control (Figure 3.10b). 
The G93A and G93R mutant expressing cells exhibited an increase in the number of 
TUNEL positive cells with number increasing by approximately 10% and 100% (p<0.0005) 
respectively compared to vector control (Figure 3.10b).
199
Figure 3.10a
stewp<0.0005 
*^<0.01
ND7 SOD G93A
Figure 3.10 Effect of 4h of simulated ischemia followed by reoxygenation on cell death 
of ND7 cells expressing wild type or mutant SOD1.
a. Control, wt and mutant SOD1 cell lines were exposed to 4h of ischemia followed by 24h 
of reoxygenation. Cell death was immediately assessed by the trypan blue assay. The 
proportion of cell death was assessed by trypan blue exclusion assay. Bars represent mean 
±S.D. calculated for triplicate counts per sample (n), n=6. Significant differences were 
calculated using Bonferroni Multiple Comparison’s t test after one-way ANOVA 
(p<0.0005). *, **, *** indicates statistically significant difference between means, when 
comparing with the control ND7 empty vector cell line.
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Figure 310b
Figure 3.10 Effect of 4h of simulated ischemia followed by reoxygenation on cell death 
of ND7 cells expressing wild type or mutant SOD1.
b. Percentage of TUNEL-positive cells counted in three different fields in six experiments 
where cell lines were exposed to treatment of 4h of ischemia followed by 24h of 
reoxygenation. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=6) 
and significant differences were calculated as above with p<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with the control ND7 
empty vector cell line.
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3.4.9 4h of Ischemia followed by 24h of Reoxygenation plus Retinoic Acid (RA)
Addition of differing concentrations of retinoic acid to the cell lines, 2 hours prior to being 
subjected to 4hr of ischemia followed by 24h of reoxygenation, produced interesting results. 
In contrast to the effect of RA when serum was removed, addition of retinoic acid under 
these conditions produced an initial protective effect in all cells with the protective effect 
lasting to varying extents across the cells. Wt-SODl cells exhibited the greatest protection 
on addition of lpM retinoic acid with death reduced by approximately 22% compared to 
control (p<0.005); (Figure 3.11a). The G93A mutant exhibited the greatest protection at 
2pM concentration of retinoic acid with death reduced by approximately 58% compared to 
control (p<0.0005). The G93R mutant exhibited the greatest reduction in death at a slightly 
higher concentration with death reduced by approximately 72% compared to control, on 
addition of 4pM retinoic acid (p<0.0005). The protection provided to the cell lines by 
differing concentrations of retinoic acid can be easily seen in Figure 3.11b.
TUNEL analysis paralleled trypan blue results with initial protection observed across all 
cells on addition of retinoic acid (Figure 3.1 lc). Wt-SODl cells exhibited a 20% reduction 
in the number of TUNEL positive cells on addition of lpM retinoic acid compared to 
control (p<0.05); (Figure 3.11c). The G93A mutant exhibited an approximately 60% 
reduction in the number of TUNEL positive cells at 2pM concentration of retinoic acid 
compared to control (p<0.0005) whereas the G93R mutant exhibited an approximately 76% 
reduction in the number of TUNEL positive cells on addition of 4pM retinoic acid compared 
to control (p<0.0005).
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Figure 3.11a Effect of 4h of ischemia followed by 24h of reoxygenation and varying 
concentrations of retinoic acid on cell death in control, wild type or mutant SOD1 
expressing cells.
Levels of total cell death in control vector, wt, mutant -G93A or G93R-SOD1 expressing 
cells exposed to 4h of ischemia followed by 24h of reoxygenation plus varying 
concentrations of retinoic acid. The proportion of cell death was assessed by trypan blue 
exclusion assay. Bars represent mean ^ .D . calculated for triplicate counts per sample (n), 
n=6. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (/?<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the control ND7 empty vector cell line.
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Figure 3.11b Effect of 4h of ischemia followed by 24h of reoxygenation and varying 
concentrations of retinoic acid on cell death in control, wild type or mutant SOD1 
expressing cells.
Line graph showing levels of total cell death in control vector, wt, mutant -G93A or G93R- 
SOD1 expressing cells exposed to 4h of ischemia followed by 24h of reoxygenation plus 
varying concentrations of retinoic acid. The proportion of cell death was assessed by trypan 
blue exclusion assay.
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Figure 3.11c Effect of 4h of ischemia followed by 24h of reoxygenation and varying 
concentrations of retinoic acid on cell death in control, wild type or mutant SOD1 
expressing cells.
Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were exposed to treatment of 4h of ischemia followed by 24h of 
reoxygenation plus varying concentrations of retinoic acid. Bars represent mean 1 S.D. 
calculated for triplicate counts per sample (n=6) and significant differences were calculated 
as above with /?<0.0005. *, **, *** indicates statistically significant difference between 
means, when comparing with the control ND7 empty vector cell line.
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3.5 Discussion
The findings presented in this chapter describe the establishment and characterisation 
of an in vitro model system where wt-SODl and the disease-associated SOD 1-mutant forms 
are over-expressed. It was shown that the response of the cell lines to various death-inducing 
stimuli depends on both the type of stress and the form of SOD1, which is over-expressed.
There was a statistically significant reduction in cell death in ND7 cells over­
expressing human wt-SODl compared to control cells (stably transfected with the vector 
alone) when cell lines were exposed to wide-range of stresses including serum withdrawal, 
serum withdrawal in the presence of retinoic acid, IFN-y, staurosporine, camptothecin, 
hydrogen peroxide, glutamate, and ischemia/reoxygenation. In the case of the two mutant 
forms of SOD1, cell death was always enhanced compared to control cells with the 
differences in cell death between control and mutant cell lines being statistically significant 
for all the stresses tested.
The above findings suggest a deleterious function for both the mutant forms of the 
protein. When the cell lines expressing the two mutant forms of SOD1 were compared 
against each together, G93R mutant exhibited an enhanced cell death over the G93A mutant 
throughout all the stresses tested. In general, the G93A mutant exhibited a slightly higher 
death than control cells under all stresses tested. The difference in cell death between the 
two mutant forms may be the result of a number of different factors such as differing 
degrees of copper binding, differences in zinc affinity, or even differences in size of active 
site. Overall, the above data provides support to the proposed hypothesis that the disease- 
associated FALS SOD1 mutations confer a gain of function and /or loss of a protective 
function on this protein, resulting in the deleterious effects observed in the cells and that wt- 
SODl protein provides a uniformly protective effect on the cells against all stresses tested.
The stresses tested have been widely used by others and are relevant to ALS in that
serum deprivation simulates deprivation of survival signals to neurons, glutamate induced
excitotoxicity as well as hydrogen peroxide induce oxidative stress which is also relevant to
the neuronal environment. IFN-y protein is significantly elevated 1.5- to 2-fold in late-stage
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G93A-SOD1 mouse spinal cords (Hensley et al., 2003) and is therefore a relevant stress. 
Camptothecin works by targeting topoisomerase I, inducing single strand breaks, thereby 
affecting the cells capacity to replicate and eventually resulting in apoptotic death mediated 
by caspase activation. The use of simulated ischemia has not been previously been reported 
but is a physiological stress that was used to challenge ND7 cells and induce cell death, 
thereby enabling assessment of the effect of SOD1 on ND7 cell survival (Wagstaff et al.,
1999). Staurosporine is a well-studied apoptotic agent, a bacterial alkaloid that inhibits 
several cellular kinases (Gill et al., 2003) and is frequently used as an inducer of the 
mitochondrial apoptotic pathway. Intracellular cascades activated by staurosporine depend 
on its concentration, with lOOnM concentration inducing cell death by means of an apoptotic 
mechanism characterised by cytochrome c release and a lpM concentration of staurosporine 
inducing cell death through a mechanism, in which caspase activation is detected, but which 
shows several nonapoptotic features (Deshmukh et al., 2000); both apoptotic and 
nonapoptotic features have been described in ALS (reviewed in Chapter 1, Introduction). 
Since apoptosis and also non-apoptotic cell death are known to be implicated in 
neurodegeneration (reviewed in Chapter 1, Introduction), all the stresses utilized in this 
study have been previously demonstrated to induce programmed cell death in ND7 cells or 
other neuronal cell lines and hence were chosen for this project.
As mentioned in the introduction of this chapter, SOD1 is an anti-apoptotic protein 
and has been intensively investigated due to its biological importance as an antioxidant; 
there exists a substantial amount of evidence which continues to accumulate that supports 
the idea that the mutations appearing in the familial cases of ALS are deleterious in most 
model systems studied. The system described in this chapter utilized a well characterized 
neuronal cell line in which the exogenous expression of SOD1 mutants has a differential 
effect on neuronal cell survival, depending on the mutant under consideration, when 
subjected to various cellular stresses that result predominantly in apoptotic cell death.
The findings presented here, suggest that the disease-associated SOD1 mutants 
G93A and G93R enhance the level of cell death observed in a neuronal cell line exposed to a 
variety of apoptotic stimuli such as serum removal, staurosporine treatment, y-interferon or 
exposure to simulated ischemia followed by reoxygenation. The results of the present study
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extends the work of Rabizadeh et al., (1995) who demonstrated that the SOD1 mutations 
G37R and A4V associated with ALS converted the anti-apoptotic SOD1 gene into a pro- 
apoptotic gene. Furthermore, in the present study the G93R mutation was observed to be a 
lot more severe and exhibited enhanced levels of death compared to the G93A mutation, 
across all the stresses investigated, paralleling the much more severe disease phenotype and 
early onset observed in ALS patients with this mutation. Even though the G93R mutation 
has only been reported in a single family (de Belleroche et al., 1995; Orrell et al., 1995 & 
1997), it is associated with a particularly early age of onset of 36 years (4 individuals with a 
range of age of onset of 29-41 years).
Several studies previously demonstrated a protective effect of the wild type SOD1 
against neuronal apoptosis (Greenlund et al., 1995; Rabizadeh et al., 1995) and this has also 
been shown to be the case in the present experimental system. Thus, the wild type SOD1 
protein possesses the ability to protect the neuronal cell line against a wide variety of 
apoptotic stresses including serum removal both in the absence and presence of lpM 
retinoic acid, staurosporine administration, IFN-y treatment, camptothecin addition, 
glutamate administration, hydrogen peroxide treatment and ischemia/reoxygenation. Hence, 
in a wide range of different situations the wild type SOD1 is protective whilst the G93A or 
G93R mutations in some way convert the protein from an anti-apoptotic into a pro-apoptotic 
form. This is in contrast to our findings with Parkinson’s disease-associated mutations of a- 
synuclein and the wild-type protein (Zourlidou et al., 2003). Zourlidou et al. (2003) have 
previously demonstrated that the two-disease associated mutations of a-synuclein result in 
enhanced sensitivity to serum removal or simulated ischemia when they are over-expressed 
in ND7 cells. In contrast however, overexpression of the wild-type a-synuclein results in a 
protective effect against serum removal but produces a damaging effect, albeit less than 
observed with the mutants, when exposed to simulated ischemia. Hence, in the case of a- 
synuclein the wild-type protein appears to produce a protective effect against some stresses 
but not others, whereas the Parkinson’s disease-associated mutations have a pro-apoptotic 
effect in cells exposed to a wide-variety of different stresses.
In this Chapter it was shown that disease-associated mutants of SOD1 enhance the
degree of cell death observed in response to a wide variety of different stimuli with the
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severity of this effect paralleling the severity of the disease caused by the specific mutation 
in question. In contrast, over-expression of wild-type SOD1 has an anti-apoptotic effect 
protecting cells from a wide range of death-inducing stimuli. One potential problem that 
arises with all experiments involving stable cell lines is variation in both the levels of 
expression of the transgene and the final phenotype of the different clones, both phenomena 
probably being a result of site of integration of DNA sequence of the transgene within the 
cell genome. However, this is easily countered by using several different cell clones with 
each plasmid.
In addition, in this study endogenous levels of SOD1 and levels of overexpression of 
SOD1 were not determined. It would be of interest to know the levels of endogenous SOD1 
and the level of overexpression of SOD1 so that one can ascertain the real extent of the 
findings presented here and also to ensure the levels are not such that the biology of the cell 
itself is altered.
Another limitation of this system is the fact that ND7 cells are not primary cells, 
which would be more relevant to the disease associated mutations, although there are 
numerous studies describing interesting effects with SOD1 and its mutant forms in non­
neuronal as well as non-mammalian systems (for review see Chapter 1). ND7 cells are 
derived from a fusion of rat dorsal root ganglion neurons and mouse neuroblastoma cells 
and they retain many of the characteristics of neurons. They are useful due to the fact that 
they are well characterized, there are several stresses known which can induce them to 
undergo apoptotic or non-apoptotic cell death, and additionally they also grow well in 
culture and when differentiated possess many characteristics of neurons (Wheatley et al., 
1992). An additional limitation, as mentioned above, is the fact that the ND7 cell line is not 
human, whilst the SOD1 cDNAs expressed are human. This could potentially complicate the 
analysis of data; however, there have been many studies where trans-species experiments 
have been successful (for examples see Darios et al. (2003) and Katzir et al. (2003)).
Therefore, having established the effects of wt or mutant forms of SOD1 in the 
neuronal cellular system described above, the following chapter attempts to answer the 
question of whether mutant SOD 1-associated toxicity can be reduced or even abolished by
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exogenous over-expression of various Hsps either singly or in combination, with the help of 
highly efficient HSV-based viral vectors. The experimental evidence provided in the next 
chapter suggests a novel neuroprotective role for Hsp27 and Hsp70 in combination, in the 
model of mutant SOD 1-associated toxicity, which was described here.
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Ch a pter  4
The Neuroprotective Effects of Heat Shock Proteins in 
In Vitro Model of Mutant-SODl-Induced Toxicity
4.1 Introduction
The previous chapter dealt with the establishment and characterisation of an in vitro 
model of mutant SOD 1-induced toxicity, where wt-SODl has a protective anti-apoptotic 
effect against cell death induced by a range of death inducing stimuli, whereas 
overexpression of either G93A or G93R mutant SOD1 enhanced cell death under all stresses 
tested. Having established these effects, I then proceeded to study the potential 
neuroprotective effect of various heat shock proteins (Hsps) in this neuronal model system, 
utilising a highly efficient HSV-based gene delivery system (Wagstaff et al., 1999). This 
section introduces some of the findings that support a potential protective role of Hsps in 
neurodegenerative disorders; a more extended review on Hsps is provided in Chapter 1.
Neuroprotection is defined as an intervention that stops, prevents, or slows neuronal 
degeneration and hence disease progression. Many factors have been involved so far in the 
aetiology of Amyotrophic Lateral Sclerosis (ALS), providing potential targets for a 
neuroprotective therapy. Among the possible neuroprotective approaches to list a few, are 
vitamin E, ascorbate, copper chelators, creatine, and heat shock proteins (see chapter 1 for 
extended review). The assessment of the protective effect of Hsp27 or of Hsps in 
combination has not been studied before in the context of mutant SOD 1-related toxicity. 
This chapter provides data that support a novel way by which mutant SOD 1-related toxicity 
and cell death can be alleviated by the overexpression of heat shock proteins, in particular 
by Hsp27 and Hsp70 in combination (Patel et al., 2005). As a result of these studies, the 
Hsp27 and Hsp70 combination is suggested to have a novel neuroprotective role that awaits 
confirmation in in vivo systems.
The accumulation of abnormally folded proteins in the nucleus or the cytosol that 
takes place as a result of stress such as elevated temperature, free oxygen radicals, heavy 
metals and even antibiotics (Sherman et al., 2001), results in the formation of aggregates that 
disturb normal cellular function and trigger cell death (Sherman et al., 2001). Such a 
mechanism has been implicated in the pathogenesis of lesions that are characteristic of a 
number of neurodegenerative diseases. Neuronal cells seem to be particularly vulnerable to 
the toxic effects of mutant or misfolded protein aggregates. Most Hsps are involved in the
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proper folding and/or elimination of misfolded protein, thereby acting as the first line of 
defence against it and contributing to cell survival.
SOD1 is a ubiquitously expressed protein and there is no change in its abundance in 
motor neurons. In SOD1 mutant cells, however, there is a reduction in the activity of 
molecular chaperones, which results in the accumulation and inefficient removal of the 
SOD1 mutant (Bruening et al., 1999). The mutated protein may be unstable and as a result 
more susceptible to precipitation and hence more likely to generate toxic aggregates (Brown.
1995). This is important when taking into consideration that SOD1 represents approximately 
1% of cytosolic protein. Changes in folding, solubility, or degradation of such an abundant 
protein may possibly result in aggregates, consistent with the detection of SOD1 
immunoreactive inclusion bodies in motor neurons expressing mutant SOD1 but not with 
wild-type SOD1 expressed to the same extent (Bredesen et al., 1996; Bruijn et al., 1998; 
Durham et al., 1997). The formation of SOD1 mutant aggregates is prevented by induction 
of stress-inducible Hsp70 in cultured neuronal cells, indicating that the decrease in the pool 
of available chaperones leaves mutant SOD1 cells particularly susceptible to physiological 
and environmental stress (Bruening et al., 1999).
As yet it remains controversial as to whether cytoplasmic mutant SOD1 aggregates 
are toxic (Bruijn et al., 1998) or not (Cummings et al., 1999; Johnston et al., 2000; Kopito.
2000). Previous studies in neuronal cells and cultured primary motor neurons have 
demonstrated that the inhibition of cytoplasmic aggregate formation by induction of heat 
shock protein Hsp70 assured cell survival at an early stage but did not prevent eventual cell 
death at the late stage in the in vitro models of FALS (Bruening et al., 1999; Takeuchi et al., 
2002).
Some of the important house-keeping functions attributed to the molecular 
chaperones include the import of proteins into cellular compartments; folding of proteins in 
the cytosol, endoplasmic reticulum, and mitochondria; degradation of unstable proteins; 
dissolution of protein complexes; prevention of protein aggregation; control of regulatory 
proteins; as well as refolding of misfolded proteins (Bukau et al., 1998). As reviewed in 
Chapter 1, it is only in the last few years that reports have started to elucidate the underlying
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mechanisms by which Hsps modulate cell death. For instance, Hsp27 expression is seen to 
correlate with increased survival in response to cytotoxic stimuli and has been shown to 
prevent cell death by a wide variety of agents that cause apoptosis (Benjamin et al., 1998; 
Wagstaff et al., 1999). Over the years, evidence has accumulated to show that Hsp27 can 
inhibit apoptosis by means of a direct inhibition of caspase activation (Garrido et al., 1999; 
Samali et al., 2001). Hsp70 functions as a major cellular defence molecule against protein 
aggregation (Glover and Lindquist, 1998) and prevents both caspase-dependent and caspase- 
independent apoptosis. It is also apparent that such anti-apoptotic functions of Hsps may be 
distinct from their role as chaperones. In addition a “protein triage” machinery has been 
proposed in which Hsps and the ubiquitin/proteasome system work together to modulate 
apoptosis, but further studies are required for a better understanding of the underlying 
mechanisms. The key inducible Hsps of the nervous system are Hsp27 and Hsp70 and both 
have been demonstrated to be neuroprotective. In particular, over-expression of Hsp27 in 
cultured neuronal cells provides protection from induction of apoptosis by a range of stimuli 
such as neurotrophic factor or serum removal (Wagstaff et al., 1999). Hsp70 enhances the 
ability of cells to deal with increased concentrations of unfolded or denatured proteins, 
(Nollen et al., 1999) and is protective against a wide range of lethal stimuli.
Over-expression of Hsp27 protects against apoptotic cell death triggered by various 
stimuli, including hyperthermia, oxidative stress, staurosporine, ligation of the Fas/Apo- 
1/CD95 death receptor, and cytotoxic drugs (Garrido et al., 1996 & 1997; Mehlen et al.,
1996). Various distinct mechanisms have been put forward to account for the anti-apoptotic 
properties of Hsp27 such as its ability to increase the anti-oxidant defence of cells by 
decreasing reactive oxygen species cell content (Mehlen et al., 1996) and its ability to 
stabilize actin microfilaments (Lavoie et al., 1995). It has been demonstrated that Hsp27 
could prevent the formation of the apoptosome and as a result the subsequent activation of 
caspases (Garrido et al., 1999) by directly sequestering cytochrome c when released from 
the mitochondria into the cytosol (Bruey et al., 2000). At higher intracellular levels, Hsp27 
has been shown to hinder caspase activation upstream of the mitochondria (Parcellier et al. 
2003). Hsp27 has also been shown to affect the Fas-mediated apoptotic pathway and 
phosphorylated Hsp27 has been shown to directly interact with Daxx to prevent cell death 
(Charette et al., 2000).
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Like Hsp27, Hsp70 protects cells from a wide variety of lethal stimuli as well as 
from stress-induced caspase-dependent apoptosis, both upstream and downstream of the 
death associated mitochondrial events. Initially, Hsp70 was proposed to rescue cells from a 
later stage of apoptosis than any other known survival enhancing drug or protein. In human 
cervix carcinoma ME-180 cells, treated with TNFa, Hsp70 over-expression did not prevent 
activation of caspase-3 but inhibited downstream morphological alterations that are 
characteristically associated with dying cells (Jaattela et al., 1998). It was subsequently 
found that elevated levels of Hsp70 could prevent both caspase activation and nuclear 
changes associated with apoptosis (Buzzard et al., 1998). In the intrinsic pathway to cell 
death, over-expression of Hsp70 did not inhibit mitochondrial cytochrome c release; 
however, caspase-3 activation was prevented (Li et al., 2000). These observations were 
subsequently linked to the ability of Hsp70 to directly bind Apaf-1 through its ATPase 
domain, and consequently prevent the recruitment of procaspase-9 to the apoptosome (Saleh 
et al., 2000; Mosser et al., 2000; Beere et al., 2000).
Although studies have examined the protective effects of over-expression of Hsps, 
none have investigated comparatively the protective effects of Hsp27 or Hsp70 over­
expression, or combined effects of both together, with respect to FALS-associated SOD1 
mutants. In the present project, herpes simplex viruses were utilised in order to assess 
whether Hsp27, Hsp70 or the combination of Hsp27 and Hsp70 have any protective effect 
against various stresses applied in an in vitro system in which wt-SODl or the disease- 
associated mutants, G93A and G93R-mutant SOD1, are stably over-expressed. Cells were 
subjected to a wide range of stresses such as serum removal, serum removal plus lpM all- 
trans retinoic acid, IFN-y treatment, staurosporine administration and camptothecin addition, 
in order to compare their response to these distinct death stimuli, in the presence or absence 
of over-expressed Hsps, at multiple time points.
These stresses predominantly result in apoptotic cell death, which was assessed by 
the trypan blue exclusion assay and TUNEL staining. The trypan blue exclusion assay is an 
easy and relatively simple yet reliable and inexpensive method of assessing total cell death 
and it is based on the fact that cell membrane permeability to trypan blue dye depends on 
membrane integrity; with non-viable cells lacking the ability to exclude the dye and hence
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staining blue. TUNEL analysis is a frequently used technique for the detection of apoptosis 
that utilises TdT-mediated X-dUTP nick end labelling (where X is a suitable conjugated 
label such as rhodamine or FITC), however its specificity is not absolute as DNA 
fragmentation is also found to be common in other types of cell death.
In order to test the potential neuroprotective role of various Hsps in this model 
system, it was important to utilize a highly efficient Hsp gene delivery system. Therefore in 
this present study HSV-based viral vectors were chosen. These viral vectors have been 
developed specifically for the efficient delivery of the gene of interest to neuronal cells and 
their use has been reported in both in vitro and in vivo studies (Wagstaff et al., 1999; Brar et 
al., 1999; Kalwy et al., 2003). The suitability and effectiveness of HSV-based gene delivery, 
was discussed in Chapter 1 (for review see Latchman and Coffin, 2001; Davidson et al., 
2003 and Goins et al., 2004).
Briefly, the viruses used in this present study, provide a highly efficient method of 
specific gene delivery to ND7 cells as well as primary neuronal cells (90-100% transduction 
efficiency). The viral vector used in this study was constructed in our laboratory by Dr 
Marcus Wagstaff and named 17+pR19 (Wagstaff et al., 1998). The transgenes (Chinese 
hamster hsp27, human inducible hsp70, or GFP) in this virus are driven by the human CMV- 
IE promoter, inserted immediately downstream of the LAT P2 promoter. Figure 4.1 below 
shows the expression cassette, which was inserted into the non-essential 2 kb LAT region of 
the HSV-1 genome of an IE2-deleted mutant HSV-1 strain (IE2 is the essential gene that 
encodes ICP27; HSV-1 strain 17+; GenBank™ accession number HE ICG) (Wagstaff et al., 
1999). The IE genes ICP4 and ICP27 are essential for viral replication. Therefore ICP27 was 
deleted in this virus type. These viruses were designed to produce a less cytopathic, latent, 
non-replicating viral mutant, which was tested and found to be suitable for gene delivery 
(Wagstaff et al., 1999; Kalwy et al., 2003). These viruses were grown on B 130/2 cells which 
complement for the deleted ICP27 (Howard et al., 1998).
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Figure 4.1 The pR19 cassette utilised in the 17+ virus constructs.
This expression construct was introduced into the non-essential LAT region of the 
IE2 deleted mutant HSV-1 DNA. The CMV-IE promoter drives the transcription of the 
transgene as well as the bovine growth hormone polyadenylation sequence. The use of the 
LAT PI and LAT P2 promoters with the CMV-IE promoter is thought to facilitate 
expression throughout viral latency in neurons.
In this present study the availability of a highly efficient HSV-1-based vector system 
capable of delivering Hsp genes to neuronal cells, and the availability of characterised stable 
cell lines expressing wt-SODl and its mutant forms proved to be very useful. As shown in 
this chapter, it allowed us to test the hypothesis of whether mutant-SODl-related toxicity in 
mammalian neuronal cells subjected to various stresses can be suppressed by individual or 
by combinations of heat shock proteins (Hsp27, Hsp70).
The following sections of this chapter briefly describe the method of viral infection 
of the cell lines, the characterisation of heat shock protein expression in the cell lines, 
followed by a description of the results obtained on exposure to each death stimulus along 
with quantification of cell death. Finally, the significance of the findings is discussed, along 
with the advantages and limitations of the model system.
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4.2 Viral Infections of Cells
4.2.1 Complementing Cell Lines of Viruses
The stocks of virus used in this study were grown and prepared as described in 
Chapter 2, section 2.4. The viruses were grown on B 130/2 BHK cells (used for 17+27- virus 
type) or M49 cells (used for 1764 27-4- virus type) as they complement the deletions in the 
disabled viruses and hence enable lytic viral growth (Howard et al., 1998; Thomas et al., 
1999). This allows the production of large quantities of the virus, which can be subsequently 
purified and concentrated into high titre stocks. Each preparation of high titre stock was 
confirmed to express the transgene, through western analysis of non-complementing ND7 
cells infected with the stock.
4.2.2 Microscopy of Virally Infected ND7 Cells and Western Blot Analysis
ND7 cells were infected as described in Chapter 2, section 2.4.2 and then left for 24h to 
allow overexpression of the transgene prior to treatment. However, GFP was visible earlier 
than 12h post-infection, and its expression continued to be seen until the end of all 
treatments. Figure 4.2a shows some ND7 cells infected with GFP virus. The HSV-vector 
17+pR19 has previously been shown to successfully infect ND7 cells and produce large 
amounts of Hsps (Wagstaff et al., 1999). Figure 4.3 shows the high levels of expression of 
the transgene after 24h in ND7 cells infected with either a control GFP, Hsp27 or Hsp70 
expressing virus. The GFP virus enables a relatively quick assessment of the percentage of 
cells expressing GFP and is used as a method of assessing efficiency of infection of the Hsp 
viruses, as the Hsp expressing viruses do not contain a visual marker; the assumption made 
is cells infected with the same amount of virus and at the same m.o.i, will result in the same 
transduction efficiency.
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(a)
Figure 4.2 Gene delivery of GFP or heat shock proteins using HSV-based viral vectors.
(a) ND7 cells 24h following infection with GFP virus and (b) ND7 cells 24h following infection 
with Hsp27 virus at 10 m.o.i. Cells exhibit normal morphology. The Hsp viruses do not possess a 
visual marker in order to enable overexpression of the appropriate Hsp to be observed, therefore the 
expression levels were assessed by means of Western blotting (Figures 4.3).
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Figure 4.3. Heat shock protein over expression in ND7 cells expressing wild type or mutant 
SOD1 at 24h following infection with recombinant HSV-based vectors expressing GFP, Hsp27 
or Hsp70.
Control, wt and mutant G93A and G93R SOD1 expressing cells were infected at an m.o.i of 10 with 
recombinant viruses over-expressing either GFP, Hsp27 or Hsp70; after which western blotting was 
carried out with antibodies: anti-(3-actin, anti-hsp27 and anti-hsp70 antibodies. There is no 
significant induction of Hsp expression as a result of infection with the virus itself and this can be 
seen with the GFP control virus, however, there is high expression of the transgenes, all driven by 
the CMV-IE promoter.
4.3 Responses of the SOD1 cell lines to Stress following Exogenous Heat 
Shock Protein Over-expression
Having characterised the expression of wt and mutant SOD1 in the ND7 cells (see 
Chapter 3) and having demonstrated that Hsps can be over expressed in those cells through 
use of viral vectors, the next step was to utilise this system and test whether or not Hsps can 
confer neuroprotection against the toxic effects of the FALS-associated mutant forms of 
SOD1 in vitro. This section therefore describes the results obtained following 
experimentation into the protective effect of individual Hsps as well as Hsps in combination, 
in this model system. As with Chapter 3, the findings for the various stresses are presented
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in this model system. As with Chapter 3, the findings for the various stresses are presented 
below the corresponding stress and as with chapter 3, cell death was assessed by trypan blue 
exclusion assay and TUNEL analysis.
4.3.1 Serum Removal
Therefore, conditions of serum removal (both in the absence and presence of 1 pM retinoic 
acid; for constituents of serum free media see Methods and Materials) were applied to the 
various cell lines for periods of 24h and 48h. Hsp27 protected both G93A and G93R mutant- 
SOD1 over-expressing cells from serum deprivation with death being reduced by 
approximately 12% for G93A and 31% for G93R, compared to the respective GFP controls, 
at 24h time point (p<0.0005) (Figure 4.4a). In addition Hsp70 virus also conferred 
protection with death being reduced by approximately 9% for G93A and 41% for G93R, 
compared to the respective GFP controls, at 24h time point (p<0.01 and /?<0.0005 
respectively). However the wt-SODl over-expressing cells which are already protected 
under this stress, when infected with Hsp27 showed an increase in death with death rising by 
approximately 14%, compared to the wt-SOD GFP control, at 24h time point (p<0.01). A 
more dramatic increase was observed when the wt-SODl cells were infected with Hsp70 
with death rising by nearly 93%, compared to the wt-SOD GFP control, at 24h time point 
(p<0.0005); (Figure 4.4a).
When a joint viral infection of Hsp27 and Hsp70 (Total m.o.i used = 10; m.o.i Hsp27=5, 
m.o.i Hsp70=5) was undertaken the results showed a greater reduction in death than was 
obtained by the respective single infections with death decreasing by almost 22% and 44% 
for G93A and G93R mutant respectively, compared to respective GFP controls, at 24h 
(p<0.0005); (Figure 4.4a). With respect to wt-SODl the joint infection brought cell death 
down to control GFP levels although this was still higher than that of uninfected wt-SODl 
control. Similar results were obtained at the 48h time point, with the protective effect of the 
Hsps still able to be seen very clearly in the mutant SOD over-expressing cells with death 
decreasing by 32% and 47% for G93A and G93R mutant respectively, compared to 
respective GFP controls (p<0.0005); (Figure 4.4a). TUNEL analysis gave similar results 
strengthening the evidence for an anti-apoptotic/protective role of Hsp27 and Hsp70. Hsp27
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and Hsp70 both reduced apoptosis significantly compared to GFP in cells expressing both 
G93A and G93R mutant SOD1 (Figure 4.4b). A dual Hsp infection of both G93A and G93R 
mutant SOD 1 over-expressing cells significantly lowered apoptosis, even further than either 
Hsp27 or Hsp70 virus singly (p<0.0005) (Figure 4.4b).
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Figure 4.4 Effect of serum withdrawal in SOD1 stable cells following Hsp infection
a. ND7 cell death following 24h and 48h serum removal after infection with HSV vectors 
expressing Hsps. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h and 48h of serum deprivation of engineered ND7 cells expressing wt or mutant 
SOD1. Cells were infected with Hsp viruses 16h prior to stress. Bars represent mean -^S.D. 
calculated for triplicate counts per sample (n), n=5. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (/?<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with the 
respective GFP virus infected cell line.
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Figure 4.4 Effect of serum withdrawal in SOD1 stable cells following Hsp infection
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express Hsps or GFP 16h prior to 
treatment of serum deprivation for 24h and 48h. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=3) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective GFP virus infected cell line.
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4.3.2 Serum Removal+ljiM Retinoic Acid
Having established that both Hsp27 and Hsp70 had a protective effect against serum 
deprivation on both G93A and G93R SOD1 mutants and a damaging effect on wt-SODl 
over-expressing cells, we further investigated the effect of the Hsp viruses on the SOD1 
mutants and wt-SODl over-expressing cells when subjected to other death-inducing stimuli. 
Serum withdrawal in the presence of all-trans-retinoic acid stimulates higher levels of 
apoptosis (Howard et al., 1993; Wagstaff et al., 1999).
The delivery of Hsps via the HSV viral vector system showed both Hsp27 and Hsp70 having 
a protective effect on both mutants with death being reduced for both SOD1 mutants 
compared to their respective GFP infected controls (p<0.0005) (Figure 4.5a). Wt-SODl 
over-expressing cells exhibited higher levels of death on infection with Hsp27 and also on 
infection with Hsp70 with the increase in death being statistically significant compared to 
GFP infected control (p<0.0005) (Figure 4.5a). On infection with Hsp27, the level of death 
in wt-SODl cells increased by approximately 34% and 80% at 24h and 48h respectively 
compared to GFP control (p<0.0005). While on infection with Hsp70, the level of death in 
wt-SODl cells increased by approximately 73% and 144% at 24h and 48h respectively 
compared to GFP control (p<0.0005). Hsp27 infection of the G93A mutant cells reduced 
death by 38% and 32% at the 24h and 48h time points compared to the respective GFP 
control (p<0.0005). Hsp27 infection of G93R mutant cells brought about an approximately 
49% and 46% reduction in total cell death at 24h and 48h respectively, compared to GFP 
infected control (p<0.0005). Hsp70 infection of mutants reduced cell death by 
approximately 36% and 18% for G93A and 53% for G93R at 24h and 48h respectively 
compared to respective GFP control (p<0.0005).
A combinational treatment of dual Hsp27 and Hsp70 gave a greater reduction in death for 
both mutants with death being reduced by approximately 50% and 48% for G93A and 60% 
and 59% for G93R, at the 24h and 48h time points, with the reduction in death being 
statistically significant compared to the respective GFP infected controls at these time points 
(p<0.0005) (Figure 4.5a). The joint infection of Hsp27 and Hsp70 on the wt-SODl over-
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expressing cells also brought the exacerbated death caused by the single infections Hsp27 
and Hsp70 down to control GFP levels.
Figure 4.5b shows the number of TUNEL positive cells is significantly reduced on infection 
with Hsp27 and also Hsp70 in control and both G93A and G93R SOD1 mutants (p<0.0005). 
Figure 4.5b also shows the significant and greater reduction in cell death of both G93A and 
G93R SOD1 mutants that follows dual Hsp27 and Hsp70 infection (p<0.0005). On 
infection with Hsp27 the number of TUNEL positive cells were reduced in the G93A mutant 
by 48% and 40% at the 24h and 48h time points compared to GFP control (p<0.0005). In the 
case of G93R mutant death was reduced by 61% and 55% at 24h and 48h compared to GFP 
infected control (p<0.0005). Hsp70 infection of G93A reduced death by 47% and 24% at 
24h and 48h respectively compared to GFP control (p<0.0005). In the case of the G93R 
mutant, Hsp70 infection reduced death by approximately 64% at both 24h and 48h time 
points compared to GFP infected control (p<0.0005). The greatest protection was seen on 
dual infection of both Hsp27 and Hsp70. Dual infection in the G93 A mutant reduced death 
by approximately 61% and 63% at 24h and 48h time points respectively compared to GFP 
control (p<0.0005). In the G93R mutant death was reduced by approximately 70% at both 
24h and 48h time points on dual infection of Hsp27 and Hsp70 when compared to respective 
GFP control (p<0.0005). Infection of wt-SODl cells with Hsp27 led to an increase in cell 
death with death being increased by 52% and 115% at 24h and 48h time points respectively 
compared to respective GFP infected control (p<0.0005). Hsp70 infection of wt-SODl cells 
increased death by an even greater extent with death being increased by 106% and 206% at 
the 24h and 48h time points respectively compared to respective GFP control (p<0.0005). 
On dual infection of wt-SODl cells with Hsp27 and Hsp70 the death was reduced back 
down to control GFP levels at both 24h and 48h time points.
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Figure 4.5 Effect of serum withdrawal plus lpM  all-trans retinoic acid in SOD1 stable 
cells following Hsp infection
a. ND7 cell death following 24h and 48h serum removal plus lpM all-trans retinoic acid 
after infection with HSV vectors expressing Hsps. The proportion of cell death was assessed 
by trypan blue exclusion assay, after 24h and 48h of serum deprivation plus 1 pM all-trans 
retinoic acid of engineered ND7 cells expressing wt or mutant SOD1. Cells were infected 
with Hsp viruses 16h prior to stress. Bars represent mean ^ .D . calculated for triplicate 
counts per sample (n), n=5. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with the respective GFP 
virus infected cell line.
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Figure 4.5 Effect of serum withdrawal plus lpM  all-trans retinoic acid in SOD1 stable 
cells following Hsp infection
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express Hsps or GFP 16h prior to 
treatment of serum deprivation plus all-trans retinoic acid for 24h and 48h. Bars represent 
mean 1 S.D. calculated for triplicate counts per sample (n=3) and significant differences 
were calculated as above with /?<0.0005. *, **, *** indicates statistically significant 
difference between means, when comparing with the respective GFP virus infected cell line.
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4.3.3 IFN-y administration
Subsequently, the cells were treated with IFN-y for 24h and 48h which induces cell death in 
a variety of neuronal and non-neuronal cell types (Figure 4.6a). A clear marked protective 
effect of Hsp27 and Hsp70 was observed compared to control GFP, in cells expressing both 
G93A and G93R SOD1 mutants (p<0.0005) (Figure 4.6a). As with serum removal and 
serum removal plus all-trans retinoic acid experiments, Hsp27 greatly reduced cell death for 
both mutants as did Hsp70. Death was reduced by approximately 30% and 32% for G93A 
and 41% and 44% for G93R following Hsp27 infection at 24h and 48h time points 
respectively compared to respective GFP controls. Hsp70 infection lowered death by 
approximately 23% and 27% for G93A and 45% and 53% for G93R respectively at 24h and 
48h, compared to respective GFP control (/?<0.0005); (Figure 4.6a). Again the dual viral 
infection of Hsp27 and Hsp70 together gave a further reduction in death in both mutants 
with death being reduced by 33% and 40% for G93A and 52% and 56% for G93R 
respectively, at 24h and 48h respectively, compared to the respective GFP controls 
(p<0.0005); (Figure 4.6a). The wt-SODl over-expressing cells showed increased levels of 
death on infection with Hsp27 and further increased levels on infection with Hsp70, with a 
dual infection again bringing levels down to that of wt-SODl GFP infected control. Death 
increased in the wt-SODl cells by 41% and 49% at 24h and 48h, compared to respective 
GFP control, on infection with Hsp27 (p<0.0005). Hsp70 infection increased death in the 
wt-SODl cells by an even greater extent with death rising by approximately 101% and 
128% at 24h and 48h respectively, compared to respective GFP control (p<0.0005). Dual 
infection of Hsp27 and Hsp70 in the wt-SODl cells reduced death back to control GFP 
levels.
Similarly, as assessed by TUNEL, Hsp27, Hsp70 and the combination of Hsp27 & Hsp70 
significantly reduced the number of TUNEL positive cells in both G93A and G93R SOD1 
mutants (p<0.0005), compared to GFP/G93A or GFP/G93R over-expressing cells (figure 
4.6b). Infection of G93A cells with Hsp27 resulted in a reduction in the number of TUNEL 
positive cells by approximately 33% and 42% at 24h and 48h respectively compared to 
control (p<0.0005). Hsp70 infection of G93A was not as effective as Hsp27 in reducing the 
number of TUNEL positive cells with a reduction of approximately 25% and 34% being
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observed at 24h and 48h respectively compared to control (p<0.0005). In the G93R cells, 
Hsp27 infection reduced the number of TUNEL positive cells by approximately 49% and 
48% at 24h and 48h respectively compared to control (p<0.0005). Hsp70 infection of the 
G93R cells was much more effective in reducing the number of TUNEL positive cells than 
Hsp27 with the numbers being reduced by approximately 52% and 57% at 24h and 48h 
respectively compared to control (p<0.0005). The dual infection of Hsp27 and Hsp70 was 
the most effective in reducing the number of TUNEL positive cells with the number being 
reduced by approximately 41% and 47% for G93A and 60% and 62% for G93R at 24h and 
48h respectively compared to control (p<0.0005). Wt-SODl cells exhibited an increase in 
the number of TUNEL positive cells on infection with Hsp27 or Hsp70 with death 
increasing by a approximately 46% and 64% on Hsp27 infection and more dramatically by 
129% and 158% on Hsp70 infection at 24h and 48h respectively compared to control 
(p<0.0005). The dual infection of Hsp27 and Hsp70 reduced the number of TUNEL positive 
cells back down toward control GFP levels in the wt-SODl cells.
229
Figure 4.6a
HSP27 HSP70 HSP27+7D
Figure 4.6 Effect of IFN-y in SOD1 stable cells following Hsp infection
a. ND7 cell death following 24h and 48h treatment with 50ng/ml IFN-y after infection with 
HSV vectors expressing Hsps. The proportion of cell death was assessed by trypan blue 
exclusion assay, after 24h and 48h treatment with IFN-y of engineered ND7 cells expressing 
wt or mutant SOD1. Cells were infected with Hsp viruses 16h prior to stress. Bars represent 
mean -^S.D. calculated for triplicate counts per sample (n), n=5. Significant differences were 
calculated using Bonferroni Multiple Comparison’s t test after one-way ANOVA 
(p<0.0005). *, **, *** indicates statistically significant difference between means, when 
comparing with the respective GFP virus infected cell line.
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Figure 4.6 Effect of IFN-y in SOD1 stable cells following Hsp infection
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express Hsps or GFP 16h prior to 
treatment of 50ng/ml IFN-y for 24h and 48h. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=3) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective GFP virus infected cell line.
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4.3.4 Staurosporine
A time course experiment was subsequently carried out to analyse the response of the cells 
to treatment with staurosporine (Figure 4.7a). A lpM  concentration of staurosporine 
increased the total cell death from 27% and 30% at 2h to 43% and 46% at 6h for G93A and 
G93R mutants respectively (Figure 4.7a). On infection with the Hsp27 and Hsp70 viruses 
the death in both mutants was again significantly reduced. In the G93A mutant Hsp27 
infection reduced death by approximately 35%, 29% and 22% at 2h, 4h and 6h respectively 
compared to respective GFP control (p<0.0005). Hsp27 infection of the G93R mutant cells 
reduced death by approximately 43%, 32% and 39% at 2h, 4h and 6h respectively, 
compared to respective GFP control (p<0.0005). Hsp70 infection of G93A mutant cells 
lowered death by 20%, 25% and 18% at 2h, 4h and 6h respectively compared to respective 
GFP control (p<0.0005). Infection of G93R mutant with Hsp70 led to a greater reduction in 
death than that seen with Hsp27 with death being reduced by approximately 48%, 40% and 
44% at 2h, 4h and 6h respectively compared to respective GFP control (p<0.0005).
The combination of Hsp27 and Hsp70 again appeared to be even more effective in 
attenuating cell death (Figure 4.7a) in both G93A and G93R SOD1 mutants with cell death 
being reduced by 45%, 36% and 38% at 2h, 4h and 6h respectively in the case of G93A 
compared to respective GFP control and for G93R mutant cells 57%, 48% and 46% at 2h, 
4h and 6h respectively compared to respective GFP control (/?<0.0005). Again as with the 
insults described above, both Hsp27 and Hsp70 individually enhanced cell death in wt- 
SODl over-expressing cell line with the combination reducing death back down to control 
levels. Infection of wt-SODl cells with Hsp27 increased death by approximately 46%, 56% 
and 42% at 2h, 4h, and 6h respectively compared to respective GFP control (p<0.0005). 
Hsp70 infection of wt-SODl cells increased death by a greater amount than Hsp27 with 
death being increased by approximately 106%, 68% and 54% at 2h, 4h and 6h respectively 
compared to respective GFP control (p<0.0005). Dual infection of Hsp27 and Hsp70 
brought the levels of death in the wt-SODl cells back down to control GFP levels.
Assessment of death by TUNEL showed Hsp27, Hsp70 and the combination of Hsp27 & 
Hsp70 significantly reduced the number of TUNEL positive cells in both G93A and G93R
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S0D1 mutants (p<0.0005), compared to respective GFP infected control cells (figure 4.7b). 
On Hsp27 infection G93A cells exhibited a reduction in the number of TUNEL positive 
cells by approximately 34%, 31%, and 24% at 2h, 4h and 6h respectively compared to 
control (p<0.0005). Hsp70 infection of G93A was not as effective in reducing the number of 
TUNEL positive cells as Hsp27 but effective nonetheless with numbers reduced by 
approximately 22% (p<0.005), 27% (p<0.0005) and 21% (p<0.0005) at 2h, 4h, and 6h 
respectively compared to control. The combination of Hsp27 and Hsp70 was the most 
effective with the death being reduced by approximately 49%, 37% and 40% at 2h, 4h and 
6h respectively compared to control (p<0.0005). In the G93R cells, Hsp27 infection reduced 
the number of TUNEL positive cells by approximately 52%, 33% and 42% at 2h, 4h and 6h 
respectively compared to control (p<0.0005). Hsp70 infection was more effective than 
Hsp27 in the G93R cells with number of TUNEL positive cells being reduced by 
approximately 53%, 38% and 44% at 2h, 4h and 6h respectively compared to control 
(p<0.0005).
The dual combination of Hsp27 and Hsp70 reduced the numbers of TUNEL positive cells 
by approximately 60%, 51% and 49% at 2h, 4h and 6h respectively compared to control 
(p<0.0005) and once again was more effective than single infections. Infection of wt-SODl 
cells with Hsp27 resulted in an increase in the numbers of TUNEL positive cells with 
numbers increasing by approximately 41%, 63% and 52% at 2h, 4h and 6h respectively 
compared to control (p<0.0005). Hsp70 infection of wt-SODl cells resulted in more 
dramatic increase in the number of TUNEL positive cells with numbers increasing by 
approximately 123%, 80% and 67% at 2h, 4h, and 6h respectively compared to control 
(p<0.0005). Once again as seen with other stresses the dual Hsp27 and Hsp70 infection 
reduced the increases seen on single infections back down to control levels with numbers 
reduced by approximately 16% (p<0.05), 19% (p<0.0005) and 18% (p<0.0005) at 2h, 4h, 
and 6h respectively compared to control.
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Figure 4.7 Effect of staurosporine in SOD1 stable cells following Hsp infection
a. ND7 cell death following 2h, 4h and 6h of lpM  staurosporine administration after 
infection with HSV vectors expressing Hsps. The proportion of cell death was assessed by 
trypan blue exclusion assay, after 2h, 4h and 6h lpM staurosporine administration of 
engineered ND7 cells expressing wt or mutant SOD1. Cells were infected with Hsp viruses 
16h prior to stress. Bars represent mean ±S.D. calculated for triplicate counts per sample (n), 
n=5. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (p<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the respective GFP virus infected cell line.
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Figure 4.7 Effect of staurosporine in SOD1 stable cells following Hsp infection
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express Hsps or GFP 16h prior to lpM 
staurosporine administration for 2h, 4h and 6h. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=3) and significant differences were calculated as above with 
/K0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective GFP virus infected cell line.
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4.3.5 Camptothecin administration
Similar results were also observed when the cells were treated with camptothecin (Figure 
4.8a). As with the previous insults, a statistically significant reduction in cell death was 
observed in the G93A and G93R SOD1 over-expressing mutants following Hsp27 and 
Hsp70 viral infection compared to respective GFP infected control (p<0.0005). Cell death 
was reduced by 27% and 24% for G93A and 41% and 27% for G93R at 24h and 48h 
respectively following Hsp27 infection, compared to respective GFP control (p<0.0005). 
Infection with Hsp70 reduced death by approximately 18% and 19% for G93A and 46% and 
34% for G93R at 24h and 48h respectively compared to respective GFP control (p<0.0005). 
Wt-SODl cells exhibited enhanced cell death with cell death increasing by 61% and 88% at 
24h and 48h respectively following Hsp27 infection and 145% and 160% at 24h and 48h 
respectively following Hsp70 infection, compared to respective GFP control (p<0.0005); 
(Figure 4.8a). As with the previous experiments, the greatest amount of protection was 
observed when the Hsp27 and Hsp70 viruses were used in combination with protection seen 
across all cell lines with even wt-SODl over-expressing cells showing a reduction in death, 
down to control GFP levels. On dual infection, death was reduced by 35% and 38% for 
G93A at 24h and 48h respectively compared to respective GFP control and 49% and 46% at 
24h and 48h respectively for G93R compared to respective GFP control (p<0.0005).
TUNEL assessment of death again showed Hsp27, Hsp70 and the combination of Hsp27 & 
Hsp70 significantly reduced the number of TUNEL positive cells in both G93A and G93R 
SOD1 mutants (/?<0.0005), compared to GFP/G93A or GFP/G93R over-expressing cells at 
24h (figure 4.8b). Hsp27 infection of G93A and G93R cells reduced the number of TUNEL 
positive cells by approximately 32% at both 24h (p<0.0005) and 48h (p<0.005) for G93A 
and 52% and 29% at 24h and 48h for G93R cells compared to control (p<0.0005). Hsp70 
infection of G93A cells was slightly less effective than Hsp27 in this case with the number 
of TUNEL positive cells reduced by approximately 21% (p<0.0005) and 12% (p<0.005) at 
24h and 48h respectively compared to control. However in the G93R cells Hsp70 infection 
was slightly more effective in reducing the number of TUNEL positive cells than Hsp27 
with numbers reduced by approximately 55% and 36% at 24h and 48h respectively 
compared to control (p<0.0005)). Hsp27 infection of wt-SODl brought about an increase in
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the number of TUNEL positive cells with numbers increasing by approximately 89% and 
109% at 24h and 48h respectively compared to control (p<0.0005). Hsp70 infection of wt- 
SODl cells brought about a more dramatic increase with numbers increasing by 
approximately 194% and 201% at 24h and 48h respectively (p<0.0005)). The dual Hsp27 
and Hsp70 infection reduced levels of TUNEL positive cells toward those seen in control. 
However at 24h the number of TUNEL positive cells was still up by approximately 21% 
compared to control (p<0.05) and at 48h up by approximately 8% compared to control 
(p<0.05).
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Figure 4.8 Effect of camptothecin in SOD1 stable cells following Hsp infection
a. ND7 cell death following 24h and 48h of lpM  camptothecin treatment after infection 
with HSV vectors expressing Hsps. The proportion of cell death was assessed by trypan blue 
exclusion assay, after 24h and 48h lpM camptothecin treatment of engineered ND7 cells 
expressing wt or mutant SOD1. Cells were infected with Hsp viruses 16h prior to stress. 
Bars represent mean ±S.D. calculated for triplicate counts per sample (n), n=5. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (p<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with the respective GFP virus infected cell line.
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Figure 4.8 Effect of camptothecin in SOD1 stable cells following Hsp infection
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express Hsps or GFP 16h prior to lpM 
camptothecin treatment for 24h and 48h. Bars represent mean 1 S.D. calculated for triplicate 
counts per sample (n=3) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective GFP virus infected cell line.
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(a) Wt-SODl TUNEL +ve cells (b) Control Vector TUNEL +ve cells
(c) G93A-SOD1 TUNEL +ve cells (d) G93R SOD1 TUNEL +ve cells
Figure 4.9 Images of ND7 cells positively stained with TdT-mediated dUTP nick end labelling
(TUNEL).
Rhodamine-conjugated nucleotides label the fragmented DNA in cells undergoing apoptosis, in this 
case on subjection to 24h serum removal. Blind counts of three random fields per slide were 
performed in order to determine the percentage of TUNEL positive cells adhered to the slide of (a) 
wt-SODl cells (b) control-vector cells (c) G93A and (d) G93R expressing cells. Only the cells that 
had a high intense fluorescence were counted as positive.
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4.4 The Effect of Caspase Inhibitors and on SOD1 cells
The observed protective effects of wt-SODl cells on subjection to a range of stresses tested, 
including serum withdrawal (in the absence and presence of lpM  retinoic acid), 
staurosporine, IFN-y, hydrogen peroxide, glutamate and camptothecin (described in Chapter 
3), and the protective effects of Hsp27 and/or Hsp70 on the mutant SOD1 cells under all 
stresses (Chapter 4) in the described cellular model required further investigation. In order 
to investigate the protective effects of the Hsps further and begin to understand the 
mechanisms involved, a pan-caspase inhibitor (zVAD-FMK) and caspase-8 and caspase-9 
specific inhibitors (z-IETD-FMK and z-LEHD-FMK, respectively) were employed to 
determine whether or not inhibition of all or parts of the caspase cascade could influence the 
survival of the SOD1 cell lines. The cells were subjected to a range of stresses as in Chapter 
3, including serum withdrawal (in the absence and presence of lpM retinoic acid), 
staurosporine, IFN-y, hydrogen peroxide, glutamate and camptothecin. These experiments 
were extended to investigate whether protection conferred by the exogenous expression of 
Hsp27, Hsp70 or the Hsp27 and Hsp70 combination, involved modulation of the caspase 
cascade.
4.4.1 Serum Removal
All three caspase inhibitors produced significant effects on cell survival not only in the
mutant-SODl cells but also in the wt-SODl cell lines following serum withdrawal, as
illustrated in Figure 4.10. The pan caspase inhibitor z-VAD, as well as specific inhibitors of
both caspase 8 and caspase 9 all significantly reduced cell death of the G93A and G93R
SOD1 mutants (figure 4.10a) compared to respective controls (p<0.0005). On addition of
zVAD death was reduced by approximately 38% and 57% for G93A and G93R mutants
respectively compared to respective control (p<0.0005). Wt-SODl cells also exhibited a
decrease in cell death on addition of zVAD with death being reduced by 36% compared to
respective control (p<0.0005). Caspase 8 inhibitor reduced death by 32% and 52% for G93A
and G93R respectively compared to respective control (p<0.0005). Caspase 9 inhibitor
reduced death by approximately 31% and 52% for G93A and G93R respectively compared
to respective control (p<0.0005). Wt-SODl death was reduced by approximately 30% and
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29% on addition of caspase-8 and caspase-9 inhibitors respectively compared to control 
(p<0.0005).
Similar results were observed by assaying apoptosis by TUNEL staining (p<0.0005); 
(Figure 4.10b). G93A and G93R cells both exhibited a decrease in the number of TUNEL 
positive cells on addition of zVAD with number being reduced by approximately 46% and 
63% respectively compared to control (p<0.0005). Caspase 8 and 9 inhibitors also reduced 
the numbers of TUNEL positive cells reducing the numbers by approximately 39% and 37% 
respectively for G93A and 56% and 57% respectively for G93R compared to control 
(p<0.0005). Addition of zVAD also reduced the number of TUNEL positive cells in the wt- 
SODl with numbers reduced by approximately 42% compared to control (p<0.0005). 
Addition of specific inhibitors for caspase 8 or caspase 9 to wt-SODl also brought about a 
reduction in the number of TUNEL positive cells with numbers decreasing by 
approximately 38% and 37% respectively compared to control (p<0.0005).
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Figure 4.10 Effect of caspase inhibitors in SOD1 stable cells following serum removal
a. ND7 cell death following 24h serum removal or serum removal after incubation with 
caspase inhibitors, z-VAD, caspase-8 (C8) or caspase-9 (C9). The proportion of cell death 
was assessed by trypan blue exclusion assay, after 24h of serum deprivation of engineered 
ND7 cells expressing wt or mutant SOD1. Cells were incubated with caspase inhibitors lh 
prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per sample (n), 
n=5. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (/?<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the respective control-vector, wt and G93A and 
G93R-SOD1 mutant control cells (cells exposed to stress of serum deprivation).
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Figure 4.10 Effect of caspase inhibitors in SOD1 stable cells following serum removal
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of serum 
deprivation for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.4.2 Serum deprivation+ RA
Levels of cell death were reduced on addition of zVAD, caspase-8 and caspase-9 inhibitors 
across all cells (Figure 4.11a). Death was reduced in G93A mutant by approximately 52% 
on addition of zVAD compared to control (p<0.0005); (Figure 4.11a). On addition of 
caspase-8 inhibitor or caspase-9 inhibitor a reduction in cell death of approximately 50% 
was seen for both compared to control (p<0.0005). On addition of zVAD levels of cell death 
in the G93R cells was reduced by approximately 57% compared to control (p<0.0005). On 
addition of caspase-8 or caspase-9 inhibitor cell death in the G93R cells was reduced by 
approximately 55% in both instances compared to control (p<0.0005). Cell death was also 
lowered in wt-SODl cells on addition of zVAD with death being decreased by 33% 
compared to control (p<0.0005). On addition of caspase-8 or caspase-9 inhibitor cell death 
was reduced by 29% and 26% respectively compared to control (p<0.0005).
TUNEL analysis revealed similar findings with addition of zVAD reducing the number of 
TUNEL positive cells across all cell lines (Figure 4.11b). Wt-SODl, G93A and G93R all 
exhibited reduction in the number of TUNEL positive cells with numbers reduced by 
approximately 42%, 57% and 61% respectively compared to respective control (p<0.0005); 
(Figure 4.11b). Both caspase-8 and caspase-9 inhibitors brought about a similar reduction 
with numbers of TUNEL positive cells. On addition of caspase-8 inhibitor to wt-SODl, 
G93A and G93R cells the number of TUNEL positive cells were reduced by approximately 
31%, 55% and 59% respectively compared to respective control (p<0.0005). On addition of 
caspase-9 inhibitor, the number of TUNEL positive cells were reduced by approximately 
29%, 56% and 59% for wt-SODl, G93A and G93R cells respectively compared to 
respective control (p<0.0005).
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Figure 4.11 Effect of caspase inhibitors in SOD1 stable cells following serum removal 
plus lpM  all-trans retinoic acid
a. ND7 cell death following 24h of serum removal plus lpM all-trans retinoic acid or serum 
removal plus lpM all-trans retinoic acid after incubation with caspase inhibitors, z-VAD, 
caspase-8 (C8) or caspase-9 (C9). The proportion of cell death was assessed by trypan blue 
exclusion assay, after 24h of serum deprivation plus lpM all-trans retinoic acid of 
engineered ND7 cells expressing wt or mutant SOD1. Cells were incubated with caspase 
inhibitors lh prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per 
sample (n), n=5. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with the respective control-vector, 
wt and G93A and G93R-SOD1 mutant control cells (cells exposed to stress of serum 
deprivation plus lpM all-trans retinoic acid).
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Figure 4.11 Effect of caspase inhibitors in SOD1 stable cells following serum removal 
plus lfiM all-trans retinoic acid
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of serum 
deprivation plus lpM  all-trans retinoic acid for 24h. Bars represent mean 1 S.D. calculated 
for triplicate counts per sample (n=3) and significant differences were calculated as above 
with /?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective control-vector, wt and G93A and G93R-SOD1 mutant control 
cells.
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4.4.3 IFN-y administration
Death was once again reduced across all cell lines on addition of pan caspase inhibitor 
zVAD and inhibitors of caspase-8 and caspase-9. Death was reduced in the G93A and G93R 
mutant on addition of zVAD by approximately 41% and 47% respectively compared to 
respective control (p<0.0005); (Figure 4.12a). Caspase-8 inhibitor reduced death by 
approximately 38% for G93A and 45% for G93R respectively compared to respective 
control (p<0.0005); (Figure 4.12a). Caspase-9 inhibitor reduced death by 37% for G93A and 
43% for G93R compared to respective control (p<0.0005). Levels of cell death were reduced 
in wt-SODl cells by approximately 18% on addition of zVAD compared to control 
(p<0.0005). Inhibitors of caspase-8 and caspase-9 reduced levels of cell death in wt-SODl 
cells by approximately 13% in both instances compared to control (p<0.0005).
Similar results were obtained on TUNEL analysis (Figure 4.12b). Addition of zVAD 
reduced the number of TUNEL positive cells by approximately 44% and 54% in G93A and 
G93R cells respectively compared to respective control (p<0.0005); (Figure 4.12b). 
Inhibitors of caspase-8 and caspase-9 brought about a similar reduction with the number of 
TUNEL positive cells reduced by approximately 40% and 39% respectively for G93A cells 
and 51% and 48% respectively for G93R cells compared to respective control (p<0.0005). 
Wt-SODl cells also exhibited a similar reduction in the number of TUNEL positive cells on 
addition of zVAD with numbers reduced by approximately 23% compared to control 
(p<0.0005). Addition of inhibitors of caspase-8 or caspase-9 brought about a similar 
reduction in wt-SODl cells with numbers reduced by approximately 14% and 15% 
respectively compared to control (p<0.005).
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Figure 4.12 Effect of caspase inhibitors in SOD1 stable cells following IFN-y 
administration
a. ND7 cell death following 24h of 50ng/ml IFN-y or 50ng/ml IFN-y after incubation with 
caspase inhibitors, z-VAD, caspase-8 (C8) or caspase-9 (C9). The proportion of cell death 
was assessed by trypan blue exclusion assay, after 24h of IFN-y treatment of engineered 
ND7 cells expressing wt or mutant SOD1. Cells were incubated with caspase inhibitors lh 
prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per sample (n), 
n=5. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (p<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the respective control-vector, wt and G93A and 
G93R-SOD1 mutant control cells (cells exposed to stress of IFN-y alone).
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Figure 4.12b
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Figure 4.12 Effect of caspase inhibitors in SOD1 stable cells following IFN- 
y administration
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of 50ng/ml 
IFN-y for 24h. Bars represent mean ± S.D. calculated for triplicate counts per sample (n=3) 
and significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with the respective 
control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.4.4 Staurosporine treatment
On addition of zVAD cell death was reduced across all cells. Level of cell death were 
reduced on addition of zVAD for G93A mutant by approximately 30% and 25% and for 
G93R mutant by 46% and 40% at 2h and 4h respectively compared to respective control 
(p<0.0005); (Figure 4.13a). Caspase-8 inhibitor reduced death in G93A cells by 28% and 
21% and in G93R cells by 44% and 37% at 2h and 4h respectively compared to respective 
control (p<0.0005); (Figure 4.13a). Caspase-9 inhibitor also reduced death in both mutants 
with death in G93A cells being reduced by 27% and 21% and in G93R cells being reduced 
by 45% and 38% at 2h and 4h respectively compared to respective control (p<0.0005). Wt- 
SODl cells also showed a decrease in death following addition of zVAD or inhibitors of 
caspase-8 or caspase-9. Death was reduced in wt-SODl cells by 34% and 21% on addition 
of zVAD at 2h and 4h respectively compared to respective control cells(p<0.0005). Inhibitor 
of caspase-8 reduced death in wt-SODl cells by approximately 23% and 14% at 2h and 4h 
respectively compared to respective control cells (p<0.0005). Inhibitor of caspase-9 reduced 
death in wt-SODl cells by approximately 20% and 14% at 2h and 4h respectively compared 
to respective control (p<0.0005).
TUNEL analysis revealed similar results with zVAD reducing the numbers of TUNEL 
positive cells in wt-SODl, G93A and G93R cells. On addition of zVAD the number of 
TUNEL positive cells was reduced by approximately 34% and 26% for G93A cells and 51% 
and 43% for G93R cells at 2h and 4h respectively compared to respective control 
(p<0.0005); (Figure 4.13b). On addition of caspase-8 inhibitor the number of TUNEL 
positive cells was reduced by approximately 31% and 22% for G93A and 49% and 40% for 
G93R cells at 2h and 4h respectively compared to respective control (p<0.0005); (Figure 
4.13b). On addition of caspase-9 inhibitor G93A and G93R cells exhibited a similar 
reduction in the number of TUNEL positive cells with numbers decreasing by 
approximately 29% and 22% for G93A and 49% and 41% for G93R cells at 2h and 4h 
respectively compared to respective control (p<0.0005). Wt-SODl cells exhibited a similar 
reduction in the number of TUNEL positive cells with zVAD addition bringing about a 
reduction of 40% and 22% at 2h and 4h respectively compared to control (p0.0005). On 
addition of caspase-8 inhibitor the number of TUNEL positive cells in the wt-SODl cells
was reduced by 28% and 16% at 2h and 4h respectively compared to control (p<0.0005). 
Addition of caspase-9 inhibitor to wt-SODl cells reduced the number of TUNEL positive 
cells by approximately 25% (p<0.0005) and 13% (p<0.005) at 2h and 4h respectively 
compared to control.
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Figure 4.13 Effect of caspase inhibitors in SOD1 stable cells following staurosporine 
treatment
a. ND7 cell death following 24h of lpM staurosporine treatment or lpM staurosporine after 
incubation with caspase inhibitors, z-VAD, caspase-8 (C8) or caspase-9 (C9). The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of 
staurosporine treatment of engineered ND7 cells expressing wt or mutant SOD1. Cells were 
incubated with caspase inhibitors lh prior to stress. Bars represent mean -^ S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells (cells exposed 
to stress of staurosporine alone).
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Figure 4.13 Effect of caspase inhibitors in SOD1 stable cells following staurosporine 
treatment
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of lpM 
staurosporine for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.4.5 Camptothecin administration
The pan-caspase inhibitor zVAD and inhibitors of caspase-8 and caspase-9 provided 
protection across all the cell lines. Addition of zVAD reduced death in the G93A and G93R 
mutant by approximately 39% and 50% respectively, compared to respective control 
(p<0.0005); (Figure 4.14a). Caspase-8 inhibitor reduced death in both G93A and G93R 
mutants by 36% and 47% respectively, compared to respective control (p<0.0005); (Figure 
4.14a). Death was also reduced on addition of caspase-9 inhibitor with G93A cells seeing a 
34% reduction and G93R cells a 46% reduction, compared to respective control (p<0.0005). 
In wt-SODl cells, zVAD reduced death by approximately 11% compared to control 
(p<0.005). On addition of caspase-8 or caspase-9 inhibitors death in wt-SODl cells was 
reduced by approximately 1% in both instances, compared to control.
TUNEL analysis revealed similar results with zVAD reducing the number of TUNEL 
positive cells in G93A and G93R by approximately 45% and 54% respectively compared to 
respective control (p<0.0005); (Figure 4.14b). On addition of caspase-8 inhibitor the number 
of TUNEL positive cells was reduced by approximately 41% and 52% for G93A and G93R 
respectively compared to respective control (p<0.0005); (Figure 4.14b). Caspase-9 inhibitor 
also reduced the number of TUNEL positive cells with numbers reduced by approximately 
36% and 51% for G93A and G93R respectively compared to respective control (p<0.0005). 
Wt-SODl cells exhibited similar results with zVAD reducing the number of TUNEL 
positive cells by approximately 10% compared to control. Caspase-8 inhibitor or caspase-9 
inhibitor both reduced the number of TUNEL positive cells in wt-SODl by approximately 
1% and 3% respectively compared to control.
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Figure 4.14 Effect of caspase inhibitors in SOD1 stable cells following camptothecin 
administration
a. ND7 cell death following 24h of lpM camptothecin or lpM camptothecin after 
incubation with caspase inhibitors, z-VAD, caspase-8 (C8) or caspase-9 (C9). The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of 
camptothecin treatment of engineered ND7 cells expressing wt or mutant SOD1. Cells were 
incubated with caspase inhibitors lh prior to stress. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells (cells exposed 
to stress of camptothecin alone).
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Figure 4.14 Effect of caspase inhibitors in SOD1 stable cells following camptothecin 
administration
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of lpM 
camptothecin for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.5 The Effect of Hsp27 and/or Hsp70 plus Caspase Inhibitors on Wild 
Type and Mutant SODI Cells
Whilst all three caspase inhibitors produced significant protective effects on cell survival in 
the SODI cells following exposure to stress, discussed in section 4.4, with zVAD (the pan- 
caspase inhibitor) and specific inhibitors of both caspase-8 and caspase-9 suppressing cell 
death in the SODI-mutant cells to the level observed in the control cell line, with the 
difference in cell death being statistically significant (p<0.0005). The degree of protection 
observed in these mutant cells following caspase inhibition was similar to that conferred by 
the exogenous expression of Hsp27 and/or Hsp70 in these cell lines. Cell death was assessed 
by both trypan blue exclusion assay (Figure 4.15a) and TUNEL analysis (Figure 4.15b). 
Interestingly, overexpression of Hsp27 and/or Hsp70 in the SODI cells in combination with 
the pan-caspase inhibitor zVAD, produced no additive protective effect on exposure to 
conditions of serum withdrawal compared infection with Hsp27 and/or Hsp70 in the absence 
of zVAD.
Similar results were also obtained in repeated experiments in which the percentage of 
apoptotic cells were assayed by TUNEL analysis with no synergy in reducing the number of 
apoptotic cells observed following the application of the pan-caspase inhibitor zVAD to the 
mutant-SODl cell lines that were over-expressing Hsp27 and/or Hsp70.
G93A and G93R mutant cells infected with Hsp27 and subjected to serum withdrawal, 
exhibited an 11% (p<0.005) and 36% (p<0.0005) reduction in cell death respectively 
compared to respective GFP infected control (Figure 4.15a). On infection of G93A and 
G93R mutant cells with Hsp70 death was reduced by 7% (p<0.05) and 44% (p<0.0005) 
respectively compared to respective GFP infected control (Figure 4.15a). The combinational 
infection of Hsp27 and Hsp70 was the most effective in the reduction of death of both G93A 
and G93R mutant cells. On dual infection of G93A mutant cells a reduction of 
approximately 21% was observed and an approximately 48% reduction in the G93R mutant 
cells compared to respective GFP control (p<0.0005). On addition of zVAD, the mutant 
G93A and G93R cells saw a reduction of approximately 40% and 61% respectively
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compared to respective GFP control (p<0.0005). The combination of Hsp27 and zVAD did 
not provide an additive effect with G93A cells exhibiting an 8% and G93R cells a 33% 
(p<0.0005) reduction in death respectively compared to respective GFP control. The 
combination of Hsp70 and zVAD was also unsuccessful in providing an addition protective 
effect with G93A cells seeing a rise of almost 1% and the G93R cells a reduction of 
approximately 38% (p<0.0005) compared to respective GFP control. The dual infection of 
Hsp27 and Hsp70 with zVAD was also not as effective in reducing death as either the dual 
infection of Hsp27 and Hsp70 alone or zVAD alone.
TUNEL analysis revealed similar results with Hsp27 reducing the number of TUNEL 
positive cells by approximately 15% (p<0.05) and 35% (p<0.0005) for G93A and G93R 
respectively compared to respective control (Figure 4.15b). Hsp70 also resulted in a 
reduction in the number of TUNEL positive cells with the numbers reduced by 
approximately 10% and 45% (p<0.0005) for G93A and G93R respectively compared to 
respective control (Figure 4.15b). The dual combination of Hsp27 and Hsp70 reduced the 
number of TUNEL positive cells by approximately 22% and 47% for G93 A and G93R cells 
respectively compared to respective control (p<0.0005). The combination of Hsp27 and 
zVAD was not as effective as either singly and reduced the number of TUNEL positive cells 
by approximately 10% and 32% (p<0.0005) for G93A and G93R respectively compared to 
respective control. The combination of Hsp70 and zVAD was also not as effective as either 
singly and only reduced the number of TUNEL positive cells by approximately 2% and 37% 
(p<0.0005) for G93A and G93R respectively compared to respective control. The 
combination of Hsp27 and Hsp70 along with zVAD was only slightly more effective than 
either Hsp27 or Hsp70 with zVAD but still not as effective as the single respective additions 
with the number of TUNEL positive cells reduced by approximately 12% (p<0.005) and 
43% (p<0.0005) for G93A and G93R respectively compared to respective control. Wt- 
SODl cells exhibited an increase in the number of TUNEL positive cells on infection with 
Hsp27 or Hsp70 with the number increasing by approximately 12% and 113% (p<0.0005) 
respectively compared to control. The dual infection with Hsp27 and Hsp70 brought the 
levels down toward control levels with the number of TUNEL positive cells reduced by 
approximately 2% compared to control. The combination of Hsp27+zVAD or 
Hsp70+zVAD increased the number of TUNEL positive cells by approximately 18% and
121% (p<0.0005) respectively compared to control. The combination of Hsp27 and Hsp70 
with zVAD resulted in an increase in the number of TUNEL positive cells by approximately 
11% compared to control. Therefore, from the results obtained it appears that the Hsps act 
via inhibition of caspases.
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Figure 4.15 The dual effect of Hsp’s and caspase inhibitors in SODI stable cells 
following serum removal
a. ND7 cell death following 24h serum removal after infection with either GFP, Hsp27, 
Hsp70 or Hsp27 and Hsp70 virus plus incubation with caspase inhibitor z-VAD. The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of serum 
deprivation of engineered ND7 cells expressing wt or mutant SODI. Cells were incubated 
with caspase inhibitors lh prior to stress. Bars represent mean ^ .D . calculated for triplicate 
counts per sample (n), n=5. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with the respective GFP 
infected control-vector, wt, G93A or G93R-SOD1 mutant control cells.
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Figure 4.15 The dual effect of Hsp’s and caspase inhibitors in SODI stable cells 
following serum removal
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with caspase inhibitors lh prior to treatment of serum 
deprivation for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective GFP infected control-vector, wt, G93A or G93R-SOD1 mutant control cells.
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4.6 Responses of the SODI cell lines to Stress following addition of ApoE2, 
ApoE3 or ApoE4 alleles
Apolipoprotein E (ApoE for the protein, APOE for the gene) is a widely distributed, 
well-characterized cholesterol transport protein that circulates in the plasma following its 
synthesis in the liver, spleen, and kidneys. It is the major apolipoprotein in the central 
nervous system (CNS) (Pitas et al., 1987), where it is synthesized by glia, macrophages 
(Boyles et al., 1985), and also neurons (Han et al., 1994). Additionally, it is also found in the 
peripheral nervous system (PNS), where it is produced by non-myelinating Schwann cells, 
ganglionic satellite cells, and macrophages (Boyles et al., 1985). In humans, ApoE exists in 
3 common isoforms: z2, s3, and s4, which differ from one another at amino acid positions 
112 and 158. Isoform s3 has a cysteine at 112, and an arginine at 158 whereas s2 has 
cysteines at both positions and e4 has arginines at both positions. The absolute frequency of 
these different isoforms is dependent on the population being studied, however the relative 
frequency is always similar, with s3 being much more common than s2 or e4.
4.6.1 Motor Neuron Disease and ALS
Despite four large studies, the association between APOE and motor neuron disease 
(MND) and/or ALS as yet remains controversial. Mui and co-workers (1995) were the first 
to investigate this relationship. They examined 170 patients with undefined "ALS" of which 
72 had sporadic disease, 77 had a family history with unknown genetic predisposition, and 
21 had a family history of a mutation in superoxide dismutase (SODI). The ALS patients 
were compared with 1209 historical age-matched controls (Ordovas et al., 1987) and 60 
ALS-free siblings or spouses of the familial group. There was no difference observed in 
APOE allele frequency in any of the ALS groups compared to controls. In addition, no 
difference was found in ALS onset age or disease duration between patients with an e4 allele 
and those without. This study along with other ALS studies to date, all used a small sample 
size. Only the patients with familial ALS were used in the analysis of disease duration, and 
only 43 of 72 patients with sporadic disease were included in the assay for onset age but the
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loss of the other 29 patients was not explained. Most seriously of all, this study did not 
define the criteria for diagnosing ALS.
Work carried out by Al-Chalabi and colleagues (1996) obtained different results. In 
this study, APOE genotyping was carried out on 123 patients with MND (diagnosed by two 
consulting neurologists) and 121 geographically similar disease-free controls. The frequency 
of APOE4 genotypes in the MND patient group was not found to be significantly different 
from that in their controls though there was a trend toward the MND population having a 
higher APOE4 genotype frequency (27.6%) than the controls (21.5%). In addition, 
subdivision of the patients with MND into those with limb-onset disease and those with 
bulbar-onset disease, revealed the latter group had a significantly higher frequency of 
APOE4 genotypes than the controls (42.4%; P= .02). On plotting the probability of survival 
as a function of time through Kaplan-Meier analysis, it was discovered that patients with e4 
alleles had a slightly greater rate of death than patients without. Even though this difference 
did not reach statistical significance, it converted to a median survival of 35 months for 
patients with an s4 allele and 49 months for those without which would seem clinically 
important.
This study conducted by Al-Chalabi et al. (1996) also suffers from small sample size, 
especially in analyses of subgroups such as patients with limb onset and bulbar onset; the 
latter group included only 33 patients. In addition, it fails to define the clinical or electrical 
criteria used in making the diagnosis of MND, and does not specify the etiology of this 
condition in its patient group apart from saying they did not have dementia, spinal muscular 
atrophy, or Kennedy syndrome.
The findings of Al-Chalabi et al (1996) were confirmed and extended by work 
carried out by Moulard and colleagues (1996) who examined 130 patients with sporadic 
ALS, defined in accordance with the El Escorial criteria (Brooks. 1994), and 675 geo­
graphically similar historical controls (Schachter et al., 1994; Luc et al., 1994). No signifi­
cant difference was observed in APOE genotype frequency between patients with ALS and 
controls. However there was a trend toward patients with ALS having a lower frequency of
e2-containing genotypes (8.5%) than the control population (15%). In this study no
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relationship was found between ALS onset age and allele type. Also no difference was 
found in ALS duration between patients with and without s4 alleles. Interestingly, however 
a statistically significant difference in disease duration was found to occur between patients 
with and without s2 alleles with those with e 2 alleles exhibiting longer survival. In addition, 
a statistically significant relationship emerged between ALS onset location and allele type, 
with patients with e2 alleles more likely to halve limb-onset disease, whereas patients with 
s4 were more likely to have bulbar-onset disease. Among the patients with limb onset, those 
possessing e 2 alleles were found to survive significantly longer than those without. Among 
the patients with bulbar onset, those possessing e 4 alleles exhibited disease symptoms at a 
significantly earlier age than those without.
Although studies have examined the protective effects of ApoE2 over ApoE4, as yet 
it remains controversial as to whether there exists an association between APOE and ALS. 
In the present project, APOE alleles were utilised in order to assess whether there exists a 
difference in relationship between the APOE alleles in the level of protection conferred 
against various stresses applied in an in vitro system in which wt-SODl or the disease- 
associated mutants, G93A and G93R-mutant SODI, are stably over-expressed. Cells were 
subjected to a wide range of stresses such as serum removal, serum removal plus lpM all- 
trans retinoic acid, IFN-y treatment, staurosporine administration and camptothecin addition, 
in order to compare their response to these distinct death stimuli at multiple time points, in 
the presence or absence APOE alleles -  APOE2, APOE3 or APOE4.
The following section briefly describes the creation of the cell lines and the method 
of isolation of the ApoE protein, followed by a description of the results obtained following 
experimentation into the protective effect of APOE alleles - APOE2, APOE3 and APOE4 - 
in this model system, on exposure to each death stimulus. The findings for the various 
stresses are presented below the corresponding stress and cell death was assessed by trypan 
blue exclusion assay and TUNEL analysis. Finally, the significance of the findings is 
discussed in the discussion for the chapter.
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4.6.2 Creation of APOE cells and Isolation of APOE
The ApoE protein isoforms were a gift from Dr B.S. Thilakawardhana, Royal Free Hospital, 
UCL. Briefly CHO (Chinese Hamster Ovary) cells -  CHOdhfr' cells were cultured in Iscove’s 
modified Dulbecco’s medium with 10% dialyzed fetal bovine serum supplemented with 
2mM glutaMAX, 100p.M hypoxanthine, 16pM thymidine, and 1% non-essential amino 
acids (see Tagalakis et al., 2001).
Human APOE2 cDNA was cloned into the expression vector p7055 (see Miloux et al., 
1994), which contains the selectable DHFR (dihydrofolate reductase) gene. Approximately 
6pg of p7055.E2 was complexed with cationic liposomes to transfect CHOdhfr' cells (2xl06). 
Cells were grown for 2-3 weeks in Iscove’s selection medium, which lacks hypoxanthine 
and thymidine, clones of CHO-E2 were isolated by limited dilution; Clones of CHO-E3 and 
CHO-E4 were produced similarly. Subsequently the medium of the clones was screened for 
ApoE by ELISA and the four most productive clones expanded for each APOE cell lines 
(see Tagalakis et al., 2001). The ApoE secreted into the culture medium was measured by 
two-antibody sandwich ELISA, using a goat polyclonal anti-human ApoE for capture and 
biotinylated goat polyclonal anti-human ApoE for detection (see Tagalakis et al., 2001).
4.7 Responses of Cell Lines to Several Death-inducing Stimuli following 
addition of ApoE
4.7.1 Serum Removal
G93A and G93R mutant SODI expressing cells exposed to serum removal and addition 
50ng of ApoE-4 exhibited an increase in total cell death by 36% and 39% respectively 
compared to respective cell control (p<0.0005); (Figure 4.16a). ApoE3 treated G93A and 
G93R mutant cells showed a reduction in total cell death of 11% and 21% respectively 
compared to respective control cells (p<0.0005); (Figure 4.16a). ApoE2 treated mutant cells 
showed an even greater reduction in cell death with death being reduced by approximately
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18% and 33% for G93A and G93R cells respectively compared to respective control 
(p<0.0005). Wt-SODl expressing cells also exhibited an increase in cell death on addition of 
ApoE4 with total cell death rising by approximately 22% compared to control (p<0.0005). 
ApoE3 addition led to reduction in total cell death of wt-SODl expressing cells by 
approximately 9% compared to control. Addition of ApoE2 was most effective in reducing 
cell death just as in case of mutants with cell death being reduced by 18% compared to 
control (p<0.0005).
TUNEL analysis brought about similar results further confirming the protective effect of 
ApoE2 and ApoE3 over ApoE4. G93A and G93R mutant expressing cells each showed an 
increase in the number of TUNEL positive cells on addition of ApoE4 with an increase of 
32% and 41% for G93A and G93R respectively compared to respective control (p<0.0005); 
(Figure 4.16b). ApoE3 and ApoE2 both brought about a reduction in number of TUNEL 
positive cells with ApoE3 reducing the number of TUNEL positive cells in the case of 
G93A by approximately 12% compared to control (p<0.05); (Figure 4.16b). In the case of 
G93R, ApoE3 brought about a reduction in TUNEL positive cells by approximately 16% 
compared to control (p<0.0005). On addition of ApoE2 apoptotic death in both mutants was 
reduced further with a reduction of 24% and 34% being observed for G93A and G93R 
respectively compared to respective control (p<0.0005). Wt-SODl cells showed a similar 
trend to the mutants with ApoE4 bringing about an increase of in the number of TUNEL 
positive cells by approximately 24% compared to control (p<0.0005). ApoE3 addition, as 
with mutants, showed a protective effect in wt-SODl cells bringing about a reduction in the 
number of TUNEL positive cells by approximately 9% compared to control. ApoE2 addition 
brought the number of TUNEL positive wt-SODl cells down even further with a reduction 
of 22% being observed compared to control (p<0.005).
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Figure 4.16 Effect of ApoE isoforms on SODI stable cells following serum removal
a. ND7 cell death following 24h of serum removal or serum removal after incubation with 
50ng/ml Apolipoprotein-E (ApoE), ApoE4, ApoE3 or ApoE2. The proportion of cell death 
was assessed by trypan blue exclusion assay, after 24h of serum deprivation of engineered 
ND7 cells expressing wt or mutant SODI. Cells were incubated with ApoE isoforms lh 
prior to stress. Bars represent mean ±S.D. calculated for triplicate counts per sample (n), 
n=5. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (p<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the respective control-vector, wt and G93A and 
G93R-SOD1 mutant control cells (cells treated with control solution obtained from control 
cells).
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Figure 4.16b
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Figure 4.16 Effect of ApoE isoforms on SODI stable cells following serum removal
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with ApoE protein lh prior to treatment of serum 
deprivation for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.7.2 Serum Removal +RA
G93A and G93R mutant SODI cells showed a similar increase when subjected to serum 
removal plus lpM retinoic acid on addition of ApoE4. Total cell death increased by 
approximately 28% and 31% for G93A and G93R respectively compared to respective 
control (p<0.0005); (Figure 4.17a). On addition of ApoE3 death was reduced in both 
instances with death decreasing by approximately 18% and 25% for G93A and G93R 
respectively compared to respective control (p<0.0005); (Figure 4.17a). Addition of ApoE2 
reduced death even further with death being reduced by approximately 36% and 50% for 
G93A and G93R respectively compared to respective control (p<0.0005). Wt-SODl cells 
also exhibited a similar trend to the mutants. Total cell death in the wt-SODl cells increased 
by approximately 12% on addition of ApoE4 compared to control (p<0.05). On addition of 
ApoE3 death was reduced as with mutants in wt-SODl cells with death decreasing by 
approximately 11% compared to control. Total cell death of wt-SODl cells was reduced the 
most by addition of ApoE2 with death being reduced by approximately 25% compared to 
control (p<0.0005).
TUNEL analysis revealed similar results with the number of TUNEL positive cells in both 
G93A and G93R mutant cells increasing by approximately 20% and 24% respectively on 
addition of ApoE4 compared to respective control (p<0.0005); (Figure 4.17b). On addition 
of ApoE3 number of TUNEL positive cells was reduced in both mutants by approximately 
19% and 25% for G93A and G93R respectively compared to respective control (p<0.0005); 
(Figure 4.17b). The number of TUNEL positive cells was reduced even further by 
approximately 33% and 45% for G93A and G93R respectively on addition of ApoE2 
compared to respective control (p<0.0005). Wt-SODl cells showed a similar trend to the 
mutants with the number of TUNEL positive cells increasing by approximately 16% on 
addition of ApoE4 compared to control (p<0.005). Addition of ApoE3 resulted in a 
reduction in the number of TUNEL positive cells with death decreasing by approximately 
15% compared to control (p<0.005). Once again ApoE2 was the most effective in reducing 
to the number of TUNEL positive cells with wt-SODl cells exhibiting a 27% reduction in 
the number of TUNEL positive cells compared to control (p<0.0005).
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Figure 4.17 Effect of ApoE isoforms on SODI stable cells following serum removal plus 
lpM all-trans retinoic acid
a. ND7 cell death following 24h of serum removal plus lpM all-trans retinoic acid or serum 
removal plus lpM  all-trans retinoic acid after incubation with 50ng/ml Apolipoprotein-E 
(ApoE), ApoE4, ApoE3 or ApoE2. The proportion of cell death was assessed by trypan blue 
exclusion assay, after 24h of serum deprivation plus lpM all-trans retinoic acid of 
engineered ND7 cells expressing wt or mutant SODI. Cells were incubated with ApoE 
isoforms lh prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per 
sample (n), n=5. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with the respective control-vector, 
wt and G93A and G93R-SOD1 mutant control cells (cells treated with control solution 
obtained from control cells).
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Figure 4.17 Effect of ApoE isoforms on SODI stable cells following serum removal plus 
lpM  all-trans retinoic acid
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with ApoE protein lh prior to treatment of serum 
deprivation plus lpM all-trans retinoic acid for 24h. Bars represent mean 1 S.D. calculated 
for triplicate counts per sample (n=3) and significant differences were calculated as above 
with /?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with the respective control-vector, wt and G93A and G93R-SOD1 mutant control 
cells.
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4.7.3 IFN-y administration
To further investigate the effects of ApoE alleles on the cells the cells were subjected to a 
range of stresses, which had been investigated previously. On exposure to IFN-y the G93A 
and G93R mutant cells reacted just as with previous experiments. On addition of ApoE4 the 
G93A and G93R mutants both exhibited an increase in total cell death with death increasing 
by approximately 29% and 32% respectively compared to respective control (p<0.0005); 
(Figure 4.18a). On addition of ApoE3 the mutants G93A and G93R exhibited a reduction in 
death with death being reduced by approximately 10% (p<0.01) and 22% (p<0.0005) 
respectively compared to respective control (Figure 4.18a). The greatest reduction in death 
was observed on addition of ApoE2 with death being reduced by approximately 26% and 
44% for G93A and G93R respectively compared to respective control (p<0.0005). Wt- 
SODl over-expressing cells exhibited a similar trend with addition of ApoE4 resulting in an 
increase in total cell death of approximately 17% compared to control (p<0.005). On 
addition of ApoE3 and ApoE2 wt-SODl cells exhibited a decrease in cell death with death 
being reduced by approximately 9% and 18% (p<0.005) respectively compared to control.
A similar trend was observed when death was analysed using TUNEL analysis. The number 
TUNEL positive cells increased across all cells on addition of ApoE4. The G93A and G93R 
mutants exhibited an increase in the number of TUNEL positive cells by approximately 35% 
and 36% respectively on addition of ApoE4 compared to respective control (p<0.0005); 
(Figure 4.18b). On addition of ApoE4 to wt-SODl cells a similar increase in the number of 
TUNEL positive cells was observed with number of TUNEL positive cells increasing by 
approximately 22% compared to control (p<0.0005); (Figure 4.18b). ApoE3 and ApoE2 
addition resulted in a decrease in the number of TUNEL positive cells with G93A cells 
exhibiting a reduction of approximately 16% and 25% respectively compared to control 
(p<0.0005). G93R cells exhibited a similar trend on addition of ApoE3 and ApoE2 with the 
number of TUNEL positive cells decreasing by approximately 22% and 43% respectively 
compared to control (p<0.0005). On addition of ApoE3 and ApoE2 to wt-SODl cells the 
number of TUNEL positive cells decreased by approximately 14% (p<0.05) and 25% 
(p<0.0005) respectively compared to control.
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Figure 4.18 Effect of ApoE isoforms on SOD1 stable cells following IFN-y 
administration
a. ND7 cell death following 24h of 50ng/ml IFN-y or 50ng/ml IFN-y after incubation with 
50ng/ml Apolipoprotein-E (ApoE), ApoE4, ApoE3 or ApoE2. The proportion of cell death 
was assessed by trypan blue exclusion assay, after 24h of IFN-y treatment of engineered 
ND7 cells expressing wt or mutant SOD1. Cells were incubated with ApoE isoforms lh 
prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per sample (n), 
n=5. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (p<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with the respective control-vector, wt and G93A and 
G93R-SOD1 mutant control cells (cells treated with control solution obtained from control 
cells).
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Figure 4.18 Effect of ApoE isoforms on SOD1 stable cells following IFN-y 
administration
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with ApoE protein lh prior to treatment of 50ng/ml IFN-y 
for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=3) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with the respective 
control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.7.4 Staurosporine treatment
On addition of ApoE4 mutant cell death increased for both mutants. G93A mutant cell death 
increased on addition of ApoE4 by approximately 34%, 25% and 24% at 2h, 4h and 6h 
respectively compared to respective control (p<0.0005) (Figure 4.19a). G93R mutant cells 
exhibited an increase in total cell death of approximately 43%, 32% and 31% at 2h, 4h and 
6h respectively on addition of ApoE4 compared to respective control (p<0.0005); (Figure 
4.19a). A similar increase in total cell death was observed in wt-SODl cells with death 
increasing by approximately 26%, 23% and 30% at 2h, 4h and 6hr respectively on addition 
of ApoE4 compared to respective control (p<0.0005). ApoE3 addition resulted in a decrease 
in total cell death of all cells. G93A mutant cell exhibited a decrease of approximately 19%, 
20% and 19% at 2h, 4h and 6h respectively on addition of ApoE3 compared to respective 
control (p<0.0005). On addition of ApoE3, G93R cells exhibited a decrease in cell death of 
approximately 26%, 21% and 16% at 2h, 4h ad 6h respectively compared to respective 
control (p<0.0005). Wt-SODl cells exhibited a decrease in cell death of approximately 22%, 
20% and 22% at 2h, 4h and 6h respectively on addition of ApoE3 compared to respective 
control (p<0.0005). Total cell death was further reduced by addition of ApoE2. G93A 
mutant cells exhibited a decrease in total cell death of approximately 59%, 57% and 50% at 
2h, 4h and 6h respectively on addition of ApoE2 compared to respective control (p<0.0005). 
G93R mutant cell death was reduced by approximately 59%, 56% and 53% at 2h, 4h and 6h 
respectively on addition of ApoE2 compared to respective control (p<0.0005). Wt-SODl 
cells also exhibited a reduction in cell death on addition of ApoE2 with death being reduced 
by approximately 47%, 43% and 39% at 2h, 4h and 6h respectively compared to respective 
control (p<0.0005).
TUNEL analysis revealed similar results with ApoE4 bringing about approximately a 39%, 
27% and 36% increase in the number of TUNEL positive cells at 2h, 4h and 6h respectively 
for G93A cells compared to control (p<0.0005); (Figure 4.19b). G93R cells exhibited a 
similar increase in the number of TUNEL positive cells with numbers increasing by 
approximately 46%, 35% and 31% at 2h, 4h and 6h respectively compared to control 
(p<0.0005); (Figure 4.19b). ApoE3 addition resulted in a reduction in the number of 
TUNEL positive cells with number decreasing by approximately 20%, 20% and 17% for
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G93A and 27%, 21% and 17% for G93R at 2h, 4h, and 6h respectively compared to 
respective control (p<0.0005). Addition of ApoE2 reduced the number of TUNEL positive 
cells by a larger extent with number reduced by approximately 63%, 58% and 51% for 
G93A and 63%, 57% and 56% for G93R cells at 2h, 4h and 6h respectively compared to 
respective control (p<0.0005). In wt-SODl cells addition of ApoE4 increased the number of 
TUNEL positive cells by approximately 31%, 24% and 35% at 2h, 4h, and 6h respectively 
compared to control (p<0.0005). ApoE3 addition to wt-SODl cells reduced the number of 
TUNEL positive cells by approximately 21% (p<0.05), 22% (p<0.0005) and 20% 
(p<0.0005) at 2h, 4h and 6h respectively compared to control. ApoE2 addition to wt-SODl 
reduced the number of TUNEL positive cells by approximately 47%, 48% and 40% at 2h, 
4h and 6h respectively compared to control (p<0.0005).
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Figure 4.19 Effect of ApoE isoforms on SOD1 stable cells following staurosporine 
treatment
a. ND7 cell death following 24h of lpM staurosporine or lpM staurosporine after 
incubation with 50ng/ml Apolipoprotein-E (ApoE), ApoE4, ApoE3 or ApoE2. The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of 
staurosporine treatment of engineered ND7 cells expressing wt or mutant SOD1. Cells were 
incubated with ApoE isoforms lh prior to stress. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells (cells treated 
with control solution obtained from control cells).
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Figure 4.19 Effect of ApoE isoforms on SOD1 stable cells following staurosporine 
treatment
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with ApoE protein lh prior to treatment of lpM 
staurosporine for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.7.5 Camptothecin administration
On exposure to camptothecin and addition of ApoE4 to G93A and G93R mutant cells total 
cell death increased by approximately 30% and 33% respectively compared to respective 
control (p<0.0005); (Figure 4.20a). ApoE3 addition, on the other hand, corresponded to a 
reduction in cell death with G93A and G93R mutants exhibiting a reduction of 
approximately 12% (p<0.005) and 19% (p<0.0005) respectively compared to respective 
control (Figure 4.20a). A greater reduction was observed on addition of ApoE2 with cell 
death decreasing by approximately 22% and 33% respectively compared to respective 
control (p<0.0005). As with previous experiments wt-SODl expressing cells exhibited a 
similar trend to the mutants with ApoE4 corresponding to an increase in cell death with 
death rising by approximately 23% compared to control (p<0.0005). Addition of ApoE3 and 
ApoE2 resulted in a reduction in cell death with death being reduced by approximately 5% 
and 17% (p<0.005) respectively compared to control.
TUNEL analysis revealed an increase in the number of TUNEL positive cells on addition of 
ApoE4 as with previous experiments. Addition of ApoE4 increased the number of TUNEL 
positive cells by approximately 31% and 35% for G93A and G93R respectively compared to 
respective control (p<0.0005); (Figure 4.20b). ApoE3 addition resulted in a reduction in the 
number of TUNEL positive cells with the number being reduced by approximately 18% for 
both G93A and G93R mutant cells compared to respective control (p<0.0005); (Figure 
4.20b). ApoE2 addition lead to a further reduction in the number of TUNEL positive cells 
with G93A and G93R exhibiting a reduction of approximately 35% and 40% respectively 
compared to respective control (p<0.0005). Wt-SODl cells exhibited an increase in the 
number of TUNEL positive cells on addition of ApoE4 with the number of TUNEL positive 
cells increasing by approximately 21% compared to control (p<0.005). Addition of ApoE3 
and ApoE2 reduced the number of TUNEL positive wt-SODl cells with number of TUNEL 
positive cells decreasing by approximately 13% and 28% (p<0.0005) respectively compared 
to control.
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Figure 4.20 Effect of ApoE isoforms on SOD1 stable cells following camptothecin 
administration
a. ND7 cell death following 24h of lpM camptothecin or lpM camptothecin after 
incubation with 50/ng/ml Apolipoprotein-E (ApoE) alleles, ApoE4, ApoE3 or ApoE2. The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of 
camptothecin treatment of engineered ND7 cells expressing wt or mutant SOD1. Cells were 
incubated with ApoE iso forms lh prior to stress. Bars represent mean ±S.D. calculated for 
triplicate counts per sample (n), n=5. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells (cells treated 
with control solution obtained from control cells).
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Figure 4.20 Effect of ApoE isoforms on SOD1 stable cells following camptothecin 
administration
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were incubated with ApoE protein lh prior to treatment of lpM 
camptothecin for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample 
(n=3) and significant differences were calculated as above with /?<0.0005. *, **, *** 
indicates statistically significant difference between means, when comparing with the 
respective control-vector, wt and G93A and G93R-SOD1 mutant control cells.
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4.8 Discussion
This chapter describes the protective effect of heat shock proteins in the in vitro 
model system of mutant-SOD 1-associated toxicity that was described in Chapter 3. HSV- 
based viral vectors were utilised in order to efficiently express Hsp27 or Hsp70. In 
summary, the wt-SODl, mutant SOD1 and empty vector control expressing cell lines were 
infected with the viral vectors or the relevant control viruses and subsequently subjected to 
various stresses as in the experiments described in Chapter 3, including serum withdrawal, 
serum withdrawal plus lpM retinoic acid, IFN-y, staurosporine, and camptothecin. The 
response of the cell lines to the above death inducing stimuli was quantified by different 
methods of cell death assessment, such as trypan blue exclusion to establish total cell death 
and TUNEL analysis to establish the number of apoptotic cells.
Briefly, the results indicate that the exogenous expression of Hsp27 and Hsp70 in an 
established in vitro mammalian model over-expressing G93A and G93R SOD1 mutants, 
confer protection against a wide range of lethal stimuli. Wt-SODl cells exhibited increased 
levels of death with Hsp70 infection bringing about a larger increase in death than Hsp27. 
Interestingly Hsp70 was much more effective in rescuing the G93R mutant than Hsp27, with 
the opposite being true for the G93A mutant. Furthermore, a joint infection of Hsp27 and 
Hsp70 rescued both G93A and G93R SOD1 mutants more effectively than single viral 
infections with Hsp27 or Hsp70 alone. In addition the enhanced cell death observed in the 
wt-SODl cells on infection of Hsp27 or Hsp70 alone was abolished on expression of the 
combination of Hsp27 and Hsp70 suggesting that Hsp27 and Hsp70 may act in synergy.
The G93R mutation is much more severe than the G93A mutation and this can be
seen throughout all the stresses tested and parallels the much more severe disease phenotype
and early onset observed in ALS patients with the G93R mutation. The levels of death
obtained with G93A mutation were not as high as the G93R mutation and only slightly
higher than control levels. However, the protective effect observed with Hsp27 or Hsp70
reduced the death observed in the G93A cells below that observed in control cells treated
with these Hsps. Here the Hsps probably provide more than a general cytoprotective effect
and impose their protective effect on the SOD1 mutant. This protective effect is probably
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through restoration of normal protein conformation rather than degradation of misfolded 
protein, as the addition of Hsps lowers the levels of death in both the mutants by a greater 
amount than that observed in control cells. The reduction in death of the mutants, beyond the 
levels of death observed in the control cells would be expected if the mutant was refolded to 
obtain wild-type conformation and thereby able to exert its wild-type anti-apoptotic 
properties through over-expression of wt-SODl protein.
A possible explanation for the increased cell death observed in the wt-SODl over­
expressing cell line following Hsp27 or Hsp70 infection may be the increased expression of 
basal levels of SOD1. It is known that over-expression of Hsps results in the corresponding 
up-regulation of wt-SODl (Hass et al., 1988; Loven et al., 1985; Yoo et al., 1999); and 
would lead to an increase in cell death through an increase in oxidative stress. It is known 
that over-expression of wt-SODl above and beyond a certain threshold can be deleterious 
and harmful to the cell (Omar et al., 1990) as the wt-SODl catalyses the reaction of O2' with 
NO resulting in the generation of ONOO' which subsequently leads to generation of 
oxidative stress. The Hsp27 and Hsp70 combination in the wt-SODl cells brought levels of 
cell death down towards control levels. This maybe brought about by the combination of 
Hsp27 and Hsp70 activating a proteolytic pathway and degrading any excess wt-SODl or 
the combination self-regulating each other and preventing over-excessive production of wt- 
SODl. Alternatively, the two factors together may have a sufficiently potent protective 
effect to neutralise the damage brought about by a large excess of wt-SODl.
The increased susceptibility of the G93A and G93R SOD1 mutants to all stresses 
tested is greatly reduced by caspase inhibitors or by both single infections of Hsp27 and 
Hsp70 and by a greater amount by dual infections of both Hsp27 and Hsp70. In an attempt 
to identify a mechanism of protection by Hsp27 or Hsp70, the serum withdrawal protocol 
was chosen initially to test whether the use of specific caspase inhibitors and/or Hsp27 or 
Hsp70 or Hsp27 and Hsp70 over-expression could reduce the levels of cell death, 
particularly in the G93A and G93R-SOD1 mutant expressing cells. The results presented in 
section 4.3 indicate that following serum withdrawal the mutants G93A and G93R increase 
toxicity in ND7 cells by increasing the activation of components of the caspase cascade in 
these cells, resulting in an increase in cell death. This sensitivity was abolished by inhibiting
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either caspase-8 or caspase-9 or by over-expressing Hsp27, Hsp70 or Hsp27 and Hsp70 
combination. Interestingly, although the G93A or G93R mutant expressing cells were 
markedly protected by either caspase inhibitors or by Hsp27, Hsp70 or Hsp27 and Hsp70 
overexpression, there was no additive effect between the Hsps and the caspase inhibitors for 
further protection to occur.
This suggests that the majority of the enhanced cell death seen upon over-expression 
of G93A or G93R SOD1 mutations is apoptotic and propagated through caspase dependent 
mechanisms, which can be blocked by either caspase inhibitors or by Hsp27 and/or Hsp70. 
The increase in cell death on treatment with zVAD-fmk and addition of either Hsp27 or 
Hsp70 may be put down to an unfavourable interaction between the inhibitor and the Hsp27 
or Hsp70 rather than toxicity of the virus itself, simply because if this was the case one 
would expect a corresponding increase on treatment of GFP+zVAD. The increase in death 
observed on treatment with zVAD-fmk and Hsp27 or Hsp70 compared to zVAD-fmk alone 
could be as a result of a competition between zVAD-fmk and Hsp27 or Hsp70 for the same 
molecules in the apoptotic cascade resulting in hindrance of the anti-apoptotic properties of 
both and leading to an increase in death when compared to treatment of zVAD-fmk alone.
Previously, Wagstaff et al. (1999) demonstrated that neuronal cells can be protected 
against harmful stimuli inducing apoptosis by Hsp27, but the exact mechanism of protection 
against these stimuli as yet still remains unclear. Recently, Zourlidou et al. (2004) 
demonstrated the protective effects of Hsp27 against the damaging effects of over­
expressing wild-type and mutant a-synuclein, in ND7 cells. Furthermore, Zourlidou et al. 
(2004) found the death brought about by mutant a-synuclein to be apoptotic with caspase 
inhibitors and Hsp27 blocking all death and a joint treatment of caspase inhibitor and Hsp27 
not producing an extra protective effect. However, Zourlidou et al. (2004) found Hsp70 did 
not provide a strong protective effect against a-synuclein toxicity under stresses tested, 
whilst simultaneous overexpression of Hsp27 and Hsp70 was as protective as Hsp27 
expression alone.
Hence the findings in this chapter could be explained partly by the fact that both
Hsp27 and Hsp70 have multiple anti-apoptotic actions (Garrido et al., 2001; Concannon et
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al., 2003; Parcellier et al., 2003). The precise mechanism of protection by Hsp27 and/or 
Hsp70 in various situations is obviously very complex and as yet remains incompletely 
understood. Over-expression of Hsp27 protects against apoptotic cell death triggered by a 
range of stimuli, including hyperthermia, oxidative stress, staurosporine, ligation of the 
Fas/Apo-l/CD95 death receptor, and cytotoxic drugs (Garrido et al., 1996 & 1997; Mehlen 
et al., 1996). Various distinct mechanisms have been put forward to account for the anti- 
apoptotic properties of Hsp27 such as its ability to increase the anti-oxidant defence of cells 
by decreasing reactive oxygen species cell content (Mehlen et al., 1996) and its ability to 
stabilize actin microfilaments (Lavoie et al., 1995).
In the intrinsic pathway of apoptosis Hsp27 prevents the formation of the 
apoptosome and thereby the subsequent activation of caspases by directly sequestering 
cytochrome c (Bruey et al., 2000; Garrido et al., 1999). Hsp27 has also been shown to 
interact with caspase-3 (Concannon et al., 2001; Pandey et al., 2000) and the phosphorylated 
form of Hsp27 has been shown to directly interact with Daxx to prevent cell death (Charette 
et al., 2000). Hsp70 has the ability to directly bind Apaf-1, thereby preventing the 
recruitment of procaspase-9 to the apoptosome (Beere et al., 2000; Mosser et al., 2000; 
Saleh et al., 2000). In addition, Hsp70 can also bind to AIF and as a result prevent AIF- 
mediated apoptosis (Creagh et al., 2000; Ravagnan et al., 2001). It is also thought that 
Hsp70 may also protect the cells from energy deprivation and/or ATP depletion associated 
with cell death (Wong et al., 1998). Furthermore, Hsp70 has also been shown to avert JNK 
activation (Meriin et al., 1999; Park et al., 2001).
As mentioned previously, Hsp70 was initially proposed to rescue cells from a later 
stage of apoptosis than any other known survival enhancing drug or protein with its 
overexpression shown to inhibit downstream morphological changes that are characteristic 
of dying cells (Jaattela et al., 1998; Li et al., 2000). It has also been found that elevated 
levels of Hsp70 could prevent both caspase activation and apoptosis-associated nuclear 
changes (Buzzard et al., 1998). This may provide a possible explanation for why Hsp70 is 
better poised to rescue the G93R SOD1 mutant than Hsp27. Under all stresses tested Hsp70 
reduced death of G93R SOD1 mutant by a greater amount than was observed with Hsp27. 
The G93R SOD1 mutation has a much more severe disease phenotype compared to G93A
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S0D1 mutation and is associated with a particularly early age of onset and this effect is 
paralleled throughout all the stresses tested by a greater enhancement of cell death with 
G93R compared to G93A. It is plausible that as the G93R SOD1 mutant is much more 
severe, both in vivo and in our experiments, that at any one time it maybe further along the 
apoptotic pathway than the corresponding less severe G93A mutant and therefore Hsp70 
would be better placed in rescuing the mutant from death. If this were thought to be true 
then it would mean that Hsp70 would be able to rescue more severe SOD1 mutants more 
effectively than Hsp27.
The mechanism by which Hsp27 exerts its protective effects may be through its 
ability to maintain redox homeostasis and mitochondrial stability. The suggestion that Hsps 
exert their protective roles at the level of the mitochondrion is not an entirely new concept. 
Previously Polla et al. (1996) proposed that mitochondria are the targets of the protective 
effects of Hsps against oxidative stress. Mutant SOD1 has been shown to localise to the 
mitochondria where it sets off caspase-dependent cell death (Takeuchi et al., 2002). It is 
possible that mutant SOD1 exerts its effects on mitochondrial SOD2 by relocating to the 
mitochondria where the SOD1 mutant catalyses the reaction of superoxide radical (O2 ) with 
nitric oxide (NO) to generate peroxynitrite (ONOO ).
Mn-SOD (SOD2), which is the enzyme responsible for the detoxification of 
intramitochondrial 02.- radical, has been shown to be nitrated and inactivated both in vitro 
and in vivo (MacMillan-Crow et al., 1996; Quijano et al., 2001; Yamakura et al., 1998). Mn- 
SOD inactivation involves peroxynitrite-mediated nitration of tyrosine-34 (Yamakura et al., 
1998) with the subsequent formation of a nitrating species, which cannot only self-nitrate 
(Tyr-34) but one that also nitrates remote tyrosine residues (Quijano et al., 2001). Mn-SOD 
inactivation may in turn promote a vicious cycle favouring further peroxynitrite formation 
and lead to further mitochondrial oxidative damage. Mitochondria possess the ability to 
detoxify peroxynitrite by one or more scavenging systems with one of these systems being 
the reaction with glutathione (Castro et al., 1998). Hsp27 can increase intracellular levels of 
glutathione (Mehlen et al., 1996) and this may be a possible additional mechanism by which 
Hsp27 exerts its protective effect.
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Following caspase inhibitor treatment, the G93A and G93R SOD1 mutants showed a 
substantial reduction in death. Both caspase-8 and caspase-9 inhibitors reduced the levels of 
death to that observed with the pan-caspase inhibitor zVAD. This indicates that in this 
present model system the majority of death is triggered through caspase dependent 
mechanisms and in particular through caspase-8 and caspase-9. However, on addition of 
caspase inhibitors and Hsps in combination, no further additive protection was observed. 
Therefore, the anti-apoptotic actions of Hsp27 and Hsp70 in inhibiting caspases are clearly 
very important in this present system but one cannot exclude the fact there could be an 
involvement of the chaperone activity of Hsp27 or Hsp70, which might assist in the folding 
of potentially aggregated mutant SOD1 or that the Hsps may play a role in protein 
degradation, and set about degrading the toxic SOD1 mutant. Shimura et al. (2004) have 
shown that Hsp27 may function in protein degradation in an ubiquitin-independent manner 
while Parcellier et al. (2003a) have shown that under conditions of stress Hsp27 favours 
ubiquitinated and phosphorylated I-K B a  (main inhibitor of NF-kB) proteosomal 
degradation. The latter finding suggests a novel function for Hsp27 that provides another 
explanation for its antiapoptotic activities through the increase in NF-kB activity.
Addition of ApoE provided some interesting results. Addition of ApoE2 or ApoE3 
appeared to provide a protective effect in all SOD1 cells on exposure to a range of stresses 
whereas ApoE4 increased the levels of death in these cells. ApoE2 provided the greatest 
level of protection by reducing death by approximately 18% and 33% for G93A and G93R 
respectively compared to control (p<0.0005) on exposure to conditions of serum withdrawal. 
The protective effect of ApoE2 and deleterious effect of ApoE4 was reflected across all the 
cells under a wide-range of stresses tested.
Among patients with MND (motor neuron disease), 2 (Al-Chalabi et al., 1996; Smith 
et al., 1996) of 4 published studies exhibit trends toward APOE4 alleles being associated 
with faster progression of disease. The only study examining APOE2 and MND progression 
demonstrates that patients with MND and APOE2 alleles live significantly longer than those 
individuals without this allele (Moulard et al., 1996). Each of these studies is open to 
methodological criticisms however their results are consistent with one another and with the 
data on disease in the CNS (central nervous system): APOE4 is associated with a worse
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prognosis and APOE2 with a better prognosis for a given neurological disease. As yet, 
associations between APOE allele type and disease progression have not been explored in 
the ALS/parkinsonism/dementia complex of Guam, in IBM (inclusion body myositis), in 
amyloidic neuropathy, or in any other PNS (peripheral nervous system) disease.
APOE could influence the progression of these very different CNS and PNS diseases 
through a variety of different mechanisms. One wide-ranging hypothesis is that certain 
APOE alleles confer an altered resistance to disease. Evidence from in vitro studies suggests 
different isoforms of ApoE confer different susceptibilities to oxidative stress (Miyata et al., 
1996). These differences may be mediated to some extent by the neuron's ability to use 
growth factors; indeed, in vitro ApoE is known to bind and potentiate the survival- 
promoting activity of ciliary neurotrophic factor (Gutman et al., 1997). In addition, the size 
and shape of axons from APOE-knockout mice (Fullerton et al., 1998) are morphologically 
similar to axons from rats treated with nerve growth factor antiserums (Gold et al., 1991). 
An alternative broad hypothesis is that certain ApoE isoforms confer an enhanced 
regenerative response to disease. For instance, in a variety of cell lines, ApoE3 is associated 
with increased neurite outgrowth, while ApoE4 is associated with decreased neurite 
outgrowth (Nathan et al., 1994; Bellosta et al., 1995; Holtzman et al., 1995). This altered 
regeneration may yet again be caused by an allele-specific use of growth factors. On the 
other hand, the response may be dependent on isoform-specific alterations in neuronal 
adhesion (Huang et al., 1995) cytoskeletal stability (Gutman et al., 1997), or the use of lipids 
for the expanding cell membrane.
Alternatively, it is thought that the protective effect of ApoE2 over ApoE4 may be 
down to the ability of ApoE2 to bind HNE (4-hydroxynonenal) to a greater extent than 
ApoE4 and as such protect against apoptosis induced by HNE (Pedersen et al., 2000). The 
differential ability of the ApoE isoforms to protect against FINE can be put down to the 
number of cysteine residues possessed by each form with ApoE2 possessing two, ApoE3 
having one and ApoE4 none (Pederson et al., 2000). A higher concentration of free HNE in 
the cerebrospinal fluid of ALS patients relative to controls (Smith et al., 1998) and an 
increase protein modification by HNE in ALS spinal cord relative to control spinal cord 
(Pedersen et al., 1998) have been reported. The latter findings are of particular interest as
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one of the proteins modified by HNE in ALS spinal cord appears to be EAAT2, and HNE 
has been shown to impair glutamate transport in NSC-19 cells (Pedersen et al., 1999). It has 
also been reported than HNE impairs the function of ion-motive ATPases, glucose and 
glutamate transporters in primary neuronal systems (Keller et al., 1997; Mark et al., 1997) 
and glutamate transporters in astrocytes (Blanc et al., 1998), indicating that HNE promotes 
excitotoxic damage. In addition it is thought the Par-4 may be a mediator of HNE-induced 
motor neuron death initiated by oxyradical attack on membrane lipids (Pedersen et al., 
2000). All this evidence and the results of this study suggest that APOE alleles influence the 
progression of ALS; APOE4 confers an increased risk of disease and a worse prognosis, 
while the presence of APOE2 confers a decreased risk of disease and a better prognosis. 
Further studies are required to solidify this relationship.
Although the cellular model presented here is not the ideal cellular model to study 
ALS - it remains a very useful mammalian neuronal system where an interesting effect of 
wt-SODl and the FALS-associated mutants has been observed (Chapter 3). This system has 
an obvious advantage over the reported use of various non-neuronal or non-mammalian 
systems. It has allowed the testing for the first time of the protective effect of various Hsps 
both singly and in combination, against the mutant SOD 1-induced cell death in a 
mammalian neuronal system. Most importantly, this system helped to conclude that Hsp27, 
Hsp70 and to a greater extent the Hsp27 and Hsp70 combination is a potent neuroprotective 
agent against mutant SOD 1-associated toxicity; this is the first report to show alleviation of 
mutant SOD 1-neurotoxicity in an in vitro mammalian neuronal system by Hsp27 and by the 
combination of Hsp27 and Hsp70 (Patel et al., 2005).
The distinct death stimuli used at various time intervals (serum withdrawal, serum 
withdrawal plus 1 pM retinoic acid, IFN-y, staurosporine and camptothecin) were selected on 
the basis of having been previously characterised in ND7 cells (as explained in Chapter 3) 
and being representative stresses inducing both apoptotic and necrotic cell death in neuronal 
cells, which are modes of neuronal death implicated in FALS pathology (see review by 
Guegan et al., 2003). In addition, there is accumulating evidence that protein misfolding as 
well as proteasome system activation take place during apoptosis (Soldatenkov et al., 1998). 
Therefore, the apoptotic stimuli used here represent some of the conditions that are
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encountered in FALS, such as protein misfolding and proteasome system activation, which 
are known to occur during the course of apoptosis (Guegan et al., 2003). In addition, the 
highly efficient gene delivery of Hsps by the HSV viral vector system assists in the study of 
the protective effects of Hsps and also enables the biochemical dissection of the mechanism 
of protection in this system.
The cell death assessment by trypan blue exclusion assay was more time consuming 
than the other death assessment as a result of the larger sample numbers that had to be 
counted in a haemocytometer. This means that the samples had to be left on ice for a 
relatively longer time period and, therefore, it is possible that as apoptotic cells lose their 
membrane integrity relatively faster they uptake the trypan blue dye, resulting in a high 
number of dead or dying blue cells in the relevant experiments. On the other hand TUNEL 
was performed on cells adhered to glass slides and hence after treatment the media was 
aspired, the cells washed, fixed and permeabilized prior to TUNEL. As a result the cells that 
had died and as a result detached from the plate at the end of the treatment were not counted. 
However, by comparing the percentage of TUNEL positive cells per cell line a fairly 
accurate estimate of the relative levels of apoptotic cell death in these different cell lines can 
be obtained. It is usually suggested in the literature that different methods of cell death 
assessment as well as assessment of cell death at multiple time points should be applied 
before one concludes on certain research questions.
From the present study it becomes apparent that no single method of cell death 
quantification is precise and totally informative and that any conclusions drawn should be 
done so very carefully after reconfirming a trend in cell death susceptibility by an alternative 
method. Trypan blue is thought to have the disadvantage of colour intensity variation 
(amount of dye uptake varies depending on cell state) which can result in an under or over­
estimation in the number of dead cells. However this can be overcome by setting the same 
thresholds for all experiments, in which cell counts are taken, in a blind fashion by the same 
researcher. On the whole, both trypan blue and TUNEL assay have been used extensively 
and remain valid and reliable assays for cell viability and apoptotic cell death assessment 
respectively. By comparing the cell death of a cell line to the appropriate control cell line, an
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effect due to treatment can be assessed by comparing the relative differences, as is the case 
in the present study.
Finally, some other points that need to be taken into account include the fact that the 
SOD1 cDNA is human and the disease mutations are found in humans with autosomal 
dominant FALS, whereas the ND7 cell line is a rat/mouse hybrid, with the Hsp27 being 
from Chinese hamster and Hsp70 being the human inducible Hsp70. However, Hsps are 
highly conserved proteins and trans-species experiments are performed regularly and often 
successfully. It is difficult to know whether or not the species origin of the cDNAs, used in 
this present study, is of significance but one needs to take them into consideration. However 
in this study the Hsps were effective in reducing the mutant associated toxicity and were 
protective for the mutants under all stresses tested.
Further support for the findings presented in this chapter could be obtained from 
experiments on the aggregation properties of wt and mutant SOD1. Experiments could be 
conducted to ascertain whether aggregates of wt-SODl or its mutants form within the cells 
and whether formation of aggregates corresponds to a decrease in cell survival; and in 
addition, whether addition of Hsp’s reduces the mean number of aggregates present in the 
cell and thereby increase survival. These experiments would provide a better understanding 
of the protection conferred by the Hsp’s and may provide an explanation as to how single 
infections of Hsp increase death in wt-SODl cells and the dual combination reduce it.
It is very likely that multiple pathways are involved in the protection conferred by 
Hsp27 and/or Hsp70, and it will be necessary to investigate the contribution of these other 
pathways to the effects reported here. It may be useful to perform caspase activation assays, 
in the model presented here, to investigate if caspase processing varies in response to 
different stresses in the presence or absence of Hsp27 and/or Hsp70 over expression, and to 
extend these investigations by transfecting dominant negative caspase constructs into the 
various SOD1 cell lines. Alternatively, one may use naturally occurring caspase inhibitor 
genes such as caspase-9S or FLIP. A similar approach could be utilized to investigate other 
signal transduction pathways involved in cell survival for instance those involving Akt and 
p42/p44 MAP kinase.
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In summary, this work has demonstrated for the first time that mammalian neuronal 
cells over-expressing FALS-associated SOD1 disease mutants G93A and G93R are 
protected from various death inducing stimuli by exogenous Hsp27 and Hsp70, and 
moreover, to a greater extent, by a combination of both. Wt-SODl over-expressing cells 
were not protected by delivery of the single exogenous Hsps but death was reduced back 
down toward control GFP levels by dual infection of Hsp27 and Hsp70. Both Hsp27 and 
Hsp70 seem to exert their protective effects by interfering with the caspase-cascade. Further 
studies are required to clarify the mechanisms of neuroprotection offered by Hsps, as there 
appears to be growing evidence of the therapeutic benefit of Hsps in many 
neurodegenerative diseases. The manipulation of endogenous cellular defence mechanisms 
such as the heat shock response, by means of nutritional antioxidants or pharmacological 
compounds, may provide an approach of therapeutic intervention in neurodegeneration. The 
following chapter further investigates the protective properties of wt-SODl and those of 
Hsp27, Hsp70 and the combination of Hsp27 and Hsp70 in relation to mutant-SODl toxicity 
in a primary cell culture model.
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C h a p t e r  5
Further investigation of the protective effects of Heat Shock Proteins 
against mutant-SODl toxicity in primary cultures 
of DRGs from Tg-Hsp27 and Tg-Hsp70 mice
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5.1 Introduction
The previous chapter dealt with the characterisation of the protective effect of heat 
shock proteins in an in vitro model of mutant-SODl-induced toxicity along with an attempt 
to identify a possible mechanism by which Hsp27 or Hsp70 conferred protection. This 
chapter provides further support to the protective effects of Hsp27, Hsp70 and the Hsp27 
and Hsp70 combination against mutant-SODl toxicity in two further primary cell culture 
model systems.
The data presented in the previous chapters suggest that, at least in the cellular model 
system described in this thesis, apoptosis appears to play a primary role in the cellular loss 
triggered by the wide-range of FALS-relevant stimuli investigated. It was therefore 
hypothesised that Hsp27 or Hsp70 may confer protection through their anti-apoptotic 
properties (reviewed in Chapter 1 and Chapter 4) and hence, through use of caspase 
inhibitors the anti-apoptotic properties were investigated.
Currently chaperones are being considered for the potential treatment of diseases 
involving protein aggregation and misfolding, from neurodegenerative diseases (Bonini, 2002) 
to cancer (Scott and Frydman, 2003). The cell has a complex system for maintaining correct 
protein folding, which begins with the facilitation of folding of nascent proteins, monitoring for 
the presence of unfolded proteins in various intracellular compartments, and targeting of 
misfolded or abnormal proteins for degradation. In addition, many facets of protein-protein 
interactions are also specifically regulated by chaperones. The accumulation of unfolded proteins 
in the endoplasmic reticulum lumen can elicit the unfolded protein response, which is implicated 
in the shutdown of protein synthesis, a hallmark of the response to a range of severe cellular 
stresses (Paschen, 2003). Therefore regulation of the state of protein folding and protein association 
is a central aspect of normal cellular homeostasis.
Recent work has highlighted the ability of Hsp70 to suppress multiple types of cell death such 
as necrotic cell death, classical apoptosis, and other programmed cell death pathways that are 
independent of caspases and not blocked by Bcl-2 (Beere et al., 2000; Jaattela et al., 1998; 
Nylandsted et al, 2000; Ravagnan et al., 2001; Saleh et al., 2000). Since both apoptotic and
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necrotic cell death are involved in FALS, the ability of Hsp70 to reduce both types of cell death 
makes it an appealing candidate for protection against this neurodegenerative disorder. 
Understanding the aspects of Hsp70 function that are necessary for protection will identify 
pathological processes that contribute to cell death and permit future work to target identified 
pathological mechanisms for neuroprotection.
Unfolded or misfolded proteins have exposed hydrophobic segments that make them 
more susceptible to aggregation. Protein aggregates are believed to be toxic to the cell 
(Taylor et al., 2002), therefore to avoid aggregation, abnormal proteins are either kept soluble by 
molecular chaperones or quickly degraded by the ubiquitin/proteasome system (Hershko and 
Ciechanover, 1998). Under pathological conditions, the level of abnormal proteins may 
overcome the ability of the cell to sustain them in a soluble form or degrade them, thereby 
allowing aggregation to proceed (Cohen, 1999; Zoghbi and Orr, 2000). Protein aggregates 
can inhibit function of the proteosome, thereby further limiting the cell's ability to dispose of 
the protein aggregates as well as interfering with the normal processing of certain short-lived 
proteins (Bence et al., 2001). Protein aggregates have been detected in many chronic 
neurodegenerative diseases (Kakizuka, 1998; Taylor et al., 2002).
In motoneurons, mitochondrial alterations such as membrane depolarization, 
decreased activity of respiratory complexes and cytochrome c release are prime 
candidates for involvement in the several aspects of ALS, because of their occurrence at the 
asymptomatic stage in FALS-SOD1 transgenic mice with relatively slow disease 
progression (Bendotti et al., 2001; Jung et al., 2002) and in cultured cells expressing the 
mutant protein (Carri et al., 1997; Beal et al., 2000). Interestingly, mitochondrial 
abnormalities have additionally been seen in motor axon terminals of muscle biopsies 
from patients with early-diagnosed sporadic ALS (Beal et al., 2000; Siklos et al., 1996). 
Mitochondrial alterations may play a role in the generation of a condition of oxidative 
stress, and markers of oxidative damage such as increased ROS flux and oxidatively 
modified proteins, have been found in cultured neuronal cells, and in both transgenic mice 
and patients with ALS (Carri et al., 1997; Ferri et al., 2000; Ciriolo et al., 2000; Liu et al.,
1999).
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Impairments in the respiratory chain, resulting in bioenergetic failure in the 
motoneurons (Jung et al., 2002; Mattiazzi et al., 2002) and in alterations in the 
mitochondrial permeability transition pore (MPTP), bringing about leakage of cytochrome 
c and apoptosis-inducing factor (AIF) (Friedlander, 2003), were suggested to contribute to 
mitochondria-dependent motoneuron death. This results in the activation of the caspase- 
cascade leading to programmed cell death, but data supporting an apoptotic form of death of 
motoneurons in models and patients with ALS are contradictory (Friedlander, 2003; 
Mighelli et al., 1999). Converging data indicate that the death of cultured cells expressing 
FALS SOD1 typically proceeds along the mitochondrial apoptotic pathway, through activation 
of executioner caspases (i.e. caspase-3) (Ghadge et al., 1997; Guegan et al., 2003; Li et al., 
2000). However, although components of the programmed cell-death machinery are 
recruited and interception of the caspase pathway appears to be beneficial to FALS SOD1- 
transgenic mice (Li et al., 2000; Guegan et al., 2003; Inoue et al., 2003), several groups 
reported that dying neurons in FALS mice exhibit a non-apoptotic morphology (Bendotti et 
al., 2001; Guegan et al., 2003).
The tendency of misfolded, metal-free SOD1 mutants to form insoluble aggregates in 
motoneurons is also regarded as an early event in the pathogenesis of ALS (Johnston et al.,
2000). Protein aggregation (Lewy-body-like inclusions containing SOD1 and ubiquitin, and 
an altered neurofilament pattern) has been observed in cultured cells expressing FALS 
SOD1 (Julien. 2001) and SOD1 is a key component of the neuronal hyaline inclusion (NHI) 
found in post-mortem tissues of patients with SOD 1-associated FALS (Kato et al., 2000). A 
pathological hallmark that is common to all forms of ALS as well as to animal models is 
cytoskeletal disorganization in the motoneurons, which is frequently associated with the 
accumulation of phosphorylated neurofilaments (pNF). Cytoskeletal abnormalities may 
come about through the alteration of protein phosphorylation by kinases such as p38 MAPK 
(mitogen activated protein kinase) which is activated in the motoneurons of asymptomatic 
SOD1-G93A mice (Kato et al., 2000) and in skein-like inclusions of patients with sporadic 
ALS (Bendotti et al., 2004). Calcineurin (PP2B), a protein phosphatase, is involved in the 
modulation of tau and is oxidatively inactivated by FALS SOD1 in experimental systems, 
for instance human cells expressing the mutant SOD1 H46R or G93A as well as in G93A-
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S0D1 mice (Ferri et al., 2000). The accumulation of pNF might perturb the axonal transport 
of substrates that are required for neuronal viability.
In addition, protein aggregates might also impair the activity of proteasomes, as 
suggested by studies conducted in neuronal cell lines (Allen et al., 2003; Urushitani et al., 
2002). In turn, proteasome inhibition could result in further accumulation of aberrant 
aggregates, which sequester other proteins and lead to the formation of cytoplasmic 
ubiquitinated inclusion bodies, similar to those found in the SOD1 mutant mice at 
advanced stages of the disease and in post-mortem tissue from ALS patients (Kato et al., 
2000).
It was therefore decided that the present study should be extended to investigate the 
effects of Hsp27 and Hsp70 in primary cell cultures of DRGs (dorsal root ganglia). The 
availability of SOD 1 viruses (wt-SODl, G93R-mutant SOD1 and GFP-control) named 1764 
27-, constructed in our lab by Dr Yolanda Collaco-Moraes enabled infection and 
experimentation in primary cultures of DRGs. This virus lacks the ICP27 gene, is deleted for 
the endogenous LAT P2 regions thereby preventing recombination with the inserted LAT 
P2-containing expression cassette pR20.5 outside the LAT region. The pR20.5 cassette 
consists of a central LAT P2 element flanked by two heterologous promoters (CMV-IE and 
RSV) arranged in a back-to-back orientation, allowing simultaneous expression of either wt- 
SODl or G93R-SOD1 mutant (under the Rous Sarcoma Virus - RSV- promoter) and GFP 
(under CMV-IE promoter) and enabling long term expression of both transgenes. This 
cassette was inserted into a plasmid to enable insertional inactivation of the gene encoding 
virion host shut off protein (vhs), which has been shown to play a role in pathogenesis and 
latency (Strelow and Leib, 1995) and further disabled the HSV virus. Since ICP27 was 
deleted, this virus type was grown on an ICP27 complementing cell line (BHK130/2), which 
over-express ICP27 and thereby complement the defect and allow growth in culture.
The availability of a highly efficient HSV-1-based vector system for delivery of both 
the Hsp gene and SOD1 or G93R-SOD1-mutant to neuronal cells, in addition to Hsp27 and 
Hsp70 transgenic mice proved very useful in the present study. As shown in this chapter, it 
allowed us to further investigate and provide further supporting evidence for the protective
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effect of Hsp27, Hsp70 and to a greater extent the Hsp27 and Hsp70 combination against 
mutant-SODl induced toxicity in a primary culture cell model on subjection to a wide-range 
of FALS relevant stresses.
The aims of this chapter are listed below:
(a) To investigate further the protection conferred by Hsp27, Hsp70 and the combination of 
Hsp27 and Hsp70 against mutant SOD1 induced toxicity in a primary culture model system
(b) To evaluate the potential of the anti-apoptotic properties of Hsp27, Hsp70 and the Hsp27 
and Hsp70 combination in this primary model system and suggest alternative mechanisms of 
action that should be tested.
5.2 Culture of primary neurons
Briefly, DRG (dorsal root ganglia) sensory neuron cultures of the peripheral nervous 
system were prepared from newborn Harlan Sprague-Dawley rat pups at postnatal day and 
Hsp27 and Hsp70 transgenic mice (C57 black x) 8-12 weeks old. Sensory neurons were 
chosen for this study as they are an easy to culture primary neuronal system and it is 
relatively easy to obtain pure cultures of sensory neurons compared to motor neurons, for 
which pure cultures are almost impossible to obtain. The animals were sacrificed by cervical 
dislocation followed by decapitation, ensuring to remove the head above the base of the 
spine. Using fine scissors cuts were made through the base of the spine and from the start of 
the neck down on each side of the animal in order to isolate the spinal cord.
Excess tissue was trimmed away from the spine, with care being taken so as not to 
cut into the spine. The spine was then placed in a fresh dish with the dorsal side (back) 
facing upwards. The spine was cut along the length to remove the top half and reveal the 
DRG and spinal cord. The spinal cord was discarded and No.5 forceps used to pinch out the 
DRGs, which were collected into 900pl HBSS in 35mm Petri dish. Dorsal root ganglia have 
a sheath that needs to be removed as it hinders dissociation and also introduces excess non­
neuronal cells such as glia and fibroblasts into the culture. The dorsal root ganglia (DRG)
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cultures of both mice and rats were dissociated in a lOOpl mix of 0.3% collegenase/0.1% 
trypsin for 25 min. Following enzyme treatment 1ml of growth media was added to the dish 
to stop the enzyme reaction and the ganglia dissociated through either a silanised flame 
polished pipette or a Gilson blue tip, approximately 10 times with care being taken not to 
introduce air bubbles as this leads to shearing of the cells.
The dissociated ganglia were then transferred to a 15ml centrifuge tube and spun at 
900rpm for 5min at room temperature. To reduce the number of non-neuronals, the cells 
were spun through a column of 6% metrizamide (Sigma M3383) in culture media following 
enzyme dissociation. This high-density solution removes the non-neuronals, which are too 
small to pass through the solution. After centrifugation at 900rpm for 5 minutes, the 
metrizamide/non-neuronal mixture was tipped off and discarded and the pellet carefully 
resuspended in appropriate growth media. The cells were plated in 50|nl droplets on laminin- 
coated coverslips. Neurons were left to attach overnight in the incubator at 37°C/5% CO2 
and then flooded with appropriate growth media next day. For more detailed methods see 
section 2.7.2.
5.3 Viral Infections of Primary Cells
5.3.1 Complementing Cell Lines of Viruses
The stocks of virus used in this study were grown and prepared as described in 
Chapter 2, section 2.4. The viruses were grown on B 130/2 BHK cells to complement the 
deletions in the disabled viruses and hence enable lytic viral growth (Howard et al., 1998; 
Thomas et al., 1999). This allows the production of large quantities of the virus, which can 
be subsequently purified and concentrated into high titre stocks. Each preparation of high 
titre stock was confirmed to express the transgene, through western analysis of non­
complementing ND7 cells infected with the stock.
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5.3.2 Microscopy of Virally Infected DRGs and Western Blot Analysis
DRGs were infected as described in Chapter 2, section 2.4.2 and then left for 24h to 
allow overexpression of the transgene prior to treatment. However, GFP was visible earlier 
than 12h post-infection, and its expression continued to be seen until the end of all 
treatments. Figure 5.1a shows some DRGs infected with GFP virus. The HSV-vector 
17+pR19 has previously been shown to successfully infect ND7 cells and produce large 
amounts of Hsps (Wagstaff et al., 1999). Figure 5.1b shows the high levels of expression of 
the transgene after 24h in DRG cells infected with either a control GFP, Hsp27 or Hsp70 
expressing virus. The GFP virus enables a relatively quick assessment of the percentage of 
cells expressing GFP and is used as a method of assessing efficiency of infection of the Hsp 
viruses, as the Hsp expressing viruses do not contain a visual marker; the assumption made 
is cells infected with the same amount of virus and at the same m.o.i, will result in the same 
transduction efficiency.
Cells were infected at an m.o.i (multiplicity of infection) of ten in figure 5.1a and
5.1b.
(a)
Figure 5.1a Representative image of DRGs infected with GFP virus
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Figure 5.1b Heat shock protein over expression in rat DRGs expressing wild type or mutant 
SOD1 at 24h following infection with recombinant HSV-based vectors expressing GFP, Hsp27 
or Hsp70.
Control DRGs, GFP control, wt and mutant G93R-SOD1 expressing cells were infected at an m.o.i 
of 10 with recombinant viruses over-expressing either GFP, Hsp27 or Hsp70; after which western 
blotting was carried out with antibodies: anti-[3-actin, anti-hsp27 and anti-hsp70 antibodies. There is 
no significant induction of Hsp expression as a result of infection with the virus itself and this can be 
seen with the GFP control virus, however, there is high expression of the transgenes, all driven by 
the CMV-IE promoter.
5.3.3 SOD HSV Virus
Having demonstrated using cell lines, that overexpression of wild type SOD1 was 
able to provide a protective effect against a variety of damaging stimuli, a system was 
developed for manipulating SOD1 expression efficiently both in cultured cells and 
ultimately in vivo. The human SOD1 gene was inserted into a nonvirulent strain (1764) of 
HSV. This virus was disabled through deletion of ICP27 preventing lytic replication and 
making the virus avirulent in vivo but requiring complementation for growth in culture. 
Further disablement was achieved by deleting nonessential HSV-1 genes ICP34.5 and 
inserting an inactivating insertion in VMW65 thereby abolishing its ability to transactivate 
immediate early genes but allowing encoding of its essential structural protein.
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The S0D1 gene was inserted into a shuttle plasmid pR20.5 also containing a GFP 
reporter gene, expression of which is driven by the CMV promoter allowing the monitoring 
of the distribution of virus. The expression of SOD1 gene is driven by the RSV promoter 
with the latent associated transcript LAT P2 region (from HSV-1) between the two 
promoters to gain long-term expression of both transgenes. The vector contains vhs flanking 
regions allowing homologous recombination into the virion host shutoff protein gene (vhs) 
in the disabled HSV-1 viral construct thereby further disabling the virus and ensuring that no 
transfer of transgenes occurs between a disabled viral vector and any wild type virus which 
it may encounter.
Following infection of cultured ND7 cells with the viruses, recombinant SOD1 
transgene insertion was confirmed by Southern blot analysis and the expression of protein 
was confirmed by Western blotting (Fig. 5.2). The protein product corresponding to human 
SOD1 was seen to be present in the two SOD1 infected cells and the white blood cell sample 
extract.
Figure 5.2 Western blot confirmation of SOD1 protein in ND7 cells. Levels of SOD1 
expression in the GFP-control infected ND7 cells (lane 2), wt-SODl infected ND7 cells (lane 
3), G93R-mutant SOD1 infected ND7 cells (lane 4), and human white blood cells (lane 5) 
compared to the control ND7 cells (lane 1).
5.3.4 Neuroprotective effect of viral delivery of SOD1
Total cell death and number of apoptotic cells after were assessed by trypan blue 
exclusion and TUNEL assay respectively, at time 24h following exposure to stress. DRG
Ctrl GFP Wt-SODl G93R Human
WBC
Actin
SOD1
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neuronal cells were either mock infected (no virus) or infected with HSV-1 vector GFP virus 
(control) or expressing wt-SODl or G93R mutant virus.
5.4 Responses of SOD Virus infected Rat DRG Cells to Death-inducing 
Stimuli
5.4.1 NGF withdrawal
Infection of rat DRGs with G93R mutant SOD1 virus brought about an approximately 60% 
increase in death, compared to GFP infected control (p<0.0005); (Figure 5.3a). Wt-SODl 
virus infected DRGs exhibited a protective effect with total cell death reduced by 
approximately 59% compared to GFP infected control (p<0.0005).
TUNEL analysis provided similar results with infection of DRGs with G93R mutant SOD1 
virus bringing an approximately 65% increase in death, compared to GFP infected control 
(p<0.0005); (Figure 5.3b). Wt-SODl virus infected DRGs exhibited a protective effect with 
the number of TUNEL positive cells reduced by approximately 62% compared to GFP 
infected control (p<0.0005).
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Figure 5.3 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected rat DRGs
a. Rat DRG cell death following 24h of NGF withdrawal after infection with HSV vectors 
expressing wt-SODl or G93R mutant. The proportion of cell death was assessed by trypan 
blue exclusion assay, after 24h of treatment of NGF withdrawal of rat DRG cells infected 
with wt or G93R-mutant S0D1 or GFP control. Cells were infected with SOD viruses 16h 
prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per sample (n), 
n=4. Significant differences were calculated using Bonferroni Multiple Comparison’s t test 
after one-way ANOVA (/?<0.0005). *, **, *** indicates statistically significant difference 
between means, when comparing with GFP virus infected control.
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Figure 5.3 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected ra t DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of NGF withdrawal for 24h. Bars represent mean1 S.D. calculated for 
triplicate counts per sample (n=4) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.4.2 IFN-y administration
G93R mutant infected DRGs exhibited an approximately 63% increase in death compared to 
GFP infected control (p<0.0005); (Figure 5.4a). Wt-SODl infected DRGs again exhibited a 
protective effect with a reduction in death by approximately 73% compared to GFP infected 
control (p<0.0005).
TUNEL analysis revealed the G93R mutant infected DRGs exhibited an approximately 63% 
increase in the number of TUNEL positive cells compared to GFP infected control 
(p<0.0005); (Figure 5.4b). Wt-SODl infected DRGs again exhibited a protective effect with 
a reduction in the number of TUNEL positive cells by approximately 75% compared to GFP 
infected control (p<0.0005).
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Figure 5.4 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected rat DRGs
a. Rat DRG cell death following 24h of treatment with 50ng/ml IFN-y after infection with 
HSV vectors expressing wt-SODl or G93R mutant. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of treatment of 50ng/ml IFN-y of rat DRG 
cells infected with wt or G93R-mutant S0D1 or GFP control. Cells were infected with SOD 
viruses 16h prior to stress. Bars represent mean -^S.D. calculated for triplicate counts per 
sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
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Figure 5.4 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected rat DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of 50ng/ml IFN-y for 24h. Bars represent mean ± S.D. calculated for 
triplicate counts per sample (n=4) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.4.3 Staurosporine treatment
G93R mutant infected DRGs exposed to lpM staurosporine exhibited an approximately 
60% increase in total cell death compared to GFP infected control(p<0.0005); (Figure 5.5a). 
Wt-SODl infected DRGs provided a protective effect against the stress with a reduction on 
death of approximately 58% compared to GFP infected control (p<0.0005).
TUNEL analysis provided similar results with G93R mutant infected DRGs exposed to lpM 
staurosporine exhibiting an approximately 63% increase in the number of TUNEL positive 
cells compared to GFP infected control(p<0.0005); (Figure 5.5b). Wt-SODl infected DRGs 
provided a protective effect against the stress with a reduction in the number of TUNEL 
positive cells by approximately 60% compared to GFP infected control (p<0.0005).
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Figure 5.5 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected rat DRGs
a. Rat DRG cell death following 24h of lpM staurosporine administration after infection 
with HSV vectors expressing wt-SODl or G93R mutant. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of treatment of lpM staurosporine of rat 
DRG cells infected with wt or G93R-mutant SOD1 or GFP control. Cells were infected with 
SOD viruses 16h prior to stress. Bars represent mean ^ .D . calculated for triplicate counts 
per sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
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Figure 5.5 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected rat DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of lpM staurosporine for 24h. Bars represent mean 1 S.D. calculated 
for triplicate counts per sample (n=4) and significant differences were calculated as above 
with /?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.5 Responses of SOD Virus infected wt-mice DRG Cells to Death- 
inducing Stimuli
5.5.1 NGF withdrawal
Wt-mice DRGs infected with G93R mutant SOD virus exhibited enhanced cell death as was 
observed in previous experiments. G93R mutant cells exhibited a 63% increase in cell death 
compared to control GFP (p<0.0005); (Figure 5.6a). The wt-SODl infected DRGs when 
exposed to stress of NGF withdrawal were protected. Wt-SODl infected DRGs showed a 
56% decrease in cell death compared to GFP control (p<0.0005).
TUNEL analysis revealed wt-mice DRGs infected with G93R mutant SOD virus exhibited 
enhanced cell death similar to that observed with trypan blue analysis. G93R mutant cells 
exhibited a 68% increase in the number of TUNEL positive cells compared to control GFP 
(p<0.0005); (Figure 5.6b). The wt-SODl infected DRGs when exposed to stress of NGF 
withdrawal were protected. Wt-SODl infected DRGs showed a 61% decrease in the number 
of TUNEL positive cells compared to GFP control (p<0.0005).
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Figure 5.6 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of NGF withdrawal after infection with HSV 
vectors expressing wt-SODl or G93R mutant. The proportion of cell death was assessed by 
trypan blue exclusion assay, after 24h of treatment of NGF withdrawal of wt-mice DRG 
cells infected with wt or G93R-mutant S0D1 or GFP control. Cells were infected with SOD 
viruses 16h prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per 
sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
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Figure 5.6 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of NGF withdrawal for 24h. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=4) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.5.2 IFN-y administration
Wt-mice DRGs infected with mutant G93R virus and then exposed to stress of IFN- 
y exhibited increased cell death with death rising by approximately 57% compared to GFP 
infected control (p<0.0005). Wt-SODl infected DRGs were protected from the stress with 
cells exhibiting a 63% reduction in cell death compared to GFP infected control (p<0.0005); 
(Figure 5.7a).
TUNEL analysis revealed wt-mice DRGs infected with mutant G93R virus and then 
exposed to stress of IFN-y exhibited an increase in the number of TUNEL positive cells with 
the number rising by approximately 62% compared to GFP infected control (p<0.0005). Wt- 
SODl infected DRGs were protected from the stress with cells exhibiting a 68% reduction 
in the number of TUNEL positive cells compared to GFP infected control (p<0.0005); 
(Figure 5.7b).
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Figure 5.7 Effect of IFN-y on cell death in control, wild type or mutant S0D1 virus 
infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of treatment with 50ng/ml IFN-y after infection 
with HSV vectors expressing wt-SODl or G93R mutant. The proportion of cell death was 
assessed by trypan blue exclusion assay, after 24h of treatment of 50ng/ml IFN-y of wt-mice 
DRG cells infected with wt or G93R-mutant S0D1 or GFP control. Cells were infected with 
SOD viruses 16h prior to stress. Bars represent mean 1 S.D calculated for triplicate counts 
per sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
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Figure 5.7 Effect of IFN-y on ceil death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of 50ng/ml IFN-y for 24h. Bars represent mean 1 S.D. calculated for 
triplicate counts per sample (n=4) and significant differences were calculated as above with 
/?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.5.3 Staurosporine treatment
G93R mutant virus infected mice DRGs exposed to staurosporine showed an 81% increase 
in total cell death compared to GFP infected control (p<0.0005). Once again mice DRGs 
infected with wt-SODl virus were protected with death being reduced by approximately 
56% compared to GFP control (p<0.0005); (Figure 5.8a).
These results were confirmed by TUNEL analysis with the G93R mutant virus infected wt- 
mice DRGs exposed to staurosporine exhibiting a 88% increase in the number of TUNEL 
positive cells compared to GFP infected control (p<0.0005). Once again wt-mice DRGs 
infected with wt-SOD 1 virus were protected with the number of TUNEL positive cells being 
reduced by approximately 61% compared to GFP control (p<0.0005); (Figure 5.8b).
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Figure 5.8 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of lpM staurosporine administration after 
infection with HSV vectors expressing wt-SODl or G93R mutant. The proportion of cell 
death was assessed by trypan blue exclusion assay, after 24h of treatment of lpM 
staurosporine of wt-mice DRG cells infected with wt or G93R-mutant S0D1 or GFP 
control. Cells were infected with SOD viruses 16h prior to stress. Bars represent mean ^ .D . 
calculated for triplicate counts per sample (n), n=4. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with GFP 
virus infected control.
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Figure 5.8 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were infected with viruses to over-express wt-SODl, G93R-mutant or GFP 
16h prior to treatment of lpM staurosporine for 24h. Bars represent mean 1 S.D. calculated 
for triplicate counts per sample (n=4) and significant differences were calculated as above 
with /?<0.0005. *, **, *** indicates statistically significant difference between means, when 
comparing with GFP virus infected control.
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5.6 Responses of the SOD virus infected DRG Neuronal Cells to Stress
following Exogenous Heat Shock Protein Over-expression
Having characterised the effect of wt-SODl, G93R-SOD1 mutant and its GFP 
control in the rat and mouse DRG neuronal cells, the next step was to demonstrate that Hsps 
can be over expressed in these cells through use of viral vectors and then to confirm the 
potential relevance of the results obtained in chapter 4 to the in vivo situation and utilise this 
system to test whether Hsps can confer neuroprotection against the toxic effects of the 
G93R-SOD1 mutant. This section therefore describes the results obtained following 
experimentation into the protective effect of individual Hsps as well as Hsps in combination, 
in this model system. As with chapters 3 and 4, the findings for the various stresses are 
presented below the corresponding stress and cell death was assessed by trypan blue 
exclusion assay and TUNEL analysis.
5.6.1 Infection of SOD virus infected DRGs with Hsp Virus
In order to investigate the protective effects of Hsps further, we infected primary 
cultures of DRGs with wt-SODl, G93R-SOD1 mutant or control GFP virus along with 
either Hsp27, Hsp70 or the combination of Hsp27 and Hsp70. The primary cultures were 
then subjected 16h post infection to NGF withdrawal, IFN-y or staurosporine administration. 
The results paralleled the results of the neuronal cell line experiments with wt-SODl 
protecting the DRGs and reducing death upon exposure to stress and G93R mutant infected 
DRGs exhibiting increased death. On infection of G93R mutant infected DRGs with Hsp27 
or Hsp70 death was reduced with the combination of Hsp27 and Hsp70 being the most 
effective in reducing mutant death. Wt-SODl infected DRGs exhibited increased death on 
infection with Hsp27 or Hsp70 as observed in the neuronal cell lines with the dual infection 
of Hsp27 and Hsp70 reducing death back down toward control levels.
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5.7 Responses of SOD Virus infected Rat DRG Cells to Stress following
Exogenous Heat Shock Protein Over-expression
5.7.1 NGF withdrawal
Rat DRGs infected with the G93R mutant virus showed a reduction in death on infection 
with Hsp virus similar to that observed in the experiments carried out in the neuronal stable 
cell lines. On infection of G93R mutant DRGs with Hsp27 virus a reduction in death of 
approximately 52% was observed, compared to GFP infected control (p<0.0005); (Figure 
5.9a). Hsp70 virus was slightly more effective in reducing the death associated with the 
G93R mutant, paralleling the findings of the stable cell line experiments, with death being 
reduced by approximately 63% compared to GFP control (p<0.0005). The combination of 
Hsp27 and Hsp70 was the most effective in reducing the mutant death with death being 
reduced by approximately 71% compared to GFP control (p<0.0005). The wt-SODl 
infected cells exhibited a dramatic increase in cell death on infection with Hsp27 or Hsp70 
with death being increased by approximately 102% and 234% respectively compared to 
GFP infected control (p<0.0005). The dual infection of Hsp27 and Hsp70 brought about a 
reduction in death toward control levels, however death was still up by approximately 54% 
compared to control GFP (p<0.0005). Addition of zVAD reduced total cell death across all 
cells with the exception of wt-SODl infected cells, which exhibited an increase in cell death 
of approximately 7% compared to control. G93R mutant death was reduced by 
approximately 70% compared to control (p<0.0005) on addition of zVAD and was almost as 
effective as the dual infection of Hsp27 and Hsp70.
TUNEL analysis confirmed and supported the results obtained by trypan blue analysis. On
infection of G93R mutant DRGs with Hsp27 virus a reduction of approximately 54% in the
number of TUNEL positive cells was observed, compared to GFP infected control
(p<0.0005); (Figure 5.9b). Hsp70 virus was slightly more effective on reducing the number
of TUNEL positive cells of the G93R mutant with number being reduced by approximately
66% compared to GFP control (p<0.0005). The combination of Hsp27 and Hsp70 was the
most effective on the G93R mutant, with the number of TUNEL positive cells being reduced
by approximately 76% compared to GFP control (p<0.0005). The wt-SODl infected cells
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exhibited an increase in the number of TUNEL positive cells, on infection with Hsp27 or 
Hsp70, with the number of TUNEL positive cells increasing by approximately 141% and 
298% respectively compared to GFP infected control (p<0.0005). The dual infection of 
Hsp27 and Hsp70 on the wt-SODl infected DRGs brought about a reduction in the number 
of TUNEL positive cells toward control levels, however the increase in death was still 
approximately 80% greater than control GFP (p<0.0005). Addition of zVAD reduced the 
number of TUNEL positive cells across all cells except those infected with wt-SODl, which 
exhibited an increase in the number of TUNEL positive cells by approximately 22% 
compared to control. G93R mutant cells exhibited an approximately 71% (p<0.0005) 
reduction in the number of TUNEL positive cells compared to control on addition of zVAD; 
this reduction was almost as effective as that observed with the dual Hsp27 and Hsp70 
infection.
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Figure 5.9 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected ra t DRGs
a. Rat DRG cell death following 24h of NGF withdrawal after co-infection with HSV 
vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or Hsp27 and Hsp70. The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of treatment 
of NGF withdrawal of rat DRG cells infected with wt or G93R-mutant SOD1 or GFP 
control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells were co-infected with SOD and Hsp 
viruses 16h prior to stress. Bars represent mean ^ .D . calculated for triplicate counts per 
sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
324
Figure 5.9b
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Figure 5.9 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected rat DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of NGF withdrawal for 
24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /K0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.7.2 IFN-y administration
G93R mutant infected DRGs exhibited an approximately 59% reduction in death on 
infection with Hsp27 compared to GFP infected control (p<0.0005). On infection with 
Hsp70 the G93R mutant infected DRGs exhibited an approximately 71% reduction in death 
compared to GFP infected control (p<0.0005); (Figure 5.10a). The dual infection of Hsp27 
and Hsp70 brought about the greatest protection by reducing the death of the G93R mutant 
infected DRGs by approximately 79% compared to GFP infected control (p<0.0005). 
Infection of the wt-SODl infected cells with Hsp27 or Hsp70 led to an increase in death 
with Hsp70 infection bringing about a larger increase in death than Hsp27. On infection of 
wt-SOD 1 infected DRGs with Hsp27 an increase in cell death of approximately 282% was 
observed and an approximately 312% increase observed on infection with Hsp70, compared 
to GFP control (p<0.0005). The dual infection of wt-SODl infected DRGs with Hsp27 and 
Hsp70 brought about a reduction in death towards control levels but still exhibited an 
approximately 79% increase over GFP infected control (p<0.0005). Total cell death was 
reduced across all cells except those infected with wt-SODl, which exhibited an 
approximately 19% increase in death compared to control. Addition of zVAD reduced the 
G93R mutant death by approximately 78% compared to control (p<0.0005) and was almost 
as effective at reducing the mutant death as the Hsp27 and Hsp70 dual infection.
TUNEL analysis confirmed the trypan blue assay results with G93R mutant infected DRGs 
exhibiting an approximately 61% reduction in the number of TUNEL positive cells on 
infection with Hsp27 compared to GFP infected control (p<0.0005). On infection with 
Hsp70 the G93R mutant infected DRGs exhibited an approximately 71% reduction in the 
number of TUNEL positive cells compared to GFP infected control (p<0.0005); (Figure 
5.10b). The dual infection of Hsp27 and Hsp70 brought about the greatest protection by 
reducing the number of TUNEL positive cells, of the G93R mutant, by approximately 81% 
compared to GFP infected control (p<0.0005). Infection of the wt-SODl infected cells with 
Hsp27 or Hsp70, led to an increase in the number of TUNEL positive cells, with Hsp70 
infection bringing about a larger increase in the number of TUNEL positive cells than 
Hsp27. On infection of wt-SODl infected DRGs with Hsp27 or FIsp70 an increase in the 
number of TUNEL positive cells by approximately 293% and 331% was observed
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respectively compared to GFP control(p<0.0005). The dual infection of wt-SODl infected 
DRGs with Hsp27 and Hsp70 brought about a reduction in the number of TUNEL positive 
cells down towards control levels but death was still approximately 88% higher than GFP 
infected control (p<0.0005). Addition of zVAD to the G93R-mutant infected cells reduced 
the number of TUNEL positive cells by approximately 80% compared to control (p<0.0005) 
with wt-SODl cells exhibiting an approximately 12% increase in the number of TUNEL 
positive cells compared to control.
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Figure 5.10a
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Figure 5.10 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected ra t DRGs
a. Rat DRG cell death following 24h of treatment with 50ng/ml IFN-y after co-infection 
with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or Hsp27 and 
Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, after 24h 
of treatment of 50ng/ml IFN-y of rat DRG cells co-infected with wt or G93R-mutant SOD1 
or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells were co-infected with SOD 
and Hsp viruses 16h prior to stress. Bars represent mean ±S.D. calculated for triplicate 
counts per sample (n), n=4. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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Figure 5.10b
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Figure 5.10 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected rat DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of 50ng/ml IFN-y for 
24h. Bars represent mean ± S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.7.3 Staurosporine treatment
DRGs infected with G93R mutant virus exhibited a reduction of approximately 58% on 
infection with Hsp27 compared to GFP infected control (p<0.0005); (Figure 5.11a). Hsp70 
infection of the G93R mutant cells brought about a slightly greater protection with death 
being reduced by approximately 71% compared to GFP control (p<0.0005). The dual 
infection of Hsp27 and Hsp70 was the most effective in reducing the G93R-mutant death 
with death being reduced by approximately 77% compared to GFP infected control 
(p<0.0005). The wt-SODl infected cells once infected with Hsp27 or Hsp70 exhibited a 
dramatic increase in cell death with death increasing by approximately 75% and 180% 
respectively compared to GFP control (p<0.0005). On dual infection with Hsp27 and Hsp70 
death in the wt-SODl infected DRGs was brought back down to control GFP levels. 
However it was still approximately 31% higher than control GFP cells (p<0.0005). Once 
again addition of zVAD reduced G93R-mutant death almost as efficiently as the dual 
infection with Hsp27 and Hsp70 with death being reduced by approximately 70% compared 
to control (p<0.0005). Wt-SODl infected cells on the other hand exhibited a 10% increase 
in cell death compared to control.
TUNEL analysis confirmed the trypan findings with DRGs infected with G93R mutant virus 
exhibiting a reduction of approximately 61% in the number of TUNEL positive cells on 
infection with Hsp27 compared to GFP infected control (p<0.0005); (Figure 5.11b). On 
infection of the G93R mutant cells with Hsp70 the number of TUNEL positive cells were 
reduced by approximately 73% compared to GFP control (p<0.0005). The dual infection of 
Hsp27 and Hsp70 reduced the number of TUNEL positive cells of the G93R mutant by 
approximately 80% compared to GFP infected control (p<0.0005). Wt-SODl infected cells 
once infected with Hsp27 or Hsp70 exhibited an increase in the number of TUNEL positive 
cells with the number increasing by approximately 77% and 192% respectively compared to 
GFP control (p<0.0005). Dual infection with Hsp27 and Hsp70 of the wt-SODl DRGs 
reduced the number of TUNEL positive cells back down to control GFP levels, however the 
number of TUNEL positive cells was still approximately 26% higher than control GFP 
(p<0.05). Addition of zVAD to G93R mutant infected cells reduced the number of TUNEL 
positive cells by approximately 71% (p<0.0005) compared to control, with wt-SODl
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infected cells exhibiting a slight increase in the number of TUNEL positive cells by 6% 
compared to control.
Figure 5.11a
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Figure 5.11 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected rat DRGs
a. Rat DRG cell death following 24h of lpM staurosporine administration after co-infection 
with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or Hsp27 and 
Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, after 24h 
of treatment of lpM staurosporine of rat DRG cells co-infected with wt or G93R-mutant 
SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells were co-infected with 
SOD and Hsp viruses 16h prior to stress. Bars represent mean ±S.D. calculated for triplicate 
counts per sample (n), n=4. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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Figure 5.11b
70
£ 6 0
5^0
A
5*0
tttft
A
***p<0j0005
*P<0j05
©
0 0
G
Ja> -a>
0
.a
**«
i
©00Q
so
r f i
*> .a Ja>
Sts
I
©
04Q
I
Ja
a-
a> Ja
tss
1
O
G
3Ja> Ja>
tss
1
o
04Q
I
Ja> .a>
GO
£
04
GO03
£
pa
Go
£
C4
QO
£
04
G©
£
04
© © ©
GFP Hsp27 HspTO Hsp27+70 i7AD
Figure 5.11 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected rat DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of lpM staurosporine 
for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.8 Responses of SOD Virus infected wt-mice DRG Cells to Stress
following Exogenous Heat Shock Protein Over-expression
5.8.1 NGF withdrawal
G93R mutant SOD infected mouse DRG exhibited a reduction in death by approximately 
43% and 61% on infection with Hsp27 and Hsp70 respectively compared to GFP infected 
control (p<0.0005); (Figure 5.12a). On dual infection of Hsp27 and Hsp70 the G93R 
infected cells exhibited the greatest reduction in cell death of approximately 68% compared 
to GFP infected control (p<0.0005). Wt-SODl infected cells exhibited a dramatic increase 
in cell death on Hsp infection, as had been observed in the neuronal cell experiments, as 
well as the rat DRG experiments. On infection of wt-SODl cells with Hsp27 death increased 
sharply by approximately 140% and by approximately 151% on Hsp70 infection, compared 
to GFP infected control (p<0.0005). As with previous experiments in neuronal cells and rat 
DRGs the dual infection of Hsp27 and Hsp70 of wt-SODl cells brought the level of death 
down toward control GFP levels but still approximately 34% higher than control GFP 
(p<0.0005).
TUNEL analysis provided similar results with G93R mutant SOD infected mouse DRG 
exhibiting a reduction in the number of TUNEL positive cells by approximately 45% and 
63% on infection with Hsp27 and Hsp70 respectively compared to GFP infected control 
(p<0.0005); (Figure 5.12b). On dual infection of Hsp27 and Hsp70 the G93R infected cells 
exhibited the greatest reduction in the number of TUNEL positive cells with the number 
decreasing by approximately 71% compared to GFP infected control (p<0.0005). Wt-SODl 
infected cells exhibited a dramatic increase in the number of TUNEL positive cells on Hsp 
infection, with Hsp27 infection bringing about a 172% increase and Hsp70 infection an 
approximately 185% increase, compared to GFP infected control (p<0.0005). The dual 
infection of Hsp27 and Hsp70 of wt-SODl infected DRGs brought the number of TUNEL 
positive cells down toward control GFP levels but still approximately 65% higher the 
control GFP (p<0.0005).
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Figure 5.12a
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Figure 5.12 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of NGF withdrawal after co-infection with HSV 
vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or Hsp27 and Hsp70. The 
proportion of cell death was assessed by trypan blue exclusion assay, after 24h of treatment 
of NGF withdrawal of wt-mice DRG cells co-infected with wt or G93R-mutant SOD1 or 
GFP control and FIsp27, Hsp70 or Hsp27 and Hsp70. Cells were infected with SOD and Hsp 
viruses 16h prior to stress. Bars represent mean 1 S.D calculated for triplicate counts per 
sample (n), n=4. Significant differences were calculated using Bonferroni Multiple 
Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates statistically 
significant difference between means, when comparing with GFP virus infected control.
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Figure 5.12 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of NGF withdrawal for 
24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.8.2 IFN-y administration
On exposure to IFN-y G93R mutant SOD1 infected mice DRGs exhibited a reduction in cell 
death on infection with Hsp-expressing viruses. On infection with Hsp27 the G93R mutant 
cell death was reduced by approximately 42% compared to GFP control (p<0.0005); (Figure 
5.13a). Hsp70 infection brought a greater reduction in death in the G93R mutant cells with 
an approximately 62% reduction in death compared to GFP control (p<0.0005). The dual 
infection of Hsp27 and Hsp70 reduced the mutant death even further with death being 
reduced by approximately 68% compared to GFP infected control (p<0.0005). Wt-SODl 
infected cells on infection with Hsp’s exhibited an increase in cell death. Wt-SODl infected 
cells infected with Hsp27 saw an increase of approximately 150% and those infected with 
Hsp70 an increase of approximately 192% compared to GFP infected control (p<0.0005). 
The dual infection of wt-SODl cells with Hsp27 and Hsp70 brought the cell death down 
toward control GFP levels however death was still approximately 52% higher than control 
GFP (p<0.0005).
TUNEL analysis confirmed the findings of the trypan blue assay with G93R mutant SOD1 
infected mice DRGs exhibiting a reduction in the number of TUNEL positive cells on 
infection with Hsps. On infection with Hsp27 the G93R mutant exhibited a reduction in the 
number of TUNEL positive cells by approximately 44% compared to GFP control 
(p<0.0005); (Figure 5.13b). Hsp70 infection brought a greater reduction in the number of 
TUNEL positive cells of G93R mutant with the number decreasing by approximately 65% 
compared to GFP control (p<0.0005). The dual infection of the G93R mutant with Hsp27 
and Hsp70 reduced the number of TUNEL positive cells even further with the number 
reduced by approximately 71% compared to GFP infected control (p<0.0005). Wt-SODl 
infected cells on infection with Hsps exhibited an increase in cell death. Wt-SODl infected 
cells infected with Hsp27 saw an increase in the number of TUNEL positive cells by 
approximately 187% and those infected with Hsp70 an increase of approximately 239% 
compared to GFP infected control (p<0.0005). The dual infection of wt-SODl cells with 
Hsp27 and Hsp70 brought the number of TUNEL positive cells down toward control GFP 
levels however death was still approximately 65% higher than control GFP (p<0.0005).
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Figure 5.13 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of treatment with 50ng/ml IFN-y after infection 
with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or Hsp27 and 
Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, after 24h 
of treatment of 50ng/ml IFN-y of wt-mice DRG cells infected with wt or G93R-mutant 
SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells were co-infected with 
SOD and Hsp viruses 16h prior to stress. Bars represent mean 1 S.D calculated for triplicate 
counts per sample (n), n=4. Significant differences were calculated using Bonferroni 
Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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Figure 5.13 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of 50ng/ml IFN-y for 
24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with p<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.8.3 Staurosporine treatment
Infection of mutant G93R infected DRGs with Hsp-expressing viruses brought about a 
reduction in the death of the mutant, as had been observed in the previous experiments. 
Hsp27 infection of mutant G93R cells reduced death by approximately 68% and Hsp70 
infection brought about a 73% reduction compared to GFP infected control (p<0.0005); 
(Figure 5.14a). The dual infection of G93R cells with Hsp27 and Hsp70 further reduced 
death with a reduction of approximately 80% compared to GFP control (p<0.0005). The wt- 
SODl cells once again on infection with Hsp27 or Hsp70 showed a dramatic increase in cell 
death with death rising by approximately 63% and 139% respectively compared to control 
GFP (p<0.0005). The dual infection of the wt-SODl cells with Hsp27 and Hsp70 reduced 
death down to control GFP levels.
TUNEL analysis provided similar results with infection of mutant G93R DRGs with Hsp’s 
bringing about a reduction in the number of TUNEL positive cells. Hsp27 infection of 
mutant G93R cells reduced the number of TUNEL positive cells by approximately 71% and 
Hsp70 infection brought about a 76% reduction compared to GFP infected control 
(p<0.0005); (Figure 5.14b). The dual infection of G93R cells with Hsp27 and Hsp70 further 
reduced the number of TUNEL positive cells with a reduction of approximately 84% 
compared to GFP control (p<0.0005). The wt-SODl cells once again on infection with 
Hsp27 or Hsp70 showed a dramatic increase in the number of TUNEL positive cells with 
the number rising by approximately 77% and 168% respectively compared to control GFP 
(p<0.0005). The dual infection of the wt-SODl cells with Hsp27 and Hsp70 reduced the 
number of TUNEL positive cells back down to control GFP levels.
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Figure 5.14 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs
a. Wt-mice DRG cell death following 24h of lpM staurosporine administration after co- 
infection with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or 
Hsp27 and Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h of treatment of lpM staurosporine of wt-mice DRG cells co-infected with wt or 
G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells were co- 
infected with SOD and Hsp viruses 16h prior to stress. Bars represent mean 1 S.D calculated 
for triplicate counts per sample (n), n=4. Significant differences were calculated using 
Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, *** 
indicates statistically significant difference between means, when comparing with GFP virus 
infected control.
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Figure 5.14 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of lpM staurosporine 
for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with p<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.9 Response of Transgenic Hsp27 mice DRGs to stress following over­
expression of wt or G93R mutant SOD1
As mentioned previously, the viruses used in the present study, offer a high efficiency 
means of specific gene delivery to primary neuronal cells (90-100% transduction 
efficiency). The Hsp viruses used in the present study were constructed in our laboratory by 
Dr Marcus Wagstaff (Wagstaff et al., 1998). The transgenes (Chinese hamster Hsp27, 
human inducible Hsp70, or GFP) in this type of virus are driven by the human CMV-IE 
promoter which was inserted immediately downstream of the LAT P2 promoter. The SOD1 
viruses (wt-SODl, G93R-mutant SOD1 and GFP-control) were constructed in our lab by Dr 
Yolanda Collaco-Moraes. The pR20.5 cassette consists of a central LAT P2 element flanked 
by two heterologous promoters (CMV-IE and RSV) arranged in a back-to-back orientation, 
allowing simultaneous expression of either wt-SODl or G93R-SOD1 mutant (under the 
Rous Sarcoma Virus - RSV- promoter) and GFP (under CMV-IE promoter) and enabling 
long term expression of both transgenes.
In order to investigate the protective effects of Hsps further, we infected primary cultures of 
Transgenic Hsp27 (Tg-Hsp27) and Transgenic Hsp70 (Tg-Hsp70) DRGs with wt-SODl, 
G93R-SOD1 mutant or control GFP virus. The transgenic Hsp27 (Tg-Hsp27) mice were a 
gift from Professor J. de Belleroche, Imperial College. The Hsp70 transgenic mice (Tg- 
Hsp70) were a gift from Dr. C.E. Angelidis, Dalhousie University, Canada. The Hsp27 
transgenic mice incorporate a transgene containing human Hsp27 cDNA with a chicken - 
actin promoter and cytomegalovirus enhancer (pCAGGS) (see Akbar et al., 2003). The 
Hsp70 transgenic mice incorporate human inducible Hsp70 gene under the regulation of P- 
actin promoter (see Plumier et al., 1995).
The combined effects of Hsps were investigated further by additional delivery of either 
Hsp27 to Tg-Hsp70 DRGs or Hsp70 to Tg-Hsp27 DRGs. The primary cultures were then 
subjected 16h post infection to NGF withdrawal, IFN-y or staurosporine administration. The 
findings for the various stresses are presented below the corresponding stress. As with 
previous experiments, cell death was assessed by trypan blue exclusion assay and TUNEL 
analysis.
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5.9.1 NGF withdrawal
Transgenic Hsp27 mice (Tg-Hsp27) DRGs infected with G93R mutant virus exhibited an 
approximately 63% reduction in death compared to wt-mice DRGs infected with G93R- 
mutant virus (p<0.0005). Wt-SODl infection of Tg-Hsp27 DRGs led to an increase in death 
of approximately 76% compared to wt-mice DRGs infected with wt-SODl virus 
(p<0.0005); (Figure 5.15a). Delivery of Hsp70 to G93R-mutant infected Tg-Hsp27 DRGs 
led to a 57% (p<0.0005) reduction in death compared to G93R-mutant infected Tg-Hsp27 
DRGs and approximately 84% (p<0.0005) reduction in death compared to G93R-mutant 
infected wt-mice DRGs. Hsp70 delivery to wt-SODl infected Tg-Hsp27 DRGs led to a 
55% (p<0.0005) decrease in cell death compared to wt-SODl infected Tg-Hsp27 DRGs and 
approximately 20% (p<0.0005) reduction in total cell death compared to wt-SODl infected 
wt-mice DRGs.
TUNEL analysis confirmed these findings with Tg-Hsp27 mice DRGs infected with G93R 
mutant virus exhibiting an approximately 65% reduction in the number of TUNEL positive 
cells compared to G93R-SOD1 mutant infected wt-mice DRGs (p<0.0005). Wt-SODl 
infection of Tg-Hsp27 DRGs led to an increase in the number of TUNEL positive cells by 
approximately 102% compared to wt-SODl virus infected wt-mice DRGs (p<0.0005); 
(Figure 5.15b). Delivery of Hsp70 to G93R-mutant infected Tg-Hsp27 DRGs led to a 64% 
(p<0.0005) reduction in the number of TUNEL positive cells compared to G93R-mutant 
infected Tg-Hsp27 DRGs and approximately 87% (p<0.0005) reduction in the number of 
TUNEL positive cells compared to G93R-SOD1 mutant infected wt-mice DRGs. Delivery 
of Hsp70 to wt-SODl infected Tg-Hsp27 DRGs led to a 59% (p<0.0005) decrease in the 
number of TUNEL positive cells compared to wt-SODl infected Tg-Hsp27 DRGs and 
approximately 17% (p<0.0005) reduction in the number of TUNEL positive cells compared 
to wt-SODl infected wt-mice DRGs.
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Figure 5.15 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs and Tg-Hsp27 DRGs
a. Wt and Tg-Hsp27 mice DRG cell death following 24h of NGF withdrawal after co- 
infection with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or 
Hsp27 and Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h of treatment of NGF withdrawal of wt-mice and Tg-Hsp27 DRG cells co-infected 
with wt or G93R-mutant S0D1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. 
Cells were infected with SOD and Hsp viruses 16h prior to stress. Bars represent mean1 S.D 
calculated for triplicate counts per sample (n), n=4. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with GFP 
virus infected control.
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Figure 5.15 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs and Tg-Hsp27 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of NGF withdrawal for 
24h. Bars represent mean ± S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.9.2 IFN-y administration
Tg-Hsp27 DRGs infected with G93R mutant virus exhibited a 61% lower death than G93R 
mutant infected wt-mice DRGs (p<0.0005); (Figure 5.16a). Wt-SODl infected Tg-Hsp27 
DRGs exhibited a 61% higher death compared to wt-SODl infected wt-mice DRGs 
(p<0.0005). Delivery of Hsp70 to G93R infected Tg-Hsp27 DRGs reduced death by 
approximately 57% (p<0.0005) compared to G93R mutant infected Tg-Hsp27 cells and 
approximately 83% (p<0.0005) compared to G93R-mutant infected wt-mice DRGs. Wt- 
SODl infected Tg-Hsp27 cells saw an approximately 43% (p<0.0005) reduction in cell 
death on delivery of Hsp70 compared to wt-SODl infected Tg-Hsp27 DRGs.
TUNEL analysis revealed similar results with Tg-Hsp27 DRGs infected with G93R mutant 
virus exhibiting a 62% reduction in the number of TUNEL positive cells compared to G93R 
mutant infected wt-mice DRGs (p<0.0005) (Figure 5.16b). Wt-SODl infected Tg-Hsp27 
DRGs exhibited a 96% increase in the number of TUNEL positive cells compared to wt- 
SODl infected wt-mice DRGs (p<0.0005). Delivery of Hsp70 to G93R mutant infected Tg- 
Hsp27 DRGs reduced the number of TUNEL positive cells by approximately 63% 
(p<0.0005) compared to G93R mutant infected Tg-Flsp27 cells and approximately 86% 
(p<0.0005) compared to G93R-mutant infected wt-mice DRGs. Delivery of Hsp70 to wt- 
SODl infected Tg-Hsp27 cells brought about a reduction in the number of TUNEL positive 
cells by approximately 49% (p<0.0005) compared to wt-SODl infected Tg-Hsp27.
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Figure 5.16 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs and Tg-Hsp27 DRGs
a. Wt-mice and Tg-Hsp27 DRG cell death following 24h of treatment with 50ng/ml IFN-y 
after infection with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or 
Hsp27 and Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h of treatment of 50ng/ml IFN-y of wt-mice and Tg-Hsp27 DRG cells infected with 
wt or G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells 
were co-infected with SOD and Hsp viruses 16h prior to stress. Bars represent mean 1 S.D 
calculated for triplicate counts per sample (n), n=4. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with GFP 
virus infected control.
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Figure 5.16 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs and Tg-Hsp27 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of 50ng/ml IFN-y for 
24h. Bars represent mean ± S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.9.3 Staurosporine treatment
G93R mutant infected Tg-Hsp27 DRGs showed an approximately 48% reduction in death 
compared to G93R mutant infected wt-mice DRGs (p<0.0005). Wt-SODl infected Tg- 
Hsp27 DRGs showed an increase in death of approximately 199% compared to wt-SODl 
infected wt-mice DRGs (p<0.0005); (Figure 5.17a). Delivery of Hsp70 to G93R mutant 
infected Tg-Hsp27 cells led to a reduction in death of approximately 55% (p<0.0005) 
compared to G93R infected Tg-Hsp27 cells and approximately 76% (p<0.0005) reduction in 
total cell death compared to G93R-mutant infected wt-mice DRGs. Delivery of Hsp70 to wt- 
SODl infected Tg-Hsp27 cells reduced death by approximately 63% compared to wt-SODl 
infected Tg-Hsp27 DRGs (p<0.0005).
TUNEL analysis revealed similar results with G93R mutant infected Tg-Hsp27 DRGs 
exhibiting a reduction in the number of TUNEL positive cells by approximately 48% 
compared to G93R mutant infected wt-mice DRGs (p<0.0005). Wt-SODl infected Tg- 
Hsp27 DRGs showed an increase in the number of TUNEL positive cells by approximately 
199% compared to wt-SODl infected wt-mice DRGs (p<0.0005); (Figure 5.17b). Delivery 
of Hsp70 to G93R mutant infected Tg-Hsp27 cells led to a reduction of approximately 58% 
(p<0.0005) in the number of TUNEL positive cells compared to G93R infected Tg-Hsp27 
cells and approximately 78% (p<0.0005) reduction in the number of TUNEL positive cells 
compared to G93R-mutant infected wt-mice DRGs. Delivery of Hsp70 to wt-SODl infected 
Tg-Hsp27 brought about an approximately 65% a reduction in number of TUNEL positive 
cells compared to wt-SODl infected Tg-Hsp27 DRGs (p<0.0005).
349
Figure 5.17a
80
?0
60
®50
Oi0
M
0 3 0H
20
10
0
»«*
I
m
i
*V A
P3 I
***P<0J0005
*P<0j05
I
ft**
fi * * x
GFP Hsp27 Hsp76 Hsp27&Hsp70
WtMie
GFP HspTO
TgHsp27Mke
Figure 5.17 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs and Tg-Hsp27 DRGs
a. Wt-mice and Tg-Hsp27 DRG cell death following 24h of lpM staurosporine 
administration after co-infection with HSV vectors expressing wt-SODl or G93R mutant 
and Hsp27, Hsp70 or Hsp27 and Hsp70. The proportion of cell death was assessed by trypan 
blue exclusion assay, after 24h of treatment of lpM staurosporine of wt-mice and Tg-Hsp27 
DRG cells co-infected with wt or G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or 
Hsp27 and Hsp70. Cells were co-infected with SOD and Hsp viruses 16h prior to stress. 
Bars represent mean 1 S.D calculated for triplicate counts per sample (n), n=4. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (p<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with GFP virus infected control.
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Figure 5.17 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs and Tg-Hsp27 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of lpM staurosporine 
for 24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.10 Response of Transgenic Hsp70 mice DRGs to stress following over­
expression of wt or G93R mutant SOD1
5.10.1 NGF withdrawal
G93R infected Tg-Hsp70 mice DRGs exhibited an approximately 73% reduction in death 
compared to wt-mice DRGs infected with G93R mutant virus (p<0.0005). Wt-SODl 
infected Tg-Hsp70 DRGs exhibited a 248% increase in death compared to wt-mice DRGs 
infected with wt-SODl virus (p<0.0005); (Figure 5.18a). Delivery of Hsp27 to G93R mutant 
infected Tg-Hsp70 DRGs reduced death by approximately 27% (p<0.005) compared to 
G93R mutant Tg-Hsp70 DRGs and approximately 80% (p<0.0005) compared to G93R- 
mutant infected wt-mice DRGs. Wt-SODl infected Tg-Hsp70 DRGs saw a reduction in 
death by approximately 66% on delivery of Hsp27 compared to wt-SODl infected Tg- 
Hsp70 DRGs (p<0.0005).
TUNEL analysis confirmed the findings on the trypan blue analysis with G93R infected Tg- 
Hsp70 mice DRGs exhibiting an approximately 75% reduction in the number of TUNEL 
positive cells compared to wt-mice DRGs infected with G93R mutant virus(p<0.0005). Wt- 
SODl infected Tg-Hsp70 DRGs exhibited a 311% increase in the number of TUNEL 
positive cells compared to wt-mice DRGs infected with wt-SODl virus (p<0.0005); (Figure 
5.18b). Delivery of Hsp27 to G93R mutant infected Tg-Hsp70 DRGs reduced the number of 
TUNEL positive cells by approximately 30% (p<0.005) compared to G93R mutant Tg- 
Hsp70 DRGs and approximately 83% (p<0.0005) compared to G93R-mutant infected wt- 
mice DRGs. Wt-SODl infected Tg-Hsp70 DRGs saw a reduction in the number of TUNEL 
positive cells by approximately 68% (p<0.0005) following delivery of Hsp27 compared to 
wt-SODl infected Tg-Hsp70 DRGs.
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Figure 5.18 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs and Tg-Hsp70 DRGs
a. Wt and Tg-Hsp70 mice DRG cell death following 24h of NGF withdrawal after co- 
infection with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or 
Hsp27 and Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h of treatment of NGF withdrawal of wt-mice and Tg-Hsp70 DRG cells co-infected 
with wt or G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. 
Cells were infected with SOD and Hsp viruses 16h prior to stress. Bars represent mean ± S.D 
calculated for triplicate counts per sample (n), n=4. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with GFP 
virus infected control.
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Figure 5.18 Effect of NGF withdrawal on cell death in control, wild type or mutant 
SOD1 virus infected wt-mice DRGs and Tg-Hsp70 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of NGF withdrawal for 
24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.10.2 IFN-y administration
G93R mutant infected Tg-Hsp70 DRGs exhibited a reduction in death of approximately 
74% compared to G93R mutant infected wt-mice DRGs (p<0.0005). On infection with wt- 
SODl, Tg-Hsp70 DRGs saw an increase in death of approximately 198% compared to wt- 
SODl infected wt-mice DRGs (p<0.0005); (Figure 5.19a). Delivery of Hsp27 to G93R 
mutant infected Tg-Hsp70 DRGs led to a reduction in death by approximately 33% 
(p<0.0005) compared to G93R mutant infected Tg-Hsp70 DRGs and an approximately 83% 
(p<0.0005) reduction in total cell death compared to G93R-mutant infected wt-mice DRGs. 
The death of wt-SODl infected Tg-Hsp70 DRGs was reduced by approximately 73% 
(p<0.0005) following delivery of Hsp27 compared to wt-SODl infected Tg-Hsp70 DRGs 
and 19% (p<0.0005) compared to wt-SODl infected wt-mice DRGs.
TUNEL analysis provided similar results with G93R mutant infected Tg-Hsp70 DRGs 
exhibiting a reduction in the number of TUNEL positive cells by approximately 76% 
compared to G93R mutant infected wt-mice DRGs(p<0.0005). On infection with wt-SODl, 
Tg-Hsp70 DRGs saw an increase in the number of TUNEL positive cells by approximately 
255% compared to wt-mice DRGs infected with wt-SODl (p<0.0005); (Figure 5.19b). 
Delivery of Hsp27 to G93R mutant infected Tg-Hsp70 DRGs led to a reduction in the 
number of TUNEL positive cells by approximately 37% (p<0.0005) compared to G93R 
mutant infected Tg-Hsp70 DRGs and approximately 85% (p<0.0005) compared to G93R- 
mutant infected wt-mice DRGs. Delivery of Hsp27 to wt-SODl infected Tg-Hsp70 DRGs 
led to a reduction in the number of TUNEL positive cells by approximately 76% (p<0.0005) 
compared to wt-SODl infected Tg-Hsp70 DRGs and 15% (p<0.0005) compared to wt- 
SODl infected wt-mice DRGs.
355
Figure 5.19a
70
2 3 0 -
5*20
a
<
***P<0.0005
1
o A
pa pa O
a S—1 64u
GfP Hsp27
Wt-Mice
Hip70
o a
pa pa o
a e— 64CJ
o
pa
a
opao pa
QO
H*Z7£H *7I GFP H>p27
TgrtpTO Mce
Figure 5.19 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs and Tg-Hsp70 DRGs
a. Wt-mice and Tg-Hsp70 DRG cell death following 24h of treatment with 50ng/ml IFN-y 
after infection with HSV vectors expressing wt-SODl or G93R mutant and Hsp27, Hsp70 or 
Hsp27 and Hsp70. The proportion of cell death was assessed by trypan blue exclusion assay, 
after 24h of treatment of 50ng/ml IFN-y of wt-mice and Tg-Hsp70 DRG cells infected with 
wt or G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or Hsp27 and Hsp70. Cells 
were co-infected with SOD and Hsp viruses 16h prior to stress. Bars represent mean 1 S.D 
calculated for triplicate counts per sample (n), n=4. Significant differences were calculated 
using Bonferroni Multiple Comparison’s t test after one-way ANOVA (p<0.0005). *, **, 
*** indicates statistically significant difference between means, when comparing with GFP 
virus infected control.
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Figure 5.19 Effect of IFN-y on cell death in control, wild type or mutant SOD1 virus 
infected wt-mice DRGs and Tg-Hsp70 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of 50ng/ml IFN-y for 
24h. Bars represent mean 1 S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with /?<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.10.3 Staurosporine treatment
Tg-Hsp70 mutant-G93R infected DRGs exhibited a reduction in death by approximately 
68% compared to G93R mutant infected wt-mice DRGs (p<0.0005). On infection of Tg- 
Hsp70 DRGs with wt-SODl virus an increase in death of approximately 260% was 
observed compared to wt-SODl infected wt-mice DRGs(p<0.0005); (Figure 5.20a). 
Delivery of Hsp27 to G93R mutant infected Tg-Hsp70 DRGs led to a reduction in death by 
approximately 47% (p<0.0005) compared to Tg-Hsp70 DRGs infected with G93R mutant 
and approximately 83% (p<0.0005) reduction in cell death compared to G93R-mutant 
infected wt-mice DRGs. Wt-SODl infected Tg-Hsp70 DRGs showed a reduction in death 
by approximately 73% on delivery of Hsp27 compared to wt-SODl infected Tg-Hsp70 
DRGs (p<0.0005).
TUNEL analysis provided similar results and confirmed the findings of the trypan blue 
assay with Tg-Hsp70 mutant-G93R infected DRGs exhibiting a reduction in the number of 
TUNEL positive cells by approximately 70% compared to G93R mutant infected wt-mice 
DRGs(p<0.0005). Infection of Tg-Hsp70 DRGs with wt-SODl virus, led to an increase in 
the number of TUNEL positive cells by approximately 325% compared to wt-SODl 
infected wt-mice DRGs(p<0.0005); (Figure 5.20b). Delivery of Hsp27 to G93R mutant 
infected Tg-Hsp70 DRGs, led to a reduction in the number of TUNEL positive cells by 
approximately 53% (p<0.0005) compared to Tg-Hsp70 DRGs infected with G93R mutant 
and approximately 86% (p<0.0005) reduction in cell death compared to G93R-mutant 
infected wt-mice DRGs. Wt-SODl infected Tg-Hsp70 DRGs showed a reduction of 
approximately 75% in the number of TUNEL positive cells following delivery of Hsp27 
compared to wt-SODl infected Tg-Hsp70 DRGs(p<0.0005).
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Figure 5.20 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs and Tg-Hsp70 DRGs
a. Wt-mice and Tg-Hsp70 DRG cell death following 24h of lpM staurosporine 
administration after co-infection with HSV vectors expressing wt-SODl or G93R mutant 
and Hsp27, Hsp70 or Hsp27 and Hsp70. The proportion of cell death was assessed by trypan 
blue exclusion assay, after 24h of treatment of lpM staurosporine of wt-mice and Tg-Hsp70 
DRG cells co-infected with wt or G93R-mutant SOD1 or GFP control and Hsp27, Hsp70 or 
Hsp27 and Hsp70. Cells were co-infected with SOD and Hsp viruses 16h prior to stress. 
Bars represent mean ±S.D. calculated for triplicate counts per sample (n), n=4. Significant 
differences were calculated using Bonferroni Multiple Comparison’s t test after one-way 
ANOVA (p<0.0005). *, **, *** indicates statistically significant difference between means, 
when comparing with GFP virus infected control.
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Figure 5.20 Effect of Staurosporine on cell death in control, wild type or mutant SOD1 
virus infected wt-mice DRGs and Tg-Hsp70 DRGs
b. Percentage of TUNEL-positive cells counted in three different fields in three experiments 
where cell lines were co-infected with viruses to over-express wt-SODl, G93R-mutant or 
GFP and Hsp27, Hsp70 or Hsp27 and Hsp70 16h prior to treatment of lpM staurosporine 
for 24h. Bars represent mean ± S.D. calculated for triplicate counts per sample (n=4) and 
significant differences were calculated as above with p<0.0005. *, **, *** indicates 
statistically significant difference between means, when comparing with GFP virus infected 
control.
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5.11 Discussion
This chapter describes the protective effect of heat shock proteins in primary DRG 
cells against the toxic effects of mutant-SODl and provides further support to the findings 
described in Chapter 4. HSV-based viral vectors were utilised in order to efficiently express 
Hsp27, Hsp70 or the Hsp27 and Hsp70 combination along with either wt-SODl or G93R- 
mutant. In summary, the wt-SODl, G93R-mutant and empty vector control infected rat 
DRGs were infected with the Hsp virus or the relevant control virus and subsequently 
subjected to stresses including NGF withdrawal, IFN-y and staurosporine. In addition 
transgenic Hsp27 or Hsp70 mice and control mice were infected with wt-SODl, G93R 
mutant or control virus to further confirm the findings of chapter 4 and those of the rat 
DRGs. The response of the primary cells to the above death inducing stimuli was quantified 
through TUNEL analysis to establish the number of apoptotic cells.
The results of chapter 4 indicate that the exogenous expression of Hsp27 or Hsp70 in 
the in vitro mammalian model system presented in this thesis, over-expressing G93A or 
G93R SOD1 mutants, confer protection against a wide range of lethal stimuli. Briefly, the 
results presented in this chapter provide further support to the findings of chapter 4 through 
investigation of protective effects of Hsps in both rat and mouse DRGs. Exogenous 
expression of Hsp27 and/or Hsp70 confers protection against G93R-mutant induced toxicity 
in rat and mouse DRGs subjected to a range of lethal stimuli. Wt-SODl infected DRGs 
exhibited increased levels of death on FIsp70 infection bringing about a larger increase in 
death than Hsp27 as seen in the ND7 cell experiments with wt-SODl cells. FIsp70 was 
much more effective in rescuing the G93R mutant than Hsp27 paralleling the findings of 
chapter 4. Furthermore, a joint infection of Hsp27 and Hsp70 rescued the G93R SOD1 
mutant more effectively than single viral infection with Hsp27 or Hsp70. In addition, as with 
the findings of chapter 4, the enhanced cell death observed in the wt-SODl infected cells on 
infection with Hsp27 or Hsp70 was abolished on infection with the Hsp27 and Hsp70 
combination suggesting that Hsp27 and Hsp70 may act in synergy.
Using retroviral vectors, it was previously shown that Hsp70 overexpression protects
astrocytes from glucose deprivation, combined oxygen-glucose deprivation, as well as from H2O2
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exposure (Papadopoulos et al., 1996; Xu and Giffard, 1997). In addition, overexpression of 
Hsp70 in cultured neurons is also associated with protection (Amin et al., 1996; Beaucamp et 
al., 1998; Fink et al., 1997; Uney et al, 1993), and overexpression of Hsp70 in astrocytes was 
found to protect co-cultured wild type neurons (Xu et al., 1999). These in vitro injury models 
mimic to some extent the injury involved in damage brought about by mutant SOD1 toxicity 
and suggest several ways in which Hsp70 could provide protection. Astrocytes protected from 
injury by Hsp70 had higher levels of glutathione than control cells under the same conditions 
of stress (Xu and Giffard, 1997). The ability to refold proteins or prevent aggregation may 
enable the cell to conserve glutathione and perhaps even ATP (Wong et al., 1998). Studies 
carried out in both in vitro and in vivo by Kelly et al. (2002) found that neurons overexpressing 
Hsp70 were also found to overexpress the anti-apoptotic protein bcl-2.
Despite intensive investigations, the prominent pathogenic mechanisms have as yet 
not been identified for any type of ALS. It is known from transgenic rodents that high levels 
of mutant SOD-1 protein kill motor neurons in a dose-dependent manner. In these models, 
multiple processes play a role in the demise of motor neurons, including early misfolding 
and aggregation of mutant SOD-1 protein (Bruijn et al., 1997), excitotoxicity mediated by 
failing synaptic transport of glutamate into glial cells, diminished energy generation as a 
result of mitochondrial dysfunction, and impaired axonal transport.
In both rodents and humans, distressed motor neurons trigger proliferation of sur­
rounding astrocytes and microglial cells in affected spinal gray matter. Gene expression and 
biochemical studies reveal characteristics of inflammation, such as cyclooxygenase 
activation. These findings are apparent in both sporadic ALS cases as well as those associ­
ated with mutant SOD-1. The process of motor neuron death is not cell-autonomous but 
rather it is considered to be intimately related to the context of surrounding cells. Clement et 
al. (2003) reported cell death of motor neurons expressing mutant SOD-1 protein could be 
rescued by surrounding non-neuronal wild-type cells.
Recently studies from a number of laboratories have begun to define the ways in which 
Hsp70 can inhibit the apoptosis signal transduction pathway. Studies performed in cell lines and 
immune cells have shown that Hsp70 can block apoptosis at both early (Gabai et al., 1998) and
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late (Jaattela et al., 1998) stages in the apoptotic cascade. A functional analysis of the role of 
the different Hsp70 subdomains in brain cells subjected to SODl-mutant induced injury will begin 
to elucidate how Hsp70 protein modulates apoptosis in this setting, and could potentially lead to 
the development of new therapeutic approaches. Since Hsp70 can block both apoptotic and 
necrotic cell deaths, it is an especially interesting target for mutant-SODl induced toxicity and 
hence its therapy. Identifying those actions of the chaperones that are most important for 
blocking injury may possibly lead to the development of novel approaches to lessen damage from 
both chronic and acute neurodegeneration. One likely direction is the reduction of protein 
aggregation. Structure-function studies of chaperones will identify which activities and which 
protein-protein interactions are most significant to different injuries as well as the most broadly 
protective.
Recently, Kieran et al (2004) provided evidence of a new category of molecules that 
may ameliorate the disease. These investigators showed that daily treatments with 
arimoclomol, a co-inducer of heat shock proteins, meaning that it induces expression of 
more than one Hsp, slows the progress of motor neuron death and consequently extends 
survival in a transgenic SOD1-G93A mouse model of ALS. The authors documented that 
arimoclomol induces the phosphorylation of a heat shock protein-inducing factor (Hsf-1), 
and as a result upregulates expression of Hsp-70 and Hsp-90 (Hargitai et al., 2003). It is 
thought that the molecule may also upregulate co-chaperones such as Hsp-40, CHIP and 
Bag.
Several aspects of these new findings are notable. First, arimoclomol prolongs sur­
vival when administered after onset of disease symptoms. To date, over 70 drugs have been 
tested in these mice, however there have been no published reports of compounds that are 
beneficial when started following disease onset. Furthermore, only a small number of 
compounds prolonged survival by more than 10%, even when started presymptomatically.
It is highly unlikely that ALS is triggered by a single abnormality or insult to the 
motor neuron. Rather, the mechanisms that trigger motor neuron degeneration are complex 
and multiple pathways are implicated such as abnormal protein aggregation, oxidative 
injury, mitochondrial defects, abnormalities of calcium homeostasis, axonal transport
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defects, proteosome dysfunction, immune marker induction, caspase activation, and multiple 
triggers of apoptotic signalling (Kawamata et al., 1992; Julien 2001; Shaw et al., 2003). The 
implication of multiple parallel pathways in neurodegeneration suggests that an effective 
alteration of any one pathway implicated in the process, will not be enough to affect the 
overall course of the disease (Rosenfeld, 2000). In addition, there is an increasing awareness 
that identified pathogenic processes may affect select subsets of ALS patients in different 
ways, suggesting the level of primary importance of different processes, may vary on an 
individual basis (Eisen et al., 1999; Ro et al., 2003; Shaw et al., 2003).
The observation that the degenerative cascade resulting in motor neuron death is 
probably multi-factorial provides support for simultaneous administration of multiple 
therapeutic agents in ALS; as interventions at a single point along the cascade are unlikely to 
improve function, survival, or quality of life to the same extent as multiple agents. Multiple 
synchronized interventions may have synergistic effects and result in a more significant 
benefit.
The difference in presentation and subsequent course of the disease between patients 
suffering from ALS is well known and striking. In some patients selective populations of 
motor neurons are spared whereas they are markedly affected in others. Although such 
selectivity can be put down to biological variability, it is also consistent with the hypothesis 
that phenotype variability may be the result of different pathophysiologic mechanisms. In 
picking subjects for a clinical trial, it is desirable to obtain a homogeneous population for the 
study. However, recent clinical trials utilising a single pharmacologic intervention have 
incorporated subjects with a surprising heterogeneity in the rate of progression, site of onset, 
and resulting functional limitations (Jackson et al., 2001; Miller et al., 2001; Cudkowicz et 
al., 2003; Groeneveld et al., 2003).
To date, multiple clinical trials have been completed using individual agents 
including recombinant human ciliary neurotrophic factor (rHCNTF), riluzole, insulin-like 
growth factor-1 (IGF-1), topiramate, alpha-tocopherol (vitamin E), creatine, selegine, 
nimodipine, verapamil, and gabapentin (Bensimon et al., 1994; Borasio et al., 1998; Miller 
et al., 1996 and2001; Jackson et al., 2001; Kwiecinski et al., 2001; Desnuelle et al., 2001;
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Cudkowicz et al., 2003; Groeneveld et al., 2003). Regrettably however, none of these single 
agents has produced significant benefit. Currently, as mentioned previously, Riluzole is the 
only FDA-approved drug for ALS patients, and has a modest effect on survival, respiratory 
capacity and rate of declining strength, but not on total strength, quality of life, or functional 
capacity (Lacomblez et al., 1996). From data obtained from animal models, it is known that 
anti-glutamate agents are thought to affect the initiation but not the propagation of motor 
neuron degeneration; the converse being true for antioxidant agents (Gurney et al., 1996; 
Torreilles et al., 1999; Ochs et al., 2000; Simpson et al., 2003).
A combinational drug treatment that addresses different pathophysiologic 
mechanisms makes sense and is necessary to achieve the most significant benefit (Eisen et 
al., 1999; Mitsumoto et al, 2001; Carter et al., 2003). Several reports, utilising different 
laboratory models of motor neuron degeneration, support the benefit of combination drug 
therapy (Iwasaki et al., 1999; Bilak et al., 2001; Mohammadi et al., 2001; Kriz et al., 2003; 
Nagano et al., 1999 and2003; Zhang et al., 2003). Some success has been obtained from 
limited combination drug trials, suggesting synergistic effects between different drugs 
(Stevie et al., 1998; Cudkowicz et al., 2003). In this study the combinational effect of Hsp27 
and Hsp70 was more effective in reducing mutant-associated toxicity than either of the 
single applications respectively.
The results presented in this chapter suggest the following hypothesis to explain how 
mutations of SOD1 may trigger neurodegeneration. SOD1 is an abundant protein that, when 
altered structurally as a direct consequence of mutations or subsequent post-translational 
modification, becomes denatured at an increased rate. As a result of SODl's abundance, it is 
likely to re-route a substantial portion of the chaperone systems toward refolding the 
denatured SOD1 or targeting it for degradation by proteasomes. The depletion of the pool of 
free chaperones would render cells expressing mutant SOD1 particularly vulnerable to 
physiological and environmental stresses, and would reduce the efficiency of several cellular 
processes dependent on chaperone proteins, and additionally might allow formation of ag­
gregates of denatured protein. Since most cells possess the ability to up-regulate the levels of 
many chaperone proteins, they remain relatively healthy. However, there is evidence that 
motor neurons may be relatively deficient in their ability to induce certain Hsps with
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chaperoning activity upon exposure to stress (Manzerra and Brown, 1992; Morrison- 
Bogorad et al., 1994; Satoh and Kim, 1995). As a result this may render them particularly 
vulnerable to damage from mutant SOD-1. In addition, due to the fact that they are also 
subjected to physiological stresses, including a high-level excitatory input, this may add to 
the overall burden on the chaperone systems.
If depletion of free chaperones were a significant factor in the toxicity of mutant 
SOD1, then by increasing the levels of chaperone proteins one would be able to confer 
protection against it. Durham et al. (1997) used intranuclear microinjection, to express 
G93A-mutant-SODl in primary motor neurons of dissociated cultures of murine spinal cord, 
which resulted in formation of cytoplasmic aggregates of SOD-1 and loss of viability over a 
2-week period. Durham et al. (1997) found that co-injection of expression vector encoding 
the murine inducible Hsp70 reduced the toxicity of mutant SOD1, dramatically decreased 
the percentage of motor neurons with SOD1 aggregates, and also prolonged survival.
Using three different experimental models, we have demonstrated that increased 
expression of Hsps protects cells from the toxicity of SOD1 mutants. Molecular chaperones 
are essential for several processes, including resistance to stress and proper protein folding, 
intracellular transport, and degradation. The diversion of the chaperones to protect the cell 
from toxicity of mutant SOD1 would have grave consequences, particularly if additional 
demands were exerted through environmental stresses. Motor neurons would be particularly 
vulnerable to mutant SOD1 associated toxicity for a number of reasons: (1) they express 
high levels of SOD 1 (2) induction of protective chaperone proteins in response to stress may 
be less robust in motor neurons than compared to other cells and (3) they are subjected to 
additional physiological stresses including a high level of excitatory synaptic input.
The work presented here provides a new therapeutic approach to this disease-the 
enhancement of the heat shock response. Indirectly, these findings support the hypothesis 
that the cellular Achilles heel in hereditary and may be also sporadic ALS is the accumula­
tion of misfolded SOD1 protein and any associated binding proteins. These accumulations 
could have calamitous downstream consequences, including direct toxicity to subcellular 
organelles and proteosomal dysfunction. The work presented here is in accordance with
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previous in vitro studies showing that expression of Hsp70 blunts the neurotoxic effects of 
acutely expressed mutant SOD1 (Shinder et al., 2001; Bruening et al., 1999; Okado- 
Matsumoto et al., 2002).
The results presented here also suggest that manipulating the heat shock pathway at 
more than one place achieves a more profound neuroprotection than altering levels of 
individual Hsp molecules. In accordance with the findings of arimoclomol other activators 
of the heat shock response may also prove beneficial in the SOD1-G93A mice and other 
related diseases for instance carbenoxolone (Nagayama et al., 2001), an anti-ulcer drug that 
directly activates the Hsp70 promoter; the herbal compound celastrol (Allison et al., 2001); 
and the anti-inflammatory drug indomethacin (Lee et al., 1995), which, among other 
mechanisms, activates DNA binding of HSF-1.
It will be important to establish whether the enhancement of heat shock and protein 
chaperone responses is beneficial in cases of ALS that are not a consequence of SOD1 gene 
mutations. Due to the existence of considerable overlap between the cellular and bio­
chemical phenotypes of sporadic and familial ALS it is anticipated that Hsp induction will 
be beneficial for all types of ALS. However, in the absence of an animal model for sporadic 
ALS, the only way to resolve this would be through human clinical trials.
The neuroprotective effects of Hsp activation may also extend to other conditions for 
instance stroke, or trauma of the brain and spinal cord. An analog of arimoclomol, 
bimoclomol, induces Hsp70 expression and prevents neuronal degeneration in a neonatal 
model of motor (Kalmar et al., 2002) and sensory (Kalmar et al., 2003) neuron death, and in 
models of diabetic neuropathies (Biro et al., 1997), cardiovascular injury (Polakowski et al., 
2002), as well as ischemia/reperfusion injury (Lubbers et al., 2002). Hargitai et al., (2003) 
demonstrated that bimoclomol mediates its co-inducer effect on heat shock protein gene 
expression and cytoprotective action via HSF-1. Although further studies are required to 
examine the precise manner in which bimoclomol exerts its effect on HSF-1 or its 
complexes with heat shock proteins, this appears to involve a moderately enhanced 
phosphorylation of HSF-1 in addition to prolonged binding of HSF-1 to DNA. Bimoclomol- 
induced fluidization of cellular membranes (Torok et al., 2003) may also lower the threshold
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of the heat shock response, and as a result contribute to the chaperone co-inductive property 
(Vigh et al., 1997) of this drug. It may also be fruitful and important to study further how 
arimoclomol works. For instance, which kinases and phosphorylases impinge on HSF-1, and 
whether these molecules may potentially be drug targets. Substances that upregulate Hsps 
and their co-chaperones may be of therapeutic importance in other neurodegenerative 
diseases, many of which are a consequence of protein instability (for example, amyloid-p in 
Alzheimer disease, a-synuclein in Parkinson disease, huntingtin in Huntington disease, and 
prion protein in Creutzfeld-Jacob disease).
Knowledge of the genetic defects triggering neurodegeneration in ALS has provided 
insight into molecular pathogenesis, and consequently led to the development of disease 
models in transgenic mice and simple in vitro systems. Ultimately it is hoped these powerful 
tools will facilitate the discovery of new drugs and therapies. The findings presented here 
are considered to be an important step in this direction.
Overall, the findings presented in this chapter do not provide sufficient evidence for 
the full understanding of the mechanism of toxicity of FALS-associated mutant-SODl or of 
the precise mechanism of action via which Hsp27 and/or Hsp70 exert their protective 
effects. However, they clearly suggest (a) that both Hsp27 and Hsp70 are of potential 
therapeutic benefit toward FALS-associated mutant SOD1 toxicity and (b) that a 
combinational approach utilizing dual expression of Hsp27 and Hsp70 together maybe more 
effective than expression of single Hsps. Further suggestions for future experiments utilising 
the simple cellular models presented here or more advanced systems to confirm these 
findings - such as more advanced in vivo models - are discussed in the next chapter, along 
with a further evaluation of the present study.
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C h a p t e r  6  
G e n e r a l  D i s c u s s i o n
6. Discussion
The work presented in this thesis demonstrates the effectiveness of using a simple 
neuronal cellular model, in addition to a primary cell model of mutant-SODl-induced 
toxicity and an efficient gene delivery method based on HSV-1 vectors, in order to test 
hypotheses relevant to FALS-related pathogenesis and to the neuroprotective effects of heat 
shock proteins. This chapter aims to discuss general aspects, as well as the advantages and 
limitations of the work presented here and in addition suggest further experiments, which 
may be carried out (more details are included in the individual Discussion sections of the 
respective Chapters 3, 4 and 5). Therefore, Chapter 3 described the establishment of the in 
vitro cellular model and characterisation of its response to a wide range of stresses relevant 
to FALS. Having demonstrated certain effects in this system, which result from the over­
expression of either wt or G93A or G93R-mutant-SODl forms, it was then possible to move 
forward and ask whether or not Hsp over-expression could possibly alleviate or prevent the 
deleterious effects of mutant-SODl under conditions of stress (Chapter 4); and then 
investigate potential mechanisms of action of Hsp27 and Hsp70 (Chapter 4) as well as the 
effects of ApoE alleles in relation to FALS; and then further investigate the effects of wt- 
SODl and its FALS-associated mutant forms and Hsps in a primary cell culture model in 
order to confirm the findings (Chapter 5).
The following sections will highlight how the findings presented in the last three 
chapters compare with the findings reported in the literature, before proceeding to 
summarise the overall advantages and the limitations of the models presented here. Lastly, 
some further experiments are suggested that may be carried out to extend the work presented 
in this thesis.
The results presented in Chapter 3 describe the establishment and characterisation of 
the in vitro model system where wt-SODl and the disease-associated SOD 1-mutant forms 
are over-expressed. It was shown that the response of the cell lines to various death-inducing 
stimuli depends on both the type of stress and the form of SOD1, which is over-expressed. 
Wt-SODl expression protected the neuronal cells against all stresses tested whereas both the 
SOD 1-mutants were more susceptible to death (also, see Patel et al., 2002 in the appendix).
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There is substantial evidence (also discussed in Chapter 3) indicating that increased 
levels of wt-SODl are protective (Greenlund et al., 1995; Rabizadeh et al., 1995; Patel et al., 
2002) whilst expression of the mutants is deleterious in vitro (Rabizadeh et al., 1995; Patel 
et al., 2002), and in vivo (Gurney et al., 1994; Dal Canto and Gurney 1995 & 1997). 
Evidence of apoptosis is observed in transgenic mice overexpressing FALS associated SOD1 
mutations from the elevated levels of caspase-1 and caspase-3 (Li et al., 2000; Pasinelli et al., 
2000) and from the observation that neuroprotection can be achieved by crossing these SOD1 
transgenics with mice overexpressing Bcl-2 (Kostic et al., 1997). Cell culture experiments 
further substantiate the pro-apoptotic properties of FALS associated SOD1 mutations 
(Rabizadeh et al., 1995; Patel et al., 2002).
The protective effect of the wild-type SOD1 against neuronal apoptosis has been 
demonstrated in several studies (Greenlund et al., 1995; Rabizadeh et al., 1995) and this has 
also been shown in our studies. Wild type SOD1 protein provided protection against a wide 
range of stresses including serum removal both in the absence and presence of lpM retinoic 
acid, staurosporine administration, IFN-y treatment, camptothecin addition, glutamate 
administration, hydrogen peroxide treatment and ischemia/reperfusion. Hence, in a wide 
range of different situations the wild-type SOD1 is protective however the disease- 
associated SOD1 mutants G93A and G93R exhibited an enhanced level of cell death on 
exposure to the same stresses. The results of the present study extends the work of 
Rabizadeh et al, (1995) who demonstrated that the SOD1 mutations G37R and A4V 
associated with ALS converted the anti-apoptotic SOD1 gene into a pro-apoptotic gene. 
Furthermore, in the present study the G93R mutation was observed to be a lot more severe 
compared to the G93A mutation paralleling the much more severe disease phenotype and 
early onset observed in ALS patients with this mutation.
As a summary, comparison of this model to mice and in vitro FALS models 
(reviewed in Chapter 1 and discussed in Chapter 3) suggest that all the findings in this 
model are in agreement the findings of others, on both the protective effect of wt-SODl 
under all stresses tested and the role of mutant-SODl in enhancing toxicity (Patel et al., 
2002). This work incorporates a wide range of FALS relevant stresses, in addition to some 
stresses, which have previously not been investigated.
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Chapter 4 presented experimental data that provided a novel neuroprotective role for 
Hsp27 and Hsp70 both singly and to a greater extent in combination, against FALS- 
associated SOD1 mutant forms expressed in neuronal cells (see also in the appendix Patel et 
al., 2005). Hsp27, Hsp70 and the Hsp27 and Hsp70 combination have a potent protective 
effect against mutant SOD 1-induced toxicity under all the pro-apoptotic and oxidative 
stresses tested. This is a novel finding in the context of FALS models, and agrees with 
numerous studies in the literature that support the protective function of Hsp27 and Hsp70 
against many stresses resulting in apoptosis (see Chapter 5 discussion below). In addition, 
investigation into the effects of the ApoE alleles revealed the protective effects of ApoE2 
over ApoE4 in the SOD1 mutant expressing cells. ApoE4 addition appeared to increase cell 
death across all cells and appeared to be deleterious for the cells.
Although studies have examined the protective effects of over-expression of Hsps, 
none have investigated conclusively the protective effects of Hsp27 or Hsp70 over­
expression, or combined effects of both together, with respect to FALS-associated SOD1 
mutants. Notably, Hsps are found to be present in aggresomes in cell culture models 
(Durham et al., 1997) and in FALS patients together with mutant SOD1 and other Hsps. 
Recently, Shimura et al. (2004) reported Hsp27 rescues pathological hyperphosphorylated 
tau-mediated cell death in a human cortical neuronal cell line. Interestingly, in human AD 
brain, Hsp27 was shown to bind to pathological hyperphosphorylated tau but not non- 
phosphorylated tau. The formation of this complex in vitro results in a decrease in its 
concentration by assisting its degradation and dephosphorylation.
In the present study Hsp27, Hsp70 and the Hsp27 and Hsp70 combination all 
conferred protection to the G93A and G93R SOD1 mutants against a wide range of lethal 
stimuli. Hsp27 was more effective in reducing death in the G93A mutant than Hsp70 
whereas in the G93R mutant the converse was true. However the combination of Hsp27 and 
Hsp70 was the most effective in reducing death in the SOD1 mutants. Interestingly, wt- 
SODl cells exhibited increased levels of death on infection with the Hsp’s, with Hsp70 
bringing about a larger increase in death than Hsp27. In addition the enhanced cell death 
observed in the wt-SODl cells on infection with Hsp27 or Hsp70 alone was abolished on
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expression of the combination of Hsp27 and Hsp70 suggesting that Hsp27 and Hsp70 may 
act in synergy.
A significant study by Bruening et a l (1999), in a mammalian system, reported that 
increasing the levels of Hsp70 reduced formation of mutant SOD-containing proteinaceous 
aggregates and prolonged survival. As yet it remains controversial as to whether cytoplasmic 
mutant SOD1 aggregates are toxic (Bruijn et al., 1998) or not (Cummings et al., 1999; 
Johnston et al., 2000; Kopito. 2000). Previous studies in neuronal cells and cultured primary 
motor neurons have demonstrated that the inhibition of cytoplasmic aggregate formation by 
induction of heat shock protein Hsp70 assured cell survival at an early stage but did not 
prevent eventual cell death at the late stage in the in vitro models of FALS (Bruening et al., 
1999; Takeuchi et al., 2002).
Work conducted by Zourlidou et al. (2004) on the protective effects of Hsps in a 
neuronal cell model of a-synuclein toxicity found Hsp70 did not provide a strong protective 
effect against a range of stresses, whilst simultaneous overexpression of Hsp27 and Hsp70 
was as protective as Hsp27 expression alone. Recently, Klucken et al. (2004) reported the 
first evidence for an effect of Hsp70 on reducing high molecular weight and detergent 
insoluble a-Syn species in an in vivo mammalian model. The study also reported protection 
from a-Syn toxicity by Hsp70 in an in vitro model of a-Syn aggregation and reduction of 
detergent insoluble a-Syn species. Over-expression of Hsp70 in several in vitro and in vivo 
models of polyQ disease has been demonstrated to be efficient in suppressing polyQ 
aggregation (Muchowski et al., 2000) or both aggregation and toxicity (Sherman and 
Goldberg, 2001). In a mouse model of SBMA, over-expression of human inducible Hsp70 
led to a reduction in the levels of aggregated and monomeric mutant androgen receptor (AR) 
in neuronal nuclei and alleviated disease phenotype (Adachi et al., 2003). In addition, in a 
SCA1 model over-expression of Hsp70 did not avert the formation of nuclear inclusions in 
Purkinje cells but suppressed degeneration and improved motor performance (Cummings et 
al., 2001). Phenotype rescue, as measured by survival, rotarod analysis and gait analysis, 
was seen on homozygous over-expression of Hsp70 with Hsp70 reducing the levels of both 
aggregated and soluble AR detected in the nucleus. Hsp70 over-expression may aid in 
degradation of the mutant AR protein via the ubiquitin-proteasome system.
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In the model presented here, the main mode of cell death induced by the various 
stimuli appears to be apoptosis. Hence the findings in this thesis could be explained partly 
by the fact that both Hsp27 and Hsp70 have multiple anti-apoptotic actions (Garrido et al., 
2001; Concannon et al., 2003; Parcellier et al., 2003). The precise mechanism of protection 
of Hsp27 and Hsp70 in various situations is obviously very complex and as yet remains 
incompletely understood. However we believe that the Hsps provide more than a general 
cytoprotective effect and impose their protective effect on the SOD1 mutant probably 
through restoration of normal protein conformation rather than degradation of misfolded 
protein, as addition of Hsps lowers levels of death in both the mutants by a greater amount 
than is seen in control cells without SOD overexpression. The reduction in death of the 
mutants, beyond the levels of control cells would be expected if the mutant was refolded to 
obtain wild-type conformation and thereby able to exert its wild-type anti-apoptotic 
properties through over-expression of wt-SODl protein.
In the case of wt-SODl, Hsp27 or Hsp70 expression resulted in an increase in cell 
death. This may be the result of increased levels of oxidative stress through increased levels 
of basal SOD1, known to be harmful to the cell (Omar et al., 1990) (discussed in Chapter 4). 
The Hsp27 and Hsp70 combination in the wt-SODl cells brought levels of cell death down 
towards control levels. This maybe brought about by the combination of Hsp27 and Hsp70 
activating a proteolytic pathway and degrading any excess wt-SODl or the combination 
self-regulating each other and preventing over-excessive production of wt-SODl. 
Alternatively, the two factors together may have a subsequently potent protective effect to 
neutralise the damage brought about by a large excess of wt-SODl. Therefore depending on 
the conditions the Hsp27 and Hsp70 combination may protect against apoptotic cell death by 
interfering with the caspase cascade (discussed in Chapter 4), or assist in the refolding of 
mutant protein or assist in the degradation of the protein via the proteasome under the 
conditions described and at the chosen time points.
The work presented in Chapter 5 provides further support to the findings of the 
previous two chapters, through work in DRGs from rats, mice and transgenic mice to 
confirm that Hsp27, Hsp70 and to a greater extent the Hsp27 and Hsp70 combination 
provide protection against mutant SOD1 induced toxicity and that the mechanism of
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cytoprotection of Hsp27 and/or Hsp70 may be through interference with caspase activation 
in cells in which mutant SOD1 is expressed. Nevertheless, and although speculative, it is 
more likely that Hsp27 or Hsp70 confer protection through involvement at a number of 
sites/pathways and this should be further investigated.
The results support the idea that it is the anti-apoptotic activity of Hsp27 or Hsp70, 
which is responsible for protection against cell death. The involvement of apoptosis in 
FALS and also the role of Hsps in suppressing apoptotic pathways were discussed 
extensively in Chapter 1 along with the role of mitochondria in both FALS and apoptosis. In 
summary, there exists work conducted by others that strongly supports the occurrence of 
apoptosis in FALS models and in FALS brain (Vila and Przedborski, 2003), as well as work 
supporting the capabilities of Hsp27 or Hsp70 in suppressing it (Concannon et al., 2003; 
Parcellier et al., 2003a; Beere, 2004).
To further investigate the protective effects of over-expression of Hsp27, Hsp70 and 
the Hsp27 and Hsp70 combination against mutant SOD1 induced toxicity, quantification of 
the cell death in primary neurons was performed for three distinct stresses all relevant to 
FALS (NGF withdrawal, IFN-y and staurosporine). Both Hsp27 and Hsp70 and to a greater 
extent the Hsp27 and Hsp70 combination, conferred protection against mutant SOD1 
induced toxicity. Although the findings presented in Chapter 5 do not provide a full 
understanding of the mechanism of protection in the model of mutant-SODl induced 
toxicity, they provide significant evidence on the interference of Hsp27, Hsp70 and the 
Hsp27 and Hsp70 combination with caspases and the apoptotic cascade events. It is possible 
that multiple sites of action as well as multiple activities of both Hsp27 and Hsp70 are 
involved in this protection. For instance, apart from suppressing apoptosis (Beere et al., 
2004), Hsp27 may act by (a) stabilising actin microfilaments (Lavoie et al., 1995) and 
interacting with cytoskeleton components to stabilise the cytoskeleton (see review of Hsp27 
roles in Chapter 1), (b) by increasing the anti-oxidant defence of cells by decreasing reactive 
oxygen species cell content (Mehlen et al., 1996), (c) assisting in proteasomal degradation 
(Parcellier et al., 2003). On the other hand, Hsp70 apart from its ability to suppress apoptosis 
is also thought to protect cells from energy deprivation and/or ATP depletion associated
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with cell death (Wong et al., 1998). Furthermore, Hsp70 has also been shown to avert JNK 
activation (Meriin et al., 1999; Park et al., 2001).
The mechanism by which Hsp27 exerts its protective effects may be through its 
ability to maintain redox homeostasis and mitochondrial stability. The suggestion that Hsps 
exert their protective roles at the level of the mitochondrion is not an entirely new concept. 
Previously Polla et al. (1996) proposed that mitochondria are the targets of the protective 
effects of Hsps against oxidative stress. Mutant SOD1 has been shown to localise to the 
mitochondria where it sets off caspase-dependent cell death (Takeuchi et al., 2002). It is 
possible that mutant SOD1 exerts its effects on mitochondrial SOD2 by relocating to the 
mitochondria where the SOD1 mutant catalyses the reaction of superoxide radical (O2 ) with 
nitric oxide (NO) to generate peroxynitrite (ONOO'). Hsp27 can increase intracellular levels 
of glutathione (Mehlen et al., 1996) and this may be a possible additional mechanism by 
which Hsp27 exerts its protective effect. The role of the mitochondrion in FALS is 
becoming increasingly important. Therefore, the protective effects of Hsp27 presented here 
may act by protecting mitochondrial integrity, however further work need to be done to 
confirm this.
In vitro cellular models have been used extensively in neurodegenerative disorders 
and have provided a substantial amount of valuable knowledge. Some of these findings were 
extended through in vivo experiments or confirmed through studies on human post mortem 
material. In the same way, the methodology used here is not novel however the model 
systems presented here have contributed overall to the field; this will be explained next 
alongside some of its limitations.
The limitations that accompany the in vitro model systems used in this study are 
mainly due to the fact that they are in vitro systems utilising a non-human hybrid cell line or 
rat or mouse DRGs. However, such limitations do not necessarily rule out the significance 
of these findings, as in total three model systems have been utilised in this study. However 
further work needs to be carried out in in-vivo systems. In addition it should be noted that 
the majority of ALS cases are not linked to SOD1 mutations.
376
Neurodegenerative diseases like ALS are often very complex and not completely 
understood at the molecular pathological level. There are additional difficulties imposed by 
the fact that they are age related disorders and progressive diseases where usually more than 
one parameter accounts for their pathology, with environmental triggers and genetic 
predisposition. Therefore, the extent to which a simple cellular model can provide a better 
understanding of the disease pathogenesis is relatively limited. However, by reviewing the 
biology of Hsps and of SOD1, the cellular model system presented here was able to 
demonstrate a novel neuroprotective role for Hsp27, Hsp70 and the Hsp27 and Hsp70 
combination on mutant-SODl induced toxicity. The role of Hsp27 and Hsp70 in conferring 
protection on this system is not surprising, in view of evidence of the anti-apoptotic 
functions for both Hsp27 and Hsp70 and protection from ROS, ATP depletion and a range 
of stimuli in non-neuronal and neuronal cells or in vivo systems (see review in Chapter 1).
As discussed in the previous chapters, advantages of the system presented here 
include the fact that ND7 cells are well characterised neuronal mammalian cells, and this 
present system has been well characterised (Chapter 3). The viral vectors used in the present 
studies provided a highly efficient mechanism of Hsp gene delivery to the neuronal cells and 
the DRGs, with a transduction efficiency of between 90-100%, as discussed in Chapter 4 & 
5. Strong evidence on the protective effect of Hsp27, Hsp70 and the Hsp27 and Hsp70 
combination against various apoptosis-inducing stresses was provided by two different 
methods of quantitative cell death assessment (trypan blue exclusion assay and TUNEL), as 
shown in Chapter 4. These are both valid and widely used methods for the assessment of cell 
death with TUNEL being more specifically used for the assessment of the apoptotic index.
As a result of time limitations there was not sufficient time to study the role of the 
proteosome, which has only recently been studied in other in vitro systems. It would be 
interesting to perform experiments involving proteasome activity assays and see if Hsp27, 
Hsp70 or the combination of both rescues the cells from a potentially toxic proteasomal 
impairment.
In order to extend the study of the Hsp27, Hsp70-mediated mechanisms that confer 
protection in our system, it would be interesting to see if there are enhanced levels of ROS
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as a result of mutant SOD1 expression and if so, whether Hsp27/Hsp70 or both suppress 
their formation and hence susceptibility to death in our system. In addition, some other 
stresses could be investigated, such as those inducing oxidative damage, proteasome 
inhibitors, inhibitors of the mitochondrial complex and so on, as these are relevant agents to 
the disease pathology and have been extensively used by others. Finally, it could be of 
interest to investigate the mitochondrial activity, for instance, by using commercially 
available assays, such as caspase activity assays, and then proceed to see if cytochrome c 
release is blocked by Hsp27, Hsp70 or the combination.
Aggregate formation by SOD1 and its mutant forms was not investigated here and 
hence could be further investigated, as this could explain the increased cell death observed 
on treatment of wt-SODl cells with the Hsp27 and Hsp70 virus, as well as the protective 
effects observed in the mutants. Therefore, immunocytochemical or electron microscopy 
studies may shed some light on this aspect of the cellular model. Alternatively, through anti­
sense, dominant negative constructs or RNA interference technology, one may ask whether 
compromising the inherent Hsp machinery in these cells sensitises them by a greater extent 
to mutant SOD 1 over-expression in the presence or absence of stress.
Furthermore, along with the use of viruses to efficiently over-express individual or 
combined Hsps in cells, drugs could have also been used in order to (a) initially characterise 
their effectiveness in Hsp induction through the drug-induced stress response and (b) 
subsequently assess cytoprotection. As chaperones are multifunctional proteins it is possible 
that their depletion may impair mechanisms, which are independent of protein folding. 
Evidence suggests that the abundance and relative levels of chaperones may be critical in 
determining cellular signalling (Nollen and Morimoto, 2002; Young et al., 2003).
The pharmacological or other Hsp inducing strategies should aim to (a) replace 
potential “losses” of chaperones, for instance those that result through sequestration in 
aggregates, which results in depletion of the cellular pool of Hsps needed for other functions 
in the cell and (b) induce Hsps at higher levels than normal to assist the cell to cope with 
stresses that would otherwise result in malfunction or death. Pharmacological modulation of 
heat shock protein levels may represent a potential therapeutic strategy toward disorders like
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FALS with prominent protein aggregation. A number of compounds have been reported to 
initiate a heat shock response in a wide range of cell lines.
Finally, confirmation of the findings presented in this study could be obtained 
through in vivo investigations by crossing mice over-expressing mutant SOD1 with available 
Hsp27, Hsp70 or Hsp27 and Hsp70 transgenic mice, to assess whether the phenotype is 
altered and if so, conduct biochemical investigations to determine how this is achieved.
Whatever the future holds, the work presented in this thesis is of significance in the 
field of FALS and heat shock protein biology. This is due to the fact that as yet, no effective 
treatment exists for FALS and heat shock proteins represent therapeutic targets and potent 
therapeutic agents for the modulation of neurotoxicity in neurodegenerative disorders. 
Before any definitive conclusions can be drawn this work needs to be extended and 
validated in more complex systems in vivo. Better understanding of FALS and its molecular 
pathogenesis will assist in the development of novel therapeutic interventions, which may 
involve manipulation of the heat shock response pharmacologically or by means of gene 
therapy.
Although the cellular model presented here is not the ideal cellular model to study 
ALS - it remains a very useful mammalian neuronal system where an interesting effect of 
wt-SODl and the FALS-associated mutants has been observed (Chapter 3). This system has 
an obvious advantage over the reported use of various non-neuronal or non-mammalian 
systems. It has allowed the testing for the first time of the protective effect of various Hsps 
both singly and in combination, against the mutant SOD 1-induced cell death in a 
mammalian neuronal system. Most importantly, this system helped to conclude that Hsp27, 
Hsp70 and to a greater extent the Hsp27 and Hsp70 combination is a potent neuroprotective 
agent against mutant SOD 1-associated toxicity; this is the first report to show alleviation of 
mutant SOD 1-neurotoxicity in an in vitro mammalian neuronal system by Hsp27 and by the 
combination of Hsp27 and Hsp70 (Patel et al., 2005).
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